{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "scrapping.ipynb",
      "provenance": [],
      "collapsed_sections": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ZJso9onMqvZT",
        "outputId": "81b3357b-0148-4894-cf73-541027133ba6"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: beautifulsoup4 in /usr/local/lib/python3.7/dist-packages (4.6.3)\n"
          ]
        }
      ],
      "source": [
        "pip install beautifulsoup4"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import requests"
      ],
      "metadata": {
        "id": "qe9BvbylrOwy"
      },
      "execution_count": 4,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from bs4 import BeautifulSoup"
      ],
      "metadata": {
        "id": "q6s9vHzYrZDT"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "url=\"https://go.drugbank.com/covid-19#drugs\""
      ],
      "metadata": {
        "id": "K4eoqrQ_r-tE"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "page=requests.get(url)"
      ],
      "metadata": {
        "id": "r8gIONcXsDxW"
      },
      "execution_count": 7,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "page.content"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "SlfH2VIasLZW",
        "outputId": "cb75018a-14a5-4996-c1c2-0d52b29ba9f7"
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "b'<!DOCTYPE html><html><head><meta content=\"width=device-width, initial-scale=1, shrink-to-fit=no\" name=\"viewport\" /><meta content=\"text/html; charset=UTF-8\" http-equiv=\"Content-Type\" /><meta content=\"fdhmwDBTGwNPe0lKcJVly7AToLfZYvJ-mtjFAPTMZGs\" name=\"google-site-verification\" /><meta content=\"296E0FF6379AE64A0D18C39BB40ECD6E\" name=\"msvalidate.01\" /><meta content=\"COVID-19 OUTBREAK SUMMARY: Coronavirus disease 2019\\n      (named COVID-19 on February 11, 2020 by the World Health Organization\\n      (WHO) [L12912,L12918]) was first identified in Wuhan, China near the end of 2019 . It is caused by the virus known as SARS-CoV-2 (previously called 2019-nCoV).\\n      This name was chosen because the virus is related to the coronavirus that\\n      caused the SARS outbreak of 2003. The two viruses are different despite their\\n      genetic similarity . COVID-19 is believed to be less lethal but much more\\n      infectious than SARS-CoV . Until the recent outbreak, this virus had not\\n      been identified in humans .\" name=\"description\" /><title>COVID-19 Dashboard | DrugBank Online</title><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-57x57-precomposed.png\" sizes=\"57x57\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-60x60-precomposed.png\" sizes=\"60x60\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-72x72-precomposed.png\" sizes=\"72x72\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-76x76-precomposed.png\" sizes=\"76x76\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-114x114-precomposed.png\" sizes=\"114x114\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-120x120-precomposed.png\" sizes=\"120x120\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-144x144-precomposed.png\" sizes=\"144x144\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-152x152-precomposed.png\" sizes=\"152x152\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-180x180-precomposed.png\" sizes=\"180x180\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon-precomposed.png\" sizes=\"57x57\" /><link rel=\"apple-touch-icon\" type=\"image/x-icon\" href=\"/favicons/apple-touch-icon.png\" sizes=\"57x57\" /><link rel=\"icon\" type=\"image/png\" href=\"/favicons/favicon-96x96.png\" sizes=\"96x96\" /><link rel=\"icon\" type=\"image/png\" href=\"/favicons/favicon-32x32.png\" sizes=\"32x32\" /><link rel=\"icon\" type=\"image/png\" href=\"/favicons/favicon-16x16.png\" sizes=\"16x16\" /><link rel=\"icon\" type=\"image/png\" href=\"/favicons/favicon.png\" sizes=\"16x16\" /><link rel=\"shortcut icon\" type=\"image/x-icon\" href=\"/favicons/favicon.ico\" /><meta content=\"#da532c\" name=\"msapplication-TileColor\" /><meta content=\"/favicons/mstile-144x144.png\" name=\"msapplication-TileImage\" /><meta content=\"#ffffff\" name=\"theme-color\" /><meta content=\"DrugBank\" name=\"application-name\" /><link as=\"font\" crossorigin=\"\" href=\"/assets/GemeliWeb-Regular-9ccb07b090f3aef673e3b29ba66e2e685ccf3d438e550624d9739f1bd5164cb2.woff2\" rel=\"preload\" type=\"font/woff2\" /><link as=\"font\" crossorigin=\"\" href=\"/assets/GemeliWeb-Bold-f344ff98a063f8cb6ac490b132bda4035ecc8984358dfa8d9bd8621fa38744e2.woff2\" rel=\"preload\" type=\"font/woff2\" /><link as=\"font\" crossorigin=\"\" href=\"/assets/GemeliWeb-Light-8227f53ee1957ae57cc0c81d1cfecb59238e3fd9d32b1e792432e1f8c81784a1.woff2\" rel=\"preload\" type=\"font/woff2\" /><link as=\"style\" data-turbolinks-track=\"true\" href=\"/assets/public_preload-7bb75340a5ff537e87bf7e9a8383724bc35f25c2f2b5d8e411fdd2a4a657bac3.css\" media=\"all\" onload=\"this.onload=null;this.rel=&#39;stylesheet&#39;\" rel=\"preload\" /><noscript><link href=\"/assets/public_preload-7bb75340a5ff537e87bf7e9a8383724bc35f25c2f2b5d8e411fdd2a4a657bac3.css\" media=\"all\" rel=\"stylesheet\" /></noscript><link rel=\"stylesheet\" media=\"all\" href=\"/assets/public-7ce82bb78ae55836a7f2a53437b0f77072d3139afdc068f210e726c7d69ac96a.css\" data-turbolinks-track=\"true\" /><script src=\"/assets/public-de346f4079123b7b086ddbb3dacbeacd104b373dfb9a9b48e26fc885e64a13ac.js\" media=\"all\" data-turbolinks-track=\"true\" defer=\"defer\"></script><script>(function(c,l,a,r,i,t,y){\\n    c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)};\\n    t=l.createElement(r);t.async=1;t.src=\"https://www.clarity.ms/tag/\"+i;\\n    y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y);\\n})(window, document, \"clarity\", \"script\", \"5600r08mxy\");</script><meta name=\"csrf-param\" content=\"authenticity_token\" />\\n<meta name=\"csrf-token\" content=\"14WKxbPQVTP9Lt6_JJv8UiPrPjgFtPIEocLD7_6V8zsUxFqHil2swH_l1kScXZCrI7fk9Ja2tjvzCm_uMWjhrg\" /></head><body class=\"pages-c covid_19-a has-banner\"><header><nav class=\"navbar fixed-top navbar-expand-custom navbar-light\" id=\"main-nav\" style=\"background-color: #ff00b8;\"><a class=\"navbar-brand\" href=\"/\"><img style=\"width: 178px; height: 20px;\" src=\"/assets/logo-white-dd185d748ee0164b8ee8f88df29235cd8cfc7936a3c974589262c667e9294219.svg\" /><div class=\"online\">Online</div></a><button aria-controls=\"navbar\" aria-expanded=\"false\" aria-label=\"Toggle navigation\" class=\"navbar-toggler navbar-toggler-right\" data-target=\"#navbar\" data-toggle=\"collapse\" type=\"button\"><span class=\"navbar-toggler-icon\"></span></button><div class=\"collapse navbar-collapse\" id=\"navbar\"><ul class=\"navbar-nav ml-auto\"><li class=\"nav-item dropdown\"><a class=\"nav-link dropdown-toggle\" data-toggle=\"dropdown\" href=\"#\">Browse</a><div class=\"dropdown-menu\"><a class=\"dropdown-item\" href=\"/drugs\"><div class=\"icon-circle drugbank-icon icon-drugs\"><svg class=\"icon\" role=\"img\" title=\"drugs\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#drugs\"></use>\\n</svg>\\n</div> Drugs</a><a class=\"dropdown-item\" href=\"/drugs/starred\"><div class=\"icon-circle drugbank-icon icon-star-fill\"><svg class=\"icon\" role=\"img\" title=\"star-fill\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#star-fill\"></use>\\n</svg>\\n</div> Starred Drugs</a><a class=\"dropdown-item\" href=\"/categories\"><div class=\"icon-circle drugbank-icon icon-categories\"><svg class=\"icon\" role=\"img\" title=\"categories\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#categories\"></use>\\n</svg>\\n</div> Categories</a><a class=\"dropdown-item\" href=\"/pathways\"><div class=\"icon-circle drugbank-icon icon-pathways\"><svg class=\"icon\" role=\"img\" title=\"pathways\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#pathways\"></use>\\n</svg>\\n</div> Pathways</a><a class=\"dropdown-item\" href=\"/reactions\"><div class=\"icon-circle drugbank-icon icon-reactions\"><svg class=\"icon\" role=\"img\" title=\"reactions\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#reactions\"></use>\\n</svg>\\n</div> Drug Reactions</a><a class=\"dropdown-item\" href=\"/classyfication\"><div class=\"icon-circle drugbank-icon icon-classifications\"><svg class=\"icon\" role=\"img\" title=\"classifications\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#classifications\"></use>\\n</svg>\\n</div> Drug Classification</a><a class=\"dropdown-item\" href=\"/targets\"><div class=\"icon-circle drugbank-icon icon-targets\"><svg class=\"icon\" role=\"img\" title=\"targets\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#targets\"></use>\\n</svg>\\n</div> Drug Targets</a><div class=\"dropdown-divider\"></div><a class=\"dropdown-item\" href=\"/pharmaco/genomics\"><div class=\"icon-circle drugbank-icon icon-geno-browse\"><svg class=\"icon\" role=\"img\" title=\"geno-browse\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#geno-browse\"></use>\\n</svg>\\n</div> Pharmaco-genomics</a><a class=\"dropdown-item\" href=\"/pharmaco/metabolomics\"><div class=\"icon-circle drugbank-icon icon-chemquery\"><svg class=\"icon\" role=\"img\" title=\"chemquery\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#chemquery\"></use>\\n</svg>\\n</div> Pharmaco-metabolomics</a><a class=\"dropdown-item\" href=\"/pharmaco/transcriptomics\"><div class=\"icon-circle drugbank-icon icon-interax\"><svg class=\"icon\" role=\"img\" title=\"interax\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#interax\"></use>\\n</svg>\\n</div> Pharmaco-transcriptomics</a><a class=\"dropdown-item\" href=\"/pharmaco/proteomics\"><div class=\"icon-circle drugbank-icon icon-interax\"><svg class=\"icon\" role=\"img\" title=\"interax\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#interax\"></use>\\n</svg>\\n</div> Pharmaco-proteomics</a></div></li><li class=\"nav-item dropdown\"><a class=\"nav-link dropdown-toggle\" data-toggle=\"dropdown\" href=\"#\">COVID-19</a><div class=\"dropdown-menu\"><a class=\"dropdown-item\" href=\"/covid-19\"><div class=\"icon-circle drugbank-icon icon-covid-overview\"><svg class=\"icon\" role=\"img\" title=\"covid-overview\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#covid-overview\"></use>\\n</svg>\\n</div> Overview</a><a class=\"dropdown-item\" href=\"/covid-19-vaccination\"><div class=\"icon-circle drugbank-icon icon-covid-vaccination\"><svg class=\"icon\" role=\"img\" title=\"covid-vaccination\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#covid-vaccination\"></use>\\n</svg>\\n</div> Vaccine Side Effects</a></div></li><li class=\"nav-item dropdown\"><a class=\"nav-link dropdown-toggle\" data-toggle=\"dropdown\" href=\"#\">Search</a><div class=\"dropdown-menu\"><a data-no-turbolink=\"true\" class=\"dropdown-item\" href=\"/structures/search/small_molecule_drugs/structure\"><div class=\"icon-circle drugbank-icon icon-chemquery\"><svg class=\"icon\" role=\"img\" title=\"chemquery\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#chemquery\"></use>\\n</svg>\\n</div> Chemical Structure</a><a data-no-turbolink=\"true\" class=\"dropdown-item\" href=\"/structures/search/small_molecule_drugs/mass\"><div class=\"icon-circle drugbank-icon icon-molecular-weight\"><svg class=\"icon\" role=\"img\" title=\"molecular-weight\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#molecular-weight\"></use>\\n</svg>\\n</div> Molecular Weight</a><a class=\"dropdown-item\" href=\"/drug-interaction-checker\"><div class=\"icon-circle drugbank-icon icon-interax\"><svg class=\"icon\" role=\"img\" title=\"interax\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#interax\"></use>\\n</svg>\\n</div> Drug & Food Interactions</a><a class=\"dropdown-item\" data-no-turbolink=\"true\" href=\"/structures/search/bonds/sequence\"><div class=\"icon-circle drugbank-icon icon-sequence\"><svg class=\"icon\" role=\"img\" title=\"sequence\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#sequence\"></use>\\n</svg>\\n</div> Target Sequences</a><a class=\"dropdown-item\" data-no-turbolink=\"true\" href=\"/pharmaco/search\"><div class=\"icon-circle drugbank-icon icon-pathways\"><svg class=\"icon\" role=\"img\" title=\"pathways\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#pathways\"></use>\\n</svg>\\n</div> Pharmaco-omics</a><a class=\"dropdown-item\" href=\"/unearth/advanced/drugs\"><div class=\"icon-circle drugbank-icon icon-advanced\"><svg class=\"icon\" role=\"img\" title=\"advanced\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#advanced\"></use>\\n</svg>\\n</div> Advanced Search</a><div class=\"dropdown-divider\"></div><a class=\"dropdown-item\" href=\"/spectra/ms/search\"><div class=\"icon-circle drugbank-icon icon-ms\"><svg class=\"icon\" role=\"img\" title=\"ms\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#ms\"></use>\\n</svg>\\n</div> MS Search</a><a class=\"dropdown-item\" href=\"/spectra/ms_ms/search\"><div class=\"icon-circle drugbank-icon icon-msms\"><svg class=\"icon\" role=\"img\" title=\"msms\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#msms\"></use>\\n</svg>\\n</div> MS/MS Search</a><a class=\"dropdown-item\" href=\"/spectra/c_ms/search\"><div class=\"icon-circle drugbank-icon icon-gcms\"><svg class=\"icon\" role=\"img\" title=\"gcms\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#gcms\"></use>\\n</svg>\\n</div> GC/MS Search</a><a class=\"dropdown-item\" href=\"/spectra/nmr_one_d/search\"><div class=\"icon-circle drugbank-icon icon-nmr-1d\"><svg class=\"icon\" role=\"img\" title=\"nmr-1d\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#nmr-1d\"></use>\\n</svg>\\n</div> 1D NMR Search</a><a class=\"dropdown-item\" href=\"/spectra/nmr_two_d/search\"><div class=\"icon-circle drugbank-icon icon-nmr-2d\"><svg class=\"icon\" role=\"img\" title=\"nmr-2d\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#nmr-2d\"></use>\\n</svg>\\n</div> 2D NMR Search</a></div></li><li class=\"nav-item\"><a class=\"nav-link\" href=\"/drug-interaction-checker\">Interaction Checker</a></li><li class=\"nav-item\"><a class=\"nav-link\" href=\"/releases/latest\">Downloads</a></li><li class=\"nav-item dropdown\" role=\"presentation\"><a class=\"nav-link dropdown-toggle\" data-toggle=\"dropdown\" href=\"#\">Solutions</a><div class=\"dropdown-menu\"><div class=\"link-header dropdown-item\">Products</div><div class=\"link-header dropdown-item blue-header\">Commercial Research</div><a class=\"dropdown-item dropdown-item-last\" target=\"_blank\" href=\"https://www.drugbank.com/datasets\"><div class=\"icon-pink product-icon drugbank-icon icon-scientific\"><svg class=\"icon\" role=\"img\" title=\"scientific\"> <use xlink:href=\"/assets/plus/icons-3af0be760cdb744eb6fd55a4d4e5ddfbe70059f381e99a13dcfb2dd8c487cc4b.svg#scientific\"> </use></svg></div> Drug Datasets</a><div class=\"link-header dropdown-item blue-header\">Academic Research</div><a class=\"dropdown-item dropdown-item-last\" target=\"_blank\" href=\"https://www.drugbank.com/academic_research\"><div class=\"icon-pink product-icon drugbank-icon icon-academic\"><svg class=\"icon\" role=\"img\" title=\"academic\"> <use xlink:href=\"/assets/plus/icons-3af0be760cdb744eb6fd55a4d4e5ddfbe70059f381e99a13dcfb2dd8c487cc4b.svg#academic\"> </use></svg></div> Drug Datasets</a><div class=\"dropdown-divider\"></div><a class=\"dropdown-item dropdown-item-extra-padding\" target=\"_blank\" href=\"https://www.drugbank.com/clinical\"><div class=\"icon-pink product-icon drugbank-icon icon-clinical\"><svg class=\"icon\" role=\"img\" title=\"clinical\"> <use xlink:href=\"/assets/plus/icons-3af0be760cdb744eb6fd55a4d4e5ddfbe70059f381e99a13dcfb2dd8c487cc4b.svg#clinical\"> </use></svg></div> Clinical API</a><div class=\"link-header dropdown-item\">Use Cases</div><a class=\"dropdown-item\" target=\"_blank\" href=\"https://www.drugbank.com/use_cases/ml-drug-discovery-repurposing\">Drug Discovery &amp; Repurposing</a><a class=\"dropdown-item\" target=\"_blank\" href=\"https://www.drugbank.com/use_cases/in-silico-testing\"><i>In Silico </i>Testing</a><a class=\"dropdown-item\" target=\"_blank\" href=\"https://www.drugbank.com/use_cases/precision_medicine\">Precision Medicine</a><a class=\"dropdown-item\" target=\"_blank\" href=\"https://www.drugbank.com/use_cases/telehealth\">Telehealth</a><a class=\"dropdown-item dropdown-item-last\" target=\"_blank\" href=\"https://www.drugbank.com/use_cases/electronic_medical_records\">Electronic Medical Records</a><div class=\"link-header dropdown-item\">Resources</div><a class=\"dropdown-item\" target=\"_blank\" href=\"https://www.drugbank.com/downloads\">White Papers</a></div></li><li class=\"nav-item dropdown\"><a class=\"nav-link dropdown-toggle\" data-toggle=\"dropdown\" href=\"#\">About</a><div class=\"dropdown-menu right-menu\"><div class=\"col-menu\"><div class=\"menu-col\"><div class=\"link-header dropdown-item\"><a target=\"_blank\" href=\"https://dev.drugbank.com/guides/index\"><div class=\" drugbank-icon icon-help_center\"><svg class=\"icon\" role=\"img\" title=\"help_center\"> <use xlink:href=\"/assets/plus/icons-3af0be760cdb744eb6fd55a4d4e5ddfbe70059f381e99a13dcfb2dd8c487cc4b.svg#help_center\"> </use></svg></div> Help Center</a></div><a class=\"dropdown-item\" target=\"_blank\" href=\"https://dev.drugbank.com/guides/drugbank/citing\"><div class=\"icon-circle drugbank-icon icon-citing\"><svg class=\"icon\" role=\"img\" title=\"citing\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#citing\"></use>\\n</svg>\\n</div> Citing DrugBank</a><a class=\"dropdown-item\" target=\"_blank\" href=\"https://dev.drugbank.com/guides/faqs\"><div class=\"icon-circle drugbank-icon icon-faq\"><svg class=\"icon\" role=\"img\" title=\"faq\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#faq\"></use>\\n</svg>\\n</div> DrugBank Online FAQs</a><a class=\"dropdown-item\" target=\"_blank\" href=\"https://dev.drugbank.com/guides/drugbank/searching\"><div class=\"icon-circle drugbank-icon icon-search\"><svg class=\"icon\" role=\"img\" title=\"search\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#search\"></use>\\n</svg>\\n</div> Searching DrugBank</a><a class=\"dropdown-item\" target=\"_blank\" href=\"https://dev.drugbank.com/guides/drugbank/other_databases\"><div class=\"icon-circle drugbank-icon icon-database\"><svg class=\"icon\" role=\"img\" title=\"database\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#database\"></use>\\n</svg>\\n</div> Other Databases</a><a class=\"dropdown-item\" target=\"_blank\" href=\"https://dev.drugbank.com/guides/fields/drugs\"><div class=\"icon-circle drugbank-icon icon-data-sources\"><svg class=\"icon\" role=\"img\" title=\"data-sources\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#data-sources\"></use>\\n</svg>\\n</div> Data Sources</a></div><div class=\"menu-col\"><div class=\"link-header dropdown-item\"><div class=\" drugbank-icon icon-quick_link\"><svg class=\"icon\" role=\"img\" title=\"quick_link\"> <use xlink:href=\"/assets/plus/icons-3af0be760cdb744eb6fd55a4d4e5ddfbe70059f381e99a13dcfb2dd8c487cc4b.svg#quick_link\"> </use></svg></div> About</div><a class=\"dropdown-item\" href=\"/about\"><div class=\"icon-circle drugbank-icon icon-drugbank\"><svg class=\"icon\" role=\"img\" title=\"drugbank\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#drugbank\"></use>\\n</svg>\\n</div> About DrugBank Online</a><a class=\"dropdown-item\" target=\"_blank\" href=\"https://dev.drugbank.com/publications\"><div class=\"icon-circle drugbank-icon icon-search\"><svg class=\"icon\" role=\"img\" title=\"search\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#search\"></use>\\n</svg>\\n</div> DrugBank in Research</a><a class=\"dropdown-item\" href=\"/stats\"><div class=\"icon-circle drugbank-icon icon-statistics\"><svg class=\"icon\" role=\"img\" title=\"statistics\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#statistics\"></use>\\n</svg>\\n</div> Statistics</a><a class=\"dropdown-item\" target=\"_blank\" rel=\"noopener\" href=\"https://blog.drugbank.com/\"><div class=\"icon-circle drugbank-icon icon-news\"><svg class=\"icon\" role=\"img\" title=\"news\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#news\"></use>\\n</svg>\\n</div> Blog</a><a target=\"_blank\" rel=\"noopener\" class=\"dropdown-item\" href=\"http://www.wishartlab.com\"><div class=\"icon-circle drugbank-icon icon-wishart\"><svg class=\"icon\" role=\"img\" title=\"wishart\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#wishart\"></use>\\n</svg>\\n</div> Wishart Research Group</a><a class=\"dropdown-item\" href=\"/contact\"><div class=\"small-icon icon-circle drugbank-icon icon-paper-plane\"><svg class=\"icon\" role=\"img\" title=\"paper-plane\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#paper-plane\"></use>\\n</svg>\\n</div> Contact Us</a></div></div></div></li></ul></div></nav><nav class=\"navbar fixed-top navbar-expand search-bar justify-content-center justify-content-sm-end d-flex\"><div class=\"form-container\"><form class=\"form-inline\" action=\"/unearth/q\" accept-charset=\"UTF-8\" method=\"get\"><div class=\"search-group d-none d-sm-block\" style=\"margin-right: 0.5rem;\"><select name=\"searcher\" id=\"searcher\" class=\"form-control input-md\"><option value=\"drugs\">Drugs</option>\\n<option value=\"bio_entities\">Targets</option>\\n<option value=\"pathways\">Pathways</option>\\n<option value=\"indications\">Indications</option></select> <div class=\"drugbank-icon icon-arrow-down\"><svg class=\"icon\" role=\"img\" title=\"arrow-down\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#arrow-down\"></use>\\n</svg>\\n</div> </div><div class=\"search-group\"><input type=\"text\" name=\"query\" id=\"query\" class=\"search-query\" /> <div class=\"drugbank-icon icon-search\"><svg class=\"icon\" role=\"img\" title=\"search\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#search\"></use>\\n</svg>\\n</div> </div></form></div><div class=\"mini-banner banner-holder\"><a target=\"_blank\" href=\"https://blog.drugbank.com/trends-and-insights-research-highlights-2022-q1-3/\"><div class=\"banner-text\"><span class=\"mr-3\">Find out what <strong>academic researchers have been up to with DrugBank data!</strong></span><span class=\"banner-link\"><span>Read Blog!</span><div class=\"icon-circle drugbank-icon icon-arrow-right\"><svg class=\"icon\" role=\"img\" title=\"arrow-right\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#arrow-right\"></use>\\n</svg>\\n</div></span></div></a><div class=\"close-banner\"><div class=\"drugbank-icon icon-cross\"><svg class=\"icon\" role=\"img\" title=\"cross\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#cross\"></use>\\n</svg>\\n</div></div></div></nav></header><main role=\"main\"><div class=\"content-container\"><div class=\"content-header d-sm-flex align-items-center\"><h1 class=\"align-self-center mr-4\">COVID-19 Dashboard</h1><div class=\"page-actions ml-auto justify-content-sm-end mt-2 mt-sm-0\"><div class=\"bond-links\"><a class=\"covid-link btn btn-pink\" href=\"#drugs\">Drugs (68)</a><a class=\"covid-link btn btn-blue\" href=\"#drug-targets\">Drug Targets (388)</a><a class=\"covid-link btn enzymes\" href=\"#clinical-trials\">Clinical Trials (3376)</a><a class=\"covid-link btn carriers\" href=\"#publications\">Publications (54)</a></div></div></div><div class=\"card-content px-md-4 px-sm-2 pb-md-4 pb-sm-2\"><dl><div class=\"dl-row col-sm-12\"><div class=\"row\"><div class=\"col-md-8 col-sm-12\"><p>In response to the COVID-19 pandemic, the DrugBank team has created this information dashboard to provide a comprehensive summary of research in an effort to help interested parties find the information they need quickly and effectively. If you are interested in licensing DrugBank data for commercial use, <a class=\"track-link\" target=\"_blank\" data-link-id=\"DB-covid-19/contact-1\" href=\"https://www.drugbank.com/contact/sales?utm_campaign=Internal%20Targeted%20Ads&amp;utm_source=DB-covid-19%2Fcontact-1\">please contact us</a>.</p><p><strong>COVID-19 OUTBREAK SUMMARY:</strong> Coronavirus disease 2019\\n(named COVID-19 on February 11, 2020 by the World Health Organization\\n(WHO) <sup class=\"text-reference-group\"><a class=\"reference-popover-link\" data-content=\"World Health Organization: Rolling updates on Coronavirus Disease (COVID-19)\" href=\"#reference-L12912\">1</a>,<a class=\"reference-popover-link\" data-content=\"Centers on Disease Control and Prevention: Coronavirus Disease 2019\" href=\"#reference-L12918\">2</a></sup>) was first identified in Wuhan, China near the end of 2019\\n<sup class=\"text-reference-group\"><a class=\"reference-popover-link\" data-content=\"World Health Organization: Rolling updates on Coronavirus Disease (COVID-19)\" href=\"#reference-L12912\">1</a></sup>. It is caused by the virus known as SARS-CoV-2 (previously called 2019-nCoV).\\nThis name was chosen because the virus is related to the coronavirus that\\ncaused the SARS outbreak of 2003. The two viruses are different despite their\\ngenetic similarity <sup class=\"text-reference-group\"><a class=\"reference-popover-link\" data-content=\"World Health Organization: Naming the coronavirus disease (COVID-19) and the virus that causes it\" href=\"#reference-L12030\">3</a></sup>. COVID-19 is believed to be less lethal but much more\\ninfectious than SARS-CoV <sup class=\"text-reference-group\"><a class=\"reference-popover-link\" data-content=\"World Health Organization: Q&amp;A on coronaviruses (COVID-19)\" href=\"#reference-L12915\">4</a></sup>. Until the recent outbreak, this virus had not\\nbeen identified in humans <sup class=\"text-reference-group\"><a class=\"reference-popover-link\" data-content=\"European Centre for Disease Prevention and Control: COVID-19\" href=\"#reference-L12921\">5</a></sup>.</p><div class=\"alert alert-danger\"><strong>Disclaimer:</strong> This dashboard is intended for research purposes only, and is not to be used for self-diagnosis. If you believe you are experiencing symptoms of COVID-19, please reach out to a medical professional. While we do our best to maintain accuracy and provide up-to-date data and information, we do not guarantee that.</div></div><div class=\"col-md-4 col-sm-12\"><a target=\"_blank\" id=\"covid-scientific-ad\" class=\"track-link\" data-link-id=\"DB-covid-19/drug-dev-1\" href=\"https://www.drugbank.com/scientific?utm_campaign=Internal%20Targeted%20Ads&amp;utm_source=DB-covid-19%2Fdrug-dev-1\"><img src=\"/assets/linkouts/Covid-Drug-Dev-1de6d74d3c70136acdb72e7d4a3883801c1a84d9db7d2c92ba3d8bab052d1080.jpg\" /></a></div></div></div><div class=\"dl-row col-sm-12\"><div class=\"row\"><div class=\"col-md-4 col-sm-12\"><div class=\"d-flex flex-column align-items-start justify-content-center\" id=\"covid-article\"><h5>COVID-19: Finding the Right Fit</h5><p>Identifying Potential Treatments Using a Data-Driven Approach</p><a target=\"_blank\" class=\"btn btn-sm btn-pink-filled track-link\" data-link-id=\"DB-covid-19/Covid-2/1\" href=\"https://blog.drugbank.com/data-driven-approaches-to-identify-potential-covid-19-therapies/?utm_campaign=Internal%20Targeted%20Ads&amp;utm_source=DB-covid-19%2FCovid-2%2F1\">Download the White Paper</a></div></div><div class=\"col-md-4 col-sm-12\"><table class=\"table table-sm link-table\"><thead><tr><th colspan=\"2\">Important Information Sources</th></tr></thead><tbody><tr><td><a target=\"_blank\" href=\"https://covid19.who.int\"><img src=\"/assets/pages/WHO@2x-19611b70a5a6b542b29985751b1136fc263b4e4cbe183b5e2ce246509ebd1727.png\" /></a></td><td><a target=\"_blank\" href=\"https://covid19.who.int\">WHO COVID-19 Dashboard</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19.html\"><img src=\"/assets/pages/HealthCanada@2x-79808f89017413e08dbe127228b094c913cd00df3136ef3138a8bee91536d18a.png\" /></a></td><td><a target=\"_blank\" href=\"https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19.html\">Health Canada COVID-19 Dashboard</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.cdc.gov/coronavirus/2019-ncov/index.html\"><img src=\"/assets/pages/CDC@2x-50fc14ba51e5fdd96698852e0f2039b6b18091a2af684d4dd61f7149a445dc9c.png\" /></a></td><td><a target=\"_blank\" href=\"https://www.cdc.gov/coronavirus/2019-ncov/index.html\">CDC COVID-19 Dashboard</a></td></tr></tbody></table></div><div class=\"col-md-4 col-sm-12\"><table class=\"table table-sm link-table\"><thead><tr><th>Dataset, Visualization, and Research Tools</th></tr></thead><tbody><tr><td><a target=\"_blank\" href=\"https://pages.semanticscholar.org/coronavirus-research\">COVID-19 Open Research Dataset (CORD-19)</a></td></tr><tr><td><a target=\"_blank\" href=\"https://covidmapper.ca/geomap/\">COVIDmapper</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.rcsb.org/news?year=2020&amp;article=5e74d55d2d410731e9944f52&amp;feature=true\">Protein Data Bank COVID-19 Resources</a></td></tr><tr><td><a target=\"_blank\" href=\"https://go.drugbank.com/releases/latest\">DrugBank Datasets</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.research.ibm.com/covid19/deep-search/\">IBM Deep Search</a></td></tr></tbody></table></div></div></div><dt class=\"col-xl-2 col-md-3 col-sm-4\" id=\"experimental-unapproved-treatments-for-covid-19\">Experimental Unapproved Treatments for COVID-19</dt><dd class=\"col-xl-10 col-md-9 col-sm-8\"><div class=\"anchor\" id=\"drugs\" style=\"top: calc(-56px - 1rem);\"></div><table class=\"table table-sm datatable dt-responsive\" style=\"width: 100%\"><thead><tr><th class=\"drug-head\">Drug</th><th class=\"description-head\">Description</th></tr></thead><tbody><tr><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An HIV protease inhibitor used in combination with other antivirals in the treatment of HIV infection.</td></tr><tr><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An antimalarial drug used to treat susceptible infections with P. vivax, P. malariae, P. ovale, and P. falciparum. It is also used for second line treatment for rheumatoid arthritis.</td></tr><tr><td><strong><a href=\"/drugs/DB01264\">Darunavir</a></strong></td><td>A HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection in patients with history of prior antiretroviral therapies.</td></tr><tr><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An HIV-1 protease inhibitor used in combination with ritonavir to treat human immunodeficiency virus (HIV) infection.</td></tr><tr><td><strong><a href=\"/drugs/DB11676\">Galidesivir</a></strong></td><td>Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various...</td></tr><tr><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>An antiviral used to manage influenza, and that has the potential to target other viral infections.</td></tr><tr><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>A dual direct-acting antiviral/host-targeting agent used in the treatment and prophylaxis of influenza and other respiratory viruses.</td></tr><tr><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td>A polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS).</td></tr><tr><td><strong><a href=\"/drugs/DB15622\">Triazavirin</a></strong></td><td>An antiviral used to treat several strains of influenza.</td></tr><tr><td><strong><a href=\"/drugs/DB15623\">TMC-310911</a></strong></td><td>TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections....</td></tr><tr><td><strong><a href=\"/drugs/DB15654\">Moderna COVID-19 Vaccine</a></strong></td><td>An mRNA vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, in patients aged 18 years and older.</td></tr><tr><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute...</td></tr><tr><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A two-dose replication-deficient adenovirus vector vaccine used to prevent COVID-19 caused by SARS-CoV-2.</td></tr><tr><td><strong><a href=\"/drugs/DB08868\">Fingolimod</a></strong></td><td>A sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19.</td></tr><tr><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>A corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases.</td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td>A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.</td></tr><tr><td><strong><a href=\"/drugs/DB05941\">Leronlimab</a></strong></td><td>A humanized monoclonal antibody being investigated</td></tr><tr><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A macrolide antibiotic used to treat a variety of bacterial infections.</td></tr><tr><td><strong><a href=\"/drugs/DB15660\">N4-Hydroxycytidine</a></strong></td><td>A cytidine analog being investigated to treat COVID-19.</td></tr><tr><td><strong><a href=\"/drugs/DB15661\">Molnupiravir</a></strong></td><td>An orally bioavailable isopropylester cytidine analog used to treat COVID-19.</td></tr><tr><td><strong><a href=\"/drugs/DB11574\">Elbasvir</a></strong></td><td>An antiviral and NS5A inhibitor used to treat hepatitis C infections.</td></tr><tr><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).</td></tr><tr><td><strong><a href=\"/drugs/DB15686\">GS-441524</a></strong></td><td>An experimental nucleoside analog antiviral investigated for its use in the treatment of Ebola and SARS-CoV-2 infections.</td></tr><tr><td><strong><a href=\"/drugs/DB15687\">Tridecactide</a></strong></td><td>An investigational modified alpha melanocyte stimulating hormone being studied for the treatment of COVID-19.</td></tr><tr><td><strong><a href=\"/drugs/DB12668\">Metenkefalin</a></strong></td><td>An investigational endogenous opioid being studied for the treatment of COVID-19.</td></tr><tr><td><strong><a href=\"/drugs/DB15688\">Vazegepant</a></strong></td><td>Vazegepant is an antagonist of the calcitonin gene-related peptide (CGRP) receptor currently in phase 3 trials in an intranasal formulation for the treatment of migraine. If FDA approved, it will...</td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td>An NSAID and non-selective COX inhibitor used to treat mild-moderate pain, fever, and inflammation.</td></tr><tr><td><strong><a href=\"/drugs/DB15691\">Anti-SARS-CoV-2 REGN-COV2</a></strong></td><td>Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of...</td></tr><tr><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>A glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders.</td></tr><tr><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>COVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2. This investigational COVID-19 treatment is...</td></tr><tr><td><strong><a href=\"/drugs/DB15693\">INO-4800</a></strong></td><td>INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that...</td></tr><tr><td><strong><a href=\"/drugs/DB15695\">BNT162b1 SARS-CoV-2 Vaccine</a></strong></td><td>BNT162b1 is one of four advanced mRNA-based vaccines being developed through &quot;Project Lightspeed,&quot; a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding...</td></tr><tr><td><strong><a href=\"/drugs/DB15697\">BNT162a1 SARS-CoV-2 Vaccine</a></strong></td><td>BNT162a1 is one of four advanced mRNA-based vaccines being developed through &quot;Project Lightspeed,&quot; a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in...</td></tr><tr><td><strong><a href=\"/drugs/DB15698\">BNT162c2 SARS-CoV-2 Vaccine</a></strong></td><td>BNT162c2 is one of four advanced mRNA-based vaccines being developed through &quot;Project Lightspeed,&quot; a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in...</td></tr><tr><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>An alkaloid used in the symptomatic relief of pain in attacks of gout and to treat the inflammatory symptoms of Familial Mediterranean Fever (FMF).</td></tr><tr><td><strong><a href=\"/drugs/DB15718\">Bamlanivimab</a></strong></td><td>A neutralizing human IgG1\\xce\\xba monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19.</td></tr><tr><td><strong><a href=\"/drugs/DB15787\">AZD7442</a></strong></td><td>AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the...</td></tr><tr><td><strong><a href=\"/drugs/DB15796\">GC-376 free acid</a></strong></td><td>GC-376 is a 3C-like protease (3CLpro or Mpro) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells . The compound...</td></tr><tr><td><strong><a href=\"/drugs/DB15797\">GC-373</a></strong></td><td>GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, GC-376 free acid[A219031,A219036]. It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease that...</td></tr><tr><td><strong><a href=\"/drugs/DB08954\">Ifenprodil</a></strong></td><td>N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer...</td></tr><tr><td><strong><a href=\"/drugs/DB15327\">Abivertinib</a></strong></td><td>Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton&#39;s tyrosine kinase (BTK). It has been investigated for use in...</td></tr><tr><td><strong><a href=\"/drugs/DB15897\">Etesevimab</a></strong></td><td>Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral...</td></tr><tr><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>A Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist.</td></tr><tr><td><strong><a href=\"/drugs/DB16406\">Subasumstat</a></strong></td><td>Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid...</td></tr><tr><td><strong><a href=\"/drugs/DB15736\">Alunacedase alfa</a></strong></td><td>Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.</td></tr><tr><td><strong><a href=\"/drugs/DB16389\">Zansecimab</a></strong></td><td>Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).</td></tr><tr><td><strong><a href=\"/drugs/DB16396\">Goflikicept</a></strong></td><td>Goflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe...</td></tr><tr><td><strong><a href=\"/drugs/DB16407\">Azvudine</a></strong></td><td>Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).</td></tr><tr><td><strong><a href=\"/drugs/DB12592\">Mosedipimod</a></strong></td><td>Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.</td></tr><tr><td><strong><a href=\"/drugs/DB16447\">Thymoquinone</a></strong></td><td>Thymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.</td></tr><tr><td><strong><a href=\"/drugs/DB16448\">CD24Fc</a></strong></td><td>CD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.</td></tr><tr><td><strong><a href=\"/drugs/DB16449\">Tin protoporphyrin IX</a></strong></td><td><span class=\\'not-available\\'>Not Available</span></td></tr><tr><td><strong><a href=\"/drugs/DB16450\">Rexin G</a></strong></td><td>Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer....</td></tr><tr><td><strong><a href=\"/drugs/DB16451\">AT-527</a></strong></td><td><span class=\\'not-available\\'>Not Available</span></td></tr><tr><td><strong><a href=\"/drugs/DB16465\">Meplazumab</a></strong></td><td>Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.</td></tr><tr><td><strong><a href=\"/drugs/DB16495\">Oleic monoethanolamide</a></strong></td><td><span class=\\'not-available\\'>Not Available</span></td></tr><tr><td><strong><a href=\"/drugs/DB16452\">MAS825</a></strong></td><td><span class=\\'not-available\\'>Not Available</span></td></tr><tr><td><strong><a href=\"/drugs/DB16453\">ATYR1923</a></strong></td><td>ATYR1923 is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2...</td></tr><tr><td><strong><a href=\"/drugs/DB16474\">Pam2csk4</a></strong></td><td><span class=\\'not-available\\'>Not Available</span></td></tr><tr><td><strong><a href=\"/drugs/DB16476\">Carrimycin</a></strong></td><td><span class=\\'not-available\\'>Not Available</span></td></tr><tr><td><strong><a href=\"/drugs/DB16479\">Inbakicept</a></strong></td><td><span class=\\'not-available\\'>Not Available</span></td></tr><tr><td><strong><a href=\"/drugs/DB16514\">PF-07304814</a></strong></td><td>PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the...</td></tr><tr><td><strong><a href=\"/drugs/DB16691\">Nirmatrelvir</a></strong></td><td>An oral protease inhibitor with emergency use authorization for the treatment of mild-to-moderate COVID-19.</td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td>A spleen tyrosine kinase inhibitor used to treat chronic immune thrombocytopenia after attempting one other treatment.</td></tr><tr><td><strong><a href=\"/drugs/DB16355\">Sotrovimab</a></strong></td><td>A monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization.</td></tr><tr><td><strong><a href=\"/drugs/DB16737\">MM3122</a></strong></td><td><span class=\\'not-available\\'>Not Annotated</span></td></tr><tr><td><strong><a href=\"/drugs/DB16393\">Cilgavimab</a></strong></td><td>An extended half-life recombinant monoclonal IgG1\\xce\\xba antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.</td></tr><tr><td><strong><a href=\"/drugs/DB16394\">Tixagevimab</a></strong></td><td>An extended half-life recombinant monoclonal IgG1\\xce\\xba antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.</td></tr></tbody></table></dd><dt class=\"col-xl-2 col-md-3 col-sm-4\" id=\"potential-drug-targets\">Potential Drug Targets</dt><dd class=\"col-xl-10 col-md-9 col-sm-8\"><div class=\"anchor\" id=\"drug-targets\"></div><table class=\"table table-sm datatable dt-responsive\" style=\"width: 100%\"><thead><tr><th class=\"drug-head\">Drug</th><th class=\"target-head\">Target</th></tr></thead><tbody><tr><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td><a href=\"/bio_entities/BE0004854\">Human immunodeficiency virus type 1 protease</a></td></tr><tr><td><strong><a href=\"/drugs/DB01264\">Darunavir</a></strong></td><td><a href=\"/bio_entities/BE0004854\">Human immunodeficiency virus type 1 protease</a></td></tr><tr><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td><a href=\"/bio_entities/BE0004854\">Human immunodeficiency virus type 1 protease</a></td></tr><tr><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td><a href=\"/bio_entities/BE0000794\">Glucocorticoid receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB05941\">Leronlimab</a></strong></td><td><a href=\"/bio_entities/BE0000911\">C-C chemokine receptor type 5</a></td></tr><tr><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td><a href=\"/bio_entities/BE0002859\">Interleukin-6 receptor subunit alpha</a></td></tr><tr><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td><a href=\"/bio_entities/BE0000143\">Tubulin beta chain</a></td></tr><tr><td><strong><a href=\"/drugs/DB11676\">Galidesivir</a></strong></td><td><a href=\"/bio_entities/BE0009862\">RNA-directed RNA polymerase L</a></td></tr><tr><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td><a href=\"/bio_entities/BE0009866\">RNA-directed RNA polymerase catalytic subunit</a></td></tr><tr><td><strong><a href=\"/drugs/DB15623\">TMC-310911</a></strong></td><td><a href=\"/bio_entities/BE0000664\">HIV-1 protease</a></td></tr><tr><td><strong><a href=\"/drugs/DB08868\">Fingolimod</a></strong></td><td><a href=\"/bio_entities/BE0002432\">Sphingosine 1-phosphate receptor 5</a></td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td><a href=\"/bio_entities/BE0000163\">Vascular endothelial growth factor A</a></td></tr><tr><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td><a href=\"/bio_entities/BE0004800\">23S ribosomal RNA</a></td></tr><tr><td><strong><a href=\"/drugs/DB11574\">Elbasvir</a></strong></td><td><a href=\"/bio_entities/BE0008651\">Nonstructural protein 5A</a></td></tr><tr><td><strong><a href=\"/drugs/DB15686\">GS-441524</a></strong></td><td><a href=\"/bio_entities/BE0003801\">Replicase polyprotein 1ab</a></td></tr><tr><td><strong><a href=\"/drugs/DB15688\">Vazegepant</a></strong></td><td><a href=\"/bio_entities/BE0009009\">Calcitonin gene-related peptide type 1 receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0000262\">Prostaglandin G/H synthase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB15691\">Anti-SARS-CoV-2 REGN-COV2</a></strong></td><td><a href=\"/bio_entities/BE0010022\">Spike glycoprotein</a></td></tr><tr><td><strong><a href=\"/drugs/DB15718\">Bamlanivimab</a></strong></td><td><a href=\"/bio_entities/BE0010022\">Spike glycoprotein</a></td></tr><tr><td><strong><a href=\"/drugs/DB15796\">GC-376 free acid</a></strong></td><td><a href=\"/bio_entities/BE0010016\">Replicase polyprotein 1ab</a></td></tr><tr><td><strong><a href=\"/drugs/DB15797\">GC-373</a></strong></td><td><a href=\"/bio_entities/BE0010016\">Replicase polyprotein 1ab</a></td></tr><tr><td><strong><a href=\"/drugs/DB08954\">Ifenprodil</a></strong></td><td><a href=\"/bio_entities/BE0000417\">Glutamate receptor ionotropic, NMDA 2B</a></td></tr><tr><td><strong><a href=\"/drugs/DB15327\">Abivertinib</a></strong></td><td><a href=\"/bio_entities/BE0000767\">Epidermal growth factor receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB15897\">Etesevimab</a></strong></td><td><a href=\"/bio_entities/BE0010022\">Spike glycoprotein</a></td></tr><tr><td><strong><a href=\"/drugs/DB16453\">ATYR1923</a></strong></td><td><a href=\"/bio_entities/BE0010030\">Neuropilin-2</a></td></tr><tr><td><strong><a href=\"/drugs/DB16514\">PF-07304814</a></strong></td><td><a href=\"/bio_entities/BE0010016\">Replicase polyprotein 1ab</a></td></tr><tr><td><strong><a href=\"/drugs/DB16691\">Nirmatrelvir</a></strong></td><td><a href=\"/bio_entities/BE0010016\">Replicase polyprotein 1ab</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001316\">Tyrosine-protein kinase SYK</a></td></tr><tr><td><strong><a href=\"/drugs/DB16355\">Sotrovimab</a></strong></td><td><a href=\"/bio_entities/BE0010022\">Spike glycoprotein</a></td></tr><tr><td><strong><a href=\"/drugs/DB16737\">MM3122</a></strong></td><td><a href=\"/bio_entities/BE0009920\">Transmembrane protease serine 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB16393\">Cilgavimab</a></strong></td><td><a href=\"/bio_entities/BE0010022\">Spike glycoprotein</a></td></tr><tr><td><strong><a href=\"/drugs/DB16394\">Tixagevimab</a></strong></td><td><a href=\"/bio_entities/BE0010022\">Spike glycoprotein</a></td></tr><tr><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td><a href=\"/bio_entities/BE0000704\">Tumor necrosis factor</a></td></tr><tr><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td><a href=\"/bio_entities/BE0002189\">Glutathione S-transferase A2</a></td></tr><tr><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td><a href=\"/bio_entities/BE0000661\">Interferon alpha/beta receptor 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td><a href=\"/bio_entities/BE0002094\">Complement C1q subcomponent subunit A</a></td></tr><tr><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td><a href=\"/bio_entities/BE0001092\">Protein-arginine deiminase type-4</a></td></tr><tr><td><strong><a href=\"/drugs/DB15686\">GS-441524</a></strong></td><td><a href=\"/bio_entities/BE0009862\">RNA-directed RNA polymerase L</a></td></tr><tr><td><strong><a href=\"/drugs/DB12668\">Metenkefalin</a></strong></td><td><a href=\"/bio_entities/BE0000420\">Delta-type opioid receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0000017\">Prostaglandin G/H synthase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB15796\">GC-376 free acid</a></strong></td><td><a href=\"/bio_entities/BE0010017\">Replicase polyprotein 1a</a></td></tr><tr><td><strong><a href=\"/drugs/DB15797\">GC-373</a></strong></td><td><a href=\"/bio_entities/BE0010017\">Replicase polyprotein 1a</a></td></tr><tr><td><strong><a href=\"/drugs/DB08954\">Ifenprodil</a></strong></td><td><a href=\"/bio_entities/BE0000365\">Glutamate receptor ionotropic, NMDA 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB15327\">Abivertinib</a></strong></td><td><a href=\"/bio_entities/BE0001284\">Tyrosine-protein kinase BTK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000354\">Adenosine receptor A3</a></td></tr><tr><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td><a href=\"/bio_entities/BE0001171\">Toll-like receptor 9</a></td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td><a href=\"/bio_entities/BE0002095\">Complement C1q subcomponent subunit B</a></td></tr><tr><td><strong><a href=\"/drugs/DB12668\">Metenkefalin</a></strong></td><td><a href=\"/bio_entities/BE0000770\">Mu-type opioid receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB15796\">GC-376 free acid</a></strong></td><td><a href=\"/bio_entities/BE0010018\">Replicase polyprotein 1ab</a></td></tr><tr><td><strong><a href=\"/drugs/DB15797\">GC-373</a></strong></td><td><a href=\"/bio_entities/BE0010018\">Replicase polyprotein 1ab</a></td></tr><tr><td><strong><a href=\"/drugs/DB08954\">Ifenprodil</a></strong></td><td><a href=\"/bio_entities/BE0001028\">G protein-activated inward rectifier potassium channel 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0008661\">vesicular monoamine transporter 2 (VMAT2)</a></td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td><a href=\"/bio_entities/BE0002096\">Complement C1q subcomponent subunit C</a></td></tr><tr><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td><a href=\"/bio_entities/BE0000794\">Glucocorticoid receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB15796\">GC-376 free acid</a></strong></td><td><a href=\"/bio_entities/BE0010020\">Replicase polyprotein 1a</a></td></tr><tr><td><strong><a href=\"/drugs/DB15797\">GC-373</a></strong></td><td><a href=\"/bio_entities/BE0010019\">Replicase polyprotein 1ab</a></td></tr><tr><td><strong><a href=\"/drugs/DB08954\">Ifenprodil</a></strong></td><td><a href=\"/bio_entities/BE0001030\">G protein-activated inward rectifier potassium channel 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002194\">Fatty-acid amide hydrolase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td><a href=\"/bio_entities/BE0002659\">Glutathione S-transferase</a></td></tr><tr><td><strong><a href=\"/drugs/DB08868\">Fingolimod</a></strong></td><td><a href=\"/bio_entities/BE0002365\">Histone deacetylase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td><a href=\"/bio_entities/BE0002097\">Low affinity immunoglobulin gamma Fc region receptor III-A</a></td></tr><tr><td><strong><a href=\"/drugs/DB15796\">GC-376 free acid</a></strong></td><td><a href=\"/bio_entities/BE0010019\">Replicase polyprotein 1ab</a></td></tr><tr><td><strong><a href=\"/drugs/DB15797\">GC-373</a></strong></td><td><a href=\"/bio_entities/BE0010020\">Replicase polyprotein 1a</a></td></tr><tr><td><strong><a href=\"/drugs/DB08954\">Ifenprodil</a></strong></td><td><a href=\"/bio_entities/BE0002218\">G protein-activated inward rectifier potassium channel 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td><a href=\"/bio_entities/BE0004145\">Tyrosine-protein kinase JAK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001204\">Equilibrative nucleoside transporter 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td><a href=\"/bio_entities/BE0000710\">High affinity immunoglobulin gamma Fc receptor I</a></td></tr><tr><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td><a href=\"/bio_entities/BE0002408\">Tyrosine-protein kinase JAK2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003541\">UDP-glucuronosyltransferase 1-1</a></td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td><a href=\"/bio_entities/BE0002098\">Low affinity immunoglobulin gamma Fc region receptor II-a</a></td></tr><tr><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td><a href=\"/bio_entities/BE0000074\">Nuclear receptor subfamily 0 group B member 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td><a href=\"/bio_entities/BE0000422\">Annexin A1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000182\">cGMP-specific 3&#39;,5&#39;-cyclic phosphodiesterase</a></td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td><a href=\"/bio_entities/BE0002099\">Low affinity immunoglobulin gamma Fc region receptor II-b</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0000246\">Apoptosis regulator Bcl-2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000248\">Arachidonate 5-lipoxygenase</a></td></tr><tr><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td><a href=\"/bio_entities/BE0003428\">High mobility group protein B1</a></td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td><a href=\"/bio_entities/BE0002100\">Low affinity immunoglobulin gamma Fc region receptor II-c</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0001151\">Thrombomodulin</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001646\">Cathepsin S</a></td></tr><tr><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td><a href=\"/bio_entities/BE0000807\">Glutathione S-transferase Mu 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB08868\">Fingolimod</a></strong></td><td><a href=\"/bio_entities/BE0008652\">Sphingosine 1-phosphate receptor 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0003591\">Fatty acid-binding protein, intestinal</a></td></tr><tr><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td><a href=\"/bio_entities/BE0000871\">Protein-tyrosine kinase 2-beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002135\">Cathepsin L1</a></td></tr><tr><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td><a href=\"/bio_entities/BE0000982\">Angiotensin-converting enzyme 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB08868\">Fingolimod</a></strong></td><td><a href=\"/bio_entities/BE0009882\">Sphingosine 1-phosphate receptor 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td><a href=\"/bio_entities/BE0000422\">Annexin A1</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0000215\">Peroxisome proliferator-activated receptor gamma</a></td></tr><tr><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td><a href=\"/bio_entities/BE0003493\">Tyrosine-protein kinase JAK3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000014\">Tyrosine-protein kinase ABL1</a></td></tr><tr><td><strong><a href=\"/drugs/DB08868\">Fingolimod</a></strong></td><td><a href=\"/bio_entities/BE0009881\">Sphingosine 1-phosphate receptor 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0001195\">Cystic fibrosis transmembrane conductance regulator</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009379\">Calcium-dependent protein kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0000071\">Peroxisome proliferator-activated receptor alpha</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001580\">Serine/threonine-protein kinase PknB</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0001025\">Platelet glycoprotein Ib alpha chain</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009380\">Ribosomal protein S6 kinase alpha-6</a></td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td><a href=\"/bio_entities/BE0003756\">Protein S100-A7</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004146\">Non-receptor tyrosine-protein kinase TYK2</a></td></tr><tr><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td><a href=\"/bio_entities/BE0000956\">Nuclear receptor subfamily 1 group I member 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009381\">Atypical kinase COQ8A, mitochondrial</a></td></tr><tr><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td><a href=\"/bio_entities/BE0000005\">Nitric oxide synthase, inducible</a></td></tr><tr><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td><a href=\"/bio_entities/BE0000956\">Nuclear receptor subfamily 1 group I member 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004145\">Tyrosine-protein kinase JAK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000915\">Hepatocyte growth factor receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009382\">Serine/threonine-protein kinase NIM1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004109\">Serine/threonine-protein kinase MST4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003761\">cAMP-dependent protein kinase catalytic subunit alpha</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009383\">Serine/threonine-protein kinase 24</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009384\">Serine/threonine-protein kinase 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009385\">Tyrosine-protein kinase Tec</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009386\">Serine/threonine-protein kinase 33</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009387\">Serine/threonine-protein kinase 35</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009388\">Serine/threonine-protein kinase 36</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009389\">Serine/threonine-protein kinase 38</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009390\">Serine/threonine-protein kinase 38-like</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009391\">STE20/SPS1-related proline-alanine-rich protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009392\">Serine/threonine-protein kinase TAO1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004632\">Serine/threonine-protein kinase TAO2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009393\">Serine/threonine-protein kinase TAO3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009394\">Serine/threonine-protein kinase TBK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003379\">Angiopoietin-1 receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009395\">Dual specificity testis-specific protein kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003782\">TGF-beta receptor type-1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001861\">TGF-beta receptor type-2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009396\">Tyrosine-protein kinase receptor Tie-1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009397\">Serine/threonine-protein kinase tousled-like 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009398\">Serine/threonine-protein kinase tousled-like 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009399\">TRAF2 and NCK-interacting protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009400\">Non-receptor tyrosine-protein kinase TNK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000772\">Activated CDC42 kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009401\">Serine/threonine-protein kinase TNNI3K</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009402\">Testis-specific serine/threonine-protein kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003791\">Dual specificity protein kinase TTK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009403\">Tyrosine-protein kinase TXK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009404\">Tyrosine-protein kinase receptor TYRO3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009405\">Serine/threonine-protein kinase ULK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009406\">Serine/threonine-protein kinase ULK2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009407\">Serine/threonine-protein kinase ULK3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003335\">Wee1-like protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000840\">Tyrosine-protein kinase Yes</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009408\">Mitogen-activated protein kinase kinase kinase 19</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0005595\">Mitogen-activated protein kinase kinase kinase MLT</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001312\">Tyrosine-protein kinase ZAP-70</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009409\">AP2-associated protein kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000435\">Abelson tyrosine-protein kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000264\">Activin receptor type-1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000665\">Activin receptor type-1B</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009410\">Atypical kinase COQ8B, mitochondrial</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000359\">ALK tyrosine kinase receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009411\">Ankyrin repeat and protein kinase domain-containing protein 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000991\">Aurora kinase A</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003404\">Aurora kinase B</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004601\">Aurora kinase C</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009412\">Tyrosine-protein kinase receptor UFO</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009413\">Tyrosine-protein kinase Blk</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009414\">BMP-2-inducible protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009415\">Bone morphogenetic protein receptor type-1B</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009324\">Bone morphogenetic protein receptor type-2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009416\">Cytoplasmic tyrosine-protein kinase BMX</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000634\">Serine/threonine-protein kinase B-raf</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001284\">Tyrosine-protein kinase BTK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009417\">Calcium/calmodulin-dependent protein kinase type 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004324\">Calcium/calmodulin-dependent protein kinase type 1D</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004147\">Calcium/calmodulin-dependent protein kinase type 1G</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004076\">Calcium/calmodulin-dependent protein kinase type II subunit alpha</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003792\">Calcium/calmodulin-dependent protein kinase type II subunit beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004108\">Calcium/calmodulin-dependent protein kinase type II subunit delta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004384\">Calcium/calmodulin-dependent protein kinase type II subunit gamma</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009418\">Calcium/calmodulin-dependent protein kinase kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009419\">Calcium/calmodulin-dependent protein kinase kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002641\">Peripheral plasma membrane protein CASK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009420\">Kappa-casein</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001082\">Cyclin-dependent kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009421\">Serine/threonine-protein kinase MRCK gamma</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002216\">Cyclin-dependent kinase 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009422\">Cyclin-dependent kinase-like 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009423\">Cyclin-dependent kinase-like 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003382\">Serine/threonine-protein kinase Chk1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003381\">Serine/threonine-protein kinase Chk2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009424\">Citron Rho-interacting kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001824\">Dual specificity protein kinase CLK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009425\">Dual specificity protein kinase CLK2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004043\">Dual specificity protein kinase CLK3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009426\">Dual specificity protein kinase CLK4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000853\">Macrophage colony-stimulating factor 1 receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001356\">Tyrosine-protein kinase CSK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009427\">Casein kinase I isoform alpha</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001209\">Casein kinase II subunit alpha</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003984\">Casein kinase II subunit alpha&#39;</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001776\">Death-associated protein kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009428\">Death-associated protein kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003788\">Death-associated protein kinase 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009429\">Serine/threonine-protein kinase DCLK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009430\">Serine/threonine-protein kinase DCLK2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009431\">Serine/threonine-protein kinase DCLK3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001124\">Epithelial discoidin domain-containing receptor 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004741\">Discoidin domain-containing receptor 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004012\">Dual specificity tyrosine-phosphorylation-regulated kinase 1A</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009432\">Dual specificity tyrosine-phosphorylation-regulated kinase 1B</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000767\">Epidermal growth factor receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009433\">Eukaryotic translation initiation factor 2-alpha kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009434\">Interferon-induced, double-stranded RNA-activated protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009435\">eIF-2-alpha kinase GCN2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009436\">Ephrin type-A receptor 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000841\">Ephrin type-A receptor 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009437\">Ephrin type-A receptor 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009438\">Ephrin type-A receptor 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0005587\">Ephrin type-A receptor 5</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009439\">Ephrin type-A receptor 6</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004140\">Ephrin type-A receptor 7</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009440\">Ephrin type-A receptor 8</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009441\">Ephrin type-B receptor 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004549\">Ephrin type-B receptor 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002453\">Ephrin type-B receptor 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009442\">Ephrin type-B receptor 6</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000511\">Receptor tyrosine-protein kinase erbB-2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004772\">Receptor tyrosine-protein kinase erbB-4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003839\">Serine/threonine-protein kinase/endoribonuclease IRE1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009443\">Tyrosine-protein kinase Fer</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009444\">Tyrosine-protein kinase Fes/Fps</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002131\">Fibroblast growth factor receptor 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000748\">Fibroblast growth factor receptor 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002133\">Fibroblast growth factor receptor 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0005539\">Tyrosine-protein kinase Fgr</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000029\">Vascular endothelial growth factor receptor 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000147\">Receptor-type tyrosine-protein kinase FLT3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000023\">Vascular endothelial growth factor receptor 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002386\">Serine/threonine-protein kinase mTOR</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004742\">Tyrosine-protein kinase FRK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000839\">Tyrosine-protein kinase Fyn</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009445\">Cyclin-G-associated kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009446\">Glycogen synthase kinase-3 alpha</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001065\">Glycogen synthase kinase-3 beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001424\">Tyrosine-protein kinase HCK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009447\">Homeodomain-interacting protein kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009448\">Homeodomain-interacting protein kinase 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009449\">Serine/threonine-protein kinase ICK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001154\">Inhibitor of nuclear factor kappa-B kinase subunit beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009450\">Inhibitor of nuclear factor kappa-B kinase subunit epsilon</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000033\">Insulin receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009451\">Insulin receptor-related protein</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009452\">Interleukin-1 receptor-associated kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009453\">Interleukin-1 receptor-associated kinase 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004344\">Interleukin-1 receptor-associated kinase 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001341\">Tyrosine-protein kinase ITK/TSK</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002408\">Tyrosine-protein kinase JAK2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003493\">Tyrosine-protein kinase JAK3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000369\">Vascular endothelial growth factor receptor 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009454\">Serine/threonine-protein kinase SIK3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000453\">Mast/stem cell growth factor receptor Kit</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009455\">Serine/threonine-protein kinase LATS1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000842\">Tyrosine-protein kinase Lck</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004759\">LIM domain kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009456\">LIM domain kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009457\">Leucine-rich repeat serine/threonine-protein kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009458\">Leukocyte tyrosine kinase receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004315\">Tyrosine-protein kinase Lyn</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004744\">Dual specificity mitogen-activated protein kinase kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009459\">Dual specificity mitogen-activated protein kinase kinase 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009460\">Dual specificity mitogen-activated protein kinase kinase 5</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009461\">Dual specificity mitogen-activated protein kinase kinase 6</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003430\">Mitogen-activated protein kinase kinase kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009462\">Mitogen-activated protein kinase kinase kinase 10</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009463\">Mitogen-activated protein kinase kinase kinase 11</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009464\">Mitogen-activated protein kinase kinase kinase 12</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009465\">Mitogen-activated protein kinase kinase kinase 13</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009466\">Mitogen-activated protein kinase kinase kinase 15</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004745\">Mitogen-activated protein kinase kinase kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009467\">Mitogen-activated protein kinase kinase kinase 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009468\">Mitogen-activated protein kinase kinase kinase 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009469\">Mitogen-activated protein kinase kinase kinase 6</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004386\">Mitogen-activated protein kinase kinase kinase 9</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009470\">Mitogen-activated protein kinase kinase kinase kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009471\">Mitogen-activated protein kinase kinase kinase kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009472\">Mitogen-activated protein kinase kinase kinase kinase 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009473\">Mitogen-activated protein kinase kinase kinase kinase 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009474\">Mitogen-activated protein kinase kinase kinase kinase 5</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001097\">Mitogen-activated protein kinase 10</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003391\">Mitogen-activated protein kinase 13</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001019\">Mitogen-activated protein kinase 14</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009475\">Mitogen-activated protein kinase 15</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009476\">Mitogen-activated protein kinase 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009477\">Mitogen-activated protein kinase 7</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003772\">Mitogen-activated protein kinase 9</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009478\">MAP kinase-activated protein kinase 5</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009479\">Serine/threonine-protein kinase MARK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009480\">Serine/threonine-protein kinase MARK2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009481\">MAP/microtubule affinity-regulating kinase 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009482\">MAP/microtubule affinity-regulating kinase 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009483\">CLIP-associating protein 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009484\">Microtubule-associated serine/threonine-protein kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009485\">Megakaryocyte-associated tyrosine-protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009486\">Maternal embryonic leucine zipper kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004271\">Tyrosine-protein kinase Mer</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009487\">Misshapen-like kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009488\">MAP kinase-interacting serine/threonine-protein kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009489\">MAP kinase-interacting serine/threonine-protein kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009490\">Macrophage-stimulating protein receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009491\">Muscle, skeletal receptor tyrosine-protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009492\">Myosin light chain kinase, smooth muscle</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004946\">Myosin light chain kinase 2, skeletal/cardiac muscle</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009493\">Myosin light chain kinase 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009494\">Myosin light chain kinase family member 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009495\">Myosin-IIIa</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009496\">Serine/threonine-protein kinase Nek1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004758\">Serine/threonine-protein kinase Nek11</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003796\">Serine/threonine-protein kinase Nek2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009497\">Serine/threonine-protein kinase Nek3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009498\">Serine/threonine-protein kinase Nek4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009499\">Serine/threonine-protein kinase Nek5</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009500\">Serine/threonine-protein kinase Nek9</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001039\">High affinity nerve growth factor receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003605\">BDNF/NT-3 growth factors receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009501\">NT-3 growth factor receptor</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009502\">NUAK family SNF1-like kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009503\">NUAK family SNF1-like kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009504\">Serine/threonine-protein kinase OSR1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009505\">Serine/threonine-protein kinase PAK 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009506\">Serine/threonine-protein kinase PAK 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009507\">Serine/threonine-protein kinase PAK 3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009508\">Serine/threonine-protein kinase PAK 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009509\">Serine/threonine-protein kinase PAK 6</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009510\">Serine/threonine-protein kinase PAK 5</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004077\">Cyclin-dependent kinase 16</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009511\">Cyclin-dependent kinase 17</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000852\">Platelet-derived growth factor receptor alpha</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000205\">Platelet-derived growth factor receptor beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001193\">3-phosphoinositide-dependent protein kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000437\">Cyclin-dependent kinase 15</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009512\">Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009513\">Phosphatidylinositol 4-kinase beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009514\">Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009515\">Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002406\">Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001315\">Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001277\">Serine/threonine-protein kinase pim-1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009516\">Serine/threonine-protein kinase pim-3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009517\">Phosphatidylinositol 5-phosphate 4-kinase type-2 beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009518\">Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009519\">Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009520\">Serine/threonine-protein kinase N1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009521\">Serine/threonine-protein kinase N2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003745\">Serine/threonine-protein kinase PLK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009522\">Serine/threonine-protein kinase PLK2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009523\">Serine/threonine-protein kinase PLK3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009524\">Serine/threonine-protein kinase PLK4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000677\">5&#39;-AMP-activated protein kinase catalytic subunit alpha-1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004907\">5&#39;-AMP-activated protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004475\">cAMP-dependent protein kinase catalytic subunit beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002417\">Protein kinase C delta type</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003431\">Protein kinase C epsilon type</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009588\">Protein kinase C gamma type (PRKCG)</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003889\">Protein kinase C iota type</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0001385\">Protein kinase C theta type</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009525\">Serine/threonine-protein kinase D1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009526\">cGMP-dependent protein kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009527\">Serine/threonine-protein kinase PRP4 homolog</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0003090\">Focal adhesion kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000871\">Protein-tyrosine kinase 2-beta</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004731\">Protein-tyrosine kinase 6</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000036\">RAF proto-oncogene serine/threonine-protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0002411\">Proto-oncogene tyrosine-protein kinase receptor Ret</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009528\">Serine/threonine-protein kinase RIO1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009529\">Serine/threonine-protein kinase RIO2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009530\">Serine/threonine-protein kinase RIO3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009531\">Receptor-interacting serine/threonine-protein kinase 1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009532\">Receptor-interacting serine/threonine-protein kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009533\">Receptor-interacting serine/threonine-protein kinase 4</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004191\">Rho-associated protein kinase 2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009534\">Proto-oncogene tyrosine-protein kinase ROS</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004274\">Ribosomal protein S6 kinase alpha-1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004876\">Ribosomal protein S6 kinase alpha-3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009535\">Serine/threonine-protein kinase SBK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009536\">Uncharacterized serine/threonine-protein kinase SBK3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009537\">Serine/threonine-protein kinase Sgk3</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004757\">Serine/threonine-protein kinase SIK1</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009538\">Serine/threonine-protein kinase SIK2</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004041\">STE20-like serine/threonine-protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009539\">SNF-related serine/threonine-protein kinase</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0000838\">Proto-oncogene tyrosine-protein kinase Src</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009540\">Tyrosine-protein kinase Srms</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009541\">Serine/threonine-protein kinase 10</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009542\">Serine/threonine-protein kinase 16</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009543\">Serine/threonine-protein kinase 17A</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0004328\">Serine/threonine-protein kinase 17B</a></td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td><a href=\"/bio_entities/BE0009544\">Serine/threonine-protein kinase 32A</a></td></tr></tbody></table></dd><dt class=\"col-xl-2 col-md-3 col-sm-4\" id=\"external-clinical-trials-for-covid-19-and-related-conditions\">External Clinical Trials for COVID-19 and Related Conditions</dt><dd class=\"col-xl-10 col-md-9 col-sm-8\"><div class=\"anchor\" id=\"clinical-trials\"></div><table class=\"table table-sm datatable dt-responsive\" style=\"width: 100%\"><thead><tr><th class=\"date-head\">Start Date</th><th class=\"name-head\">Drug</th><th class=\"title-head\">Title</th><th class=\"purpose-head\">Purpose</th><th class=\"phase-head\">Phase</th><th class=\"status-head\">Status</th><th class=\"identifier\">Identifier</th></tr></thead><tbody><tr><td>2021-06-15</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Low Dose Aspirin in Moderate to Severe SARS- CoV-2 Infected Patients : A Pilot Randomized Controlled Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44980\">CTRI/2020/08/027503</a></td></tr><tr><td>2021-03-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Phase I, Randomized, Double Blinded, Placebo Control Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 With Moderate to Severe Symptoms</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04490486\">NCT04490486</a></td></tr><tr><td>2021-01-10</td><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374474\">NCT04374474</a></td></tr><tr><td>2021-01-01</td><td><strong><a href=\"/drugs/DB16445\">ChulaCov19 mRNA vaccine</a></strong></td><td>A Phase 1 / 2, Dose-finding Study to Evaluate Safety, Tolerability, and Immunogenicity of the ChulaCov19 mRNA Vaccine in Healthy Adults</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04566276\">NCT04566276</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>A Phase 1 Study of the Safety and Tolerability of BX-U001 for the Treatment of Severe COVID-19 Pneumonia With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS).</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04452097\">NCT04452097</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB16360\">Anti-SARS-CoV-2 immunoglobulin</a></strong></td><td>TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19 : A PHASE I / II STUDY</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04573855\">NCT04573855</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>Phase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and Symptoms</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04436458\">NCT04436458</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Proof-of-concept Open-label Randomized Dose-response Comparison Study of Famotidine Plus Vitamins C and D3 for Adults With Probable COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04565392\">NCT04565392</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Proof-of-concept Open-label Randomized Dose-response Comparison Study of Famotidine Plus Vitamins C and D3 for Adults With Probable COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04565392\">NCT04565392</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB00927\">Famotidine</a></strong></td><td>Proof-of-concept Open-label Randomized Dose-response Comparison Study of Famotidine Plus Vitamins C and D3 for Adults With Probable COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04565392\">NCT04565392</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04563208\">NCT04563208</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04563208\">NCT04563208</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF / DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04561063\">NCT04561063</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF / DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04561063\">NCT04561063</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF / DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04561063\">NCT04561063</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Assessment of the Safety and Efficacy of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above Illness</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04521036\">NCT04521036</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Randomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental Oxygen</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04398290\">NCT04398290</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB09274\">Artesunate</a></strong></td><td>Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04387240\">NCT04387240</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB13132\">Artemisinin</a></strong></td><td>Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04387240\">NCT04387240</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB00982\">Isotretinoin</a></strong></td><td>Evaluation of the Safety and Efficacy of Isotretinoin in Treatment of COVID-19 : Clinical Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361422\">NCT04361422</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB16434\">IN01</a></strong></td><td>Phase Ib Controlled Exploratory Trial for Treatment of Fibrosing Interstitial Lung Disease Patients Secondary to SARS-CoV-2 Infection With IN01 Vaccine (COVINVAC)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537130\">NCT04537130</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB00302\">Tranexamic acid</a></strong></td><td>Antiviral Effects of Tranexamic Acid (TXA) as a Preventative Treatment Following COVID-19 Exposure</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04550338\">NCT04550338</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>A Phase I / ?a Trial to Explore the Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell (AstroStem-V) Therapy in Patients With COVID-19 Pneumonia</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04527224\">NCT04527224</a></td></tr><tr><td>2020-12-01</td><td><strong><a href=\"/drugs/DB07795\">Fisetin</a></strong></td><td>COVID-FIS : A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537299\">NCT04537299</a></td></tr><tr><td>2020-11-30</td><td><strong><a href=\"/drugs/DB15890\">RAPA-501-Allo</a></strong></td><td>Phase I / Phase II Trial of Off-the-Shelf Allogeneic Hybrid TREG / Th2 Cell (RAPA-501-ALLO) Therapy for Severe, Post-Intubation Stage 3 COVID-19 Disease</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04482699\">NCT04482699</a></td></tr><tr><td>2020-11-19</td><td><strong><a href=\"/drugs/DB10317\">Rubella virus vaccine</a></strong></td><td>Investigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control group</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50035\">IRCT20200802048266N1</a></td></tr><tr><td>2020-11-19</td><td><strong><a href=\"/drugs/DB10316\">Mumps virus strain B level jeryl lynn live antigen</a></strong></td><td>Investigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control group</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50035\">IRCT20200802048266N1</a></td></tr><tr><td>2020-11-19</td><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>Investigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control group</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50035\">IRCT20200802048266N1</a></td></tr><tr><td>2020-11-14</td><td><strong><a href=\"/drugs/DB15858\">KBP-COVID-19</a></strong></td><td>A Phase I / II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-COVID-19 Vaccine in Healthy Seronegative Adults Aged 18-49 and 50-70</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04473690\">NCT04473690</a></td></tr><tr><td>2020-11-13</td><td><strong><a href=\"/drugs/DB15750\">Trefoil Factor 2</a></strong></td><td>Clinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK / PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patients</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=57741\">ChiCTR2000035633</a></td></tr><tr><td>2020-11-13</td><td><strong><a href=\"/drugs/DB15749\">Interferon Kappa</a></strong></td><td>Clinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK / PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patients</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=57741\">ChiCTR2000035633</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB11720\">Angiotensin 1-7</a></strong></td><td>A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570501\">NCT04570501</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB11580\">Ravulizumab</a></strong></td><td>C5 Complement Inhbition Using Ravulizumab for the Treatment of COVID-19 Induced Thrombotic Microangiopathy</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570397\">NCT04570397</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Study Evaluating AVM0703 in Patients With COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366115\">NCT04366115</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB04968\">PH94B</a></strong></td><td>A Phase 2a Open-label Study of the Efficacy and Safety of PRN PH94B Neuroactive Nasal Spray in the Treatment of Adjustment Disorder With Anxiety (AjDA) Associated With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04404192\">NCT04404192</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB12038\">Ulinastatin</a></strong></td><td>A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04393311\">NCT04393311</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB01128\">Bicalutamide</a></strong></td><td>A Phase II Trial to Promote Recovery From COVID-19 With Endocrine Therapy</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374279\">NCT04374279</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Safety and Efficacy of Ruxolitinib for COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348071\">NCT04348071</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>Safety and Efficacy of Baricitinib for COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04340232\">NCT04340232</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB01224\">Quetiapine</a></strong></td><td>A Practical, Pilot, Randomized, Controlled Trial of Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04513314\">NCT04513314</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB00313\">Valproic acid</a></strong></td><td>A Practical, Pilot, Randomized, Controlled Trial of Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04513314\">NCT04513314</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>A Phase 2 Randomized Double Blind, Placebo-controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542434\">NCT04542434</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB15864\">Oral Polio Vaccine</a></strong></td><td>A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04540185\">NCT04540185</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB11859\">Brexanolone</a></strong></td><td>A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537806\">NCT04537806</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB10572\">Corn</a></strong></td><td>A Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka\\xc2\\xae Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRC</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537585\">NCT04537585</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB10544\">Cultivated mushroom</a></strong></td><td>A Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka\\xc2\\xae Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRC</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537585\">NCT04537585</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB10568\">Soybean</a></strong></td><td>A Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka\\xc2\\xae Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRC</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537585\">NCT04537585</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB12665\">Isoquercetin</a></strong></td><td>An Open-Label Randomized Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of 2019 Novel Coronavirus Disease (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04536090\">NCT04536090</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB09274\">Artesunate</a></strong></td><td>Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12343\">PACTR202009642148520</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB12975\">Pyronaridine</a></strong></td><td>Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12343\">PACTR202009642148520</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir / Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04455958\">NCT04455958</a></td></tr><tr><td>2020-11-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir / Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04455958\">NCT04455958</a></td></tr><tr><td>2020-10-31</td><td><strong><a href=\"/drugs/DB09152\">Nitrogen</a></strong></td><td>Phase 1b Safety Trial for S-Nitrosylation Therapy to Treat COVID-19 Induced Respiratory Distress</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528771\">NCT04528771</a></td></tr><tr><td>2020-10-31</td><td><strong><a href=\"/drugs/DB00302\">Tranexamic acid</a></strong></td><td>A Phase 2 Study to Evaluate LB1148 for the Treatment of Pulmonary Dysfunction Associated With COVID-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390217\">NCT04390217</a></td></tr><tr><td>2020-10-31</td><td><strong><a href=\"/drugs/DB16395\">Efineptakin alfa</a></strong></td><td>A Phase I and Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04498325\">NCT04498325</a></td></tr><tr><td>2020-10-31</td><td><strong><a href=\"/drugs/DB00477\">Chlorpromazine</a></strong></td><td>Evaluation of efficacy and safety of adding Chlorpromazine to Atazanavir / Ritonavir regimen in the treatment of COVID-19 patients, a randomized double-blind clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50959\">IRCT20200913048708N1</a></td></tr><tr><td>2020-10-31</td><td><strong><a href=\"/drugs/DB14597\">Lanadelumab</a></strong></td><td>A Phase 1b, Randomized, Double-blind, Single and Repeat Dosing Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab When Added to Standard-of-Care in Subjects Hospitalized With COVID-19 Pneumonia</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04460105\">NCT04460105</a></td></tr><tr><td>2020-10-30</td><td><strong><a href=\"/drugs/DB15735\">Virus Specific T-Cell</a></strong></td><td>BAT IT : Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04401410\">NCT04401410</a></td></tr><tr><td>2020-10-30</td><td><strong><a href=\"/drugs/DB08882\">Linagliptin</a></strong></td><td>Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341935\">NCT04341935</a></td></tr><tr><td>2020-10-30</td><td><strong><a href=\"/drugs/DB16357\">BGB-DXP593</a></strong></td><td>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04551898\">NCT04551898</a></td></tr><tr><td>2020-10-30</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Umbilical cord-derived mesenchymal stromal cells therapy for SARS-CoV-2 infection (COVID-19) related Acute Respiratory Distress Syndrome</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205465\">JPRN-JapicCTI-205465</a></td></tr><tr><td>2020-10-27</td><td><strong><a href=\"/drugs/DB00480\">Lenalidomide</a></strong></td><td>Double-blind Randomized Controlled Clinical Trial of Low-dose Lenalidomide in the Treatment of COVID-19 Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361643\">NCT04361643</a></td></tr><tr><td>2020-10-26</td><td><strong><a href=\"/drugs/DB00052\">Somatotropin</a></strong></td><td>The Impact of Growth Hormone in Obese Cases With Covid-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532554\">NCT04532554</a></td></tr><tr><td>2020-10-22</td><td><strong><a href=\"/drugs/DB16437\">V590</a></strong></td><td>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04569786\">NCT04569786</a></td></tr><tr><td>2020-10-22</td><td><strong><a href=\"/drugs/DB05974\">Transcrocetinate</a></strong></td><td>Evaluation of trans sodium crocetinate spray against on mild to moderate ARDS induced by COVID-19 patients : A Randomized Open label Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47441\">IRCT20081019001369N7</a></td></tr><tr><td>2020-10-20</td><td><strong><a href=\"/drugs/DB00051\">Adalimumab</a></strong></td><td>Adalimumab in COVID-19 to prevent respiratory failure in community care (AVID-CC) : A randomised controlled trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN33260034\">ISRCTN33260034</a></td></tr><tr><td>2020-10-20</td><td><strong><a href=\"/drugs/DB16368\">Anti-SARS-CoV-2 equine immunoglobulin fragments</a></strong></td><td>Pilot Study to Evaluate Safety and Efficacy of Anti-SARS-CoV-2 Equine Immunoglobulin F(ab&#39;)2 Fragments (INOSARS) in Hospitalized Patients With COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04514302\">NCT04514302</a></td></tr><tr><td>2020-10-19</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Tocilizumab for the treatment of COVID-19 in intensive care patients : effect on days free of ventilatory support.</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000580976.aspx\">ACTRN12620000580976</a></td></tr><tr><td>2020-10-15</td><td><strong><a href=\"/drugs/DB00009\">Alteplase</a></strong></td><td>Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS) : A Multicentral Randomized Trial (AtTAC-trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04453371\">NCT04453371</a></td></tr><tr><td>2020-10-15</td><td><strong><a href=\"/drugs/DB01072\">Atazanavir</a></strong></td><td>Randomized Controlled Phase 2 / 3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04452565\">NCT04452565</a></td></tr><tr><td>2020-10-15</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Randomized Controlled Phase 2 / 3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04452565\">NCT04452565</a></td></tr><tr><td>2020-10-15</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>A Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04517188\">NCT04517188</a></td></tr><tr><td>2020-10-10</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Inhaled Nitric Oxide for Treatment of SARS-CoV-2 Infection : An Open-Label, Multicenter, Parallel, Randomized Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-8nfx26/\">RBR-8nfx26</a></td></tr><tr><td>2020-10-09</td><td><strong><a href=\"/drugs/DB16366\">F-652</a></strong></td><td>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22 : IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04498377\">NCT04498377</a></td></tr><tr><td>2020-10-07</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection : a Randomized, Phase 2 / 3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX : REVOLUTIOn</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468087\">NCT04468087</a></td></tr><tr><td>2020-10-07</td><td><strong><a href=\"/drugs/DB01072\">Atazanavir</a></strong></td><td>Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection : a Randomized, Phase 2 / 3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX : REVOLUTIOn</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468087\">NCT04468087</a></td></tr><tr><td>2020-10-07</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection : a Randomized, Phase 2 / 3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX : REVOLUTIOn</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468087\">NCT04468087</a></td></tr><tr><td>2020-10-07</td><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>A 2-Part, Phase I, Open-label, Single-dose, Sequential, Randomized, Crossover Study of Acalabrutinib Tablet Suspension Delivered Via Nasogastric Tube in Healthy Subjects to Evaluate Relative Bioavailability and Proton-pump Inhibitor (Rabeprazole) Effect</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04564040\">NCT04564040</a></td></tr><tr><td>2020-10-07</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Efficacy of Dexamethasone Treatment for Patients With Acute Hypoxemic Respiratory Failure (Including ARDS) Caused by Infections (Including COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04545242\">NCT04545242</a></td></tr><tr><td>2020-10-06</td><td><strong><a href=\"/drugs/DB12592\">Mosedipimod</a></strong></td><td>Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04569227\">NCT04569227</a></td></tr><tr><td>2020-10-06</td><td><strong><a href=\"/drugs/DB05511\">Piclidenoson</a></strong></td><td>Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333472\">NCT04333472</a></td></tr><tr><td>2020-10-06</td><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04541485\">NCT04541485</a></td></tr><tr><td>2020-10-05</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A randomized double-blind placebo-controlled trial of oral ivermectin outpatient treatment, to prevent hospitalisation, of those at high risk for hospitalization due to SARS-CoV-2 (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000982910.aspx\">ACTRN12620000982910</a></td></tr><tr><td>2020-10-05</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04539275\">NCT04539275</a></td></tr><tr><td>2020-10-03</td><td><strong><a href=\"/drugs/DB14597\">Lanadelumab</a></strong></td><td>Lanadelumab for Treatment of COVID-19 Disease</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04422509\">NCT04422509</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomized, placebo-controlled prophylaxis study (COPCOV)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11019\">PACTR202009786901147</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB16432\">MVA-SARS-2-S</a></strong></td><td>An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04569383\">NCT04569383</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB06608\">Tafenoquine</a></strong></td><td>A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04533347\">NCT04533347</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Outpatient Use of Ivermectin in COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530474\">NCT04530474</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00975\">Dipyridamole</a></strong></td><td>A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04410328\">NCT04410328</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04410328\">NCT04410328</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00755\">Tretinoin</a></strong></td><td>Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04396067\">NCT04396067</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00471\">Montelukast</a></strong></td><td>Repurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms : The COvid-19 Symptom MOntelukast (COSMO) Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389411\">NCT04389411</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04406389\">NCT04406389</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00569\">Fondaparinux</a></strong></td><td>InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04406389\">NCT04406389</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00278\">Argatroban</a></strong></td><td>InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04406389\">NCT04406389</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04406389\">NCT04406389</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN88057279\">ISRCTN88057279</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392427\">NCT04392427</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392427\">NCT04392427</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392427\">NCT04392427</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392427\">NCT04392427</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382625\">NCT04382625</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A phase Ib / II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya (COV004)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10988\">PACTR202005681895696</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Prospective Phase II Study : MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377334\">NCT04377334</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB08882\">Linagliptin</a></strong></td><td>Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371978\">NCT04371978</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (EVICT-CORONA-ALI)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344184\">NCT04344184</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB15811\">BacTRL-spike</a></strong></td><td>A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334980\">NCT04334980</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343001\">NCT04343001</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00641\">Simvastatin</a></strong></td><td>Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343001\">NCT04343001</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343001\">NCT04343001</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB11248\">Zinc gluconate</a></strong></td><td>Randomized, Double -Blind, Placebo Controlled, Trial to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04558424\">NCT04558424</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Randomized, Double -Blind, Placebo Controlled, Trial to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04558424\">NCT04558424</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB09075\">Edoxaban</a></strong></td><td>Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516941\">NCT04516941</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516941\">NCT04516941</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00877\">Sirolimus</a></strong></td><td>Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of Acute Respiratory Distress Syndrome (RAPA-CARDS)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04482712\">NCT04482712</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00898\">Ethanol</a></strong></td><td>Disinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract by Controlled Ethanol Vapor Inhalation Combined With Oral Asprin .</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04554433\">NCT04554433</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Disinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract by Controlled Ethanol Vapor Inhalation Combined With Oral Asprin .</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04554433\">NCT04554433</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04524663\">NCT04524663</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Multicentre Randomized Controlled Trial of Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04500626\">NCT04500626</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Can Nebulised HepArin Reduce morTality and Time to Extubation in Patients With COVID-19 Requiring Mechanical Ventilation Meta-Trial (CHARTER-MT) : Protocol for an Investigator-initiated International Meta-trial of Randomised Studies</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04545541\">NCT04545541</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00977\">Ethinylestradiol</a></strong></td><td>Estrogen Therapy in Non-severe COVID-19 Patients : Proposed Treatment Scheme in a Tertiary Hospital</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04539626\">NCT04539626</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB06713\">Norelgestromin</a></strong></td><td>Estrogen Therapy in Non-severe COVID-19 Patients : Proposed Treatment Scheme in a Tertiary Hospital</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04539626\">NCT04539626</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002282-33\">EUCTR2020-002282-33-DE</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB11863\">Alvelestat</a></strong></td><td>A Phase Ib / II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (&gt; 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04539795\">NCT04539795</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB00770\">Alprostadil</a></strong></td><td>Effectiveness and Safety of the Administration of Intravenous Prostaglandin E1 Analog in the Reduction of Mortality and Complications of Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04536363\">NCT04536363</a></td></tr><tr><td>2020-10-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Phase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456413\">NCT04456413</a></td></tr><tr><td>2020-09-30</td><td><strong><a href=\"/drugs/DB03823\">Epigallocatechin</a></strong></td><td>A Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Protect Health Workers Against COVID-19 by Using Previfenon\\xc2\\xae as Chemoprophylaxis During a SARS-CoV-2 Outbreak. The HERD Study</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04446065\">NCT04446065</a></td></tr><tr><td>2020-09-30</td><td><strong><a href=\"/drugs/DB00302\">Tranexamic acid</a></strong></td><td>Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Inpatients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338126\">NCT04338126</a></td></tr><tr><td>2020-09-30</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377568\">NCT04377568</a></td></tr><tr><td>2020-09-30</td><td><strong><a href=\"/drugs/DB11952\">Duvelisib</a></strong></td><td>A Pilot Study of Duvelisib to Combat COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372602\">NCT04372602</a></td></tr><tr><td>2020-09-30</td><td><strong><a href=\"/drugs/DB11720\">Angiotensin 1-7</a></strong></td><td>Angiotensin-(1,7) Treatment in COVID-19 : the ATCO Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04332666\">NCT04332666</a></td></tr><tr><td>2020-09-30</td><td><strong><a href=\"/drugs/DB12160\">Bucillamine</a></strong></td><td>Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04504734\">NCT04504734</a></td></tr><tr><td>2020-09-30</td><td><strong><a href=\"/drugs/DB16429\">CoVac-1</a></strong></td><td>P-pVAC-SARS-CoV-2 : Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04546841\">NCT04546841</a></td></tr><tr><td>2020-09-30</td><td><strong><a href=\"/drugs/DB08954\">Ifenprodil</a></strong></td><td>AN OPEN LABEL PHYSICIAN INITIATED 28 DAY PHASE 2A STUDY OF IFENPRODIL ON LUNG FUNCTION IN CONFIRMED COVID-19 INFECTED PATIENTS WITH SEVERE PNEUMONIA</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=17062\">KCT0005307</a></td></tr><tr><td>2020-09-30</td><td><strong><a href=\"/drugs/DB16360\">Anti-SARS-CoV-2 immunoglobulin</a></strong></td><td>An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19 - Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002542-16\">EUCTR2020-002542-16-GB</a></td></tr><tr><td>2020-09-29</td><td><strong><a href=\"/drugs/DB15859\">NasoVAX</a></strong></td><td>Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04442230\">NCT04442230</a></td></tr><tr><td>2020-09-29</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04552366\">NCT04552366</a></td></tr><tr><td>2020-09-29</td><td><strong><a href=\"/drugs/DB15866\">CK0802</a></strong></td><td>Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468971\">NCT04468971</a></td></tr><tr><td>2020-09-28</td><td><strong><a href=\"/drugs/DB00155\">Citrulline</a></strong></td><td>Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570384\">NCT04570384</a></td></tr><tr><td>2020-09-28</td><td><strong><a href=\"/drugs/DB15848\">Gam-COVID-Vac</a></strong></td><td>?linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-?oV-2 Infection Prophylactic Treatment in Republic of Belarus</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04564716\">NCT04564716</a></td></tr><tr><td>2020-09-28</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic : A Randomized Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04551339\">NCT04551339</a></td></tr><tr><td>2020-09-28</td><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04558021\">NCT04558021</a></td></tr><tr><td>2020-09-28</td><td><strong><a href=\"/drugs/DB15862\">Inactivated SARS-Cov-2 Vaccine</a></strong></td><td>A Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04551547\">NCT04551547</a></td></tr><tr><td>2020-09-26</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04568811\">NCT04568811</a></td></tr><tr><td>2020-09-25</td><td><strong><a href=\"/drugs/DB16444\">UB-612</a></strong></td><td>A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04545749\">NCT04545749</a></td></tr><tr><td>2020-09-25</td><td><strong><a href=\"/drugs/DB16130\">Dapansutrile</a></strong></td><td>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04540120\">NCT04540120</a></td></tr><tr><td>2020-09-25</td><td><strong><a href=\"/drugs/DB00031\">Tenecteplase</a></strong></td><td>Tenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04505592\">NCT04505592</a></td></tr><tr><td>2020-09-25</td><td><strong><a href=\"/drugs/DB12525\">Molgramostim</a></strong></td><td>Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia - GI-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001654-21\">EUCTR2020-001654-21-DE</a></td></tr><tr><td>2020-09-25</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of safety and efficacy of post exposure prophylaxis with hydroxychloroquine aiming at prevention of COVID-19 for medical care workers</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs051200060\">JPRN-jRCTs051200060</a></td></tr><tr><td>2020-09-25</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>Estudo Multicentrico da pr\\xc3\\xa1tica Integrativa e complementar de Ozonioterapia em pacientes ambulatoriais com Covid- 19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-97nt6j/\">RBR-97nt6j</a></td></tr><tr><td>2020-09-24</td><td><strong><a href=\"/drugs/DB12525\">Molgramostim</a></strong></td><td>Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04569877\">NCT04569877</a></td></tr><tr><td>2020-09-24</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04566770\">NCT04566770</a></td></tr><tr><td>2020-09-24</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Favipiravir, Lopinavir / Ritonavir or Combination Therapy : a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04499677\">NCT04499677</a></td></tr><tr><td>2020-09-24</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Favipiravir, Lopinavir / Ritonavir or Combination Therapy : a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04499677\">NCT04499677</a></td></tr><tr><td>2020-09-24</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Favipiravir, Lopinavir / Ritonavir or Combination Therapy : a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04499677\">NCT04499677</a></td></tr><tr><td>2020-09-23</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04419025\">NCT04419025</a></td></tr><tr><td>2020-09-23</td><td><strong><a href=\"/drugs/DB15810\">Nuvaxovid</a></strong></td><td>A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1\\xe2\\x84\\xa2 Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004123-16\">EUCTR2020-004123-16-GB</a></td></tr><tr><td>2020-09-22</td><td><strong><a href=\"/drugs/DB14358\">Tribulus terrestris</a></strong></td><td>The effect of herbal tea (including mallow flower, chicory seeds, sweet violet flower, Melilotus officinalis and Bindii) on improving respiratory symptoms in patients with Covid-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50227\">IRCT20200806048318N1</a></td></tr><tr><td>2020-09-22</td><td><strong><a href=\"/drugs/DB10859\">Melilotus officinalis pollen</a></strong></td><td>The effect of herbal tea (including mallow flower, chicory seeds, sweet violet flower, Melilotus officinalis and Bindii) on improving respiratory symptoms in patients with Covid-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50227\">IRCT20200806048318N1</a></td></tr><tr><td>2020-09-22</td><td><strong><a href=\"/drugs/DB06174\">Noscapine</a></strong></td><td>Evaluation and comparison of the effectiveness of two herbal products containing Noscapine (Opiucough and Noscough) on clinical symptoms and para-clinical parameters in adults hospitalized with severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49775\">IRCT20180103038199N3</a></td></tr><tr><td>2020-09-22</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Evaluation of Convalescent Plasma Therapy for COVID-19 Patients</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47632\">IRCT20200503047281N1</a></td></tr><tr><td>2020-09-22</td><td><strong><a href=\"/drugs/DB00482\">Celecoxib</a></strong></td><td>Evaluation of short-term effects of Celecoxib on clinical improvement of COVID-19 patients : A randomized clinical trial study</td><td>Treatment</td><td>1</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/50932\">IRCT20200907048644N1</a></td></tr><tr><td>2020-09-22</td><td><strong><a href=\"/drugs/DB11114\">Eucalyptus oil</a></strong></td><td>Evaluation of therapeutic effects of oral eucalyptus tablets on the treatment process of patients with Covid 19 infection.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50912\">IRCT20200913048701N1</a></td></tr><tr><td>2020-09-22</td><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>Verification of the efficacy of Bromhexine-hydrochloride in treatment of patients with COVID19 disease</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50780\">IRCT20200818048444N1</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB01072\">Atazanavir</a></strong></td><td>A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12266\">PACTR202008855701534</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12266\">PACTR202008855701534</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>A Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04573153\">NCT04573153</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB00583\">Levocarnitine</a></strong></td><td>A Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04573153\">NCT04573153</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB14933\">Nicotinamide riboside</a></strong></td><td>A Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04573153\">NCT04573153</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB00133\">Serine</a></strong></td><td>A Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04573153\">NCT04573153</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB04835\">Maraviroc</a></strong></td><td>Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435522\">NCT04435522</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459286\">NCT04459286</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB01072\">Atazanavir</a></strong></td><td>A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459286\">NCT04459286</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459286\">NCT04459286</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission : Co-CLARITY Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04567173\">NCT04567173</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Prospective, Randomized, Placebo-controlled, Double-blinded, Phase III Clinical Trial of the Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516811\">NCT04516811</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB12326\">Antroquinonol</a></strong></td><td>A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04523181\">NCT04523181</a></td></tr><tr><td>2020-09-21</td><td><strong><a href=\"/drugs/DB16529\">Biomodulin T</a></strong></td><td>Safety and effectiveness of BIOMODULINA T in a long-lived population at high risk of COVID-19 infection. Interventional Study (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000335-En\">RPCEC00000335</a></td></tr><tr><td>2020-09-20</td><td><strong><a href=\"/drugs/DB16360\">Anti-SARS-CoV-2 immunoglobulin</a></strong></td><td>A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04555148\">NCT04555148</a></td></tr><tr><td>2020-09-20</td><td><strong><a href=\"/drugs/DB11133\">Omega-3 fatty acids</a></strong></td><td>Impact of Different Treatment Modalities on Immunity Against COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04553705\">NCT04553705</a></td></tr><tr><td>2020-09-20</td><td><strong><a href=\"/drugs/DB00468\">Quinine</a></strong></td><td>Impact of Different Treatment Modalities on Immunity Against COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04553705\">NCT04553705</a></td></tr><tr><td>2020-09-19</td><td><strong><a href=\"/drugs/DB16441\">QazCovid-in</a></strong></td><td>Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-IN\\xc2\\xae- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530357\">NCT04530357</a></td></tr><tr><td>2020-09-18</td><td><strong><a href=\"/drugs/DB16356\">Anti-SARS-CoV-2 IgY</a></strong></td><td>A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04567810\">NCT04567810</a></td></tr><tr><td>2020-09-18</td><td><strong><a href=\"/drugs/DB01097\">Leflunomide</a></strong></td><td>A Phase 1 / 2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532372\">NCT04532372</a></td></tr><tr><td>2020-09-18</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734\\xe2\\x84\\xa2) Treatment of COVID-19 in an Outpatient Setting</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04501952\">NCT04501952</a></td></tr><tr><td>2020-09-18</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>The Effect of Melatonin and Vitamin C on COVID-19</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530539\">NCT04530539</a></td></tr><tr><td>2020-09-18</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>The Effect of Melatonin and Vitamin C on COVID-19</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530539\">NCT04530539</a></td></tr><tr><td>2020-09-18</td><td><strong><a href=\"/drugs/DB15844\">CVnCoV</a></strong></td><td>COVID-19 : A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults &gt;60 Years of Age and 18 to 60 Years of Age</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04515147\">NCT04515147</a></td></tr><tr><td>2020-09-17</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia - An open-label randomized controlled study -</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002728-35\">EUCTR2020-002728-35-HU</a></td></tr><tr><td>2020-09-17</td><td><strong><a href=\"/drugs/DB00176\">Fluvoxamine</a></strong></td><td>A randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-19 patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002299-11\">EUCTR2020-002299-11-HU</a></td></tr><tr><td>2020-09-17</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04480424\">NCT04480424</a></td></tr><tr><td>2020-09-17</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Study on the use of Convalescent plasma therapy as a COVID-19 treatment - Study on the use of Convalescent plasma therapy as a COVID-19 treatment</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs031200124\">JPRN-jRCTs031200124</a></td></tr><tr><td>2020-09-16</td><td><strong><a href=\"/drugs/DB08895\">Tofacitinib</a></strong></td><td>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04469114\">NCT04469114</a></td></tr><tr><td>2020-09-16</td><td><strong><a href=\"/drugs/DB15862\">Inactivated SARS-Cov-2 Vaccine</a></strong></td><td>Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04560881\">NCT04560881</a></td></tr><tr><td>2020-09-16</td><td><strong><a href=\"/drugs/DB12612\">Ozanimod</a></strong></td><td>A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405102\">NCT04405102</a></td></tr><tr><td>2020-09-16</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A placebo-controlled, randomized, double-blind study in COvid-19 patients with iveRmectin ; An inVEstigator iniTiaTEd trial - CORVETTE-01</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCT2031200120\">JPRN-jRCT2031200120</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB09228\">Conestat alfa</a></strong></td><td>Recombinant Human C1 Esterase Inhibitor (Ruconest\\xc2\\xae) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 : a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530136\">NCT04530136</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB00155\">Citrulline</a></strong></td><td>CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04404426\">NCT04404426</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338360\">NCT04338360</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB15854\">MVC-COV1901</a></strong></td><td>A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04487210\">NCT04487210</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase ? Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04526990\">NCT04526990</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB16521\">Prolectin-M</a></strong></td><td>Effect of Prolectin-M ; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers : A Proof of Concept, Open Label Randomized Controlled Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04512027\">NCT04512027</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Intravenous Immunoglobulins for the Treatment of Covid-19 Patients : a Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04548557\">NCT04548557</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers ; a Pilot Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04497519\">NCT04497519</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>A Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons With Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household Members</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04536298\">NCT04536298</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB16361\">Descartes-30</a></strong></td><td>Phase I / IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04524962\">NCT04524962</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB15871\">Human Amniotic Fluid</a></strong></td><td>A Phase I / II Randomized Double-blinded Placebo-controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04497389\">NCT04497389</a></td></tr><tr><td>2020-09-15</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04480333\">NCT04480333</a></td></tr><tr><td>2020-09-14</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Glasgow Early Treatment Arm FavIpiravir : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN31062548\">ISRCTN31062548</a></td></tr><tr><td>2020-09-14</td><td><strong><a href=\"/drugs/DB01262\">Decitabine</a></strong></td><td>Decitabine for COVID-19 Pneumonia-ARDS Treatment : DART Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04482621\">NCT04482621</a></td></tr><tr><td>2020-09-14</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase 1b / 2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04539262\">NCT04539262</a></td></tr><tr><td>2020-09-14</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Pilot study platform to investigate the pharmacodynamics on QT-prolongation and pharmacokinetics after multiple dose administration of potential combination treatments for COVID-19 in healthy volunteers</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002314-40\">EUCTR2020-002314-40-AT</a></td></tr><tr><td>2020-09-14</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>A Pilot study platform to investigate the pharmacodynamics on QT-prolongation and pharmacokinetics after multiple dose administration of potential combination treatments for COVID-19 in healthy volunteers</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002314-40\">EUCTR2020-002314-40-AT</a></td></tr><tr><td>2020-09-14</td><td><strong><a href=\"/drugs/DB10548\">Onion</a></strong></td><td>Evaluation of safety and efficacy of T-AYU-HM Premium and Onion Steam vaporisation / nebulization in Covid-19 patients (mild to moderate)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46654\">CTRI/2020/08/027477</a></td></tr><tr><td>2020-09-11</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04540419\">NCT04540419</a></td></tr><tr><td>2020-09-11</td><td><strong><a href=\"/drugs/DB12386\">Bacillus calmette-guerin substrain danish 1331 live antigen</a></strong></td><td>Using BCG Vaccine to Enhance Non-specific Protection of Senior Citizens During the COVID-19 Pandemic. A Randomized Clinical Trial.</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542330\">NCT04542330</a></td></tr><tr><td>2020-09-11</td><td><strong><a href=\"/drugs/DB16529\">Biomodulin T</a></strong></td><td>Safety and effectiveness of BIOMODULIN T in protective therapy in events of local transmission of COVID-19. Interventional Study (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000334-En\">RPCEC00000334</a></td></tr><tr><td>2020-09-11</td><td><strong><a href=\"/drugs/DB12386\">Bacillus calmette-guerin substrain danish 1331 live antigen</a></strong></td><td>BCG vaccination to Reduce the impact of COVID-19 in healthcare workers following Coronavirus Exposure (BRACE) Trial - BRACE</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002503-19\">EUCTR2020-002503-19-GB</a></td></tr><tr><td>2020-09-11</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients : Randomized, Double-blind, and Placebo-controlled</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04535856\">NCT04535856</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB05974\">Transcrocetinate</a></strong></td><td>Open-label, Pharmacokinetic, Pharmacodynamic, Ascending Dose Safety lead-in Followed by a Single-center, Placebo-controlled, Double-blind, Adaptive, Safety and Efficacy, Pilot Study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 Infected Subjects</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04573322\">NCT04573322</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466241\">NCT04466241</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466241\">NCT04466241</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466241\">NCT04466241</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466241\">NCT04466241</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>A Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With Lymphocytopenia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04487444\">NCT04487444</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB15737\">Dental Mesenchymal Pulp Stem Cells</a></strong></td><td>Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia- A Phase 2&amp;3 Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/50848\">IRCT20140911019125N8</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>A Multicentre, Quadruple-blind, Randomized, Parallel-group Study to Compare the Efficacy of Sofosbuvir and Daclatasvir vs. Placebo in the Outpatient Treatment of COVID-19 in adults</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/50601\">IRCT20200831048568N1</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>A Multicentre, Quadruple-blind, Randomized, Parallel-group Study to Compare the Efficacy of Sofosbuvir and Daclatasvir vs. Placebo in the Outpatient Treatment of COVID-19 in adults</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/50601\">IRCT20200831048568N1</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB11580\">Ravulizumab</a></strong></td><td>A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCT2031200126\">JPRN-jRCT2031200126</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY IN ADULTS TO DETERMINE THE SAFETY, EFFICACY, AND IMMUNOGENICITY OF AZD1222, A NON-REPLICATING CHADOX1 VECTOR VACCINE, FOR THE PREVENTION OF COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=059-20\">PER-059-20</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB15844\">CVnCoV</a></strong></td><td>COVID-19 : A PHASE 2A, PARTIALLY OBSERVER-BLIND, MULTICENTER, CONTROLLED, DOSE-CONFIRMATION CLINICAL TRIAL TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE INVESTIGATIONAL SARS-COV-2 MRNA VACCINE CVNCOV IN ADULTS &gt;60 YEARS OF AGE AND 18 TO 60 YEARS OF AGE</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=054-20\">PER-054-20</a></td></tr><tr><td>2020-09-10</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>COVIDOSE-2 : A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive Ventilation</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04479358\">NCT04479358</a></td></tr><tr><td>2020-09-09</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial : The International ALLIANCE Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04395768\">NCT04395768</a></td></tr><tr><td>2020-09-09</td><td><strong><a href=\"/drugs/DB16354\">Avasopasem manganese</a></strong></td><td>A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04555096\">NCT04555096</a></td></tr><tr><td>2020-09-09</td><td><strong><a href=\"/drugs/DB16442\">BNT162b3</a></strong></td><td>A Multi-site, Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537949\">NCT04537949</a></td></tr><tr><td>2020-09-08</td><td><strong><a href=\"/drugs/DB16519\">Zofin</a></strong></td><td>A Phase I / II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Moderate to SARS Related to COVID-19 Infection vs Placebo</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04384445\">NCT04384445</a></td></tr><tr><td>2020-09-08</td><td><strong><a href=\"/drugs/DB05983\">Bardoxolone methyl</a></strong></td><td>BARCONA : A Phase II / III, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04494646\">NCT04494646</a></td></tr><tr><td>2020-09-08</td><td><strong><a href=\"/drugs/DB00031\">Tenecteplase</a></strong></td><td>Low-Dose Tenecteplase in Covid-19 Patients With Acture Pulmonary Embolism : A Randomized, Double-Blind, Placebo-Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04558125\">NCT04558125</a></td></tr><tr><td>2020-09-08</td><td><strong><a href=\"/drugs/DB16365\">Treamid</a></strong></td><td>Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04527354\">NCT04527354</a></td></tr><tr><td>2020-09-08</td><td><strong><a href=\"/drugs/DB16357\">BGB-DXP593</a></strong></td><td>A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects</td><td>Basic Science</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532294\">NCT04532294</a></td></tr><tr><td>2020-09-08</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Phase 3, Randomized, Double-blind, Placebo control trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45236\">CTRI/2020/09/027535</a></td></tr><tr><td>2020-09-07</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel at All Levels of Care, During the 2020 Pandemic : A Randomized Clinical Controled Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04527211\">NCT04527211</a></td></tr><tr><td>2020-09-07</td><td><strong><a href=\"/drugs/DB15848\">Gam-COVID-Vac</a></strong></td><td>Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-?oV-2 Infection Prophylactic Treatment</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530396\">NCT04530396</a></td></tr><tr><td>2020-09-07</td><td><strong><a href=\"/drugs/DB15857\">Janssen COVID-19 Vaccine</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04505722\">NCT04505722</a></td></tr><tr><td>2020-09-07</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF THE USE OF PLASMA FROM CONVALESCENT PATIENTS WITH THE NEW CORONAVIRUS DISEASE (COVID-19) FOR THE EXPERIMENTAL TREATMENT OF PATIENTS HOSPITALIZED IN THE CENTRO MEDICO NAVAL &quot;CIRUJANO MAYOR SANTIAGO TAVARA&quot;</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=060-20\">PER-060-20</a></td></tr><tr><td>2020-09-07</td><td><strong><a href=\"/drugs/DB01132\">Pioglitazone</a></strong></td><td>Non-blinded, Randomized and Controlled Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04535700\">NCT04535700</a></td></tr><tr><td>2020-09-07</td><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>Randomized, Open, Parallel, Single-center, Non-inferiority Clinical Trial, With an Active Control Group, Comparing Two Oral Prednisone Regimens With the Aim of Optimizing the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04534478\">NCT04534478</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB15718\">Bamlanivimab</a></strong></td><td>A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19 - Therapeutics for Inpatients with COVID-19 (TICO)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003278-37\">EUCTR2020-003278-37-DK</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB16425\">Rintatolimod</a></strong></td><td>Phase 1 / 2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection</td><td>Supportive Care</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04379518\">NCT04379518</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB00105\">Interferon alfa-2b</a></strong></td><td>Phase 1 / 2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection</td><td>Supportive Care</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04379518\">NCT04379518</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB14352\">Azadirachta indica leaf</a></strong></td><td>Use of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357990\">NCT04357990</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB01323\">St. John&#39;s Wort</a></strong></td><td>Use of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357990\">NCT04357990</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB10317\">Rubella virus vaccine</a></strong></td><td>An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare Workers</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333732\">NCT04333732</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare Workers</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333732\">NCT04333732</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB10316\">Mumps virus strain B level jeryl lynn live antigen</a></strong></td><td>An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare Workers</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333732\">NCT04333732</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361032\">NCT04361032</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB00746\">Deferoxamine</a></strong></td><td>Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361032\">NCT04361032</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB06779\">Dalteparin</a></strong></td><td>A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04505774\">NCT04505774</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04505774\">NCT04505774</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04505774\">NCT04505774</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB00569\">Fondaparinux</a></strong></td><td>A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04505774\">NCT04505774</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB06822\">Tinzaparin</a></strong></td><td>A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04505774\">NCT04505774</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04535869\">NCT04535869</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04535869\">NCT04535869</a></td></tr><tr><td>2020-09-04</td><td><strong><a href=\"/drugs/DB09153\">Sodium chloride</a></strong></td><td>Impact of Nasopharyngeal wash on Virion Load in COVID-19 Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45634\">CTRI/2020/08/027465</a></td></tr><tr><td>2020-09-03</td><td><strong><a href=\"/drugs/DB01430\">Almitrine</a></strong></td><td>Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia : a Randomized Controlled Double-blind Study From the Skip-icu Consortium</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357457\">NCT04357457</a></td></tr><tr><td>2020-09-03</td><td><strong><a href=\"/drugs/DB16427\">SARS-CoV-2 vaccine</a></strong></td><td>Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537208\">NCT04537208</a></td></tr><tr><td>2020-09-03</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532931\">NCT04532931</a></td></tr><tr><td>2020-09-03</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532931\">NCT04532931</a></td></tr><tr><td>2020-09-03</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532931\">NCT04532931</a></td></tr><tr><td>2020-09-03</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532931\">NCT04532931</a></td></tr><tr><td>2020-09-03</td><td><strong><a href=\"/drugs/DB00613\">Amodiaquine</a></strong></td><td>Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532931\">NCT04532931</a></td></tr><tr><td>2020-09-03</td><td><strong><a href=\"/drugs/DB09274\">Artesunate</a></strong></td><td>Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532931\">NCT04532931</a></td></tr><tr><td>2020-09-03</td><td><strong><a href=\"/drugs/DB12975\">Pyronaridine</a></strong></td><td>Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04532931\">NCT04532931</a></td></tr><tr><td>2020-09-02</td><td><strong><a href=\"/drugs/DB12534\">Mavrilimumab</a></strong></td><td>Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04463004\">NCT04463004</a></td></tr><tr><td>2020-09-02</td><td><strong><a href=\"/drugs/DB16442\">BNT162b3</a></strong></td><td>A Multi-site, Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of a BNT162 Vaccine Against COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003267-26\">EUCTR2020-003267-26-DE</a></td></tr><tr><td>2020-09-02</td><td><strong><a href=\"/drugs/DB15857\">Janssen COVID-19 Vaccine</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002584-63\">EUCTR2020-002584-63-DE</a></td></tr><tr><td>2020-09-02</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392128\">NCT04392128</a></td></tr><tr><td>2020-09-02</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392128\">NCT04392128</a></td></tr><tr><td>2020-09-02</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04383002\">NCT04383002</a></td></tr><tr><td>2020-09-02</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Assessment of response of ivermectin on virological clearance in COVID 19 : single centre, open labelled, randomised controlled trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46873\">CTRI/2020/08/027394</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15895\">XAV-19</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Phase 2 (2a and 2b) Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04453384\">NCT04453384</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID)</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04448119\">NCT04448119</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>A Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement Therapy</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445220\">NCT04445220</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Multi-Center, Double-Blinded, Placebo-Controlled, Phase II Clinical Efficacy Study Evaluating NORS To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Mild COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04443868\">NCT04443868</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00472\">Fluoxetine</a></strong></td><td>Pilot Randomized Controlled Trial : Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570449\">NCT04570449</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04424056\">NCT04424056</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04424056\">NCT04424056</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04424056\">NCT04424056</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00675\">Tamoxifen</a></strong></td><td>Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04568096\">NCT04568096</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00755\">Tretinoin</a></strong></td><td>Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04568096\">NCT04568096</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Safety and efficacy of a pharmacological strategy using Losartan in hospital patients with COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000731998.aspx\">ACTRN12620000731998</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>A Pilot Trial of Thymalfasin (Ta1) to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04428008\">NCT04428008</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB05266\">Ibudilast</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04429555\">NCT04429555</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB16433\">VXA-CoV2-1</a></strong></td><td>A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04563702\">NCT04563702</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00618\">Demeclocycline</a></strong></td><td>Multicenter Study to evaluate efficacy and safety of Demethylchlortetracycline in Patients of COVID-19 (COVID-DMC)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs051200049\">JPRN-jRCTs051200049</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>An Exploratory Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infection (COVID-19)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205416\">JPRN-JapicCTI-205416</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04400019\">NCT04400019</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>Selective Estrogen Modulation and Melatonin in Early COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04531748\">NCT04531748</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00539\">Toremifene</a></strong></td><td>Selective Estrogen Modulation and Melatonin in Early COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04531748\">NCT04531748</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB04932\">Defibrotide</a></strong></td><td>Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530604\">NCT04530604</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528888\">NCT04528888</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528888\">NCT04528888</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528888\">NCT04528888</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15327\">Abivertinib</a></strong></td><td>A Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528667\">NCT04528667</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>High Dose Vitamin-D Substitution in Patients With COVID-19 : a Randomized Controlled, Multi Center Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04525820\">NCT04525820</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00331\">Metformin</a></strong></td><td>MET-Covid Trial - METformin for Prevention and Outpatient Treatment of COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04510194\">NCT04510194</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB09153\">Sodium chloride</a></strong></td><td>Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19</td><td>Health Services Research</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04419610\">NCT04419610</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) and Human Intravenous Anti COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04395170\">NCT04395170</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00982\">Isotretinoin</a></strong></td><td>Isotretinoin in Treatment of COVID-19 (Randomized)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04353180\">NCT04353180</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>IMPACT RAPPORT : IMPact of Antimalarials on Covid Infections : a Case Control sTudy of RAPPORT</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347798\">NCT04347798</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>IMPACT RAPPORT : IMPact of Antimalarials on Covid Infections : a Case Control sTudy of RAPPORT</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347798\">NCT04347798</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15735\">Virus Specific T-Cell</a></strong></td><td>Viral Specific T-cells (VSTs) for Treatment of SARS-CoV-2 / COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04406064\">NCT04406064</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04399356\">NCT04399356</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00107\">Oxytocin</a></strong></td><td>Phase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04386447\">NCT04386447</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Safety and Efficacy of Intravenous Infusion of Wharton&#39;s Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19 : A Randomized Controlled Trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390152\">NCT04390152</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB14767\">Peginterferon lambda-1a</a></strong></td><td>A Randomized Phase 2 Trial of Peginterferon Lambda-1a (Lambda) for the Treatment of Hospitalized Patients Infected With SARS-CoV-2 With Non-critical Illness</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04388709\">NCT04388709</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>PROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT) : a Basket Trial of Prophylactic Interventions Amongst At-risk Patients</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389359\">NCT04389359</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15741\">Recombinant Bacterial ACE2 Receptors-like Enzyme</a></strong></td><td>Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04375046\">NCT04375046</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371965\">NCT04371965</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe / Very Severe COVID-19 Illness</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04337359\">NCT04337359</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Targeted Steroids for ARDS Due to COVID-19 Pneumonia : A Pilot Randomized Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360876\">NCT04360876</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357613\">NCT04357613</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE\\xc2\\xae (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356677\">NCT04356677</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50199\">ChiCTR2000030944</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15721\">Natural Killer Cell</a></strong></td><td>An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50199\">ChiCTR2000030944</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Inflammatory regulation effect of N-acetylcysteine on COVID-19 treatment, pilot, double blinded randomized placebo controlled multicenter clinical trial</td><td>Treatment</td><td>3, 4</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN60069084\">ISRCTN60069084</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15148\">Lenzilumab</a></strong></td><td>COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study Arm 4 : Effect of Lenzilumab in cancer patients with severe COVID-19 infection.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000844943.aspx\">ACTRN12620000844943</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB11942\">Selinexor</a></strong></td><td>COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study. Arm 3 : Effect of selinexor in cancer patients with moderate COVID-19 infection.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000841976.aspx\">ACTRN12620000841976</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB05258\">Interferon alfa</a></strong></td><td>COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study. Arm 2 : Effect of daily Interferon-alpha on cancer patients with known positive contact with COVID-19.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000842965.aspx\">ACTRN12620000842965</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB05258\">Interferon alfa</a></strong></td><td>COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study. Arm 1 : Effect of daily Interferon-alpha on cancer patients without known positive contact with COVID-19.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000843954.aspx\">ACTRN12620000843954</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB13924\">Varicella zoster vaccine (recombinant)</a></strong></td><td>Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents : A Randomized, Doubled-Blinded, Comparative Group Observational Study</td><td>Basic Science</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04523246\">NCT04523246</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04522986\">NCT04522986</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15743\">Stem-cell derived exosome vesicle products</a></strong></td><td>Extracellular Vesicle Infusion Treatment for Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04493242\">NCT04493242</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation : the CONFIDENT Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04558476\">NCT04558476</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Phase 2 / 3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate / Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492358\">NCT04492358</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>Phase 2 / 3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate / Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492358\">NCT04492358</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00822\">Disulfiram</a></strong></td><td>Virologic and Immunologic Response to Disulfiram in Early Symptomatic COVID+ Outpatients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04485130\">NCT04485130</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB06168\">Canakinumab</a></strong></td><td>Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04510493\">NCT04510493</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01128\">Bicalutamide</a></strong></td><td>Randomized Trial of Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04509999\">NCT04509999</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB16367\">Autologous peripheral blood-derived CD34+ cells</a></strong></td><td>CLBS119 (Autologous Peripheral Blood Derived CD34+ Cells) for Repair of COVID-19 Induced Pulmonary Damage</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04522817\">NCT04522817</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB16359\">CSL324</a></strong></td><td>A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL324 in Coronavirus Disease 2019 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04519424\">NCT04519424</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams (PROTECT)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04483635\">NCT04483635</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04482686\">NCT04482686</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>A Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04482686\">NCT04482686</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB06605\">Apixaban</a></strong></td><td>FREEDOM COVID Anticoagulation Strategy Randomized Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04512079\">NCT04512079</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>FREEDOM COVID Anticoagulation Strategy Randomized Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04512079\">NCT04512079</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Can Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Mechanical Ventilation in Ireland</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04511923\">NCT04511923</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01645\">Genistein</a></strong></td><td>A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04482595\">NCT04482595</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB16353\">Razuprotafib</a></strong></td><td>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (RESCUE Study)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04511650\">NCT04511650</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Ivermectin Inhalation Forms in the Management of COVID-19 Egyptian Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04510233\">NCT04510233</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04510038\">NCT04510038</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Real-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and / or Gougerot&#39;s Disease</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04481633\">NCT04481633</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00980\">Ramelteon</a></strong></td><td>Adjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04470297\">NCT04470297</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB09122\">Peginterferon beta-1a</a></strong></td><td>A Cluster Randomised Trial of Interferon Versus Standard of Care in the Reduction of Transmission of SARS-Cov-2. The Containing Coronavirus Disease 19 Trial (ConCorD-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04552379\">NCT04552379</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00146\">Calcifediol</a></strong></td><td>A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04551911\">NCT04551911</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE\\xc2\\xae (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04551768\">NCT04551768</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>The Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases : a Randomized Double Blind Placebo Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04551755\">NCT04551755</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>The Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases : a Randomized Double Blind Placebo Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04551755\">NCT04551755</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04534803\">NCT04534803</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB16423\">AK119</a></strong></td><td>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516564\">NCT04516564</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00058\">Alpha-1-proteinase inhibitor</a></strong></td><td>A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04547140\">NCT04547140</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB16360\">Anti-SARS-CoV-2 immunoglobulin</a></strong></td><td>An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04546581\">NCT04546581</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00927\">Famotidine</a></strong></td><td>A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04545008\">NCT04545008</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00151\">Cysteine</a></strong></td><td>A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04545008\">NCT04545008</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB09113\">Poractant alfa</a></strong></td><td>Multicenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, Curosurf\\xc2\\xae) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04502433\">NCT04502433</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00855\">Aminolevulinic acid</a></strong></td><td>An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542850\">NCT04542850</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB13771\">Ferric sodium citrate</a></strong></td><td>An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542850\">NCT04542850</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB09075\">Edoxaban</a></strong></td><td>Hamburg Edoxaban for Anticoagulation in COVID-19 Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542408\">NCT04542408</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04540926\">NCT04540926</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Impact of Colchicine in Hospitalized Colombian Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04539873\">NCT04539873</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB06260\">Aviptadil</a></strong></td><td>Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS : a Randomized, Placebo Controlled, Multicenter Trial</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04536350\">NCT04536350</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15160\">Asunercept</a></strong></td><td>A Multicenter, Randomised, Controlled, Open Label Trial on the Efficacy and Safety of Asunercept for Patients With Severe COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04535674\">NCT04535674</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB11942\">Selinexor</a></strong></td><td>COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART Study.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04534725\">NCT04534725</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15148\">Lenzilumab</a></strong></td><td>COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART Study.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04534725\">NCT04534725</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB05258\">Interferon alfa</a></strong></td><td>COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART Study.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04534725\">NCT04534725</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB16597\">Artemisia annua leaf</a></strong></td><td>Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530617\">NCT04530617</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530617\">NCT04530617</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB15798\">Mycobacterium w. Vaccine</a></strong></td><td>&quot;Randomized Controlled Trial Of Immunomodulator Mycobacterium w In Mild And Moderate Cases of Covid-19 Pneumonia&quot;</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45627\">CTRI/2020/08/027475</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>Randomized, Controlled, Open Label, Phase 2 Clinical Trial of Interferon-\\xc3\\x9f-1a (IFN\\xc3\\x9f-1a) in COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04449380\">NCT04449380</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Role of Tocilizumab in Patients with Moderate to Severe COVID-19 Pneumonia</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46546\">CTRI/2020/08/027246</a></td></tr><tr><td>2020-09-01</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04476680\">NCT04476680</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Post Exposure Prophylaxis (PEP) in Healthcare Workers Exposed to COVID-19 Patients : A Double-blind Randomized Clinical Trial</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04437693\">NCT04437693</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB13961\">Fish oil</a></strong></td><td>Randomized, Open-label, Parallel Study to Investigate Safety and Efficacy of CARDIO Softgels Plus Best Standard-of-care vs. Best Standard-of-care Alone on a Former Smoker and / or Steroid-resistant Asthma Population With COVID-19 Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04465513\">NCT04465513</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>Evaluation the effectiveness of curcumin in the treatment of patients with covid-19 sever acute respiratory syndrome</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47231\">IRCT20200418047119N1</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB16435\">AG0302-COVID19</a></strong></td><td>A Randomized, Open-label, Non-controlled Phase I / II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04527081\">NCT04527081</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB16364\">Recombinant Human Thrombopoietin</a></strong></td><td>The Combination of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) Versus Eltrombopag Monotherapy as Subsequent Treatment for Immune Thrombocytopenia During the COVID-19 Pandemic</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516837\">NCT04516837</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB06210\">Eltrombopag</a></strong></td><td>The Combination of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) Versus Eltrombopag Monotherapy as Subsequent Treatment for Immune Thrombocytopenia During the COVID-19 Pandemic</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516837\">NCT04516837</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB09027\">Ledipasvir</a></strong></td><td>Selection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients : A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45932\">CTRI/2020/08/027345</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Selection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients : A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45932\">CTRI/2020/08/027345</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Selection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients : A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45932\">CTRI/2020/08/027345</a></td></tr><tr><td>2020-08-31</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Effectiveness of Ivermectin in preventing development of symptomatic Covid-19 among primary contacts of newly diagnosed Covid-19 positive patients at a tertiary care hospital in North India - an interventional study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46676\">CTRI/2020/08/027282</a></td></tr><tr><td>2020-08-30</td><td><strong><a href=\"/drugs/DB14126\">Tenofovir</a></strong></td><td>Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir / Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04519125\">NCT04519125</a></td></tr><tr><td>2020-08-30</td><td><strong><a href=\"/drugs/DB00879\">Emtricitabine</a></strong></td><td>Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir / Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04519125\">NCT04519125</a></td></tr><tr><td>2020-08-30</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Time to Recover of Anosmia and / or Ageusia and Early Corticosteroid Use</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528329\">NCT04528329</a></td></tr><tr><td>2020-08-28</td><td><strong><a href=\"/drugs/DB16443\">Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)</a></strong></td><td>Safety, Tolerability and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population Aged 18 Years and Older : A Phase I, Single-center, Randomized, Placebo-controlled, Double-blind Study</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530656\">NCT04530656</a></td></tr><tr><td>2020-08-28</td><td><strong><a href=\"/drugs/DB09029\">Secukinumab</a></strong></td><td>Use of Anti-IL-17 in patients with the severe acute respiratory syndrome (SARS) associated with Covid-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-5vpyh4/\">RBR-5vpyh4</a></td></tr><tr><td>2020-08-28</td><td><strong><a href=\"/drugs/DB12270\">Losmapimod</a></strong></td><td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04511819\">NCT04511819</a></td></tr><tr><td>2020-08-28</td><td><strong><a href=\"/drugs/DB15857\">Janssen COVID-19 Vaccine</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04535453\">NCT04535453</a></td></tr><tr><td>2020-08-28</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Ivermectin as a potential treatment for COVID 19 : A double blind randomized placebo-controlled trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46660\">CTRI/2020/08/027225</a></td></tr><tr><td>2020-08-27</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>The C3 Nitazoxanide for Mild to Moderate COVID-19 in HIV-infected and HIV-uninfected Adults With Enhanced Risk : a Double-blind, Randomised, Placebo-controlled Trial in a Resource-poor Setting</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04523090\">NCT04523090</a></td></tr><tr><td>2020-08-27</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Higher vs. Lower Doses of Dexamethasone in Patients With COVID-19 and Severe Hypoxia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04509973\">NCT04509973</a></td></tr><tr><td>2020-08-27</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>IGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-SARS-CoV2 Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04524507\">NCT04524507</a></td></tr><tr><td>2020-08-27</td><td><strong><a href=\"/drugs/DB16438\">V591</a></strong></td><td>A Phase 1 / Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04498247\">NCT04498247</a></td></tr><tr><td>2020-08-27</td><td><strong><a href=\"/drugs/DB12386\">Bacillus calmette-guerin substrain danish 1331 live antigen</a></strong></td><td>BACILLUS CALMETTE-GU\\xc3\\x89RIN VACCINATION TO PREVENT SERIOUS RESPIRATORY TRACT INFECTION AND COVID-19 IN VULNERABLE ELDERLY \\xe2\\x80\\x93 AN ADAPTIVE RANDOMIZED CONTROLLED TRIAL - BCG-PRIME</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003470-47\">EUCTR2020-003470-47-NL</a></td></tr><tr><td>2020-08-27</td><td><strong><a href=\"/drugs/DB16355\">Sotrovimab</a></strong></td><td>A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04545060\">NCT04545060</a></td></tr><tr><td>2020-08-26</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Timing of Corticosteroids in COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530409\">NCT04530409</a></td></tr><tr><td>2020-08-26</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A Phase III Open-label Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04540393\">NCT04540393</a></td></tr><tr><td>2020-08-25</td><td><strong><a href=\"/drugs/DB12764\">Opaganib</a></strong></td><td>Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2 / 3 Study, in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia - -</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002677-95\">EUCTR2020-002677-95-IT</a></td></tr><tr><td>2020-08-25</td><td><strong><a href=\"/drugs/DB11758\">Cenicriviroc</a></strong></td><td>Charit\\xc3\\xa9 Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04500418\">NCT04500418</a></td></tr><tr><td>2020-08-25</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Phase 2b / 3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04388410\">NCT04388410</a></td></tr><tr><td>2020-08-25</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Bacillus Calmette-Gu\\xc3\\xa9rin Vaccination To Prevent Serious Respiratory Tract Infection And Covid-19 In Vulnerable Elderly - An Adaptive Randomized Controlled Trial</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537663\">NCT04537663</a></td></tr><tr><td>2020-08-24</td><td><strong><a href=\"/drugs/DB15730\">Placental Mesenchymal Stem Cells</a></strong></td><td>DSC-COVID-19 : An Open-label Study on the Safety and Efficacy of Decidual Stromal Cells in Respiratory Failure Induced by COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04451291\">NCT04451291</a></td></tr><tr><td>2020-08-24</td><td><strong><a href=\"/drugs/DB15739\">Mesenchymoangioblast-derived mesenchymal stem cells</a></strong></td><td>A Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care With COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04537351\">NCT04537351</a></td></tr><tr><td>2020-08-24</td><td><strong><a href=\"/drugs/DB16436\">AdimrSC-2f</a></strong></td><td>A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04522089\">NCT04522089</a></td></tr><tr><td>2020-08-24</td><td><strong><a href=\"/drugs/DB16524\">FINLAY-FR-1</a></strong></td><td>Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. (COVID-19) - SOBERANA 01</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000332-En\">RPCEC00000332</a></td></tr><tr><td>2020-08-24</td><td><strong><a href=\"/drugs/DB16533\">OM85</a></strong></td><td>Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04496245\">NCT04496245</a></td></tr><tr><td>2020-08-24</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A Phase 2 / 3, Observer-Blind, Randomized, Controlled Study to Determine the Safety and Immunogenicity of Covishield (COVID-19 Vaccine) in Healthy Indian Adults - ICMR / SII-COVISHIELD</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46186\">CTRI/2020/08/027170</a></td></tr><tr><td>2020-08-23</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A Phase I / II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04568031\">NCT04568031</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>Evaluation of the efficacy and safety of Melatonin in patients with COVID-19 : a randomized clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50239\">IRCT20200506047323N5</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB09153\">Sodium chloride</a></strong></td><td>Evaluating the effectiveness of intravenous ozonized saline in treatment of severe COVID-19 disease : A randomized Control trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50031\">IRCT20200730048253N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>Evaluating the effectiveness of intravenous ozonized saline in treatment of severe COVID-19 disease : A randomized Control trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50031\">IRCT20200730048253N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation and comparison of the effectiveness of Hydroxychloroquin versus Clarithromycin in recovery of dyspnea and Caugh at the end of the acute phase of COVID-19 treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49729\">IRCT20200718048129N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB01211\">Clarithromycin</a></strong></td><td>Evaluation and comparison of the effectiveness of Hydroxychloroquin versus Clarithromycin in recovery of dyspnea and Caugh at the end of the acute phase of COVID-19 treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49729\">IRCT20200718048129N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB10532\">Garlic</a></strong></td><td>The effect of garlic and cinnamon essential oil on the treatment of patients with corona (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49481\">IRCT20200705048011N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB10520\">Cinnamon</a></strong></td><td>The effect of garlic and cinnamon essential oil on the treatment of patients with corona (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49481\">IRCT20200705048011N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Evaluation effects of the standard regimen along with ivermectin on treatment of corona virus type 2 pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49280\">IRCT20190624043993N2</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB00982\">Isotretinoin</a></strong></td><td>The evaluation of isotretinoin effects on treatment of COVID-19 infections</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49257\">IRCT20190624043993N3</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB00898\">Ethanol</a></strong></td><td>Prophylaxis and treatment of COVID-19 using a nasal spray containing 3% dimethyl sulfoxide (DMSO) and 20% ethanol solution</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49924\">IRCT20200727048217N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB01093\">Dimethyl sulfoxide</a></strong></td><td>Prophylaxis and treatment of COVID-19 using a nasal spray containing 3% dimethyl sulfoxide (DMSO) and 20% ethanol solution</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49924\">IRCT20200727048217N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB01075\">Diphenhydramine</a></strong></td><td>Clinical Trial on Diphenhydramine Compound in Covid-19 Treatment</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49696\">IRCT20200504047298N3</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB09145\">Water</a></strong></td><td>Evaluation of the effect of inhaled solution based on silver colloid with the brand name colloide silver nasal spray 10ppm to control COVID-19-induced lung infection and increase patients&#39; respiratory volume</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48462\">IRCT20190226042851N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB12965\">Silver</a></strong></td><td>Evaluation of the effect of inhaled solution based on silver colloid with the brand name colloide silver nasal spray 10ppm to control COVID-19-induced lung infection and increase patients&#39; respiratory volume</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48462\">IRCT20190226042851N1</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB16431\">Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine</a></strong></td><td>A randomized, observer-blind, placebo-controlled, Phase I / II study to evaluate the safety, reactogenicity and immunogenicity of Receptor Binding Domain (RBD) SARS-CoV-2 (COVID-19) Hepatitis B surface antigen (HBsAg) virus like particle (VLP) Vaccine in Healthy Adults</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000817943.aspx\">ACTRN12620000817943</a></td></tr><tr><td>2020-08-22</td><td><strong><a href=\"/drugs/DB12255\">Vadadustat</a></strong></td><td>Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04478071\">NCT04478071</a></td></tr><tr><td>2020-08-21</td><td><strong><a href=\"/drugs/DB12764\">Opaganib</a></strong></td><td>Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2 / 3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467840\">NCT04467840</a></td></tr><tr><td>2020-08-21</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Study to assess and establish safety of convalescent plasma (CVP) drawn from mild symptomatic COVID-19 patients. - mCCP</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45050\">CTRI/2020/08/027285</a></td></tr><tr><td>2020-08-20</td><td><strong><a href=\"/drugs/DB00145\">Glycine</a></strong></td><td>Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04443673\">NCT04443673</a></td></tr><tr><td>2020-08-20</td><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>Effect of atorvastatin on mortality rate and symptom improvement in hospitalized patients with COVID-19</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49893\">IRCT20190831044653N5</a></td></tr><tr><td>2020-08-20</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04521400\">NCT04521400</a></td></tr><tr><td>2020-08-20</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>Randomized Phase IIa Clinical Trial Of Cyclosporine For The Treatment Of Covid-19(+) Non-ICU Hospital Inpatients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492891\">NCT04492891</a></td></tr><tr><td>2020-08-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>PERUCONPLASMA : Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04497324\">NCT04497324</a></td></tr><tr><td>2020-08-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04529499\">NCT04529499</a></td></tr><tr><td>2020-08-20</td><td><strong><a href=\"/drugs/DB15893\">CHO Cells Recombinant Vaccine</a></strong></td><td>A randomized, double-blind, placebo-controlled phase I clinical trial for evaluation of the safety and tolerability of recombinant novel coronavirus vaccines (CHO cells) in healthy people aged 60 years and above</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=58207\">ChiCTR2000035691</a></td></tr><tr><td>2020-08-20</td><td><strong><a href=\"/drugs/DB13156\">Inosine pranobex</a></strong></td><td>An Open-Label, Prospective, Randomized, Comparative, Parallel Group, Multi-Center, Proof of Concept Study to Assess the Efficacy and Safety of Inosine Pranobex Added to Current Standard of Care (CSC) in COVID-19 Patients.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46240\">CTRI/2020/08/027162</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB00151\">Cysteine</a></strong></td><td>Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570254\">NCT04570254</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB00806\">Pentoxifylline</a></strong></td><td>Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570254\">NCT04570254</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570254\">NCT04570254</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570254\">NCT04570254</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB00163\">Vitamin E</a></strong></td><td>Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570254\">NCT04570254</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04303299\">NCT04303299</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04303299\">NCT04303299</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04303299\">NCT04303299</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB01264\">Darunavir</a></strong></td><td>A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04303299\">NCT04303299</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04303299\">NCT04303299</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04303299\">NCT04303299</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB15718\">Bamlanivimab</a></strong></td><td>Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04518410\">NCT04518410</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Ivermectin to Prevent Hospitalizations in COVID-19 : Randomized, Double-blind, Placebo-controlled</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04529525\">NCT04529525</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB16563\">Pediococcus acidilactici</a></strong></td><td>Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota : A Randomized Clinical Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04517422\">NCT04517422</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB11360\">Lactobacillus plantarum</a></strong></td><td>Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota : A Randomized Clinical Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04517422\">NCT04517422</a></td></tr><tr><td>2020-08-19</td><td><strong><a href=\"/drugs/DB16525\">Collagen-polyvinylpyrrolidone</a></strong></td><td>Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04517162\">NCT04517162</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>Study of intra-venous ozonated auto-hemotherapy on severe cases of COVID-19 : A randomized clinical trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48978\">IRCT20200616047792N1</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy and Safety of Using Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528368\">NCT04528368</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB01039\">Fenofibrate</a></strong></td><td>FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04517396\">NCT04517396</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB15787\">AZD7442</a></strong></td><td>A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04507256\">NCT04507256</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia : the COVID STEROID 2 trial - COVID STEROID 2</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003363-25\">EUCTR2020-003363-25-DK</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB00020\">Sargramostim</a></strong></td><td>A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04411680\">NCT04411680</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB01098\">Rosuvastatin</a></strong></td><td>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359095\">NCT04359095</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB14126\">Tenofovir</a></strong></td><td>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359095\">NCT04359095</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359095\">NCT04359095</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB00879\">Emtricitabine</a></strong></td><td>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359095\">NCT04359095</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB16533\">OM85</a></strong></td><td>Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000473965.aspx\">ACTRN12620000473965</a></td></tr><tr><td>2020-08-18</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Multicenter, prospective, randomized, double-blind clinical trial for the use of Hyperbaric Oxygen Therapy in patients hospitalized with Covid-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-2fvjjm/\">RBR-2fvjjm</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB16369\">Matrix-M</a></strong></td><td>A Phase 2A / B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1\\xe2\\x84\\xa2 Adjuvant in South African Adult Subjects Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04533399\">NCT04533399</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB15810\">Nuvaxovid</a></strong></td><td>A Phase 2A / B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1\\xe2\\x84\\xa2 Adjuvant in South African Adult Subjects Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04533399\">NCT04533399</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB11154\">Zinc citrate</a></strong></td><td>Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000557932.aspx\">ACTRN12620000557932</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000557932.aspx\">ACTRN12620000557932</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000557932.aspx\">ACTRN12620000557932</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000557932.aspx\">ACTRN12620000557932</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB03614\">Mecobalamin</a></strong></td><td>Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000557932.aspx\">ACTRN12620000557932</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516746\">NCT04516746</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Safety and efficacy of intranasal delivery of BromAc\\xc2\\xae (Bromelain &amp; Acetylcysteine) in swab positive SARS-CoV-2 patients \\xe2\\x80\\x93 inactivating the COVID-19 virus by cleavage of the spike and other glycoproteins</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000788976.aspx\">ACTRN12620000788976</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB13281\">Bromelains</a></strong></td><td>Safety and efficacy of intranasal delivery of BromAc\\xc2\\xae (Bromelain &amp; Acetylcysteine) in swab positive SARS-CoV-2 patients \\xe2\\x80\\x93 inactivating the COVID-19 virus by cleavage of the spike and other glycoproteins</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000788976.aspx\">ACTRN12620000788976</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB14586\">Citrus bioflavonoids</a></strong></td><td>A single centric, prospective, open label, interventional study to evaluate the efficacy and safety of CitriobioShield as an adjunct with standard of care therapy in improving immunity in mild to moderate COVID 19 patients through inhalation of fog.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46278\">CTRI/2020/08/027085</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB10316\">Mumps virus strain B level jeryl lynn live antigen</a></strong></td><td>Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / Inflammation</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475081\">NCT04475081</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB10317\">Rubella virus vaccine</a></strong></td><td>Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / Inflammation</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475081\">NCT04475081</a></td></tr><tr><td>2020-08-17</td><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / Inflammation</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475081\">NCT04475081</a></td></tr><tr><td>2020-08-16</td><td><strong><a href=\"/drugs/DB09298\">Silibinin</a></strong></td><td>Trial of Silymarin in Adults With COVID-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394208\">NCT04394208</a></td></tr><tr><td>2020-08-15</td><td><strong><a href=\"/drugs/DB00877\">Sirolimus</a></strong></td><td>Efficacy and Safety of Sirolimus for Treating COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04461340\">NCT04461340</a></td></tr><tr><td>2020-08-15</td><td><strong><a href=\"/drugs/DB09241\">Methylene blue</a></strong></td><td>Methylene Blue for the Treatment of COVID-19 : A Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/50275\">IRCT20090701002113N2</a></td></tr><tr><td>2020-08-15</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Preventing Pulmonary Complications In Surgical Patients At Risk Of COVID-19 - PROTECT-Surg</td><td>Treatment</td><td>3, 4</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482\">CTRI/2020/06/026196</a></td></tr><tr><td>2020-08-15</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Preventing Pulmonary Complications In Surgical Patients At Risk Of COVID-19 - PROTECT-Surg</td><td>Treatment</td><td>3, 4</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482\">CTRI/2020/06/026196</a></td></tr><tr><td>2020-08-15</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>High Flow Nasal Oxygen Versus Continuous Positive Airway Pressure Helmet Evaluation : A Randomized Crossover Trial in COVID-19 Pneumonia</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04381923\">NCT04381923</a></td></tr><tr><td>2020-08-15</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347954\">NCT04347954</a></td></tr><tr><td>2020-08-15</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>COVID-19 Stem Cell Therapy : A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem Cells</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04486001\">NCT04486001</a></td></tr><tr><td>2020-08-15</td><td><strong><a href=\"/drugs/DB01240\">Epoprostenol</a></strong></td><td>Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04452669\">NCT04452669</a></td></tr><tr><td>2020-08-14</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Lessening Organ Dysfunction With VITamin C - COVID</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04401150\">NCT04401150</a></td></tr><tr><td>2020-08-14</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04513158\">NCT04513158</a></td></tr><tr><td>2020-08-13</td><td><strong><a href=\"/drugs/DB00806\">Pentoxifylline</a></strong></td><td>Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04433988\">NCT04433988</a></td></tr><tr><td>2020-08-13</td><td><strong><a href=\"/drugs/DB12598\">Nafamostat</a></strong></td><td>Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390594\">NCT04390594</a></td></tr><tr><td>2020-08-13</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04486313\">NCT04486313</a></td></tr><tr><td>2020-08-13</td><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04508023\">NCT04508023</a></td></tr><tr><td>2020-08-13</td><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>A Prospective, Single-Center, Investigator Initiated Clinical Study to Evaluate the Effectiveness and Safety of Thymosin \\xc3\\x8e\\xc2\\xb1-1 (T\\xc3\\x8e\\xc2\\xb11) in severe COVID-19 patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45729\">CTRI/2020/08/027061</a></td></tr><tr><td>2020-08-12</td><td><strong><a href=\"/drugs/DB14533\">Zinc chloride</a></strong></td><td>A Phase 2 evaluation of the efficacy of homoeopathic remedy Zincum Muriaticum as an adjuvant therapy to standard of care in adult patients with moderate to severe COVID-19 : Randomized, double-blind, parallel group, placebo controlled, multicenter trial (ZIMCOV)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46189\">CTRI/2020/08/027005</a></td></tr><tr><td>2020-08-12</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04438057\">NCT04438057</a></td></tr><tr><td>2020-08-12</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04411446\">NCT04411446</a></td></tr><tr><td>2020-08-12</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04411446\">NCT04411446</a></td></tr><tr><td>2020-08-12</td><td><strong><a href=\"/drugs/DB14810\">AZD-1656</a></strong></td><td>A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516759\">NCT04516759</a></td></tr><tr><td>2020-08-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine : a Randomized Comparator Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04387760\">NCT04387760</a></td></tr><tr><td>2020-08-11</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine : a Randomized Comparator Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04387760\">NCT04387760</a></td></tr><tr><td>2020-08-11</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Clinical-trial of COVID-19 Convalescent Plasma in Outpatients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355767\">NCT04355767</a></td></tr><tr><td>2020-08-11</td><td><strong><a href=\"/drugs/DB15857\">Janssen COVID-19 Vaccine</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Adults</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04509947\">NCT04509947</a></td></tr><tr><td>2020-08-11</td><td><strong><a href=\"/drugs/DB12814\">Cepeginterferon alfa-2B</a></strong></td><td>A Phase II, Multicenter, Open-label, Randomized, Comparator Controlled Study to Evaluate the Efficacy and Safety of Pegylated Interferon - a2b in the Treatment of Adult Patients Diagnosed With SARS-CoV2 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04480138\">NCT04480138</a></td></tr><tr><td>2020-08-11</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - Discovery</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23\">EUCTR2020-000936-23-PT</a></td></tr><tr><td>2020-08-11</td><td><strong><a href=\"/drugs/DB15809\">CIGB-258 peptide</a></strong></td><td>Evaluation of the effect and safety of the CIGB-258 peptide in the treatment of seriously or critically ill patients due to COVID-19. (COVID-19)</td><td>Treatment</td><td>2</td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000330-En\">RPCEC00000330</a></td></tr><tr><td>2020-08-11</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04474483\">NCT04474483</a></td></tr><tr><td>2020-08-10</td><td><strong><a href=\"/drugs/DB16428\">GRAd-COV2</a></strong></td><td>A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528641\">NCT04528641</a></td></tr><tr><td>2020-08-10</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>COVID-19 : BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04369794\">NCT04369794</a></td></tr><tr><td>2020-08-10</td><td><strong><a href=\"/drugs/DB15862\">Inactivated SARS-Cov-2 Vaccine</a></strong></td><td>A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04508075\">NCT04508075</a></td></tr><tr><td>2020-08-10</td><td><strong><a href=\"/drugs/DB16430\">TMV-083</a></strong></td><td>A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04497298\">NCT04497298</a></td></tr><tr><td>2020-08-10</td><td><strong><a href=\"/drugs/DB00746\">Deferoxamine</a></strong></td><td>Evaluation of the effects of Desferal on clinical symptoms in patients with COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49881\">IRCT20200506047323N4</a></td></tr><tr><td>2020-08-10</td><td><strong><a href=\"/drugs/DB15730\">Placental Mesenchymal Stem Cells</a></strong></td><td>A Phase 1 clinical trial of intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with novel COVID-19 virus pneumonia.</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43175\">CTRI/2020/08/027043</a></td></tr><tr><td>2020-08-10</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>A Phase 1 clinical trial of intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with novel COVID-19 virus pneumonia.</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43175\">CTRI/2020/08/027043</a></td></tr><tr><td>2020-08-09</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>Curcumin for COVID-19 Pre Exposure Prophylaxis : A Randomised Controlled Trail</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45936\">CTRI/2020/07/026820</a></td></tr><tr><td>2020-08-08</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for Patients With COVID-19 : A Randomized, Single Blinded, Parallel, Controlled Clinical Study</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04332835\">NCT04332835</a></td></tr><tr><td>2020-08-08</td><td><strong><a href=\"/drugs/DB14512\">Mometasone furoate</a></strong></td><td>Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04484493\">NCT04484493</a></td></tr><tr><td>2020-08-07</td><td><strong><a href=\"/drugs/DB08887\">Icosapent ethyl</a></strong></td><td>A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE)</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04505098\">NCT04505098</a></td></tr><tr><td>2020-08-07</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>CSP #2030 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04545047\">NCT04545047</a></td></tr><tr><td>2020-08-07</td><td><strong><a href=\"/drugs/DB15895\">XAV-19</a></strong></td><td>A randomized, double-blind, placebo-controlled phase 2a and 2b study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia - POLYCOR</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002574-27\">EUCTR2020-002574-27-FR</a></td></tr><tr><td>2020-08-07</td><td><strong><a href=\"/drugs/DB16358\">MW33</a></strong></td><td>A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Immunogenicity of a Single Dose of MW33 Injection in Healthy Subjects</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04533048\">NCT04533048</a></td></tr><tr><td>2020-08-06</td><td><strong><a href=\"/drugs/DB09228\">Conestat alfa</a></strong></td><td>Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 : a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04414631\">NCT04414631</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>To evaluate efficacy of Bacillus Calmette-Guerin (BCG) in Reducing the Incidence and severity of COVID-19 in the high-risk population (BRIC) : a phase III, Multicentric, Quadruple blind Randomized controlled trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45677\">CTRI/2020/07/026668</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>Investigating the effect of curcumin-piperine supplementation in accelerating the recovery period of patients with covid-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48275\">IRCT20200514047445N1</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB14767\">Peginterferon lambda-1a</a></strong></td><td>Pegylated Interferon Lambda for Treatment of COVID-19 Infection- A Randomized Open Label Pilot Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04534673\">NCT04534673</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB00758\">Clopidogrel</a></strong></td><td>A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409834\">NCT04409834</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409834\">NCT04409834</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409834\">NCT04409834</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB08954\">Ifenprodil</a></strong></td><td>A Randomized Open Label Phase 2b / 3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382924\">NCT04382924</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB11133\">Omega-3 fatty acids</a></strong></td><td>The Effect of Omega-3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19 ; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04483271\">NCT04483271</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB16360\">Anti-SARS-CoV-2 immunoglobulin</a></strong></td><td>A Phase 1 / 2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04550325\">NCT04550325</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>BCG revaccination of health care professionals working in the COVID-19 pandemic, a preventive strategy to improve innate immune response</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-4kjqtg/\">RBR-4kjqtg</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB11720\">Angiotensin 1-7</a></strong></td><td>Randomized clinical trial phase I / II for the use of angiotensin-(1-7) in the treatment of severe infection by Sara-CoV-2</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-35734p/\">RBR-35734p</a></td></tr><tr><td>2020-08-05</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>The Effect of Weekly 50,000 IU Vitamin D3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19 ; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People With Vitamin D Deficiency</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04476745\">NCT04476745</a></td></tr><tr><td>2020-08-04</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492475\">NCT04492475</a></td></tr><tr><td>2020-08-04</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492475\">NCT04492475</a></td></tr><tr><td>2020-08-04</td><td><strong><a href=\"/drugs/DB15718\">Bamlanivimab</a></strong></td><td>A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04501978\">NCT04501978</a></td></tr><tr><td>2020-08-04</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04501978\">NCT04501978</a></td></tr><tr><td>2020-08-03</td><td><strong><a href=\"/drugs/DB14276\">Turmeric</a></strong></td><td>Efficacy of Ayurvedic Medicine Haldi 30 drops as an Add on medication to standard of care in adult patients of mild to moderate COVID 19. A Phase II randomized, single - blind, parallel group, placebo - controlled trial.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45659\">CTRI/2020/07/026841</a></td></tr><tr><td>2020-08-03</td><td><strong><a href=\"/drugs/DB13906\">Aloe vera leaf</a></strong></td><td>A clinical study to evaluate the efficacy of tablet of Aloe Vera gel (Aloe barbadenesis),Mur Makki (Commiphora myrrha) and Sanna-e-Makki (Senna Alexandrina) in the management of mild cases of confirmed Covid -19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45623\">CTRI/2020/07/026669</a></td></tr><tr><td>2020-08-03</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>RAAS blockagE in SARS COV-2 Critically ill patiEnts\\xe2\\x80\\x93 a Randomized controlled trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN48734830\">ISRCTN48734830</a></td></tr><tr><td>2020-08-03</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical Ventilation</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04397796\">NCT04397796</a></td></tr><tr><td>2020-08-03</td><td><strong><a href=\"/drugs/DB15869\">Platelet Lysate</a></strong></td><td>Autologous Nebulized Platelet Lysate for Post COVID-19 Syndrome</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04487691\">NCT04487691</a></td></tr><tr><td>2020-08-03</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM (RUXCOVID)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=030-20\">PER-030-20</a></td></tr><tr><td>2020-08-03</td><td><strong><a href=\"/drugs/DB07795\">Fisetin</a></strong></td><td>COVID-FISETIN : A Phase 2 Placebo-Controlled Pilot Study in Covid-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04476953\">NCT04476953</a></td></tr><tr><td>2020-08-02</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04499313\">NCT04499313</a></td></tr><tr><td>2020-08-02</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04499313\">NCT04499313</a></td></tr><tr><td>2020-08-02</td><td><strong><a href=\"/drugs/DB15718\">Bamlanivimab</a></strong></td><td>A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff ; a NIAID and Lilly Collaborative Study</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04497987\">NCT04497987</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A randomized control trial comparing convalescent plasma therapy plus standard treatment versus standard treatment alone in patients with severe COVID-19 pneumonia at a tertiary hospital</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11047\">PACTR202007653923168</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB14256\">Centella asiatica</a></strong></td><td>Survey on depression, anxiety and stress during Covid-19 in general population of Hassan district and its management with Brahmi (Bacopa monnieri (L.) Pennell) - DAS-COVID-19-AYU</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45683\">CTRI/2020/07/026952</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445467\">NCT04445467</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Pilot Double Blinded Randomized Placebo Controlled Multi Central Clinical Trial on Inflammatory Regulation Effect of NAC on COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04455243\">NCT04455243</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>A Randomised Control Trial of Statin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection (RESIST Trial) - RESIST Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44814\">CTRI/2020/07/026791</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>A Randomised Control Trial of Statin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection (RESIST Trial) - RESIST Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44814\">CTRI/2020/07/026791</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>Clinical Study for the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus 2019 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04428801\">NCT04428801</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15327\">Abivertinib</a></strong></td><td>A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04440007\">NCT04440007</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00443\">Betamethasone</a></strong></td><td>Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04569825\">NCT04569825</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435015\">NCT04435015</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Phase I Study of the Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04462848\">NCT04462848</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00220\">Nelfinavir</a></strong></td><td>Clinical Trial Evaluating the Therapeutic Potential of Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04471662\">NCT04471662</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Clinical Trial Evaluating the Therapeutic Potential of Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04471662\">NCT04471662</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04460443\">NCT04460443</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04460443\">NCT04460443</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB09027\">Ledipasvir</a></strong></td><td>Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04460443\">NCT04460443</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 &amp; magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45075\">CTRI/2020/06/026191</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15664\">Vitamin K7</a></strong></td><td>Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 &amp; magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45075\">CTRI/2020/06/026191</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00170\">Menadione</a></strong></td><td>Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 &amp; magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45075\">CTRI/2020/06/026191</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB14513\">Magnesium</a></strong></td><td>Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 &amp; magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45075\">CTRI/2020/06/026191</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB14936\">Menaquinone 6</a></strong></td><td>Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 &amp; magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45075\">CTRI/2020/06/026191</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB11189\">Magnesium glycinate</a></strong></td><td>Randomized, Double Blind, Parallel Group Study of Vitamin D3 &amp; Magnesium in Covid 19 Infection - Covid</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45029\">CTRI/2020/06/026189</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Randomized, Double Blind, Parallel Group Study of Vitamin D3 &amp; Magnesium in Covid 19 Infection - Covid</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45029\">CTRI/2020/06/026189</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04416048\">NCT04416048</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15730\">Placental Mesenchymal Stem Cells</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389450\">NCT04389450</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB02285\">Protoporphyrin</a></strong></td><td>Efficacy of Based MRI Contrast Media Against Covid-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371822\">NCT04371822</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB11720\">Angiotensin 1-7</a></strong></td><td>Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04401423\">NCT04401423</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>A Randomized, Observer-Blind, Dose-escalation Phase I / II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to &lt;85 Years of Age in Canada</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04398147\">NCT04398147</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID19-Induced ARDS : A Randomized, Controlled Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345601\">NCT04345601</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00477\">Chlorpromazine</a></strong></td><td>Administration of Chlorpromazine as a Treatment for COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354805\">NCT04354805</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>Phase I Study to Evaluate the Safety, Tolerability, Pharmacodynamics (PD) and Pharmacokinetics (PK) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in Healthy Volunteers</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04524052\">NCT04524052</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Intranasal Heparin Tolerability Study</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04490239\">NCT04490239</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00203\">Sildenafil</a></strong></td><td>Sildenafil for Treating Patients With COVID-19 and Perfusion Mismatch : A Pilot Randomised Trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04489446\">NCT04489446</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB11952\">Duvelisib</a></strong></td><td>Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04487886\">NCT04487886</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Assessment of the Safety of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above Illness</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516954\">NCT04516954</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04513184\">NCT04513184</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB12610\">Ebselen</a></strong></td><td>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04484025\">NCT04484025</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB12610\">Ebselen</a></strong></td><td>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04483973\">NCT04483973</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto\\xc2\\xae) for High Risk People With Mild COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04504032\">NCT04504032</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Clinical Trial of the Safety and Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Hospitalized Patients in Lagos State</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12168\">PACTR202006760881890</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB16424\">Allocetra</a></strong></td><td>A Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory Dysfunction</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04513470\">NCT04513470</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Effectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04510662\">NCT04510662</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Phase I / II Trial (Safety and Dosing) of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04510402\">NCT04510402</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis / Plasmaf\\xc3\\xa9resis terap\\xc3\\xa9utica en Pacientes Adultos cr\\xc3\\xadticamente Enfermos Con diagn\\xc3\\xb3stico Confirmado de COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04480632\">NCT04480632</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Controlled, Phase 2, Randomized Study to Evaluate Safety and Efficacy of Oral Maraviroc and / or Favipiravir vs Currently Used Therapy in Severe Adults With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475991\">NCT04475991</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB04835\">Maraviroc</a></strong></td><td>A Controlled, Phase 2, Randomized Study to Evaluate Safety and Efficacy of Oral Maraviroc and / or Favipiravir vs Currently Used Therapy in Severe Adults With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475991\">NCT04475991</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB01098\">Rosuvastatin</a></strong></td><td>Colchicine / Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04472611\">NCT04472611</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Colchicine / Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04472611\">NCT04472611</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00927\">Famotidine</a></strong></td><td>Role of Famotidine in the Symptomatic Improvement of Moderate to Severe COVID-19 Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04504240\">NCT04504240</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB12764\">Opaganib</a></strong></td><td>Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen But Not Mechanical Ventilation</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04502069\">NCT04502069</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB16395\">Efineptakin alfa</a></strong></td><td>A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04501796\">NCT04501796</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB06605\">Apixaban</a></strong></td><td>COVID-19 Outpatient Thrombosis Prevention Trial : A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of Diagnosis</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04498273\">NCT04498273</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>COVID-19 Outpatient Thrombosis Prevention Trial : A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of Diagnosis</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04498273\">NCT04498273</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB06303\">Otilimab</a></strong></td><td>A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=042-20\">PER-042-20</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB08882\">Linagliptin</a></strong></td><td>Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542213\">NCT04542213</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Trial of Anti-SARS-CoV-2 Plasma in Hospitalized Non-ICU Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467151\">NCT04467151</a></td></tr><tr><td>2020-08-01</td><td><strong><a href=\"/drugs/DB01281\">Abatacept</a></strong></td><td>Abatacept for Patients With COVID-19 and Respiratory Distress</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04477642\">NCT04477642</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB10672\">Clove</a></strong></td><td>Clinical trials to evaluate prophylactic action of Twakadi herbal tea in police professionals working in COVID19 pandemic</td><td>Treatment</td><td>3, 4</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45587\">CTRI/2020/07/026925</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB14275\">Indian frankincense</a></strong></td><td>A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45111\">CTRI/2020/07/026789</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB13132\">Artemisinin</a></strong></td><td>A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45111\">CTRI/2020/07/026789</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45111\">CTRI/2020/07/026789</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45111\">CTRI/2020/07/026789</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04438850\">NCT04438850</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB09299\">Tenofovir alafenamide</a></strong></td><td>Randomized, Double-blind, Placebo-controlled Trial of TAF / FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405271\">NCT04405271</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB00879\">Emtricitabine</a></strong></td><td>Randomized, Double-blind, Placebo-controlled Trial of TAF / FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405271\">NCT04405271</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390022\">NCT04390022</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB14810\">AZD-1656</a></strong></td><td>A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCADIA Trial - ARCADIA</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002211-21\">EUCTR2020-002211-21-GB</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB06196\">Icatibant</a></strong></td><td>I-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04488081\">NCT04488081</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>I-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04488081\">NCT04488081</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB05676\">Apremilast</a></strong></td><td>I-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04488081\">NCT04488081</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB11758\">Cenicriviroc</a></strong></td><td>I-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04488081\">NCT04488081</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>The Role of Vitamin D in Mitigating COVID-19 Infection Severity : Focusing on Reducing Health Disparities in South Carolina</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04482673\">NCT04482673</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48583\">IRCT20200525047570N1</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48583\">IRCT20200525047570N1</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB15753\">Interferon Gamma</a></strong></td><td>A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48583\">IRCT20200525047570N1</a></td></tr><tr><td>2020-07-31</td><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>An Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04497948\">NCT04497948</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB15810\">Nuvaxovid</a></strong></td><td>A Phase 2A / B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1\\xe2\\x84\\xa2 Adjuvant in South African Adult Subjects Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV. COVID-19</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12319\">PACTR202009726132275</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Compassionate Use of Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Prospective Observational Study (Amended Protocol)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04570982\">NCT04570982</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Multi-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466098\">NCT04466098</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB14509\">Lithium carbonate</a></strong></td><td>A randomized control study to evaluate the therapeutic effects of Lithium in Covid-19 patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44766\">CTRI/2020/06/026193</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB11590\">Thimerosal</a></strong></td><td>A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04522830\">NCT04522830</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Nested Interventional Cohort Study to Assess the Efficacy and Safety of Adjunctive Humanized Monoclonal Interleukin-6 Receptor Blocker Tocilizumab (TCZ) Therapy to Standard of Care for the Reduction of Hyperinflammation Related Mortality in SARS-Cov2 Positive Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04423042\">NCT04423042</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB15746\">Recombinant Human Plasma Gelsolin</a></strong></td><td>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358406\">NCT04358406</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04486508\">NCT04486508</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04486508\">NCT04486508</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04486508\">NCT04486508</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Evaluating the efficacy and safety of Ivermectin in the treatment of COVID-19 patients : A double-blind randomized controlled trial, phase II</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49935\">IRCT20200404046937N4</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB06260\">Aviptadil</a></strong></td><td>RLF-100 (Aviptadil) Intermediate Population Expanded Access Protocol</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04453839\">NCT04453839</a></td></tr><tr><td>2020-07-30</td><td><strong><a href=\"/drugs/DB15853\">RUTI\\xc2\\xae Vaccine</a></strong></td><td>Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of the RUTI\\xc2\\xae Vaccine to Prevent SARS-CoV-2 Infection</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04453488\">NCT04453488</a></td></tr><tr><td>2020-07-29</td><td><strong><a href=\"/drugs/DB15728\">Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media</a></strong></td><td>Emergency Use Pilot Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of COVID-19 Related Acute Respiratory Distress Syndrome</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04565665\">NCT04565665</a></td></tr><tr><td>2020-07-29</td><td><strong><a href=\"/drugs/DB08895\">Tofacitinib</a></strong></td><td>Investigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04415151\">NCT04415151</a></td></tr><tr><td>2020-07-29</td><td><strong><a href=\"/drugs/DB01261\">Sitagliptin</a></strong></td><td>The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365517\">NCT04365517</a></td></tr><tr><td>2020-07-29</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Early Treatment of Cytokine Storm Syndrome in Covid-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362111\">NCT04362111</a></td></tr><tr><td>2020-07-29</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04494399\">NCT04494399</a></td></tr><tr><td>2020-07-29</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04494399\">NCT04494399</a></td></tr><tr><td>2020-07-28</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>RECOVER : Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04470544\">NCT04470544</a></td></tr><tr><td>2020-07-28</td><td><strong><a href=\"/drugs/DB04743\">Nimesulide</a></strong></td><td>The role of Nimesulide in the treatment of COVID-19 infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49901\">IRCT20200723048178N1</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Comparison of High Flow Nasal Oxygen and Non Invasive Ventilation in Acute Hypoxemic Respiratory Failure due to Severe COVID-19 pneumonia : A Randomized Controlled Trial</td><td>Treatment</td><td>3, 4</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44539\">CTRI/2020/07/026835</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Efficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 Patients</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04443270\">NCT04443270</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB14276\">Turmeric</a></strong></td><td>&quot;Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patients\\xc3\\xa2??</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45712\">CTRI/2020/07/026674</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB10344\">Ginger</a></strong></td><td>&quot;Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patients\\xc3\\xa2??</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45712\">CTRI/2020/07/026674</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB14312\">Glycyrrhiza glabra</a></strong></td><td>&quot;Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patients\\xc3\\xa2??</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45712\">CTRI/2020/07/026674</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB10675\">Licorice</a></strong></td><td>&quot;Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patients\\xc3\\xa2??</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45712\">CTRI/2020/07/026674</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB10557\">Black pepper</a></strong></td><td>&quot;Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patients\\xc3\\xa2??</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45712\">CTRI/2020/07/026674</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB10520\">Cinnamon</a></strong></td><td>&quot;Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patients\\xc3\\xa2??</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45712\">CTRI/2020/07/026674</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45728\">CTRI/2020/07/026671</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Randomized Study Of the Effect of Dexamethasone and Methylprednisolone on levels of IL-6 and clinical outcome in severe COVID-19 - REDMIC</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45638\">CTRI/2020/07/026608</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Randomized Study Of the Effect of Dexamethasone and Methylprednisolone on levels of IL-6 and clinical outcome in severe COVID-19 - REDMIC</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45638\">CTRI/2020/07/026608</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>A Randomised Phase II / III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04455815\">NCT04455815</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB16439\">EpiVacCorona</a></strong></td><td>Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04527575\">NCT04527575</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB15654\">Moderna COVID-19 Vaccine</a></strong></td><td>A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04470427\">NCT04470427</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB00653\">Magnesium sulfate</a></strong></td><td>Evaluation of the efficacy and safety of inhaled magnesium sulfate in combination with standard treatment in Covid-19 patients : a clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49879\">IRCT20191211045691N1</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB09079\">Nintedanib</a></strong></td><td>Efficacy and safety of nintedanib on lung fibrosis in severe pneumonia induced by coronavirus disease 2019 : Historical control study.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs051200036\">JPRN-jRCTs051200036</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB16363\">PlasmaCord</a></strong></td><td>Clinical study to evaluate the safety and tolerability of intravenous infusion of plasma from human umbilical cord and placental blood (Plasmacord\\xc2\\xae) in patients with Severe Acute Respiratory Syndrome resulting from Sars-Cov-2 infection</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-4pfygr/\">RBR-4pfygr</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB14940\">Aspartyl-alanyl-diketopiperazine</a></strong></td><td>A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampion\\xe2\\x84\\xa2 in Adult COVID-19 Patients Requiring Oxygen Supplementation</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456452\">NCT04456452</a></td></tr><tr><td>2020-07-27</td><td><strong><a href=\"/drugs/DB12534\">Mavrilimumab</a></strong></td><td>A Phase 2 / 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04447469\">NCT04447469</a></td></tr><tr><td>2020-07-26</td><td><strong><a href=\"/drugs/DB15691\">Anti-SARS-CoV-2 REGN-COV2</a></strong></td><td>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04519437\">NCT04519437</a></td></tr><tr><td>2020-07-26</td><td><strong><a href=\"/drugs/DB14342\">Taraxacum officinale leaf</a></strong></td><td>Determination of dandelion herbal capsule (Dandelherb) efficacy on symptom of patient with Covid-19 virus : a clinical trial study</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49803\">IRCT20180513039641N2</a></td></tr><tr><td>2020-07-26</td><td><strong><a href=\"/drugs/DB10755\">Taraxacum officinale pollen</a></strong></td><td>Determination of dandelion herbal capsule (Dandelherb) efficacy on symptom of patient with Covid-19 virus : a clinical trial study</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49803\">IRCT20180513039641N2</a></td></tr><tr><td>2020-07-25</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Safety and Feasibility of Allogenic Mesenchymal Stromal Cells in the Treatment of COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467047\">NCT04467047</a></td></tr><tr><td>2020-07-25</td><td><strong><a href=\"/drugs/DB15313\">DAS-181</a></strong></td><td>DAS181 for COVID-19 : A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind Study</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354389\">NCT04354389</a></td></tr><tr><td>2020-07-25</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>Evaluation of the efficacy and safety of Favipiravir and Interferon beta compared to Lopinavir / Ritonavir and Interferon beta in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49463\">IRCT20200506047323N3</a></td></tr><tr><td>2020-07-25</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Evaluation of the efficacy and safety of Favipiravir and Interferon beta compared to Lopinavir / Ritonavir and Interferon beta in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49463\">IRCT20200506047323N3</a></td></tr><tr><td>2020-07-24</td><td><strong><a href=\"/drugs/DB12849\">Clazakizumab</a></strong></td><td>A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. - CLiCK Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002476-13\">EUCTR2020-002476-13-GB</a></td></tr><tr><td>2020-07-24</td><td><strong><a href=\"/drugs/DB15304\">iota-Carrageenan</a></strong></td><td>Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02)</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04521322\">NCT04521322</a></td></tr><tr><td>2020-07-24</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>A Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04476992\">NCT04476992</a></td></tr><tr><td>2020-07-23</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04464408\">NCT04464408</a></td></tr><tr><td>2020-07-23</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Phase 1 / 2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04494386\">NCT04494386</a></td></tr><tr><td>2020-07-23</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04447235\">NCT04447235</a></td></tr><tr><td>2020-07-23</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04447235\">NCT04447235</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB09053\">Ibrutinib</a></strong></td><td>Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04439006\">NCT04439006</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB09130\">Copper</a></strong></td><td>A Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45584\">CTRI/2020/07/026515</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB16522\">Sodium copper chlorophyllin</a></strong></td><td>A Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45584\">CTRI/2020/07/026515</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB02709\">Resveratrol</a></strong></td><td>A Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45584\">CTRI/2020/07/026515</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB02709\">Resveratrol</a></strong></td><td>A Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45580\">CTRI/2020/07/026514</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB16522\">Sodium copper chlorophyllin</a></strong></td><td>A Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45580\">CTRI/2020/07/026514</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB09130\">Copper</a></strong></td><td>A Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45580\">CTRI/2020/07/026514</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB00220\">Nelfinavir</a></strong></td><td>Evaluation of Nelfinavir for asymptomatic and mild COVID-19 : A multicenter open-label, blinded outcome, randomized controlled trial - NFV trial for asymptomatic and mild COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCT2071200023\">JPRN-jRCT2071200023</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB09112\">Nitrous acid</a></strong></td><td>Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite : A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04401527\">NCT04401527</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Clinical trial of efficacy and safety of mesenchymal stem cell transplantation in patients with COVID-19 pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49385\">IRCT20200426047206N2</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>Evaluating the effect of Cyclosporine in prognosis and clinical improvement in patients with COVID-19 : A Randomized Clinical Trial Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49579\">IRCT20200426047206N3</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Evaluation of the effect of Ivermectin in hospitalized patients with COVID-19 in Imam Reza Hospital in Mashhad</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49180\">IRCT20190602043787N3</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB00176\">Fluvoxamine</a></strong></td><td>Effect of fluvoxamine medicine on cytokine level of COVID-19 patients, hospitalized in ICU ward</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50977\">IRCT20131115015405N4</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB12534\">Mavrilimumab</a></strong></td><td>A PHASE 2 / 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAVRILIMUMAB (KPL-301) TREATMENT IN ADULT SUBJECTS HOSPITALIZED WITH SEVERE COVID-19 PNEUMONIA AND HYPER-INFLAMMATION</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=032-20\">PER-032-20</a></td></tr><tr><td>2020-07-22</td><td><strong><a href=\"/drugs/DB01117\">Atovaquone</a></strong></td><td>Atovaquone for Treatment of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456153\">NCT04456153</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04461379\">NCT04461379</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB14352\">Azadirachta indica leaf</a></strong></td><td>Prophylaxis with Neem Capsules (Azadirachta indica) in Healthcare personnel and relatives in Contact with COVID-19 Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45385\">CTRI/2020/07/026560</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB15744\">CAP-1002</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients With Severe COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338347\">NCT04338347</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB01097\">Leflunomide</a></strong></td><td>Targeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19) - DEFEAT- Covid Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002952-18\">EUCTR2020-002952-18-GB</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04483960\">NCT04483960</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04483960\">NCT04483960</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04483960\">NCT04483960</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04483960\">NCT04483960</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>Evaluation of atorvastatin tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad : A double-blind randomized placebo controlled clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49629\">IRCT20200408046990N3</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB00471\">Montelukast</a></strong></td><td>Effect of Montelukast on inflammatory factors in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49420\">IRCT20180624040213N2</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase 2 / 3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734\\xe2\\x84\\xa2) in Participants From Birth to &lt; 18 Years of Age With COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04431453\">NCT04431453</a></td></tr><tr><td>2020-07-21</td><td><strong><a href=\"/drugs/DB15806\">CoronaVac</a></strong></td><td>Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456595\">NCT04456595</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB00673\">Aprepitant</a></strong></td><td>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04470622\">NCT04470622</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB01390\">Sodium bicarbonate</a></strong></td><td>A randomized open label parallel group trial to study the safety and efficacy of steam impregnated with 8.4 % Sodium Bicarbonate in patients with Covid-19 infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45535\">CTRI/2020/07/026535</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB06243\">Eflornithine</a></strong></td><td>An open label, randomized, three treatment, three arm, parallel group, investigator initiated, comparative clinical trial to evaluate the safety and efficacy of Eflornithine against the standard of care in human adult hospitalized COVID-19 patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45475\">CTRI/2020/07/026529</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04384458\">NCT04384458</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04384458\">NCT04384458</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia : A Randomized, Controlled, 2x2 Factorial Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04485429\">NCT04485429</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia : A Randomized, Controlled, 2x2 Factorial Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04485429\">NCT04485429</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12183\">PACTR202007720062393</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12183\">PACTR202007720062393</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150\">PACTR202006537901307</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150\">PACTR202006537901307</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150\">PACTR202006537901307</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB01281\">Abatacept</a></strong></td><td>Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04472494\">NCT04472494</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB16520\">COVID-19 Spike-GM-CSF Protein Lactated Ringer&#39;s Injection</a></strong></td><td>Conducting an Initial Small, Controlled Clinical Trial to Assess for COVID-19 Therapeutic Biologics Activity (Proof-of-concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients.</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT03348670\">NCT03348670</a></td></tr><tr><td>2020-07-20</td><td><strong><a href=\"/drugs/DB15695\">BNT162b1 SARS-CoV-2 Vaccine</a></strong></td><td>Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects : A Phase I, Randomized, Placebo-controlled, Observer-blind Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=56834\">ChiCTR2000034825</a></td></tr><tr><td>2020-07-18</td><td><strong><a href=\"/drugs/DB00764\">Mometasone</a></strong></td><td>Effect of inhaled corticosteroids in the treatment of anosmia in patients with COVID-19</td><td>Treatment</td><td>1</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48379\">IRCT20200522047542N1</a></td></tr><tr><td>2020-07-17</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04477993\">NCT04477993</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Favipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARE</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002106-68\">EUCTR2020-002106-68-GB</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Favipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARE</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002106-68\">EUCTR2020-002106-68-GB</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Favipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARE</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002106-68\">EUCTR2020-002106-68-GB</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB15862\">Inactivated SARS-Cov-2 Vaccine</a></strong></td><td>Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Safety and Protective Efficacy of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 18 Years and above</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=56651\">ChiCTR2000034780</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04432272\">NCT04432272</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB15870\">Probiorinse</a></strong></td><td>Randomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04458519\">NCT04458519</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>Use of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and Hospitalisation</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04416399\">NCT04416399</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Controlled clinical trial of hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002038-33\">EUCTR2020-002038-33-FI</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for Severe COVID-19 Patients : a Randomized, Open-label, Phase 3 Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04547660\">NCT04547660</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB15862\">Inactivated SARS-Cov-2 Vaccine</a></strong></td><td>Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04510207\">NCT04510207</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04476979\">NCT04476979</a></td></tr><tr><td>2020-07-16</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04476979\">NCT04476979</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB15693\">INO-4800</a></strong></td><td>A Phase I / IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04447781\">NCT04447781</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB11133\">Omega-3 fatty acids</a></strong></td><td>COVID-19 Anosmia Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04495816\">NCT04495816</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB05611\">Apilimod</a></strong></td><td>A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04446377\">NCT04446377</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB15864\">Oral Polio Vaccine</a></strong></td><td>Oral Polio Vaccine as Potential Protection Against COVID-19 : A Cluster-randomised Trial in Guinea-Bissau</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445428\">NCT04445428</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB15857\">Janssen COVID-19 Vaccine</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Phase 1 / 2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04436276\">NCT04436276</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB10520\">Cinnamon</a></strong></td><td>\\xc3\\xa2??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild &amp; moderate cases of COVID-19.\\xc3\\xa2??</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44497\">CTRI/2020/06/026231</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB10543\">Cow milk</a></strong></td><td>\\xc3\\xa2??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild &amp; moderate cases of COVID-19.\\xc3\\xa2??</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44497\">CTRI/2020/06/026231</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB10344\">Ginger</a></strong></td><td>\\xc3\\xa2??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild &amp; moderate cases of COVID-19.\\xc3\\xa2??</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44497\">CTRI/2020/06/026231</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB14276\">Turmeric</a></strong></td><td>\\xc3\\xa2??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild &amp; moderate cases of COVID-19.\\xc3\\xa2??</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44497\">CTRI/2020/06/026231</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19 : Open Controlled Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04502667\">NCT04502667</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Efficacy of Adding Sofosbuvir / Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19 : A Randomized Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04498936\">NCT04498936</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Efficacy of Adding Sofosbuvir / Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19 : A Randomized Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04498936\">NCT04498936</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB09027\">Ledipasvir</a></strong></td><td>Efficacy of Adding Sofosbuvir / Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19 : A Randomized Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04498936\">NCT04498936</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>BCG vaccine as preventive measure against COVID-19 in health care workers</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-5ysj54/\">RBR-5ysj54</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients with COVID-19-Moderate Type</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001608-40\">EUCTR2020-001608-40-DE</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04535791\">NCT04535791</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04535791\">NCT04535791</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456088\">NCT04456088</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Development and Validation of &quot;Ready-to-Use&quot; Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04477083\">NCT04477083</a></td></tr><tr><td>2020-07-15</td><td><strong><a href=\"/drugs/DB08899\">Enzalutamide</a></strong></td><td>A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475601\">NCT04475601</a></td></tr><tr><td>2020-07-14</td><td><strong><a href=\"/drugs/DB05382\">Iodine</a></strong></td><td>Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04473261\">NCT04473261</a></td></tr><tr><td>2020-07-14</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa : a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04472585\">NCT04472585</a></td></tr><tr><td>2020-07-14</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa : a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04472585\">NCT04472585</a></td></tr><tr><td>2020-07-14</td><td><strong><a href=\"/drugs/DB00845\">Clofazimine</a></strong></td><td>An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04465695\">NCT04465695</a></td></tr><tr><td>2020-07-14</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04465695\">NCT04465695</a></td></tr><tr><td>2020-07-14</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase 2 / 3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734\\xe2\\x84\\xa2) in Participants from Birth to &lt; 18 Years of Age with COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001803-17\">EUCTR2020-001803-17-GB</a></td></tr><tr><td>2020-07-14</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Colchicine in Moderate Symptomatic COVID-19 Patients : Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04527562\">NCT04527562</a></td></tr><tr><td>2020-07-14</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04408040\">NCT04408040</a></td></tr><tr><td>2020-07-14</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405843\">NCT04405843</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>TOGETHER 3 Trial : An Adaptive Randomized Platform Trial to Investigate the Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults. COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12194\">PACTR202007700757139</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>TOGETHER 3 Trial : An Adaptive Randomized Platform Trial to Investigate the Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults. COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12194\">PACTR202007700757139</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB15847\">BBV152</a></strong></td><td>An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04471519\">NCT04471519</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB08899\">Enzalutamide</a></strong></td><td>A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) - COVIDENZA</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002027-10\">EUCTR2020-002027-10-SE</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB14276\">Turmeric</a></strong></td><td>A clinical study to evaluate the effect of AYUSH medicines in the management of COVID-19</td><td>Treatment</td><td>3, 4</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45272\">CTRI/2020/07/026371</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB15892\">ZYCOV-D</a></strong></td><td>A prospective, randomized, adaptive, phase I / II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M / s Cadila Healthcare Limited by intradermal route in healthy subjects</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306\">CTRI/2020/07/026352</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>Phase I / II randomized controlled clinical trial to assess safety and efficacy of ozone therapy via rectal insufflation and minor auto haemotherapy as an adjuvant in mild to moderate Covid-19 subjects. - Nil</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45173\">CTRI/2020/07/026354</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB05768\">Alkaline Phosphatase</a></strong></td><td>Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8578\">NL8578</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB10317\">Rubella virus vaccine</a></strong></td><td>Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357028\">NCT04357028</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357028\">NCT04357028</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB10316\">Mumps virus strain B level jeryl lynn live antigen</a></strong></td><td>Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357028\">NCT04357028</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB15849\">SARS-CoV-2 Sclamp</a></strong></td><td>A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study To Evaluate The Safety And Immunogenicity Of An Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine (COVID-19 vaccine) In Healthy Adults Aged 18 To 55 Years Old</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000674932.aspx\">ACTRN12620000674932</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB12849\">Clazakizumab</a></strong></td><td>A Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab\\xc2\\xae [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04494724\">NCT04494724</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Evaluation of the effect of sofosbuvir / daclatasvir in COVID-19 patients : a double-blind randomized clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49198\">IRCT20200624047908N1</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Evaluation of the effect of sofosbuvir / daclatasvir in COVID-19 patients : a double-blind randomized clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49198\">IRCT20200624047908N1</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB15849\">SARS-CoV-2 Sclamp</a></strong></td><td>A Phase 1 randomised, double-blind, placebo-controlled, dosage-escalation, single centre study to evaluate the safety and immunogenicity of an adjuvanted SARS-CoV-2 Sclamp protein subunit vaccine (COVID-19 vaccine) In healthy adults aged 18 to 55 years and healthy older adults, aged 56 years and over</td><td>Treatment</td><td>1</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN51232965\">ISRCTN51232965</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB15849\">SARS-CoV-2 Sclamp</a></strong></td><td>A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04495933\">NCT04495933</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB16386\">Astegolimab</a></strong></td><td>A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA - COVASTIL</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002713-17\">EUCTR2020-002713-17-ES</a></td></tr><tr><td>2020-07-13</td><td><strong><a href=\"/drugs/DB16398\">Efmarodocokin alfa</a></strong></td><td>A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA - COVASTIL</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002713-17\">EUCTR2020-002713-17-ES</a></td></tr><tr><td>2020-07-12</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04421508\">NCT04421508</a></td></tr><tr><td>2020-07-12</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346628\">NCT04346628</a></td></tr><tr><td>2020-07-12</td><td><strong><a href=\"/drugs/DB15893\">CHO Cells Recombinant Vaccine</a></strong></td><td>A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466085\">NCT04466085</a></td></tr><tr><td>2020-07-11</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>Prospective study to assess therapeutic role of Zinc in COVID-19 patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44929\">CTRI/2020/07/026340</a></td></tr><tr><td>2020-07-11</td><td><strong><a href=\"/drugs/DB12598\">Nafamostat</a></strong></td><td>An Open Label, Randomized, Multicenter, Controlled Clinical Study to Evaluate the Efficacy and Safety of Nafamostat Mesilate in the Treatment of Moderate COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44350\">CTRI/2020/06/026220</a></td></tr><tr><td>2020-07-11</td><td><strong><a href=\"/drugs/DB11651\">Dactolisib</a></strong></td><td>Randomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults =65 Years in a Nursing Home in Which =1 Person(s) Have Lab Confirmed COVID19</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409327\">NCT04409327</a></td></tr><tr><td>2020-07-11</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Evaluation of the Effectiveness of Mouthwashes in Early Reducing the mouth Viral Load Among COVID-19 Patients : A double-blind randomized clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49534\">IRCT20170117032025N7</a></td></tr><tr><td>2020-07-10</td><td><strong><a href=\"/drugs/DB15863\">Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled, Phase Ib / IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged ?60 Years</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04470609\">NCT04470609</a></td></tr><tr><td>2020-07-10</td><td><strong><a href=\"/drugs/DB15852\">Coronavirus-Like Particle COVID-19 Vaccine</a></strong></td><td>A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04450004\">NCT04450004</a></td></tr><tr><td>2020-07-10</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>The efficacy of methylprednisolone mini pulse on the treatment of COVID-19 patients admitted to intensive care unit</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49519\">IRCT20170716035126N4</a></td></tr><tr><td>2020-07-10</td><td><strong><a href=\"/drugs/DB02709\">Resveratrol</a></strong></td><td>Routine use of over-the-counter Nutraceuticals, Resveretrol-Copper with standard treatment in Hospitalized Patients With Pneumonia / Acute Respiratory Distress Syndrome Due To SARS-CoV-2 (Covid-19)- Retrospective Analysis</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45115\">CTRI/2020/06/026256</a></td></tr><tr><td>2020-07-10</td><td><strong><a href=\"/drugs/DB09130\">Copper</a></strong></td><td>Routine use of over-the-counter Nutraceuticals, Resveretrol-Copper with standard treatment in Hospitalized Patients With Pneumonia / Acute Respiratory Distress Syndrome Due To SARS-CoV-2 (Covid-19)- Retrospective Analysis</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45115\">CTRI/2020/06/026256</a></td></tr><tr><td>2020-07-10</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A Clinical Trial to Study the Efficacy of \\xc3\\xa2??Ivermectin\\xc3\\xa2?? in the prevention of Covid-19. .A Single Arm Study. \\xc3\\xa2??</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45156\">CTRI/2020/06/026232</a></td></tr><tr><td>2020-07-10</td><td><strong><a href=\"/drugs/DB12814\">Cepeginterferon alfa-2B</a></strong></td><td>A phase II, randomized, controlled, open-label study to evaluate the efficacy and safety of Pegylated IFN alfa-2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43775\">CTRI/2020/06/026087</a></td></tr><tr><td>2020-07-10</td><td><strong><a href=\"/drugs/DB14828\">ABX-464</a></strong></td><td>A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75\">EUCTR2020-001673-75-DE</a></td></tr><tr><td>2020-07-10</td><td><strong><a href=\"/drugs/DB14291\">Wormwood</a></strong></td><td>Evaluation of the effect of Afsantin in the treatment of COVID 19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49544\">IRCT20190415043279N6</a></td></tr><tr><td>2020-07-09</td><td><strong><a href=\"/drugs/DB15271\">Crizanlizumab</a></strong></td><td>Crizanlizumab for Treating COVID-19 Vasculopathy</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435184\">NCT04435184</a></td></tr><tr><td>2020-07-09</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>A randomised controlled trial of Nebulised Heparin in critically ill mechanically ventilated patients with COVID-19 to assess the effect on the duration of mechanical ventilation.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000517976.aspx\">ACTRN12620000517976</a></td></tr><tr><td>2020-07-09</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>MATIS : Phase 2 / 3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia - Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001750-22\">EUCTR2020-001750-22-GB</a></td></tr><tr><td>2020-07-09</td><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td>MATIS : Phase 2 / 3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia - Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001750-22\">EUCTR2020-001750-22-GB</a></td></tr><tr><td>2020-07-09</td><td><strong><a href=\"/drugs/DB00151\">Cysteine</a></strong></td><td>Effective of Elman tablet on illness severity and length of hospital stay in the patients with COVID-19 infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48764\">IRCT20200609047707N1</a></td></tr><tr><td>2020-07-09</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Evaluating the efficacy and safety of intravenous immunoglobulin (IVIG) in COVID-19 patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49638\">IRCT20151227025726N20</a></td></tr><tr><td>2020-07-09</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>RANDOMIZED PHASE IIA CLINICAL TRIAL TO COMPARE THE EFFICACY OF IVERMECTIN VERSUS PLACEBO TO OBTAIN NEGATIVE PCR RESULTS IN PATIENTS WITH EARLY PHASE COVID-19</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=034-20\">PER-034-20</a></td></tr><tr><td>2020-07-09</td><td><strong><a href=\"/drugs/DB05173\">PTC299</a></strong></td><td>Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04439071\">NCT04439071</a></td></tr><tr><td>2020-07-09</td><td><strong><a href=\"/drugs/DB06196\">Icatibant</a></strong></td><td>Randomized, open, multicenter phase II clinical trial, proof of concept, to evaluate efficacy and safety of Icatibant in hospitalized patients with SARS-COV-2 (COVID-19) without assisted ventilation compared with standard care - HUB-MdI-ICAT-COVID-201</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002166-13\">EUCTR2020-002166-13-ES</a></td></tr><tr><td>2020-07-08</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466670\">NCT04466670</a></td></tr><tr><td>2020-07-08</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466670\">NCT04466670</a></td></tr><tr><td>2020-07-08</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466670\">NCT04466670</a></td></tr><tr><td>2020-07-08</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>BCG vaccination to Reduce the impact of COVID-19 in healthcare workers following Coronavirus Exposure (BRACE) Trial - BRACE</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002503-19\">EUCTR2020-002503-19-NL</a></td></tr><tr><td>2020-07-07</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Role of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission : SHIELD Study</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04478019\">NCT04478019</a></td></tr><tr><td>2020-07-06</td><td><strong><a href=\"/drugs/DB00471\">Montelukast</a></strong></td><td>Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19) : an investigator-initiated open labelled randomized controlled pragmatic trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001747-21\">EUCTR2020-001747-21-PT</a></td></tr><tr><td>2020-07-06</td><td><strong><a href=\"/drugs/DB09061\">Cannabidiol</a></strong></td><td>Cannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019 : A Randomized, Double-blind, Placebo-controlled Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467918\">NCT04467918</a></td></tr><tr><td>2020-07-06</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Covid-19 Convalescent Plasma Used for Treatment of Patients in Norway - a Monitoring Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04463823\">NCT04463823</a></td></tr><tr><td>2020-07-06</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Pilot Clinical, Statistical and Epidemiological Study on Efficacy and Safety of Convalescent Plasma for the Management of Patients With COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04452812\">NCT04452812</a></td></tr><tr><td>2020-07-06</td><td><strong><a href=\"/drugs/DB08895\">Tofacitinib</a></strong></td><td>A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE SAFETY AND EFFICACY OF TOFACITINIB IN HOSPITALIZED PARTICIPANTS WITH COVID-19 PNEUMONIA WHO ARE RECEIVING STANDARD OF CARE THERAPY</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412252\">NCT04412252</a></td></tr><tr><td>2020-07-06</td><td><strong><a href=\"/drugs/DB06699\">Degarelix</a></strong></td><td>Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH) : A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04397718\">NCT04397718</a></td></tr><tr><td>2020-07-06</td><td><strong><a href=\"/drugs/DB15035\">Zanubrutinib</a></strong></td><td>A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382586\">NCT04382586</a></td></tr><tr><td>2020-07-06</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>PHASE 2 STUDY OF EFFICACY AND SAFETY OF PLASMA FROM CONVALESCENT PATIENTS WITH COVID-19 IN PATIENTS WITH MODERATE DISEASE (AUNA 20-01)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=031-20\">PER-031-20</a></td></tr><tr><td>2020-07-06</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04477954\">NCT04477954</a></td></tr><tr><td>2020-07-05</td><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>A PHASE 2, OPEN LABEL, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ACALABRUTINIB WITH BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE IN SUBJECTS HOSPITALIZED WITH COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=018-20\">PER-018-20</a></td></tr><tr><td>2020-07-05</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>Evaluation of the effect of nano micelles containing curcumin (Sina Ccurcumin) as a therapeutic supplement in patients with COVID-19 and investigating of immune responses balance changes following treatment : A randomized double blind clinical trial.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48843\">IRCT20200611047735N1</a></td></tr><tr><td>2020-07-05</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>Clinical, Open label, Phase III, Multicenter, Prospective, Comparative, Controlled, Randomized Study to Assess the Effectiveness of Systemic Oxygen Therapy with Medicinal Ozone in Early Control of Disease Progression in Patients with COVID-19 who have Acute Infectious Respiratory Symptoms</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-5v3k5d/\">RBR-5v3k5d</a></td></tr><tr><td>2020-07-04</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Utiliza\\xc3\\xa7\\xc3\\xa3o da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com s\\xc3\\xadndrome respirat\\xc3\\xb3ria Aguda Grave Por COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04444700\">NCT04444700</a></td></tr><tr><td>2020-07-03</td><td><strong><a href=\"/drugs/DB12895\">TD-139</a></strong></td><td>Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04473053\">NCT04473053</a></td></tr><tr><td>2020-07-03</td><td><strong><a href=\"/drugs/DB12598\">Nafamostat</a></strong></td><td>Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04473053\">NCT04473053</a></td></tr><tr><td>2020-07-03</td><td><strong><a href=\"/drugs/DB06761\">Beractant</a></strong></td><td>Open-label Trial to Assess the Efficacy and Safety of Inhalation Use of the Approved Drug Surfactant-BL (Biosurf LLC, Russia) as a Part of Complex Therapy of Acute Respiratory Distress Syndrome (ARDS) in Patients With SARS-CoV-2 Coronavirus Infection (COVID-19)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04568018\">NCT04568018</a></td></tr><tr><td>2020-07-03</td><td><strong><a href=\"/drugs/DB06292\">Dapagliflozin</a></strong></td><td>mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04393246\">NCT04393246</a></td></tr><tr><td>2020-07-03</td><td><strong><a href=\"/drugs/DB06403\">Ambrisentan</a></strong></td><td>mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04393246\">NCT04393246</a></td></tr><tr><td>2020-07-03</td><td><strong><a href=\"/drugs/DB16529\">Biomodulin T</a></strong></td><td>Evaluation of the effect and safety of BIOMODULIN T(R) for the stimulation of the immune response in patients with Stage 5 Chronic Kidney Disease under an iterated hemodialysis regimen. Exploratory study. (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000316-En\">RPCEC00000316</a></td></tr><tr><td>2020-07-02</td><td><strong><a href=\"/drugs/DB14828\">ABX-464</a></strong></td><td>A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75\">EUCTR2020-001673-75-GB</a></td></tr><tr><td>2020-07-02</td><td><strong><a href=\"/drugs/DB12764\">Opaganib</a></strong></td><td>Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04414618\">NCT04414618</a></td></tr><tr><td>2020-07-02</td><td><strong><a href=\"/drugs/DB16531\">KB109</a></strong></td><td>A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04414124\">NCT04414124</a></td></tr><tr><td>2020-07-02</td><td><strong><a href=\"/drugs/DB14533\">Zinc chloride</a></strong></td><td>High-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients : A pilot randomized controlled trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000454976.aspx\">ACTRN12620000454976</a></td></tr><tr><td>2020-07-02</td><td><strong><a href=\"/drugs/DB01126\">Dutasteride</a></strong></td><td>Anti-Androgen Treatment for COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04446429\">NCT04446429</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB08995\">Diosmin</a></strong></td><td>Randomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in Egypt</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04452799\">NCT04452799</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB04703\">Hesperidin</a></strong></td><td>Randomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in Egypt</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04452799\">NCT04452799</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB16526\">BACTEK-R</a></strong></td><td>Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to SARS-CoV-2 Infection in Healthcare Personnel</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04452643\">NCT04452643</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>The Efficacy of Topical Povidone-Iodine Rinses in the Management of the Coronavirus Disease 2019 (COVID-19)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04449965\">NCT04449965</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td>Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04469491\">NCT04469491</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB06209\">Prasugrel</a></strong></td><td>Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445623\">NCT04445623</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>Measles Vaccine : Is There a Protective Role in COVID 19 Pandemic?</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445610\">NCT04445610</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Efficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04443725\">NCT04443725</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04443725\">NCT04443725</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Efficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04443725\">NCT04443725</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita -RJ</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04441398\">NCT04441398</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Comparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir / Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435587\">NCT04435587</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>Randomized Clinical Trial to Evaluate Efficacy and Safety of Systemic Indirect Endovenous Ozone Therapy (SIEVOT) as Adjuvant Treatment in COVID19 Non-intubated Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359303\">NCT04359303</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04431466\">NCT04431466</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB08887\">Icosapent ethyl</a></strong></td><td>PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04460651\">NCT04460651</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04429763\">NCT04429763</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15846\">Covax-19\\xe2\\x84\\xa2</a></strong></td><td>A Phase I Trial of a Therapeutic Vaccine (Covax-19\\xe2\\x84\\xa2) in SARS-CoV-2 Infected Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04428073\">NCT04428073</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 : A Randomized, Controlled Study CRI-CP (Coronavirus Investigation - Convalescent Plasma)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425837\">NCT04425837</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459702\">NCT04459702</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459702\">NCT04459702</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459702\">NCT04459702</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459702\">NCT04459702</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients : A Feasibility Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04458363\">NCT04458363</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15735\">Virus Specific T-Cell</a></strong></td><td>Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04457726\">NCT04457726</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04457609\">NCT04457609</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04457609\">NCT04457609</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04457609\">NCT04457609</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB12038\">Ulinastatin</a></strong></td><td>A Phase 3, Prospective, Randomized, Open Label, Comparative, Clinical Study To Evaluate Efficacy And Safety Of Ulinastatin Plus Standard-Of-Care Compared To Standard-Of-Care In Treatment Of Acute Respiratory Distress Syndrome (ARDS) In Hospitalized COVID-19 Infection Patient</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44170\">CTRI/2020/06/025704</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Mesenchymal Stromal Cell-based Therapy for COVID-19-associated Acute Respiratory Distress Syndrome : a Pilot Clinical Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04525378\">NCT04525378</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day, Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Non-critical Condition</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04423861\">NCT04423861</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15629\">Garadacimab</a></strong></td><td>A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409509\">NCT04409509</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Hydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia : A Randomized,Open-label,Controlled Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405921\">NCT04405921</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia : A Randomized,Open-label,Controlled Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405921\">NCT04405921</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB06546\">Atibuclimab</a></strong></td><td>Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04391309\">NCT04391309</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15741\">Recombinant Bacterial ACE2 Receptors-like Enzyme</a></strong></td><td>Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382950\">NCT04382950</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00982\">Isotretinoin</a></strong></td><td>Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382950\">NCT04382950</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335305\">NCT04335305</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB09037\">Pembrolizumab</a></strong></td><td>A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335305\">NCT04335305</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB01390\">Sodium bicarbonate</a></strong></td><td>Sodium Bicarbonate for Treatment of COVID-19 Pneumonia : A Preliminary Prospective Controlled Crossover Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374591\">NCT04374591</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB14803\">AMY-101</a></strong></td><td>A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04395456\">NCT04395456</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15802\">AV-COVID-19</a></strong></td><td>Adaptive Phase IB-II Randomized Clinical Trial Of Preventive Vaccine Consisting Of Autologous Dendritic Cells Loaded With Antigens From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), With Or Without GM-CSF, In Subjects Negative For COVID-19 Infection And Anti-SARS-CoV-2 Antibodies</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04386252\">NCT04386252</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB06761\">Beractant</a></strong></td><td>Phase I / II Trial : Exogenous Surfactant Administration for Patients With COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04375735\">NCT04375735</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360551\">NCT04360551</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB06260\">Aviptadil</a></strong></td><td>Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360096\">NCT04360096</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359290\">NCT04359290</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15313\">DAS-181</a></strong></td><td>A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04298060\">NCT04298060</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00058\">Alpha-1-proteinase inhibitor</a></strong></td><td>A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (Prolastin\\xc2\\xae) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04495101\">NCT04495101</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Early Thromboprophylaxis in COVID-19 (ETHIC Trial) : an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care in COVID-19 Positive Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492254\">NCT04492254</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB16531\">KB109</a></strong></td><td>An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04486482\">NCT04486482</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Therapeutic effectiveness of COVID-19 convalescent plasma produced by HEMOPE : a multicenter, randomized and controlled clinical trial - PLAVID-TRIAL : Covid convalescent plasma - Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-7jqpnw/\">RBR-7jqpnw</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB10317\">Rubella virus vaccine</a></strong></td><td>Effectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12175\">PACTR202006883882711</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB10316\">Mumps virus strain B level jeryl lynn live antigen</a></strong></td><td>Effectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12175\">PACTR202006883882711</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>Effectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12175\">PACTR202006883882711</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Japanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease 2019 (COVID-19) patients with mild respiratory failure - J-CRITICAL trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs041200025\">JPRN-jRCTs041200025</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Japanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease 2019 (COVID-19) patients with mild respiratory failure - J-CRITICAL trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs041200025\">JPRN-jRCTs041200025</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>Multiple-dose study of FOY-305 in Japanese healthy adult male subject(FOY-305-02)(COVID-19)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205326\">JPRN-JapicCTI-205326</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB10804\">Bacillus calmette-guerin substrain connaught live antigen</a></strong></td><td>Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475302\">NCT04475302</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB12975\">Pyronaridine</a></strong></td><td>A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase ? Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475107\">NCT04475107</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB09274\">Artesunate</a></strong></td><td>A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase ? Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475107\">NCT04475107</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo : an Open Label Randomized Clinical Trial</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04549376\">NCT04549376</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients : A Randomized Controlled Trial.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04497649\">NCT04497649</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients : A Randomized Controlled Trial.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04497649\">NCT04497649</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers : A Randomized-Controlled Trial</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04438837\">NCT04438837</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB01075\">Diphenhydramine</a></strong></td><td>Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456439\">NCT04456439</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456439\">NCT04456439</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00741\">Hydrocortisone</a></strong></td><td>Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456439\">NCT04456439</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB08899\">Enzalutamide</a></strong></td><td>COVID_ENZA Trial : Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456049\">NCT04456049</a></td></tr><tr><td>2020-07-01</td><td><strong><a href=\"/drugs/DB00193\">Tramadol</a></strong></td><td>Safety and Efficacy of Tramadol Adjuvant Therapy to Standard Care for COVID-19 Egyptian Patients : A Randomized Double Blind Controlled Clinical Trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04454307\">NCT04454307</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB13127\">Olokizumab</a></strong></td><td>A Multicenter, Randomized, Double-blind, Adaptive, Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04452474\">NCT04452474</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB15566\">Prednisolone acetate</a></strong></td><td>Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis ; a Pilot Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04451239\">NCT04451239</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis ; a Pilot Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04451239\">NCT04451239</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB15801\">VPM1002</a></strong></td><td>A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of the recombinant BCG VPM1002 on the Incidence or Disease Severity of SARS-COV-2 / COVID-19 Among High-Risk Participants in Australia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000707965.aspx\">ACTRN12620000707965</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB11997\">Interleukin-7</a></strong></td><td>A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious Cohort</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04442178\">NCT04442178</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>A randomized, double blind, placebo controlled, comparative study to investigate the efficacy of N-acetylcysteine in COVID-19 patients with standard therapy.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44341\">CTRI/2020/06/026194</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707\">CTRI/2020/06/025998</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB01169\">Arsenic trioxide</a></strong></td><td>To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707\">CTRI/2020/06/025998</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB12965\">Silver</a></strong></td><td>To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707\">CTRI/2020/06/025998</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB10517\">Celery</a></strong></td><td>To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707\">CTRI/2020/06/025998</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707\">CTRI/2020/06/025998</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Povidone Iodine Gargle and Intranasal application : A Quasi-Experimental study to reduce the spread of coronavirus infection in community with Covid-19 positive clusters.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44664\">CTRI/2020/06/025928</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04420988\">NCT04420988</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362189\">NCT04362189</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>A Pilot Study of Ruxolitinib to Combat COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354714\">NCT04354714</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB15743\">Stem-cell derived exosome vesicle products</a></strong></td><td>Effect of stromal vascular fraction (SVF), blood and condition medium derived exosomes on treatment of covid-19 patients with Acute Respiratory Distress Syndrome(ARDS) / clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48099\">IRCT20200510047385N1</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>Efficacy evaluation of inhalation therapy (nasal spray) of Interferon Beta-1a in hospitalized Covid-19 patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48048\">IRCT20200511047396N1</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB11073\">Cetylpyridinium</a></strong></td><td>Evaluating the comparative efficacy of virucidal mouth-rinses in reducing SARS-CoV-2 viral load in saliva as a pre-procedural prophylactic strategy in healthcare settings</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN95933274\">ISRCTN95933274</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Evaluating the comparative efficacy of virucidal mouth-rinses in reducing SARS-CoV-2 viral load in saliva as a pre-procedural prophylactic strategy in healthcare settings</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN95933274\">ISRCTN95933274</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB00878\">Chlorhexidine</a></strong></td><td>Evaluating the comparative efficacy of virucidal mouth-rinses in reducing SARS-CoV-2 viral load in saliva as a pre-procedural prophylactic strategy in healthcare settings</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN95933274\">ISRCTN95933274</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB14317\">Pomegranate</a></strong></td><td>Evaluation of the effectiveness of dietary plan for pulmonary diseases based on Persian medicine in patients infected with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49365\">IRCT20200105046009N4</a></td></tr><tr><td>2020-06-30</td><td><strong><a href=\"/drugs/DB15846\">Covax-19\\xe2\\x84\\xa2</a></strong></td><td>A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04453852\">NCT04453852</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001549-38\">EUCTR2020-001549-38-DE</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001549-38\">EUCTR2020-001549-38-DE</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001549-38\">EUCTR2020-001549-38-DE</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001549-38\">EUCTR2020-001549-38-DE</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB15856\">AG0301-COVID19</a></strong></td><td>A Non-randomized, Open-label, Non-controlled Phase I / II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg / 2mg) in Healthy Adults</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04463472\">NCT04463472</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB15868\">Amniotic Epithelial Cells</a></strong></td><td>Allogeneic Amniotic Epithelial Cells for the Treatment of COVID-19 related respiratory failure, a pilot feasibility randomised controlled trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000676910.aspx\">ACTRN12620000676910</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB11135\">Selenium</a></strong></td><td>The effect of combination of selenium, vitamin C and methylprednisolone in acute respiratory distress syndrome mortality and morbidity from COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49508\">IRCT20190312043030N2</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>The effect of combination of selenium, vitamin C and methylprednisolone in acute respiratory distress syndrome mortality and morbidity from COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49508\">IRCT20190312043030N2</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>The effect of combination of selenium, vitamin C and methylprednisolone in acute respiratory distress syndrome mortality and morbidity from COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49508\">IRCT20190312043030N2</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB10984\">Peppermint</a></strong></td><td>The effect of nebulizing Peppermint extract and Rose extract on percentage of blood oxygen saturation in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48311\">IRCT20190131042569N5</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>A Phase II Safety and Efficacy Study on prognosis of Moderate Pneumonia in COVID-19 patients with Regular Intravenous Immunoglobulin Therapy</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44299\">CTRI/2020/06/026222</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>A Phase II, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554\">CTRI/2020/06/026228</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>A Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian COVID-19 Patients.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44709\">CTRI/2020/06/025957</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian COVID-19 Patients.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44709\">CTRI/2020/06/025957</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB05076\">Fenretinide</a></strong></td><td>RESOLUTION : A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04417257\">NCT04417257</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>CoV-Hep Study : Randomized and Paired Clinical Trial Comparing Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04487990\">NCT04487990</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB09154\">Sodium citrate</a></strong></td><td>CoV-Hep study : Randomized and paired clinical trial comparing regional anticoagulation modalities in continuous venous venous hemodialysis in patients with COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-45kf9p/\">RBR-45kf9p</a></td></tr><tr><td>2020-06-29</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>CoV-Hep study : Randomized and paired clinical trial comparing regional anticoagulation modalities in continuous venous venous hemodialysis in patients with COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-45kf9p/\">RBR-45kf9p</a></td></tr><tr><td>2020-06-28</td><td><strong><a href=\"/drugs/DB00006\">Bivalirudin</a></strong></td><td>Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial</td><td>Supportive Care</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445935\">NCT04445935</a></td></tr><tr><td>2020-06-27</td><td><strong><a href=\"/drugs/DB14275\">Indian frankincense</a></strong></td><td>Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44764\">CTRI/2020/06/025999</a></td></tr><tr><td>2020-06-27</td><td><strong><a href=\"/drugs/DB10672\">Clove</a></strong></td><td>Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44764\">CTRI/2020/06/025999</a></td></tr><tr><td>2020-06-27</td><td><strong><a href=\"/drugs/DB14352\">Azadirachta indica leaf</a></strong></td><td>Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44764\">CTRI/2020/06/025999</a></td></tr><tr><td>2020-06-27</td><td><strong><a href=\"/drugs/DB10683\">Spearmint</a></strong></td><td>Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44764\">CTRI/2020/06/025999</a></td></tr><tr><td>2020-06-27</td><td><strong><a href=\"/drugs/DB10549\">Orange</a></strong></td><td>Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44764\">CTRI/2020/06/025999</a></td></tr><tr><td>2020-06-27</td><td><strong><a href=\"/drugs/DB10520\">Cinnamon</a></strong></td><td>Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44764\">CTRI/2020/06/025999</a></td></tr><tr><td>2020-06-27</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04353206\">NCT04353206</a></td></tr><tr><td>2020-06-26</td><td><strong><a href=\"/drugs/DB04835\">Maraviroc</a></strong></td><td>Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04441385\">NCT04441385</a></td></tr><tr><td>2020-06-26</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>A multi-centre, randomised, double-blind, placebo-controlled phase III study assessing the impact of BCG vaccination on the incidence and course of SARS-CoV-2 infection among healthcare workers in Poland during the COVID-19 pandemic.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002111-22\">EUCTR2020-002111-22-PL</a></td></tr><tr><td>2020-06-26</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04463264\">NCT04463264</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive decline in respiratory function and evolving systemic inflammation on time to intubation, non-invasive ventilation and / or all-cause mortality</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001767-86\">EUCTR2020-001767-86-IE</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB15855\">SARS-CoV-2 mRNA vaccine</a></strong></td><td>A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=55524\">ChiCTR2000034112</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB01410\">Ciclesonide</a></strong></td><td>Ciclesonide Clinical Trial for COVID-19 Treatment</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435795\">NCT04435795</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A phase II, Open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma in severe COVID-19. - PLATINA TRIAL.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44667\">CTRI/2020/06/026123</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Randomised Controlled Trial of Ivermectin in hospitalised patients with COVID19 - RIVET-COV</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44196\">CTRI/2020/06/026001</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Study to Evaluate the Effectiveness of BCG vaccine in Reducing Morbidity and Mortality in Elderly individuals in COVID-19 Hotspots in India - BCG for COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44078\">CTRI/2020/06/025854</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468009\">NCT04468009</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB15850\">IMM-101</a></strong></td><td>COV-IMMUNO : A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04442048\">NCT04442048</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB03523\">Brequinar</a></strong></td><td>The CRISIS Study : A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425252\">NCT04425252</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB13968\">Plasma protein fraction (human)</a></strong></td><td>A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX) - PEX in severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002668-29\">EUCTR2020-002668-29-GB</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>PHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION - TOCICOVID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001707-16\">EUCTR2020-001707-16-ES</a></td></tr><tr><td>2020-06-25</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>PHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION - TOCICOVID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001707-16\">EUCTR2020-001707-16-ES</a></td></tr><tr><td>2020-06-24</td><td><strong><a href=\"/drugs/DB15801\">VPM1002</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Phase 3 Study : Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04439045\">NCT04439045</a></td></tr><tr><td>2020-06-24</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>An Adaptive Phase I / II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04444674\">NCT04444674</a></td></tr><tr><td>2020-06-24</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>CONCOR-1 : A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04418518\">NCT04418518</a></td></tr><tr><td>2020-06-24</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>COVID-19 : An Adaptive Phase I / II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARSCoV-2 Vaccine in South African Adults Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV.</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12166\">PACTR202006922165132</a></td></tr><tr><td>2020-06-23</td><td><strong><a href=\"/drugs/DB12598\">Nafamostat</a></strong></td><td>Rapid Experimental Medicine for COVID-19 - DEFINE</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002230-32\">EUCTR2020-002230-32-GB</a></td></tr><tr><td>2020-06-23</td><td><strong><a href=\"/drugs/DB12895\">TD-139</a></strong></td><td>Rapid Experimental Medicine for COVID-19 - DEFINE</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002230-32\">EUCTR2020-002230-32-GB</a></td></tr><tr><td>2020-06-23</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine / Hydroxychloroquine in Treatment of COVID-19?</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04447534\">NCT04447534</a></td></tr><tr><td>2020-06-23</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine / Hydroxychloroquine in Treatment of COVID-19?</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04447534\">NCT04447534</a></td></tr><tr><td>2020-06-23</td><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>Early Use of Corticosteroids in Hospitalized Patients With Moderate COVID19 Pneumonia (PREDCOVID)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04451174\">NCT04451174</a></td></tr><tr><td>2020-06-23</td><td><strong><a href=\"/drugs/DB09153\">Sodium chloride</a></strong></td><td>Hypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19 : Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382131\">NCT04382131</a></td></tr><tr><td>2020-06-23</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>Randomized, controlled, open label, phase 2 clinical trial of Interferon-\\xc3\\x9f-1a (IFN\\xc3\\x9f-1a) in COVID-19 patients. - Clinical study for the treatment with Interferon-\\xc3\\x9f-1a (IFN\\xc3\\x9f-1a) of COVID-19 patients</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002458-25\">EUCTR2020-002458-25-IT</a></td></tr><tr><td>2020-06-23</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542967\">NCT04542967</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>Prospective, randomized, parallel-group, open-label study to evaluate the efficacy and safety of IMU-838, in combination with oseltamivir, in adults with coronavirus disease COVID-19</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN53038326\">ISRCTN53038326</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB15446\">Vidofludimus</a></strong></td><td>Prospective, randomized, parallel-group, open-label study to evaluate the efficacy and safety of IMU-838, in combination with oseltamivir, in adults with coronavirus disease COVID-19</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN53038326\">ISRCTN53038326</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB15893\">CHO Cells Recombinant Vaccine</a></strong></td><td>A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445194\">NCT04445194</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>RepurpoSing Old Drugs TO SuppRess a Modern Threat : The STORM Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04433078\">NCT04433078</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445207\">NCT04445207</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002060-31\">EUCTR2020-002060-31-CZ</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002060-31\">EUCTR2020-002060-31-CZ</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002060-31\">EUCTR2020-002060-31-CZ</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002060-31\">EUCTR2020-002060-31-CZ</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002060-31\">EUCTR2020-002060-31-CZ</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB11997\">Interleukin-7</a></strong></td><td>A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04426201\">NCT04426201</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB15865\">Pentaglobin</a></strong></td><td>The effect of pentaglobin in the treatment of critically ill patients with COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48312\">IRCT20151227025726N18</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild or moderate corona virus disease (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002394-94\">EUCTR2020-002394-94-BE</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412785\">NCT04412785</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04410159\">NCT04410159</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB09145\">Water</a></strong></td><td>A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04410159\">NCT04410159</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A double-blind clinical trial to repurpose and assess the efficacy and safety of ivermectin in COVID-19</td><td>Treatment</td><td>3</td><td>Completed</td><td><a href=\"http://isrctn.com/ISRCTN40302986\">ISRCTN40302986</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335084\">NCT04335084</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335084\">NCT04335084</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335084\">NCT04335084</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335084\">NCT04335084</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334512\">NCT04334512</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334512\">NCT04334512</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334512\">NCT04334512</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334512\">NCT04334512</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334512\">NCT04334512</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB14767\">Peginterferon lambda-1a</a></strong></td><td>A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343976\">NCT04343976</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT-2)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCT2031200035\">JPRN-jRCT2031200035</a></td></tr><tr><td>2020-06-22</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT-2)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCT2031200035\">JPRN-jRCT2031200035</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>?Evaluation of Safety and efficacy of anakinra utilization in COVID-19, a randomized controlled clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48702\">IRCT20120703010178N20</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB00927\">Famotidine</a></strong></td><td>The effect of Famotidine on the improvement of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49657\">IRCT20200509047364N2</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB00016\">Erythropoietin</a></strong></td><td>Evaluation of the effect of recombinant erythropoietin on the improvement of COVID-19 patients</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49282\">IRCT20200509047364N1</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB05974\">Transcrocetinate</a></strong></td><td>Evaluation of the effect of trans sodium crocetinate in respiratory distress caused by COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47188\">IRCT20081019001369N6</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394377\">NCT04394377</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID-19 PNEUMONIA</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=027-20\">PER-027-20</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB12243\">Edaravone</a></strong></td><td>Effect of edaravone on clinical improvement and outcome of patients with respiratory distress syndrome caused by COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48500\">IRCT20200317046797N6</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Effect of vitamin D supplementation in diagnosed cases of 2019 Novel Coronavirus ; a randomized clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48287\">IRCT20110726007117N11</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The prophylactic effect of oral hydroxy-chloroquine in close contacts of COVID-19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48236\">IRCT20200513047426N1</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Plasma exchange in patients with COVID-19 to reduce viral load and inflammatory molecules</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47357\">IRCT20200416047099N2</a></td></tr><tr><td>2020-06-21</td><td><strong><a href=\"/drugs/DB00062\">Albumin human</a></strong></td><td>Plasma exchange in patients with COVID-19 to reduce viral load and inflammatory molecules</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47357\">IRCT20200416047099N2</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB14952\">Pamrevlumab</a></strong></td><td>Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF), in Hospitalized Patients With Acute COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04432298\">NCT04432298</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04568863\">NCT04568863</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB04216\">Quercetin</a></strong></td><td>The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468139\">NCT04468139</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468139\">NCT04468139</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB13281\">Bromelains</a></strong></td><td>The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468139\">NCT04468139</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468139\">NCT04468139</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48226\">IRCT20200517047485N1</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48226\">IRCT20200517047485N1</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48226\">IRCT20200517047485N1</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB01072\">Atazanavir</a></strong></td><td>Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48226\">IRCT20200517047485N1</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Inactivated Convalescent Plasma as a Therapeutic Alternative in Hospitalized Patients CoViD-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04385186\">NCT04385186</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04508439\">NCT04508439</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Efficacy &amp; Safety of Sofosbuvir / Daclatasvir treatment in COVID-19 : A randomized, controlled study</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00022203\">DRKS00022203</a></td></tr><tr><td>2020-06-20</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Efficacy &amp; Safety of Sofosbuvir / Daclatasvir treatment in COVID-19 : A randomized, controlled study</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00022203\">DRKS00022203</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04432103\">NCT04432103</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>Evaluation the effect of raltegravir, and raltegravir / interferon beta combination on covid 19 patients admitted in Peymanieh hospital of Jahrom in 2020</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48749\">IRCT20200412047042N1</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB06817\">Raltegravir</a></strong></td><td>Evaluation the effect of raltegravir, and raltegravir / interferon beta combination on covid 19 patients admitted in Peymanieh hospital of Jahrom in 2020</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48749\">IRCT20200412047042N1</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB15805\">SCB-2019</a></strong></td><td>A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405908\">NCT04405908</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB05463\">ISS-1018</a></strong></td><td>A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405908\">NCT04405908</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394117\">NCT04394117</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB00177\">Valsartan</a></strong></td><td>Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394117\">NCT04394117</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB11842\">Angiotensin II</a></strong></td><td>Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394117\">NCT04394117</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB13919\">Candesartan</a></strong></td><td>Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394117\">NCT04394117</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB00876\">Eprosartan</a></strong></td><td>Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394117\">NCT04394117</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394117\">NCT04394117</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB00275\">Olmesartan</a></strong></td><td>Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394117\">NCT04394117</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB01029\">Irbesartan</a></strong></td><td>Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394117\">NCT04394117</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients : An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04353284\">NCT04353284</a></td></tr><tr><td>2020-06-19</td><td><strong><a href=\"/drugs/DB16360\">Anti-SARS-CoV-2 immunoglobulin</a></strong></td><td>Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04521309\">NCT04521309</a></td></tr><tr><td>2020-06-18</td><td><strong><a href=\"/drugs/DB15844\">CVnCoV</a></strong></td><td>A Phase 1, Partially Blind, Placebo-controlled, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04449276\">NCT04449276</a></td></tr><tr><td>2020-06-18</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>SPIKE-1 TRIAL : A Randomised Phase II / III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. - SPIKE-1</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002110-41\">EUCTR2020-002110-41-GB</a></td></tr><tr><td>2020-06-18</td><td><strong><a href=\"/drugs/DB00878\">Chlorhexidine</a></strong></td><td>Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado m\\xc3\\xa9dico en Casa en Cali - 2020.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04563689\">NCT04563689</a></td></tr><tr><td>2020-06-18</td><td><strong><a href=\"/drugs/DB11073\">Cetylpyridinium</a></strong></td><td>Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado m\\xc3\\xa9dico en Casa en Cali - 2020.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04563689\">NCT04563689</a></td></tr><tr><td>2020-06-18</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 : A Randomized Control Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44478\">CTRI/2020/06/025803</a></td></tr><tr><td>2020-06-18</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>Pulmozyme to Improve COVID-19 ARDS Outcomes</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04402944\">NCT04402944</a></td></tr><tr><td>2020-06-18</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04399889\">NCT04399889</a></td></tr><tr><td>2020-06-18</td><td><strong><a href=\"/drugs/DB15801\">VPM1002</a></strong></td><td>A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and / or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435379\">NCT04435379</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>PHASE II CLINICAL TRIAL, SINGLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TO EXPLORE THE EFFECTIVENESS AND SAFETY OF MELATONIN I.V. IN PATIENTS WITH COVID-19 ENTERED INTO THE ICU (MELCOVID STUDY) - MELCOVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001808-42\">EUCTR2020-001808-42-ES</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>A randomized, single blind, placebo-controlled, parallel-arm study to investigate the safety and preliminary efficacy of Niclosamide and Camostat alone and in combination to treat Covid-19 (\\xe2\\x80\\x9cNICCAM\\xe2\\x80\\x9d)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002233-15\">EUCTR2020-002233-15-DE</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>A randomized, single blind, placebo-controlled, parallel-arm study to investigate the safety and preliminary efficacy of Niclosamide and Camostat alone and in combination to treat Covid-19 (\\xe2\\x80\\x9cNICCAM\\xe2\\x80\\x9d)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002233-15\">EUCTR2020-002233-15-DE</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB15848\">Gam-COVID-Vac</a></strong></td><td>An Open Study of the Safety, Tolerability and Immunogenicity of the Drug &quot;Gam-COVID-Vac Lyo&quot; Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04437875\">NCT04437875</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB15848\">Gam-COVID-Vac</a></strong></td><td>An Open Study of the Safety, Tolerability and Immunogenicity of the Drug &quot;Gam-COVID-Vac&quot; a Solution for Intramuscular Injection With the Participation of Healthy Volunteers</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04436471\">NCT04436471</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Randomized, Open Label, Prospective, Comparative, Parallel Group, Multicentre Study To Evaluate Efficacy And Safety Of Favipiravir With Supportive Care Versus Supportive Care Alone In Subjects With Mild To Moderate Coronavirus Disease (COVID-19). - NA</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44480\">CTRI/2020/06/025799</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Efficacy of Sofosbuvir in the management of hospitalized COVID 19 patients.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44441\">CTRI/2020/06/025760</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB01257\">Eculizumab</a></strong></td><td>SOLIRIS\\xc2\\xae (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID 19) - An Expanded Access Program for Hospital-based Emergency Treatment</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355494\">NCT04355494</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Evaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patient</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48929\">IRCT20200515047456N1</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB00009\">Alteplase</a></strong></td><td>Evaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patient</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48929\">IRCT20200515047456N1</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>COVIDSTORM - study protocol COVID-19 : Slavage TOcilizumab as a Rescue Measure - COVIDSTORM</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002039-31\">EUCTR2020-002039-31-FI</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB15891\">GX-19 Vaccine</a></strong></td><td>A Phase 1 / 2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445389\">NCT04445389</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB15897\">Etesevimab</a></strong></td><td>A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04427501\">NCT04427501</a></td></tr><tr><td>2020-06-17</td><td><strong><a href=\"/drugs/DB15718\">Bamlanivimab</a></strong></td><td>A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04427501\">NCT04427501</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB09112\">Nitrous acid</a></strong></td><td>An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with COVID-19 requiring supplemental oxygen (NOCoV2)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002120-37\">EUCTR2020-002120-37-GB</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB04862\">Merimepodib</a></strong></td><td>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04410354\">NCT04410354</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04410354\">NCT04410354</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409262\">NCT04409262</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409262\">NCT04409262</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19 : a Randomised, Double-blind, Placebo-controlled Trial.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407130\">NCT04407130</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19 : a Randomised, Double-blind, Placebo-controlled Trial.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407130\">NCT04407130</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB15661\">Molnupiravir</a></strong></td><td>A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405570\">NCT04405570</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB15060\">Human interleukin-6</a></strong></td><td>Prognostic Value of Serum Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R) in Severe Coronavirus Disease (COVID-19) Pneumonia Treated With Tocilizumab - a Prospective Single Center Study (UHID-COVID19)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359667\">NCT04359667</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB15799\">LNP-nCoVsaRNA Vaccine</a></strong></td><td>A first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN17072692\">ISRCTN17072692</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Remdesivir in COVID 19 Treatment : A Randomised Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345419\">NCT04345419</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Remdesivir in COVID 19 Treatment : A Randomised Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345419\">NCT04345419</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Remdesivir in COVID 19 Treatment : A Randomised Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345419\">NCT04345419</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351347\">NCT04351347</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351347\">NCT04351347</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda ; A Randomised Controlled Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542941\">NCT04542941</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB09061\">Cannabidiol</a></strong></td><td>Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19 : a Randomised Controlled Trial</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04504877\">NCT04504877</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB15691\">Anti-SARS-CoV-2 REGN-COV2</a></strong></td><td>A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425629\">NCT04425629</a></td></tr><tr><td>2020-06-16</td><td><strong><a href=\"/drugs/DB01132\">Pioglitazone</a></strong></td><td>Controlled, randomized, non-blind trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19. - ESCORPIO</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001929-31\">EUCTR2020-001929-31-ES</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Clinical Course of COVID-19 in Patients With Rheumatoid Arthritis Treated With or Without Hydroxychloroquine : a Case-control Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04471649\">NCT04471649</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Double-blind, randomized, controlled, clinical trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002193-27\">EUCTR2020-002193-27-ES</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB06717\">Fosaprepitant</a></strong></td><td>To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468646\">NCT04468646</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB00673\">Aprepitant</a></strong></td><td>To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468646\">NCT04468646</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Effectiveness of Adding Standard Plasma or COVID-19 Convalescent Plasma to Standard Treatment, Versus Standard Treatment Alone, in Patients With Recent Onset of COVID-19 Respiratory Failure. A Randomized, Three-arms, Phase 2 Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04428021\">NCT04428021</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Short Term, High Dose Vitamin D Supplementation for COVID-19 Disease : Double Blind, Controlled, Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459247\">NCT04459247</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB09153\">Sodium chloride</a></strong></td><td>Homeopathy for Covid-19 in primary care : randomized, parallel-group, double-blind, placebo-controlled, clinical trial - Homeopathy for Covid-19 in primary care : randomized, parallel-group, double-blind, placebo-controlled, clinical trial (Covid-Simile study)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046338\">JPRN-UMIN000040602</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>A Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44408\">CTRI/2020/06/025849</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44408\">CTRI/2020/06/025849</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>Melatonin For COVID 19 pre exposure prophylaxis in High Risk population . (MELATONIN IMMUNE BOOST COVID 19 STUDY )</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44346\">CTRI/2020/06/025613</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB01088\">Iloprost</a></strong></td><td>Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng) / Kilo(kg) / Minute(Min)) in Patients With COVID-19 Induced Pulmonary Endotheliopathy</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04420741\">NCT04420741</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB01236\">Sevoflurane</a></strong></td><td>SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU : Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04415060\">NCT04415060</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB00753\">Isoflurane</a></strong></td><td>SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU : Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04415060\">NCT04415060</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB09035\">Nivolumab</a></strong></td><td>Study of the Efficiency and Security of NIVOLUMAB Therapy, Used in Immuno-stimulation, in Hospitalized Obese Individuals at Risk to Evolve Towards Severe Forms of COVID-19 Infection. Multicentric, Paralleled, Randomized, Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04413838\">NCT04413838</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB06271\">Sulodexide</a></strong></td><td>Sulodexide in the treatment of early stages of COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN59048638\">ISRCTN59048638</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB11842\">Angiotensin II</a></strong></td><td>Angiotensin II Infusion in COVID-19-Associated Vasodilatory Shock : A multinational, multicentre registry</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000620921.aspx\">ACTRN12620000620921</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus : The Multicenter Randomized Controlled Ovid Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04400799\">NCT04400799</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43019\">CTRI/2020/05/025067</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A phase III randomized controlled trial to determine safety, efficacy, and immunogenicity of the non-replicating ChAdOx1 nCoV-19 vaccine</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN89951424\">ISRCTN89951424</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516915\">NCT04516915</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB15446\">Vidofludimus</a></strong></td><td>Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04516915\">NCT04516915</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Nebulized heparin in patients with mainly moderate coronavirus disease 2019 : Randomized controlled trial. COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12158\">PACTR202007606032743</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Anti-interleukin IL-1 receptor antagonist (anakinra) for the treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome in patients admitted at Sultan Qaboos University Hospital</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"http://isrctn.com/ISRCTN74727214\">ISRCTN74727214</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Pilot trial on early treatment with hydroxychloroquine in patients with COVID-19 who do not have hospital admission at diagnosis. - PRE-COVID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002449-41\">EUCTR2020-002449-41-ES</a></td></tr><tr><td>2020-06-15</td><td><strong><a href=\"/drugs/DB00264\">Metoprolol</a></strong></td><td>Intravenous Metoprolol in Respiratory Distress Due to COVID-19 : Pilot Study &quot;MADRID-COVID&quot; - \\xe2\\x80\\x9cMADRID-COVID\\xe2\\x80\\x9d</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002310-41\">EUCTR2020-002310-41-ES</a></td></tr><tr><td>2020-06-14</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 : A Randomized Control Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425915\">NCT04425915</a></td></tr><tr><td>2020-06-14</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Evolution of Allogenic Mesenchymal stem cell- derived Umbilical cord transplantation for ARDS patients infected with COVID19.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48187\">IRCT20160809029275N1</a></td></tr><tr><td>2020-06-14</td><td><strong><a href=\"/drugs/DB01072\">Atazanavir</a></strong></td><td>Evaluation of Atazanavir / Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / Ritonavir</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48640\">IRCT20200504047298N1</a></td></tr><tr><td>2020-06-14</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation of Atazanavir / Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / Ritonavir</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48640\">IRCT20200504047298N1</a></td></tr><tr><td>2020-06-14</td><td><strong><a href=\"/drugs/DB02709\">Resveratrol</a></strong></td><td>Evaluation of the effect of Resveratrol on the effectiveness of antiviral drug regimen in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48330\">IRCT20200112046089N1</a></td></tr><tr><td>2020-06-14</td><td><strong><a href=\"/drugs/DB00177\">Valsartan</a></strong></td><td>Treatment of Sars-CoV2 infections (Covid-19) with valsartan vs placebo, a three-armed randomized, partly blinded trial - CovidVal01</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021732\">DRKS00021732</a></td></tr><tr><td>2020-06-13</td><td><strong><a href=\"/drugs/DB15864\">Oral Polio Vaccine</a></strong></td><td>Short-term Protection for COVID-19 by Oral Polio Vaccine</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47989\">IRCT20140428017469N1</a></td></tr><tr><td>2020-06-13</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04397692\">NCT04397692</a></td></tr><tr><td>2020-06-13</td><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380688\">NCT04380688</a></td></tr><tr><td>2020-06-12</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445454\">NCT04445454</a></td></tr><tr><td>2020-06-12</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>The efficacy and safety of convalescent plasma therapy in novel coronavirus pneumonia (COVID-19) : A medical records based retrospective cohort study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=55194\">ChiCTR2000033798</a></td></tr><tr><td>2020-06-12</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>\\xc3\\xa2??Relative efficacy of hydroxy-chloroquine prophylaxis to healthcare-professionals for Covid-19 mitigation : a pragmatic prospective observational study (RE-HCP2 COVID study)\\xc3\\xa2?? - RE-HCP2 COVID study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44173\">CTRI/2020/06/025593</a></td></tr><tr><td>2020-06-12</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04421027\">NCT04421027</a></td></tr><tr><td>2020-06-12</td><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346199\">NCT04346199</a></td></tr><tr><td>2020-06-12</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the early Treatment of COVID-19 - COVER</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002283-32\">EUCTR2020-002283-32-IT</a></td></tr><tr><td>2020-06-12</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Mesenchymal stromal cell therapy for severe COVID-19 infection - MSC therapy for severe COVID-19 infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002102-58\">EUCTR2020-002102-58-BE</a></td></tr><tr><td>2020-06-11</td><td><strong><a href=\"/drugs/DB06692\">Aprotinin</a></strong></td><td>An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04527133\">NCT04527133</a></td></tr><tr><td>2020-06-11</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>A Single-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412291\">NCT04412291</a></td></tr><tr><td>2020-06-11</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Single-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412291\">NCT04412291</a></td></tr><tr><td>2020-06-11</td><td><strong><a href=\"/drugs/DB15446\">Vidofludimus</a></strong></td><td>A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator&#39;s Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04379271\">NCT04379271</a></td></tr><tr><td>2020-06-11</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Multicenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs031200026\">JPRN-jRCTs031200026</a></td></tr><tr><td>2020-06-11</td><td><strong><a href=\"/drugs/DB12598\">Nafamostat</a></strong></td><td>Multicenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs031200026\">JPRN-jRCTs031200026</a></td></tr><tr><td>2020-06-11</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>An ObservationaI Study to Evaluate the Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age Who Are Receiving Favipiravir</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04474457\">NCT04474457</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complication. Assessment of IL-6. - Tocilizumab vs. its combination with Vitamin D. Variation in IL-6</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001903-17\">EUCTR2020-001903-17-ES</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>A randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complication. Assessment of IL-6. - Tocilizumab vs. its combination with Vitamin D. Variation in IL-6</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001903-17\">EUCTR2020-001903-17-ES</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>A Phase 2, Open-Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 - CALAVI</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001644-25\">EUCTR2020-001644-25-DE</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB12598\">Nafamostat</a></strong></td><td>Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia : Open Labelled Randomized Controlled Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04418128\">NCT04418128</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma to Stem Coronavirus : A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04323800\">NCT04323800</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>In vivo use of ivermectin (IVR) for treatment for corona virus infected patients : a randomized controlled trial</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=54707\">ChiCTR2000033627</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB16526\">BACTEK-R</a></strong></td><td>A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363814\">NCT04363814</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Use of mesenchymal cells for the treatment of patients with severe acute respiratory syndrome caused by SARS-CoV-2 - : Coronavirus infections</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3fz9yr/\">RBR-3fz9yr</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB15691\">Anti-SARS-CoV-2 REGN-COV2</a></strong></td><td>A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04426695\">NCT04426695</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB09298\">Silibinin</a></strong></td><td>Phase II Clinical Trial to evaluate the efficacy of silibinin supplementation in the prevention of the progression of the respiratory failure in patients with onco-hematological diseases and infection by COVID-19 positive. - SilCOVID19</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001794-77\">EUCTR2020-001794-77-ES</a></td></tr><tr><td>2020-06-10</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Double-blind randomized placebo-controlled clinical trial to evaluate the efficacy and safety of the use of intravenous gammaglobulins in the treatment of patients with COVID-19</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001890-56\">EUCTR2020-001890-56-ES</a></td></tr><tr><td>2020-06-09</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>The Use of Ivermectin In the Treatment of COVID 19 Patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425707\">NCT04425707</a></td></tr><tr><td>2020-06-09</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04421404\">NCT04421404</a></td></tr><tr><td>2020-06-08</td><td><strong><a href=\"/drugs/DB11997\">Interleukin-7</a></strong></td><td>A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407689\">NCT04407689</a></td></tr><tr><td>2020-06-08</td><td><strong><a href=\"/drugs/DB01410\">Ciclesonide</a></strong></td><td>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377711\">NCT04377711</a></td></tr><tr><td>2020-06-08</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>EXPLORATORY STUDY OF THE THERAPEUTIC EFFECT AND SAFETY OF RECTAL OZONE THERAPY IN PATIENTS POSITIVE TO SARS-CoV 2 WITH MILD TO MODERATE SYMPTOMS (COVID-19) - ORC</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000320-En\">RPCEC00000320</a></td></tr><tr><td>2020-06-08</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04552483\">NCT04552483</a></td></tr><tr><td>2020-06-08</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Effects of Early Use of Nitazoxanide in Patients with COVID-19</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-4nr86m/\">RBR-4nr86m</a></td></tr><tr><td>2020-06-06</td><td><strong><a href=\"/drugs/DB09037\">Pembrolizumab</a></strong></td><td>The evaluation of safety and efficacy of Pembrolizumab (CinnaGen Co, Iran) in patients with COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47335\">IRCT20150303021315N19</a></td></tr><tr><td>2020-06-06</td><td><strong><a href=\"/drugs/DB09053\">Ibrutinib</a></strong></td><td>IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04375397\">NCT04375397</a></td></tr><tr><td>2020-06-06</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Comparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery process</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46732\">IRCT20200324046850N1</a></td></tr><tr><td>2020-06-06</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Comparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery process</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46732\">IRCT20200324046850N1</a></td></tr><tr><td>2020-06-06</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04502472\">NCT04502472</a></td></tr><tr><td>2020-06-05</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>Evaluation the anti-inflammatory effects of curcumin in the treatment of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48292\">IRCT20200519047510N1</a></td></tr><tr><td>2020-06-05</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380818\">NCT04380818</a></td></tr><tr><td>2020-06-05</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380818\">NCT04380818</a></td></tr><tr><td>2020-06-05</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380818\">NCT04380818</a></td></tr><tr><td>2020-06-05</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380818\">NCT04380818</a></td></tr><tr><td>2020-06-05</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380818\">NCT04380818</a></td></tr><tr><td>2020-06-05</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380818\">NCT04380818</a></td></tr><tr><td>2020-06-05</td><td><strong><a href=\"/drugs/DB06271\">Sulodexide</a></strong></td><td>Sulodexide in the Treatment of Early Stages of COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04483830\">NCT04483830</a></td></tr><tr><td>2020-06-05</td><td><strong><a href=\"/drugs/DB00177\">Valsartan</a></strong></td><td>Treatment of Sars-CoV2 infections (Covid-19) in patients without or with chronic kidney disease (CKD) with valsartan vs placebo, a three-armed randomized, partly blinded trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001431-27\">EUCTR2020-001431-27-DE</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB11133\">Omega-3 fatty acids</a></strong></td><td>The effect of omega-3 supplementation on inflammatory and biochemical markers in critical ill patients with COVID-19 a randomized clinical trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48213\">IRCT20151226025699N3</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Evaluating the effect of intravenous N-acetyl cysteine versus placebo in the treatment of patients with mild and moderate acute respiratory distress syndrome caused by COVID-19 : A double-blind randomized clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48039\">IRCT20120215009014N355</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Investigating the Effect of BCG Vaccine on Preventing COVID-19 Infection in Healthcare Staff Exposed to SARS-CoV-2</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47279\">IRCT20200411047019N1</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB09258\">Bemiparin</a></strong></td><td>A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04420299\">NCT04420299</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB08887\">Icosapent ethyl</a></strong></td><td>An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412018\">NCT04412018</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB00898\">Ethanol</a></strong></td><td>Evaluation of Shift, a smartphone application for New South Wales Junior Medical Officers, on depression and anxiety during the COVID-19 epidemic.</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000571976.aspx\">ACTRN12620000571976</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48043\">IRCT20120215009014N354</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48043\">IRCT20120215009014N354</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB00741\">Hydrocortisone</a></strong></td><td>Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48043\">IRCT20120215009014N354</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB16523\">Deoxyribonuclease I</a></strong></td><td>Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 - a Phase 2, Single-blinded, Randomized Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04541979\">NCT04541979</a></td></tr><tr><td>2020-06-04</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04479163\">NCT04479163</a></td></tr><tr><td>2020-06-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The NOR-SWE Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients. - S-ReCOVID 19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18\">EUCTR2020-000982-18-SE</a></td></tr><tr><td>2020-06-03</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>The NOR-SWE Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients. - S-ReCOVID 19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18\">EUCTR2020-000982-18-SE</a></td></tr><tr><td>2020-06-03</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Hydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : &quot;The Hope Coalition&quot;</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403100\">NCT04403100</a></td></tr><tr><td>2020-06-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : &quot;The Hope Coalition&quot;</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403100\">NCT04403100</a></td></tr><tr><td>2020-06-03</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Hydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : &quot;The Hope Coalition&quot;</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403100\">NCT04403100</a></td></tr><tr><td>2020-06-03</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373460\">NCT04373460</a></td></tr><tr><td>2020-06-03</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Efficacy of the early use of corticotherapy in CoV-2 infection to prevent the progression of acute respiratory distress syndrome (ARDS) in COVID-19</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002186-34\">EUCTR2020-002186-34-ES</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>Use of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation - The STOIC Study (STerOids in COVID)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001889-10\">EUCTR2020-001889-10-GB</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394416\">NCT04394416</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347512\">NCT04347512</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347512\">NCT04347512</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB00020\">Sargramostim</a></strong></td><td>Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04400929\">NCT04400929</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354155\">NCT04354155</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB13888\">Meningococcal polysaccharide vaccine group Y</a></strong></td><td>A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04536051\">NCT04536051</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB13887\">Meningococcal polysaccharide vaccine group W-135</a></strong></td><td>A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04536051\">NCT04536051</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB13890\">Meningococcal polysaccharide vaccine group C</a></strong></td><td>A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04536051\">NCT04536051</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04536051\">NCT04536051</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB13889\">Meningococcal polysaccharide vaccine group A</a></strong></td><td>A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04536051\">NCT04536051</a></td></tr><tr><td>2020-06-02</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Pragmatic study &quot;CORIVER&quot; : Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19) - CORIVER</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001971-33\">EUCTR2020-001971-33-ES</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Vitamin D Supplementation in Patients With COVID-19 : A Randomized, Double-blind, Placebo-controlled Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04449718\">NCT04449718</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04433910\">NCT04433910</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04438694\">NCT04438694</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04437823\">NCT04437823</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day for Post Exposure Prophylaxis of COVID-19 in Subjects From Vulnerable Communities</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435314\">NCT04435314</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425850\">NCT04425850</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15304\">iota-Carrageenan</a></strong></td><td>USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425850\">NCT04425850</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04432324\">NCT04432324</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00065\">Infliximab</a></strong></td><td>A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425538\">NCT04425538</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients With COVID-19-Moderate Type</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425460\">NCT04425460</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00565\">Cisatracurium</a></strong></td><td>The Use of Neuromuscular Blockade Monitor as a Strategy for Neuromuscular Blockade Agents Saving in ICU COVID-19 Patients</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459533\">NCT04459533</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB13295\">Atracurium</a></strong></td><td>The Use of Neuromuscular Blockade Monitor as a Strategy for Neuromuscular Blockade Agents Saving in ICU COVID-19 Patients</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459533\">NCT04459533</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>A Prospective Open-label Study of the Tigerase\\xc2\\xae Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04459325\">NCT04459325</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Randomized Prospective Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma in Prevention of Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04383548\">NCT04383548</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530578\">NCT04530578</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04560231\">NCT04560231</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized, placebo-controlled multiple dose study to evaluate the effect of hydroxychloroquine on the general immuno-competence in young and elderly healthy male volunteers</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"https://trialregister.nl/trial/8726\">NL8726</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia : A Pilot Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04422678\">NCT04422678</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Pilot Study to Explore the Efficacy and Safety of Rescue Therapy With Antibodies From Convalescent Patients Obtained With Double-filtration Plasmapheresis (DFPP) and Infused in Patients With Coronavirus Disease 2019 (COVID-19) and Need of Oxygen Support Without Mechanical Ventilation</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04418531\">NCT04418531</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Treatment of Patients With COVID-19 With Convalescent Plasma Transfusion : a Multicenter, Open-labeled, Randomized and Controlled Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04415086\">NCT04415086</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Safety and Efficacy Study of Ruxolitinib in the Treatment of Severe Acute Respiratory Syndrome Due to SARS-COV-2</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04414098\">NCT04414098</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412772\">NCT04412772</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>An Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients With Moderate to Severe COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412486\">NCT04412486</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB05426\">Talactoferrin alfa</a></strong></td><td>Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory Therapy in Patients Diagnosed With COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412395\">NCT04412395</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency : Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04410536\">NCT04410536</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00328\">Indomethacin</a></strong></td><td>Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency : Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04410536\">NCT04410536</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>Phase I Pilot Study Investigating the Safety and Tolerability of Inhaled rhDNase1 and Its Impact on Neutrophil Extracellular Traps (NETs) in Non-Ventilated COVID-19 Infected Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409925\">NCT04409925</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Evaluation of Additional Treatments for COVID-19 : a Randomized Trial in Niger</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409483\">NCT04409483</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation of Additional Treatments for COVID-19 : a Randomized Trial in Niger</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409483\">NCT04409483</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB11842\">Angiotensin II</a></strong></td><td>Efficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress Syndrome</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04408326\">NCT04408326</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Efficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress Syndrome</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04408326\">NCT04408326</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB14933\">Nicotinamide riboside</a></strong></td><td>Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407390\">NCT04407390</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15661\">Molnupiravir</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults With PCR-Confirmed COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405739\">NCT04405739</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04397510\">NCT04397510</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00675\">Tamoxifen</a></strong></td><td>Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389580\">NCT04389580</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00982\">Isotretinoin</a></strong></td><td>Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389580\">NCT04389580</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Improving Vitamin D Status in the Management of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04385940\">NCT04385940</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk (PREVENT)</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371926\">NCT04371926</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation : Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366232\">NCT04366232</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation : Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366232\">NCT04366232</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359511\">NCT04359511</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00741\">Hydrocortisone</a></strong></td><td>Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359511\">NCT04359511</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00041\">Aldesleukin</a></strong></td><td>Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357444\">NCT04357444</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Exploratory Clinical Study to Assess the Efficacy of NestaCell\\xc2\\xae Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04315987\">NCT04315987</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An international, multi-site, Bayesian platform adaptive, randomised, placebo-controlled trial assessing the effectiveness of varied doses of oral Chloroquine in preventing or reducing the severity of COVID-19 disease in healthcare workers</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN99916292\">ISRCTN99916292</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15743\">Stem-cell derived exosome vesicle products</a></strong></td><td>Rationale and investigational study for the treatment of COVID-19 with severe viral pneumonia with isolated, placental, mesenchymal stem cell exosomes</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN33578935\">ISRCTN33578935</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Randomised Controlled Trial Comparing High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Not Requiring Invasive Mechanical Ventilation</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04408235\">NCT04408235</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407507\">NCT04407507</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB14509\">Lithium carbonate</a></strong></td><td>SARS-CoV-2 Specific Memory B and T- CD4+ Cells</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04402892\">NCT04402892</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>ARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04193878\">NCT04193878</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00983\">Formoterol</a></strong></td><td>ARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04193878\">NCT04193878</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403555\">NCT04403555</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403555\">NCT04403555</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04400058\">NCT04400058</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>A pilot study of virucidal activity of povidone-iodine (PVP-I) 0.5% aqueous solution oral / nasal spray and mouthwash in people with COVID-19 and confirmed oral / nasal shedding of SARS-CoV-2</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN13447477\">ISRCTN13447477</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15739\">Mesenchymoangioblast-derived mesenchymal stem cells</a></strong></td><td>A pilot, open-label, randomised controlled clinical trial to investigate early efficacy of CYP-001 in adults admitted to intensive care with COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000612910.aspx\">ACTRN12620000612910</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Heparins for Thromboprophylaxis in COVID-19 Patients : HETHICO Study in Veneto</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04393805\">NCT04393805</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection : A Randomized, Open Label Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04391101\">NCT04391101</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372628\">NCT04372628</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372628\">NCT04372628</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00302\">Tranexamic acid</a></strong></td><td>Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338074\">NCT04338074</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB08895\">Tofacitinib</a></strong></td><td>TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia : a Multicenter Randomized Controlled Open Label Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390061\">NCT04390061</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia : a Multicenter Randomized Controlled Open Label Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390061\">NCT04390061</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00746\">Deferoxamine</a></strong></td><td>The Use of Desferal and Adjuvants for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection : A Randomized Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389801\">NCT04389801</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria : Prospective, Multicenter, Randomized, Double-blind Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371952\">NCT04371952</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB04897\">Lucinactant</a></strong></td><td>A Multicenter, Single-Treatment Study to Assess the Safety and Preliminary Efficacy of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389671\">NCT04389671</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB06515\">Resiniferatoxin</a></strong></td><td>A Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin (RTX) Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed Due to the COVID-19-related Moratoria on Elective Procedures</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04386980\">NCT04386980</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia \\xc3\\xa2?? An open-label randomized controlled study \\xc3\\xa2??</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=6236\">TCTR20200514001</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15814\">COVID19 s-vax loaded autologous dendritic cell vaccine</a></strong></td><td>A safety and immune response study of novel coronavirus pneumonia (COVID-19) s-vax loaded autologous dendritic cells</td><td>Prevention</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53790\">ChiCTR2000033003</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363853\">NCT04363853</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15751\">MRx-4DP0004</a></strong></td><td>A Pilot, Multiple Dose Study to Evaluate the Efficacy and Safety of MRx-4DP0004 in Hospitalised Patients With Symptoms of COVID-19 (SARS-CoV-2 Infection)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363372\">NCT04363372</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Expanded Access Protocol For The Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360486\">NCT04360486</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15723\">Umbilical Cord Blood Hematopoietic Stem Cells</a></strong></td><td>Cord Blood Therapy to prevent progression of COVID-19 related pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000478910.aspx\">ACTRN12620000478910</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338906\">NCT04338906</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338906\">NCT04338906</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00295\">Morphine</a></strong></td><td>Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04522037\">NCT04522037</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43005\">CTRI/2020/05/025346</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB02709\">Resveratrol</a></strong></td><td>A Phase-III, Open Label, Randomized Controlled Trial Of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment In Asymptomatic Or Mildly Symptomatic Patients With SARS-CoV-2 Infection (Covid-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43934\">CTRI/2020/05/025336</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>To Assess the Safety and Efficacy of Convalescent Plasma on outcome of COVID-19 Associated Complications - COVID PLASMA STUDY</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43703\">CTRI/2020/05/025328</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Angiotensin Receptor Blocker Losartan for prevention of COVID 19 complications : a randomized placebo controlled trial - LICCI</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42751\">CTRI/2020/05/025319</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma to Limit Coronavirus Associated Complications : An Open label Clinical Study of Anti-SARS-CoV-2 Plasma in Hospitalized Patients with COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43752\">CTRI/2020/05/025299</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>PERUCONPLASMA : RANDOMIZED CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF THE USE OF CONVALESCENT PLASMA IN HOSPITALIZED PATIENTS WITH COVID-19</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=016-20\">PER-016-20</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>CONVALESCENT PLASMA USE AS TREATMENT FOR HOSPITALIZED PATIENTS WITH COVID-19 IN ESSALUD</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=013-20\">PER-013-20</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3rywwg/\">RBR-3rywwg</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00788\">Naproxen</a></strong></td><td>A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3rywwg/\">RBR-3rywwg</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00766\">Clavulanic acid</a></strong></td><td>A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3rywwg/\">RBR-3rywwg</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01060\">Amoxicillin</a></strong></td><td>A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3rywwg/\">RBR-3rywwg</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01137\">Levofloxacin</a></strong></td><td>A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3rywwg/\">RBR-3rywwg</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3rywwg/\">RBR-3rywwg</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04523831\">NCT04523831</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04523831\">NCT04523831</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11053\">PACTR202005622389003</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Efficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11053\">PACTR202005622389003</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>Efficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11053\">PACTR202005622389003</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB04335\">Inosine</a></strong></td><td>A low-intervention study to determine whether pre-exposure prophylaxis with low dose aerosol combination medication (ACM) can reduce SARS-CoV-2 incidence in healthcare workers exposed to routing COVID-19 positive contacts (LOWACM)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"http://isrctn.com/ISRCTN34160010\">ISRCTN34160010</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00143\">Glutathione</a></strong></td><td>A low-intervention study to determine whether pre-exposure prophylaxis with low dose aerosol combination medication (ACM) can reduce SARS-CoV-2 incidence in healthcare workers exposed to routing COVID-19 positive contacts (LOWACM)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"http://isrctn.com/ISRCTN34160010\">ISRCTN34160010</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00761\">Potassium chloride</a></strong></td><td>A low-intervention study to determine whether pre-exposure prophylaxis with low dose aerosol combination medication (ACM) can reduce SARS-CoV-2 incidence in healthcare workers exposed to routing COVID-19 positive contacts (LOWACM)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"http://isrctn.com/ISRCTN34160010\">ISRCTN34160010</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00613\">Amodiaquine</a></strong></td><td>\\xc3\\x89valuationefficacit\\xc3\\xa9 et tol\\xc3\\xa9rance d&#39;Une m\\xc3\\xa9dication \\xc3\\xa0 Base de Cosph\\xc3\\xa9runate et d&#39;un phytom\\xc3\\xa9dicament Antiviral Par Voie Orale en Comparaison Avec un Traitement \\xc3\\xa0 Base d&#39;Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04502342\">NCT04502342</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB09274\">Artesunate</a></strong></td><td>\\xc3\\x89valuationefficacit\\xc3\\xa9 et tol\\xc3\\xa9rance d&#39;Une m\\xc3\\xa9dication \\xc3\\xa0 Base de Cosph\\xc3\\xa9runate et d&#39;un phytom\\xc3\\xa9dicament Antiviral Par Voie Orale en Comparaison Avec un Traitement \\xc3\\xa0 Base d&#39;Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04502342\">NCT04502342</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Evaluation de l&#39;efficacit\\xc3\\xa9 et de la tol\\xc3\\xa9rance de Quinquina et d&#39;un phytom\\xc3\\xa9dicament &quot; ACAR &quot; en Comparaison Avec l&#39;Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans sympt\\xc3\\xb4mes</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04501965\">NCT04501965</a></td></tr><tr><td>2020-06-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation de l&#39;efficacit\\xc3\\xa9 et de la tol\\xc3\\xa9rance de Quinquina et d&#39;un phytom\\xc3\\xa9dicament &quot; ACAR &quot; en Comparaison Avec l&#39;Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans sympt\\xc3\\xb4mes</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04501965\">NCT04501965</a></td></tr><tr><td>2020-05-31</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Use of Ivermectin as a Therapeutic Option for Patients With COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445311\">NCT04445311</a></td></tr><tr><td>2020-05-31</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04422561\">NCT04422561</a></td></tr><tr><td>2020-05-31</td><td><strong><a href=\"/drugs/DB00975\">Dipyridamole</a></strong></td><td>Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04391179\">NCT04391179</a></td></tr><tr><td>2020-05-31</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49544\">ChiCTR2000030039</a></td></tr><tr><td>2020-05-31</td><td><strong><a href=\"/drugs/DB15798\">Mycobacterium w. Vaccine</a></strong></td><td>Observational study to assess safety and efficacy of Inj Sepsivac in patients of Covid-19 at R D Gardi Medical College, Ujjain, India</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43559\">CTRI/2020/05/025350</a></td></tr><tr><td>2020-05-31</td><td><strong><a href=\"/drugs/DB15798\">Mycobacterium w. Vaccine</a></strong></td><td>A Randomized, Double-blind, Two arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in preventing COVID-19 in subjects at risk of getting infected with COVID-19.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43176\">CTRI/2020/05/025277</a></td></tr><tr><td>2020-05-31</td><td><strong><a href=\"/drugs/DB15798\">Mycobacterium w. Vaccine</a></strong></td><td>A Randomized, Double-blind, Two arm, controlled clinical trial to compare the Efficacy and Safety of Mycobacterium w (Mw) administered along with Standard of care versus Placebo administered along with Standard of care, in adult, COVID 19 positive patients hospitalized but not critically ill.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43206\">CTRI/2020/05/025271</a></td></tr><tr><td>2020-05-31</td><td><strong><a href=\"/drugs/DB00916\">Metronidazole</a></strong></td><td>Evaluation of therapeutic effects of Metronidazole In Inpatients with Pneuomonia Due to COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48717\">IRCT20200608047686N1</a></td></tr><tr><td>2020-05-30</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A randomized clinical trial study, comparison of the therapeutic effects of Ivermectin, Kaletra and Chloroquine with Kaletra and Chloroquine in the treatment of patients with coronavirus 2019 (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48444\">IRCT20200422047168N2</a></td></tr><tr><td>2020-05-30</td><td><strong><a href=\"/drugs/DB14242\">Honey</a></strong></td><td>Comparison effect of N-Chromosome royal jelly, propolis, and mixed honey supplementation on clinical and laboratory findings of COVID-19 patients with standard treatment : a randomized clinical trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47504\">IRCT20200209046427N1</a></td></tr><tr><td>2020-05-30</td><td><strong><a href=\"/drugs/DB11355\">Propolis wax</a></strong></td><td>Comparison effect of N-Chromosome royal jelly, propolis, and mixed honey supplementation on clinical and laboratory findings of COVID-19 patients with standard treatment : a randomized clinical trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47504\">IRCT20200209046427N1</a></td></tr><tr><td>2020-05-30</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Full versus prophylactic heparinization for the treatment of severe forms of SARS-Covid-19 : clinical, randomized, open and controlled study - HeSAcovid trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-949z6v/\">RBR-949z6v</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB11133\">Omega-3 fatty acids</a></strong></td><td>Resolving inflammatory storm in COVID-19 patients by Omega-3 polyunsaturated fatty acids. - A single-blind, randomized, placebo-controlled feasibility study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002293-28\">EUCTR2020-002293-28-SE</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530370\">NCT04530370</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04381962\">NCT04381962</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB00279\">Liothyronine</a></strong></td><td>Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348513\">NCT04348513</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB14767\">Peginterferon lambda-1a</a></strong></td><td>Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344600\">NCT04344600</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB15801\">VPM1002</a></strong></td><td>A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and / or severe respiratory infectious diseases in elderly in the SARS-CoV-2 pandemic by modulating the immune system</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001675-33\">EUCTR2020-001675-33-DE</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB15751\">MRx-4DP0004</a></strong></td><td>A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001597-30\">EUCTR2020-001597-30-GB</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB15654\">Moderna COVID-19 Vaccine</a></strong></td><td>A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405076\">NCT04405076</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001605-23\">EUCTR2020-001605-23-ES</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001605-23\">EUCTR2020-001605-23-ES</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001605-23\">EUCTR2020-001605-23-ES</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001605-23\">EUCTR2020-001605-23-ES</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB09113\">Poractant alfa</a></strong></td><td>Randomized Controlled Phase II Trial of Poractant Alfa (Curosurf\\xc2\\xae) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04384731\">NCT04384731</a></td></tr><tr><td>2020-05-29</td><td><strong><a href=\"/drugs/DB01410\">Ciclesonide</a></strong></td><td>Inhalation of Ciclesonide for Patients With COVID-19 : A Randomised Open Treatment Study (HALT COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04381364\">NCT04381364</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB15446\">Vidofludimus</a></strong></td><td>A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator\\xe2\\x80\\x99s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001264-28\">EUCTR2020-001264-28-DE</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB01410\">Ciclesonide</a></strong></td><td>Inhalation of Ciclesonide for patients with Covid-19 : A randomised open treatment study (HALT Covid-19).</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001928-34\">EUCTR2020-001928-34-SE</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Subcutaneous and Intravenous IL-1Ra (Anakinra) in COVID-19 Infection - Feasibility &amp; Pharmacokinetics / Pharmacodynamics Study</td><td>Health Services Research</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04462757\">NCT04462757</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB15446\">Vidofludimus</a></strong></td><td>A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator\\xe2\\x80\\x99s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001264-28\">EUCTR2020-001264-28-HU</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB15718\">Bamlanivimab</a></strong></td><td>A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19</td><td>Basic Science</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04411628\">NCT04411628</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377672\">NCT04377672</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB06303\">Otilimab</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04376684\">NCT04376684</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370834\">NCT04370834</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A Phase 2 / 3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04400838\">NCT04400838</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Clinical trial, PHASE III, randomized, open-label, to evaluate the efficacy of administering high-dose cholecalciferol orally alongside standard therapy in patients with COVID-19 pneumonia (COVID-19 HUSO). - Efficacy of high dose vitamin D in COVID-19 pneumonia</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002312-43\">EUCTR2020-002312-43-ES</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil) A single-arm, open-label, proof of concept study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001732-10\">EUCTR2020-001732-10-DE</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB12386\">Bacillus calmette-guerin substrain danish 1331 live antigen</a></strong></td><td>Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) - BCG-PLUS</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002456-21\">EUCTR2020-002456-21-NL</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB00630\">Alendronic acid</a></strong></td><td>Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) - BCG-PLUS</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002456-21\">EUCTR2020-002456-21-NL</a></td></tr><tr><td>2020-05-28</td><td><strong><a href=\"/drugs/DB12592\">Mosedipimod</a></strong></td><td>Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04500132\">NCT04500132</a></td></tr><tr><td>2020-05-27</td><td><strong><a href=\"/drugs/DB15446\">Vidofludimus</a></strong></td><td>A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator\\xe2\\x80\\x99s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001264-28\">EUCTR2020-001264-28-BG</a></td></tr><tr><td>2020-05-27</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374526\">NCT04374526</a></td></tr><tr><td>2020-05-27</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection - Not applicable</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43449\">CTRI/2020/05/025068</a></td></tr><tr><td>2020-05-27</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Multi-center, Randomized Controlled, Phase III Study to evaluate the Clinical Outcomes and Safety of Tocilizumab along with Standard of Care in Patients with Cytokine Release Syndrome associated with COVID-19 infection - None</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43485\">CTRI/2020/05/025369</a></td></tr><tr><td>2020-05-27</td><td><strong><a href=\"/drugs/DB01257\">Eculizumab</a></strong></td><td>Eculizumab for the treatment of Covid-19 severe cases - : Eculizumabe for COVID</td><td>Treatment</td><td>1, 2</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-876qb5/\">RBR-876qb5</a></td></tr><tr><td>2020-05-26</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Gu\\xc3\\xa9rin Vaccination to Prevent Infections by COVID-19 : The ACTIVATE II Trial</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04414267\">NCT04414267</a></td></tr><tr><td>2020-05-26</td><td><strong><a href=\"/drugs/DB15636\">Zilucoplan</a></strong></td><td>A prospective, randomized, open-label, interventional study to investigate the efficacy of complement C5 inhibition with Zilucoplan\\xc2\\xae in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - ZILU-COV</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002130-33\">EUCTR2020-002130-33-BE</a></td></tr><tr><td>2020-05-26</td><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td>Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19 : a Multicentre, Randomised, Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334629\">NCT04334629</a></td></tr><tr><td>2020-05-26</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GU\\xc3\\x89RIN VACCINATION TO PREVENT INFECTIONS ?? COVID-19 : THE ACTIVATE II TRIAL</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002448-21\">EUCTR2020-002448-21-GR</a></td></tr><tr><td>2020-05-26</td><td><strong><a href=\"/drugs/DB14276\">Turmeric</a></strong></td><td>ASSESSMENT OF CLINICAL ACCEPTABILITY OF MOUTH-DISSOLVING TURMERIC LOZENGES IN HEALTHCARE WORKERS INVOLVED IN COVID-19</td><td>Other</td><td>4</td><td>Completed</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43754\">CTRI/2020/05/025317</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>Determination of Dornase Alpha Effectiveness in COVID-19 Treatment</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04432987\">NCT04432987</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB15801\">VPM1002</a></strong></td><td>A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals&#39; Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04387409\">NCT04387409</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04416334\">NCT04416334</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>A Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370223\">NCT04370223</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348409\">NCT04348409</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB15810\">Nuvaxovid</a></strong></td><td>A 2-Part, Phase 1 / 2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M\\xe2\\x84\\xa2 Adjuvant In Healthy Subjects</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04368988\">NCT04368988</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB16369\">Matrix-M</a></strong></td><td>A 2-Part, Phase 1 / 2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M\\xe2\\x84\\xa2 Adjuvant In Healthy Subjects</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04368988\">NCT04368988</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Colchicine for the Treatment of Hyperinflammation associated with Pneumonia due to COVID-19</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001841-38\">EUCTR2020-001841-38-ES</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Efficacy of vitamin D treatment in patients diagnosed with pneumonia who require hospital admission and have vitamin D deficiency and a positive diagnosis for SARS-Cov-2 (COVID-19)</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001960-28\">EUCTR2020-001960-28-ES</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized Patients</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002037-15\">EUCTR2020-002037-15-ES</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB10317\">Rubella virus vaccine</a></strong></td><td>Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8609\">NL8609</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8609\">NL8609</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB00630\">Alendronic acid</a></strong></td><td>Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8609\">NL8609</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8609\">NL8609</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB10316\">Mumps virus strain B level jeryl lynn live antigen</a></strong></td><td>Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8609\">NL8609</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia in Japan</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205270\">JPRN-JapicCTI-205270</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB12598\">Nafamostat</a></strong></td><td>Treatment effect of Nafamostat mesilate in patients with COVID-19 pneumonia : open labelled randomized controlled clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16635\">KCT0005003</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Population pharmacokinetics of hydroxychloroquine sulphate in healthcare workers given for prophylaxis against Corona Virus Disease 2019 (COVID 19) pandemic in India</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43057\">CTRI/2020/05/025242</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>A prospective, single centre, randomized open labelled comparative clinical study to evaluate the effectiveness of Siddha medicine, Kabasura kudineer and vitamin c-zinc supplementation in the management of asymptomatic COVID 19 patients.</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43769\">CTRI/2020/05/025215</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Immediate uses of convalescent covid-19 plasma in the treatment of new infected patients at the first day of hospitalization in a clinical trail</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48493\">IRCT20200525047562N1</a></td></tr><tr><td>2020-05-25</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>A Randomized, Controlled, Open Label, Multicentre Clinical Trial to explore Safety and Efficacy of Hyperbaric Oxygen for preventing ICU admission, Morbidity and Mortality in Adult Patients With COVID-19 - COVID-19-HBO</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021626\">DRKS00021626</a></td></tr><tr><td>2020-05-24</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377620\">NCT04377620</a></td></tr><tr><td>2020-05-24</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Interventional study to assess the efficacy of Ivermectin with standard of care treatment versus standard of care in patients of COVID-19 at R D Gardi Medical College, Ujjain, India</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43728\">CTRI/2020/05/025224</a></td></tr><tr><td>2020-05-23</td><td><strong><a href=\"/drugs/DB01088\">Iloprost</a></strong></td><td>Inhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory Failure</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445246\">NCT04445246</a></td></tr><tr><td>2020-05-23</td><td><strong><a href=\"/drugs/DB15814\">COVID19 s-vax loaded autologous dendritic cell vaccine</a></strong></td><td>A safety and immune response trial of novel coronavirus pneumonia (COVID-19) S-Vax loaded autologous dendritic cells</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=55582\">ChiCTR2000034076</a></td></tr><tr><td>2020-05-23</td><td><strong><a href=\"/drugs/DB05258\">Interferon alfa</a></strong></td><td>Evaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48329\">IRCT20161206031256N3</a></td></tr><tr><td>2020-05-23</td><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td>Evaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48329\">IRCT20161206031256N3</a></td></tr><tr><td>2020-05-22</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia : the BREATH-19 Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445272\">NCT04445272</a></td></tr><tr><td>2020-05-22</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Intermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19 : A Pilot Phase II Single-arm Study, INHIXACOVID19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04427098\">NCT04427098</a></td></tr><tr><td>2020-05-22</td><td><strong><a href=\"/drugs/DB11697\">Pacritinib</a></strong></td><td>A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04404361\">NCT04404361</a></td></tr><tr><td>2020-05-22</td><td><strong><a href=\"/drugs/DB12534\">Mavrilimumab</a></strong></td><td>A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04397497\">NCT04397497</a></td></tr><tr><td>2020-05-22</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04332107\">NCT04332107</a></td></tr><tr><td>2020-05-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prevention of COVID19 infection with hydroxychloroquine in institutionalized older people and nursing home staff. An open, randomized controlled stepped-wedge clinical trial by clusters. PREVICHARM Study - PREVICHARM</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002287-31\">EUCTR2020-002287-31-ES</a></td></tr><tr><td>2020-05-22</td><td><strong><a href=\"/drugs/DB15806\">CoronaVac</a></strong></td><td>A Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged =60 Years</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04383574\">NCT04383574</a></td></tr><tr><td>2020-05-22</td><td><strong><a href=\"/drugs/DB15636\">Zilucoplan</a></strong></td><td>A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan\\xc2\\xae in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382755\">NCT04382755</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB10344\">Ginger</a></strong></td><td>The effects of Ginger on clinical manifestations and paraclinical features of patients with COVID-19 : A randomized double-blind placebo-control clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48114\">IRCT20200506047323N1</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB11135\">Selenium</a></strong></td><td>Effect of the combination of BCc1 &amp; Hep-S on the improvement of clinical &amp; laboratory symptoms of hospitalized COVID-19 patients in a randomized, double-blind, clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48049\">IRCT20170731035423N2</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB10675\">Licorice</a></strong></td><td>Evaluation of the effects of Licorice on clinical symptoms and laboratory signs in patients with COVID-19 : An open-label randomized clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47990\">IRCT20200506047323N2</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Evaluation of the efficacy and safety of oral N-acetylcysteine in treatment and recovery of patients with COVID-19 who are under treatment with routine protocols</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49277\">IRCT20200623047897N1</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB10520\">Cinnamon</a></strong></td><td>Comparison Efficacy of extract plants of Zingiber , cinnamon , zataria multiflora with standard protocol in treatment and clinical improvement of patients with moderate to severe symptoms of covid-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47935\">IRCT20081011001323N25</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB14690\">Ginger oil</a></strong></td><td>Comparison Efficacy of extract plants of Zingiber , cinnamon , zataria multiflora with standard protocol in treatment and clinical improvement of patients with moderate to severe symptoms of covid-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47935\">IRCT20081011001323N25</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB00162\">Vitamin A</a></strong></td><td>The effect of supplementation with vitamin A on improvement of symptoms of acute respiratory syndrome in patients with COVID-19 : A randomized clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47722\">IRCT20200405046951N1</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB00099\">Filgrastim</a></strong></td><td>Evaluation of the effect of GCSF injection in treatment of COVID-19 patients with lymphopenia (less than 1000)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47692\">IRCT20200502047268N1</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04406246\">NCT04406246</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>High Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS : a Multicenter and Randomized Open-label Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04395105\">NCT04395105</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392973\">NCT04392973</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392973\">NCT04392973</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19, determining indications within the paradigm of host-directed therapy</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48024\">IRCT20200510047383N1</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB15747\">CoviGlobulin</a></strong></td><td>Evaluation of the efficacy and safety of Rabbit polyclonal antibody (CoviGlobulin) in patients with coronavirus COVID-19 virus moderate to severe</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47953\">IRCT20200508047346N1</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB11355\">Propolis wax</a></strong></td><td>The effect of propolis supplementation on clinical manifestations and inflammatory biomarkers in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47934\">IRCT20200326046868N1</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49174\">IRCT20111224008507N3</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542694\">NCT04542694</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/51310\">IRCT20131125015536N13</a></td></tr><tr><td>2020-05-21</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients : Multicenter Interventional Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04474340\">NCT04474340</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Subcutaneous and Intravenous anakinra in COVID-19 Infection - Feasibility &amp; Pharmacokinetics / Pharmacodynamics study - SCIL-COV19 PK / PD trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001636-95\">EUCTR2020-001636-95-GB</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Antithrombotic Therapy to Ameliorate Complications of COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372589\">NCT04372589</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356482\">NCT04356482</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Glasgow Early Treatment Arm FavIpiravir? : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients - GETAFIX</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001904-41\">EUCTR2020-001904-41-GB</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405310\">NCT04405310</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403477\">NCT04403477</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB12534\">Mavrilimumab</a></strong></td><td>Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04399980\">NCT04399980</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB06303\">Otilimab</a></strong></td><td>A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease. - OSCAR</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001759-42\">EUCTR2020-001759-42-GB</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB15446\">Vidofludimus</a></strong></td><td>A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator\\xe2\\x80\\x99s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001264-28\">EUCTR2020-001264-28-GR</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB00279\">Liothyronine</a></strong></td><td>Triiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study) - Thy-Support STUDY</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001623-13\">EUCTR2020-001623-13-GR</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB06692\">Aprotinin</a></strong></td><td>A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCo</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001739-28\">EUCTR2020-001739-28-BE</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB08813\">Nadroparin</a></strong></td><td>A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCo</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001739-28\">EUCTR2020-001739-28-BE</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCo</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001739-28\">EUCTR2020-001739-28-BE</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCo</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001739-28\">EUCTR2020-001739-28-BE</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB00316\">Acetaminophen</a></strong></td><td>Evaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000309-En\">RPCEC00000309</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB09153\">Sodium chloride</a></strong></td><td>Evaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000309-En\">RPCEC00000309</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB15638\">Brensocatib</a></strong></td><td>A randomised double-blind placebo-controlled trial of brensocatib (INS1007) in patients with severe COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN30564012\">ISRCTN30564012</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>BARICIVID-19 STUDY : MultiCentre, Randomised, Phase IIa Clinical Trial Evaluating Efficacy and Tolerability of Baricitinib as add-on Treatment of In-patients With COVID-19 Compared to Standard Therapy</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04393051\">NCT04393051</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380402\">NCT04380402</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Randomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and Gu\\xc3\\xa9rin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04384549\">NCT04384549</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Randomized, Open-label, multicenter study to evaluate the efficacy and safety of Favipiravir combined with STANDARD supportive care in adult Indian patients with mild to moderate COVID-19</td><td>Treatment</td><td>3</td><td>Completed</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43504\">CTRI/2020/05/025114</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB11135\">Selenium</a></strong></td><td>The effect of addition of selenium to treatment regimen of hospitalized patients with COVID-19 on the outcome of disease compared with control group</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47682\">IRCT20160706028815N5</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04376788\">NCT04376788</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB09241\">Methylene blue</a></strong></td><td>Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04376788\">NCT04376788</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB00848\">Levamisole</a></strong></td><td>Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360122\">NCT04360122</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB13156\">Inosine pranobex</a></strong></td><td>Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360122\">NCT04360122</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Effectiveness of Prophylactic Hydroxychloroquine on incidence of COVID-19 infection in Front-line Health and Allied Health Care Workers : The COVID-SHIELD Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000501943.aspx\">ACTRN12620000501943</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB12534\">Mavrilimumab</a></strong></td><td>Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492514\">NCT04492514</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>AN OPEN LABEL RANDOMISED CONTROL TRIAL ON PASSIVE IMMUNIZATION WITH CONVALESCENT PLASMA IN SEVERE COVID-19 DISEASE - PICP19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43251\">CTRI/2020/05/025209</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB13925\">Dotatate gallium Ga-68</a></strong></td><td>[68Ga]Ga-DOTA-(RGD)2 PET / CT imaging of activated endothelium in lung parenchyma of COVID-19 patients. - RDG-PET / CT imaging in COVID-19 patients.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001325-31\">EUCTR2020-001325-31-NL</a></td></tr><tr><td>2020-05-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2 / COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04501783\">NCT04501783</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Evaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48096\">IRCT20200428047228N2</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48096\">IRCT20200428047228N2</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Telmisartan for Treatment of COVID-19 Patients : an Open Label Randomized Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355936\">NCT04355936</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Vitamin D Testing and Treatment for Adults With COVID 19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407286\">NCT04407286</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOV</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001754-21\">EUCTR2020-001754-21-FR</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOV</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001754-21\">EUCTR2020-001754-21-FR</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOV</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001754-21\">EUCTR2020-001754-21-FR</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care : A Double-blind Randomized Control Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04397328\">NCT04397328</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Usefulness of vitamin D on morbidity and mortality of SARS-COV-2 virus infection (Covid-19) at the Central University Hospital of Asturias - Vitamin D and COVID-19</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002274-28\">EUCTR2020-002274-28-ES</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB13941\">Piperaquine</a></strong></td><td>A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53840\">ChiCTR2000033049</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB13132\">Artemisinin</a></strong></td><td>A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53840\">ChiCTR2000033049</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47559\">IRCT20200428047228N1</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47559\">IRCT20200428047228N1</a></td></tr><tr><td>2020-05-19</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>Evaluation of SinaCurcumin as a complementary therapy in mild to moderate COVID-19 : An open label non-randomized clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47061\">IRCT20200408046990N1</a></td></tr><tr><td>2020-05-18</td><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361474\">NCT04361474</a></td></tr><tr><td>2020-05-18</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>Aerosolized DNase I for the treatment of severe respiratory failure in COVID-19 - a phase 2, randomized controlled trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001849-39\">EUCTR2020-001849-39-SE</a></td></tr><tr><td>2020-05-18</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04381884\">NCT04381884</a></td></tr><tr><td>2020-05-18</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380935\">NCT04380935</a></td></tr><tr><td>2020-05-18</td><td><strong><a href=\"/drugs/DB14312\">Glycyrrhiza glabra</a></strong></td><td>Observational Study of YASHTIMADHU TABLET intake as a preventive measure in pandemic of COVID-19 \\xc3\\xa2?? An open label, Randomized, Controlled, Prospective, interventional, Community-based Cclinical study on healthy subjects</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43539\">CTRI/2020/05/025093</a></td></tr><tr><td>2020-05-18</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Effect of Hydroxychloroquine Prophylaxis on QTc Interval of Health Care Workers during COVID-19 Pandemic : An Observational Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43506\">CTRI/2020/05/025089</a></td></tr><tr><td>2020-05-18</td><td><strong><a href=\"/drugs/DB11942\">Selinexor</a></strong></td><td>A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25\">EUCTR2020-001411-25-DE</a></td></tr><tr><td>2020-05-16</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>Evaluation efficacy of &quot;Curcumin and Resveratrol&quot; capsule in controlling symptoms in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48116\">IRCT20080901001165N56</a></td></tr><tr><td>2020-05-16</td><td><strong><a href=\"/drugs/DB02709\">Resveratrol</a></strong></td><td>Evaluation efficacy of &quot;Curcumin and Resveratrol&quot; capsule in controlling symptoms in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48116\">IRCT20080901001165N56</a></td></tr><tr><td>2020-05-16</td><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>Open Label Randomized Clinical Trial BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalization</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04424134\">NCT04424134</a></td></tr><tr><td>2020-05-16</td><td><strong><a href=\"/drugs/DB00421\">Spironolactone</a></strong></td><td>Open Label Randomized Clinical Trial BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalization</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04424134\">NCT04424134</a></td></tr><tr><td>2020-05-16</td><td><strong><a href=\"/drugs/DB00056\">Gemtuzumab ozogamicin</a></strong></td><td>A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN40580903\">ISRCTN40580903</a></td></tr><tr><td>2020-05-16</td><td><strong><a href=\"/drugs/DB14276\">Turmeric</a></strong></td><td>Evaluation of the Immuno-stimulatory(Shareera Bala) potential of Ayurveda management protocol in Cohort of Delhi Police - An Exploratory clinical Study - EBAMD</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43487\">CTRI/2020/05/025171</a></td></tr><tr><td>2020-05-16</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19 : an Open-label, Pilot Study</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04320277\">NCT04320277</a></td></tr><tr><td>2020-05-16</td><td><strong><a href=\"/drugs/DB14566\">Lavender oil</a></strong></td><td>Investigating the effect of Lavender (Lavandula angustifolia L.) syrup on improving the severity of cough in patients with definite or highly suspicious COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48013\">IRCT20110907007511N4</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04442958\">NCT04442958</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04569188\">NCT04569188</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04438980\">NCT04438980</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment. The Immunomodulation-CoV Assessment (ImmCoVA) study. - The Immunomodulation-CoV Assessment (ImmCoVA) study.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001748-24\">EUCTR2020-001748-24-SE</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment. The Immunomodulation-CoV Assessment (ImmCoVA) study. - The Immunomodulation-CoV Assessment (ImmCoVA) study.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001748-24\">EUCTR2020-001748-24-SE</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528927\">NCT04528927</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528927\">NCT04528927</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528927\">NCT04528927</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04528927\">NCT04528927</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB15863\">Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled, Phase Ia / IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412538\">NCT04412538</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB06260\">Aviptadil</a></strong></td><td>Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04311697\">NCT04311697</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and manifested clinical symptoms.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002091-12\">EUCTR2020-002091-12-BG</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>A proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04399798\">NCT04399798</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB15812\">V-SARS</a></strong></td><td>Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380532\">NCT04380532</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB14547\">Chloride ion</a></strong></td><td>Hypernatremia in critically ill patients with Covid-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021611\">DRKS00021611</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB03904\">Urea</a></strong></td><td>Hypernatremia in critically ill patients with Covid-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021611\">DRKS00021611</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB14500\">Potassium</a></strong></td><td>Hypernatremia in critically ill patients with Covid-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021611\">DRKS00021611</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19) the Vanguard Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04400032\">NCT04400032</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Retrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04275388\">NCT04275388</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Retrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04275388\">NCT04275388</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Controlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19 -SANsinCOVID-19). - Sanitarios sin COVID -SANsinCOVID-</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001704-42\">EUCTR2020-001704-42-ES</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia : the BREATH-19 Study</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001995-13\">EUCTR2020-001995-13-ES</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IE</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IE</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IE</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IE</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB06415\">Calfactant</a></strong></td><td>A clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults - COVID-19 Surfactant Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001886-35\">EUCTR2020-001886-35-GB</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB15446\">Vidofludimus</a></strong></td><td>Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 - IONIC study -IMU838 and Oseltamivir in treatment of Novel Coronavirus</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001805-21\">EUCTR2020-001805-21-GB</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 - IONIC study -IMU838 and Oseltamivir in treatment of Novel Coronavirus</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001805-21\">EUCTR2020-001805-21-GB</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB15638\">Brensocatib</a></strong></td><td>A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 - STOP-COVID19 : Superiority Trial Of Protease inhibition in COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001643-13\">EUCTR2020-001643-13-GB</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04386070\">NCT04386070</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04386070\">NCT04386070</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04386070\">NCT04386070</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04383535\">NCT04383535</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>EFFICACY OF ORAL NICLOSAMIDE IN TREATMENT OF MILD AND VERY MILD COVID-19 CASES : AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL - EONIC-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43400\">CTRI/2020/04/024949</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01410\">Ciclesonide</a></strong></td><td>EFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43364\">CTRI/2020/04/024948</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>EFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43364\">CTRI/2020/04/024948</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>EFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43364\">CTRI/2020/04/024948</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377997\">NCT04377997</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377997\">NCT04377997</a></td></tr><tr><td>2020-05-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure : Randomised Control Trial</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370015\">NCT04370015</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. - Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infectio</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001921-30\">EUCTR2020-001921-30-IT</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. - Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infectio</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001921-30\">EUCTR2020-001921-30-IT</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001528-32\">EUCTR2020-001528-32-IT</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001528-32\">EUCTR2020-001528-32-IT</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB01264\">Darunavir</a></strong></td><td>Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001528-32\">EUCTR2020-001528-32-IT</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001528-32\">EUCTR2020-001528-32-IT</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001528-32\">EUCTR2020-001528-32-IT</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372017\">NCT04372017</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>PROTECT : A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363827\">NCT04363827</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB00009\">Alteplase</a></strong></td><td>Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection : A Phase 2a Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357730\">NCT04357730</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348656\">NCT04348656</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease : a Randomised Controlled Trial</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04405999\">NCT04405999</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372186\">NCT04372186</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients : Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366960\">NCT04366960</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB15732\">FT516</a></strong></td><td>Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363346\">NCT04363346</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB11997\">Interleukin-7</a></strong></td><td>A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04379076\">NCT04379076</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>Investigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48066\">IRCT20080901001165N53</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Effect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19 : a randomized clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47501\">IRCT20120215009014N353</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348435\">NCT04348435</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB15751\">MRx-4DP0004</a></strong></td><td>Investigation of the effect of Lactocare\\xc2\\xae synbiotic on the prevention of COVID-19 infection in the staff of emergency department</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49670\">IRCT20101020004976N6</a></td></tr><tr><td>2020-05-14</td><td><strong><a href=\"/drugs/DB11997\">Interleukin-7</a></strong></td><td>InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK)</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN15913068\">ISRCTN15913068</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04446104\">NCT04446104</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04446104\">NCT04446104</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04446104\">NCT04446104</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04446104\">NCT04446104</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Investigating the efficacy and safety of N-Acetyl Cysteine (NAC) inhalation spray in controlling the symptoms of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48061\">IRCT20080901001165N55</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB10506\">Barley</a></strong></td><td>Investigating the effect of barely-based traditional remedy on controlling of clinical symptoms and paraclinical results in hospitalized patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47974\">IRCT20180923041093N6</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04410562\">NCT04410562</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04397757\">NCT04397757</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359680\">NCT04359680</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04339816\">NCT04339816</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04339816\">NCT04339816</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB15722\">CYNK-001</a></strong></td><td>A Phase I / II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365101\">NCT04365101</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB15801\">VPM1002</a></strong></td><td>A phase III, double-blind, randomized, placebo-controlled multicentre clinical trial to assess the efficacy and safety of VPM1002 in reducing healthcare professionals\\xe2\\x80\\x99 absenteeism in the SARS-CoV-2 pandemic by modulating the immune system</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001376-15\">EUCTR2020-001376-15-DE</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390139\">NCT04390139</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373707\">NCT04373707</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB08813\">Nadroparin</a></strong></td><td>Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373707\">NCT04373707</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB06779\">Dalteparin</a></strong></td><td>Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373707\">NCT04373707</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373707\">NCT04373707</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB06822\">Tinzaparin</a></strong></td><td>Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373707\">NCT04373707</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB00457\">Prazosin</a></strong></td><td>Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome : A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365257\">NCT04365257</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB14767\">Peginterferon lambda-1a</a></strong></td><td>Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD) : A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354259\">NCT04354259</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB01169\">Arsenic trioxide</a></strong></td><td>EFFECTIVENESS OF ARSENICUM ALBUM 30C IN PREVENTION OF COVID-19 IN INDIVIDUALS RESIDING IN HOSPOTS OF RED ZONES IN DELHI\\xc3\\xa2?? A PROSPECTIVE COHORT STUDY</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43455\">CTRI/2020/05/024986</a></td></tr><tr><td>2020-05-13</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infections</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8633\">NL8633</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04466540\">NCT04466540</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04429711\">NCT04429711</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04409522\">NCT04409522</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB00927\">Famotidine</a></strong></td><td>Famotidine Use in Non-hospitalized Patients With COVID-19 : A Case Series</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389567\">NCT04389567</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB04977\">Plitidepsin</a></strong></td><td>Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382066\">NCT04382066</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343248\">NCT04343248</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB11580\">Ravulizumab</a></strong></td><td>A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001497-30\">EUCTR2020-001497-30-FR</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation : Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib - JAKINCOV</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001963-10\">EUCTR2020-001963-10-FR</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation : Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib - JAKINCOV</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001963-10\">EUCTR2020-001963-10-FR</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04388683\">NCT04388683</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>#StayHome : Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland : A Double-blind, Randomised, Placebo-controlled Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04385264\">NCT04385264</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Assessment of safety, efficacy and effective dose determination of human umbilical cord Wharton\\xe2\\x80\\x99s jelly mesenchymal stem cell transplantation on treatment of COVID-19 (coronavirus) pneumonia and complications in humans</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47964\">IRCT20200421047150N1</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>The Effect of Convalescent Plasma Therapy on the Outcomes of Patients with 19-COVID</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47594\">IRCT20150808023559N21</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB15661\">Molnupiravir</a></strong></td><td>AGILE : Seamless Phase I / IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment - AGILE</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001860-27\">EUCTR2020-001860-27-GB</a></td></tr><tr><td>2020-05-12</td><td><strong><a href=\"/drugs/DB14991\">Nomacopan</a></strong></td><td>AGILE : Seamless Phase I / IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment - AGILE</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001860-27\">EUCTR2020-001860-27-GB</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A phase II / III study to determine the efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN90906759\">ISRCTN90906759</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB15740\">Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells</a></strong></td><td>Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382547\">NCT04382547</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Severe Reluctant COVID-19 Patients Responding to Convalescent Plasma ; A case series</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=54346\">ChiCTR2000033323</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Coagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362085\">NCT04362085</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB06779\">Dalteparin</a></strong></td><td>Coagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362085\">NCT04362085</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Coagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362085\">NCT04362085</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB06822\">Tinzaparin</a></strong></td><td>Coagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362085\">NCT04362085</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354831\">NCT04354831</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04352933\">NCT04352933</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>Low-dose Hydroxychloroquine and Bromhexine : a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04340349\">NCT04340349</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Low-dose Hydroxychloroquine and Bromhexine : a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04340349\">NCT04340349</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomised Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19 - HAZES</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43130\">CTRI/2020/04/024904</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomised Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19 - HAZES</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43130\">CTRI/2020/04/024904</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Open Label, parallel arm, phase I / II clinical trial to evaluate Safety and efficacy of Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42849\">CTRI/2020/04/024804</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB11580\">Ravulizumab</a></strong></td><td>A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04369469\">NCT04369469</a></td></tr><tr><td>2020-05-11</td><td><strong><a href=\"/drugs/DB00178\">Ramipril</a></strong></td><td>A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366050\">NCT04366050</a></td></tr><tr><td>2020-05-10</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Investigating the use of convalescent plasma from patients who have recovered from COVID-19 in the management of Ecuadorian patients infected with SARS-CoV-2 with clinical deterioration : IMPACT</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN85216856\">ISRCTN85216856</a></td></tr><tr><td>2020-05-09</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Intravenous immunoglubolin (IVIG) effect on improvement of severe pulmonary damage in COVID 19 disease</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47609\">IRCT20200501047259N1</a></td></tr><tr><td>2020-05-09</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43332\">CTRI/2020/04/024915</a></td></tr><tr><td>2020-05-09</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47578\">IRCT20200418047121N1</a></td></tr><tr><td>2020-05-09</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47578\">IRCT20200418047121N1</a></td></tr><tr><td>2020-05-09</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47578\">IRCT20200418047121N1</a></td></tr><tr><td>2020-05-09</td><td><strong><a href=\"/drugs/DB00331\">Metformin</a></strong></td><td>Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47578\">IRCT20200418047121N1</a></td></tr><tr><td>2020-05-09</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Investigation the adipose and placenta-derived mesenchymal stem cells effect on the respiratory distress syndrome in patients with COVID-19 : a pilot study</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47275\">IRCT20200418047121N2</a></td></tr><tr><td>2020-05-09</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374487\">NCT04374487</a></td></tr><tr><td>2020-05-09</td><td><strong><a href=\"/drugs/DB01041\">Thalidomide</a></strong></td><td>Effectiveness and safety of thalidomide in moderate COVID-19 pneumonia : A randomized clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47637\">IRCT20200428047232N1</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2 / 3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04443881\">NCT04443881</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV - Study of COVID-19 and Chloroquine / hydroxychloroquine in healthcare setting</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001441-39\">EUCTR2020-001441-39-IT</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV - Study of COVID-19 and Chloroquine / hydroxychloroquine in healthcare setting</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001441-39\">EUCTR2020-001441-39-IT</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04411433\">NCT04411433</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04411433\">NCT04411433</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04411433\">NCT04411433</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04401579\">NCT04401579</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04401579\">NCT04401579</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB13132\">Artemisinin</a></strong></td><td>A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382040\">NCT04382040</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382040\">NCT04382040</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382040\">NCT04382040</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB14275\">Indian frankincense</a></strong></td><td>A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382040\">NCT04382040</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00661\">Verapamil</a></strong></td><td>Amiodarone or Verapamil in COVID-19 hospitalized patients with symptoms : Randomized clinical trial - ReCOVery-SIRIO</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001951-42\">EUCTR2020-001951-42-PL</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB01118\">Amiodarone</a></strong></td><td>Amiodarone or Verapamil in COVID-19 hospitalized patients with symptoms : Randomized clinical trial - ReCOVery-SIRIO</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001951-42\">EUCTR2020-001951-42-PL</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers : a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403685\">NCT04403685</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403243\">NCT04403243</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB09029\">Secukinumab</a></strong></td><td>COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403243\">NCT04403243</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403243\">NCT04403243</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390464\">NCT04390464</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB11580\">Ravulizumab</a></strong></td><td>mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390464\">NCT04390464</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Novel Treatment Regimens in Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382846\">NCT04382846</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Novel Treatment Regimens in Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382846\">NCT04382846</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Novel Treatment Regimens in Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382846\">NCT04382846</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Novel Treatment Regimens in Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382846\">NCT04382846</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00773\">Etoposide</a></strong></td><td>A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection</td><td>Supportive Care</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356690\">NCT04356690</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04337918\">NCT04337918</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00328\">Indomethacin</a></strong></td><td>Efficacy and safety of oral indomethacin for treatment of covid 19 induced pneumonia</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47520\">IRCT20200427047215N1</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333355\">NCT04333355</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00058\">Alpha-1-proteinase inhibitor</a></strong></td><td>A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin\\xc2\\xae plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001953-36\">EUCTR2020-001953-36-ES</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19 - Study to Evaluate the Safety and Efficacy of High Dose IVIG in Patients with Mild / Moderate COVID19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001696-32\">EUCTR2020-001696-32-ES</a></td></tr><tr><td>2020-05-08</td><td><strong><a href=\"/drugs/DB15745\">Washed Microbiota Transplantation</a></strong></td><td>Clinical trial for the washed microbiota transplantation in the treatment of novel coronavirus pneumonia (COVID-19) patients suspected with gut microbiota dysbiosis</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53458\">ChiCTR2000032737</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB12534\">Mavrilimumab</a></strong></td><td>A randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyperinflammation : the COMBAT-19 trial - Mavrilimumab in COVID-19 pneumonia with hyperinflammation</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001795-15\">EUCTR2020-001795-15-IT</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine Use in Hospitalized Patients With COVID-19 : Impact on Progression to Severe or Critical Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04429867\">NCT04429867</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB11580\">Ravulizumab</a></strong></td><td>COVID-19 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001497-30\">EUCTR2020-001497-30-GB</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for Treatment of COVID-19 : An Exploratory Dose Identifying Study</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04384497\">NCT04384497</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 \\xe2\\x80\\x93 Repurposed Drugs (TACTIC-R)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN11188345\">ISRCTN11188345</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB11580\">Ravulizumab</a></strong></td><td>mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 \\xe2\\x80\\x93 Repurposed Drugs (TACTIC-R)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN11188345\">ISRCTN11188345</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB12849\">Clazakizumab</a></strong></td><td>A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363502\">NCT04363502</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04381988\">NCT04381988</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366271\">NCT04366271</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB13941\">Piperaquine</a></strong></td><td>A randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53658\">ChiCTR2000032915</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB13132\">Artemisinin</a></strong></td><td>A randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53658\">ChiCTR2000032915</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001474-29\">EUCTR2020-001474-29-ES</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>RANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDY</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002123-11\">EUCTR2020-002123-11-ES</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>RANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDY</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002123-11\">EUCTR2020-002123-11-ES</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 - USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001934-37\">EUCTR2020-001934-37-ES</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB01211\">Clarithromycin</a></strong></td><td>ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY : THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIAL</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001882-36\">EUCTR2020-001882-36-GR</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent Hospitalization</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365582\">NCT04365582</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent Hospitalization</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365582\">NCT04365582</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent Hospitalization</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365582\">NCT04365582</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent Hospitalization</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365582\">NCT04365582</a></td></tr><tr><td>2020-05-07</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04500067\">NCT04500067</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>PRECOV : a randomized controlled clinical trial on the effects of hydroxychloroquine in the prevention of COVID-19 in healthcare workers at risk - PRECOV</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001987-28\">EUCTR2020-001987-28-IT</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB04932\">Defibrotide</a></strong></td><td>Use of Defibrotide to reduce progression of acute respiratory failure rate in patients with COVID-19 pneumonia - Defibrotide in COVID19</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001513-20\">EUCTR2020-001513-20-IT</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB01211\">Clarithromycin</a></strong></td><td>Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early : The ACHIEVE Open-label Non-randomized Clinical Trial</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04398004\">NCT04398004</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB01088\">Iloprost</a></strong></td><td>Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng / kg / min) in patients with COVID-19 induced respiratory failure \\xe2\\x80\\x93 a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001296-33\">EUCTR2020-001296-33-DK</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB14828\">ABX-464</a></strong></td><td>A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75\">EUCTR2020-001673-75-FR</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 - CALAVI</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001644-25\">EUCTR2020-001644-25-FR</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia : A Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04381858\">NCT04381858</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia : A Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04381858\">NCT04381858</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB06683\">Clevudine</a></strong></td><td>A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347915\">NCT04347915</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An open label randomised controlled trial to assess the efficacy of Hydroxychloroquine in patients with mild COVID -19 illness with risk factors for severe disease.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43183\">CTRI/2020/05/025022</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Phase 2 Clinical Trial for the Evaluation of BCG as potential therapy for CoVID-I9 - COVID-19 BCG</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42858\">CTRI/2020/05/025013</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>COVID-19-associated Coagulopathy : Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360824\">NCT04360824</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Ramdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001994-66\">EUCTR2020-001994-66-ES</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>A RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOPING SEVERE PULMONARY COMPLICATIONS ASSOCIATED WITH CORONAVIRUS SARS-CoV2 PNEUMONIA (COVID-19) - COLCHI-COVID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001603-16\">EUCTR2020-001603-16-ES</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN - RAVEN</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001777-71\">EUCTR2020-001777-71-GB</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GU\\xc3\\x89RIN) VACCINATION - BACH (BCG Against COVID-19 in Hunga</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001783-28\">EUCTR2020-001783-28-HU</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB11997\">Interleukin-7</a></strong></td><td>Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection \\xe2\\x80\\x9cILIAD 7 trial\\xe2\\x80\\x9d - ILIAD</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001786-36\">EUCTR2020-001786-36-GB</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB01197\">Captopril</a></strong></td><td>Efficacy of captopril nebulization in Covid-19 patients suffering of SARS-CoV-2 pneumonia. A randomized phase II study - CAPTOCOVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001700-42\">EUCTR2020-001700-42-FR</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for the Treatment of Patients With COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372368\">NCT04372368</a></td></tr><tr><td>2020-05-06</td><td><strong><a href=\"/drugs/DB12614\">Reparixin</a></strong></td><td>Adaptive phase 2 / 3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia - REPAVID-19</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001645-40\">EUCTR2020-001645-40-IT</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Infusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19) : A Double-blinded, Placebo-controlled, Proof-of-concept Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04442191\">NCT04442191</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB13156\">Inosine pranobex</a></strong></td><td>The Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19 : A Proposed Therapeutic Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04383717\">NCT04383717</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB00848\">Levamisole</a></strong></td><td>The Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19 : A Proposed Therapeutic Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04383717\">NCT04383717</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351919\">NCT04351919</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351919\">NCT04351919</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications : A Phase II Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374565\">NCT04374565</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg / kg or 4mg / kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363736\">NCT04363736</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID) - RUXCOVID</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001662-11\">EUCTR2020-001662-11-DE</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>&quot;STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE&quot; GERONIMO 19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04403269\">NCT04403269</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB13037\">Namilumab</a></strong></td><td>CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001684-89\">EUCTR2020-001684-89-GB</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB00065\">Infliximab</a></strong></td><td>CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001684-89\">EUCTR2020-001684-89-GB</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB00056\">Gemtuzumab ozogamicin</a></strong></td><td>CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001684-89\">EUCTR2020-001684-89-GB</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392232\">NCT04392232</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB01097\">Leflunomide</a></strong></td><td>Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361214\">NCT04361214</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections.</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365725\">NCT04365725</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04379492\">NCT04379492</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB00281\">Lidocaine</a></strong></td><td>Usage of topical lignocaine to decrease the gag reflex while sampling for Covid-19 : Does it affect the yield of specimen?</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43204\">CTRI/2020/05/024983</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Effectiveness of topical povidone iodine (PVP-I) oropharyngeal and intranasal application during the current coronavirus pandemic amongst COVID-19 positive patients in Andhra Pradesh, India</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43237\">CTRI/2020/05/024962</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374552\">NCT04374552</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374552\">NCT04374552</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2) - ATOMIC2, Version 1.0</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001740-26\">EUCTR2020-001740-26-GB</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB01197\">Captopril</a></strong></td><td>Efficacy of Captopril Nebulization in Covid-19 Patients Suffering of SARS CoV-2 Pneumonia. A Randomized Phase II Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355429\">NCT04355429</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Phase I trial on safety and tolerability of bone-marrow derived mesenchymal stromal cells (MSC) for deteriorating COVID-19 pneumonia</td><td>Treatment</td><td>1</td><td>Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000840987.aspx\">ACTRN12620000840987</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>TRANSFUSION WITH CONVALING PLASMA IMMUNIZES THE ASYMPTOMATIC PATIENT WITH COVID INFECTION 19 THAT FOR MORE THAN 30 DAYS IS POSITIVE SARS CoV-2 PCR (COVID-19)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000323-En\">RPCEC00000323</a></td></tr><tr><td>2020-05-05</td><td><strong><a href=\"/drugs/DB00099\">Filgrastim</a></strong></td><td>Treatment of lung lesions with autologous stem cells in patients recovered from COVID-19 (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000322-En\">RPCEC00000322</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Unicenter, Randomized, Open-label Clinical Trial on the Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435717\">NCT04435717</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB00162\">Vitamin A</a></strong></td><td>Assessment of vitamin A effectiveness on COVID-19 patients and treatment outcomes referred to health centers of Qom province</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46519\">IRCT20200314046774N1</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB07615\">Tranilast</a></strong></td><td>Assessment of the effect of Tranilast on the efficacy of antiviral drug regimens in the treatment of patients with severe COVID19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47265\">IRCT20200419047128N1</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection : Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04391127\">NCT04391127</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection : Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04391127\">NCT04391127</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB00105\">Interferon alfa-2b</a></strong></td><td>Pharmacodynamics and safety of recombinant interferon alfa 2b, by different routes of administration, in healthy volunteers (COVID-19).</td><td>Treatment</td><td>1</td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000308-En\">RPCEC00000308</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Effect of high dose intravenous vitamin C on moderate novel coronavirus pneumonia (COVID-19) patients : a medical records based retrospective study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53590\">ChiCTR2000033050</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04385199\">NCT04385199</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Generic Protocol on Hydroxychloroquine Prophylaxis for COVID-19 Infection Among Healthcare Workers : A Proof-of-Concept, Observational Study - HCQPRo</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43269\">CTRI/2020/05/025010</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01744\">Camphor</a></strong></td><td>Proving the efficacy of Homeopathic treatment in prevention and cure of COVID-19.</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43212\">CTRI/2020/04/024857</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel : a placebo-controlled, randomized, clinical trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://slctr.lk/trials/slctr-2020-011\">SLCTR/2020/011</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Evaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47707\">IRCT20200418047126N1</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Investigation of the effects of COVID-19 convalescent plasma in acute respiratory distress syndrome due to COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47629\">IRCT20200501047258N1</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>Effect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19) : A randomized, double-blind, placebo-controlled clinical trial study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47529\">IRCT20121216011763N46</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB12582\">Piperine</a></strong></td><td>Effect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19) : A randomized, double-blind, placebo-controlled clinical trial study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47529\">IRCT20121216011763N46</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB08826\">Deferiprone</a></strong></td><td>Investigating the effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47475\">IRCT20180114038350N3</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01261\">Sitagliptin</a></strong></td><td>Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47334\">IRCT20200420047147N1</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB00831\">Trifluoperazine</a></strong></td><td>Evaluation of Trifluoperazine Effectiveness in Treatment Process, Survival rate and Cure rate of COVID-19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47300\">IRCT20200329046892N1</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB10906\">Sugarcane</a></strong></td><td>Effect evaluation of herbal supplementation from the combination of sugarcane, black myrobalan and mastic along with the treatment protocol of the Ministry of Health on the course of COVID-19 disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47193\">IRCT20200415047082N1</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47115\">IRCT20200406046968N2</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Dose-Finding study of Ivermectin treatment on patients infected with Covid-19 : A clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47012\">IRCT20200408046987N1</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB00848\">Levamisole</a></strong></td><td>Assessment of effect of levamisole on pneumonia caused by COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46887\">IRCT20131215015805N2</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Gu\\xc3\\xa9rin Vaccination, a Randomized Controlled Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04379336\">NCT04379336</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377646\">NCT04377646</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377646\">NCT04377646</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection : a Randomized Phase II Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04375098\">NCT04375098</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Single-center, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002032-69\">EUCTR2020-002032-69-ES</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Impact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) - Heparin-SARS-CoV2</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001891-14\">EUCTR2020-001891-14-ES</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A phase 2 / 3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 - Investigating a Vaccine Against COVID-19 (COV002)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001228-32\">EUCTR2020-001228-32-GB</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease - RECOVER</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001632-10\">EUCTR2020-001632-10-DE</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB09113\">Poractant alfa</a></strong></td><td>Preliminary randomized controlled trial of poractant alfa (Curosurf\\xc2\\xae) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia. - CAARDS-1</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001598-66\">EUCTR2020-001598-66-FR</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB12665\">Isoquercetin</a></strong></td><td>A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001635-27\">EUCTR2020-001635-27-FR</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001635-27\">EUCTR2020-001635-27-FR</a></td></tr><tr><td>2020-05-04</td><td><strong><a href=\"/drugs/DB11526\">Masitinib</a></strong></td><td>A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001635-27\">EUCTR2020-001635-27-FR</a></td></tr><tr><td>2020-05-03</td><td><strong><a href=\"/drugs/DB00975\">Dipyridamole</a></strong></td><td>A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04424901\">NCT04424901</a></td></tr><tr><td>2020-05-03</td><td><strong><a href=\"/drugs/DB14131\">Basic Fibroblast Growth Factor</a></strong></td><td>Identification of predictive biomarkers for severe progression of COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021591\">DRKS00021591</a></td></tr><tr><td>2020-05-03</td><td><strong><a href=\"/drugs/DB12880\">Interleukin-10</a></strong></td><td>Identification of predictive biomarkers for severe progression of COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021591\">DRKS00021591</a></td></tr><tr><td>2020-05-03</td><td><strong><a href=\"/drugs/DB14076\">Interleukin-1 alpha, human recombinant</a></strong></td><td>Identification of predictive biomarkers for severe progression of COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021591\">DRKS00021591</a></td></tr><tr><td>2020-05-03</td><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td>Identification of predictive biomarkers for severe progression of COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021591\">DRKS00021591</a></td></tr><tr><td>2020-05-03</td><td><strong><a href=\"/drugs/DB15753\">Interferon Gamma</a></strong></td><td>Identification of predictive biomarkers for severe progression of COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021591\">DRKS00021591</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04434144\">NCT04434144</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04434144\">NCT04434144</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04434144\">NCT04434144</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04434144\">NCT04434144</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB15730\">Placental Mesenchymal Stem Cells</a></strong></td><td>Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04461925\">NCT04461925</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04461925\">NCT04461925</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19 : DAWN-PLASMA</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04429854\">NCT04429854</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362137\">NCT04362137</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 : A Cluster Based Randomized Selection Trial (IMPROVE-COVID)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04367831\">NCT04367831</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 : A Cluster Based Randomized Selection Trial (IMPROVE-COVID)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04367831\">NCT04367831</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB14509\">Lithium carbonate</a></strong></td><td>Clinical trial of lithium in improving the clinical and laboratory symptoms of patients with COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47141\">IRCT20081019001369N5</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients : Randomized Controlled Trial : MG-COVID</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371406\">NCT04371406</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients : Randomized Controlled Trial : MG-COVID</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371406\">NCT04371406</a></td></tr><tr><td>2020-05-02</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Evaluation of the Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention in COVID-19 Intensive Unit Care Patients.</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04520620\">NCT04520620</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Prospective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04444271\">NCT04444271</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425863\">NCT04425863</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425863\">NCT04425863</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425863\">NCT04425863</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425863\">NCT04425863</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for Passive Immunization in COVID-19 ICU Patients : An Interventional Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04565197\">NCT04565197</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Tocilizumab : A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04560205\">NCT04560205</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Perks of Methylprednisolone for Hospitalized COVID-19 Patients : A Clinical Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04559113\">NCT04559113</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04416139\">NCT04416139</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma Therapy in Patients With COVID-19</td><td>Health Services Research</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407208\">NCT04407208</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392414\">NCT04392414</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td>Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04382768\">NCT04382768</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01373\">Calcium</a></strong></td><td>Evaluation of Demographic and Clinical Parameters on Admission and Medications Used for Comorbidities in Patients With Covid-19 Pneumonia : A Single Center Experience in Turkey</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04379310\">NCT04379310</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374461\">NCT04374461</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373044\">NCT04373044</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373044\">NCT04373044</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358068\">NCT04358068</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358068\">NCT04358068</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377659\">NCT04377659</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345289\">NCT04345289</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04402203\">NCT04402203</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A pilot randomized clinical trial of therapeutic plasma exchange (TPE) in serious SARS CoV-2 disease (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN21363594\">ISRCTN21363594</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma To Limit COVID-19 Associated Complications : A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV-2 Plasma To Placebo in COVID-19 Hospitalized Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04404634\">NCT04404634</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>A Phase 1 / 2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04398303\">NCT04398303</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15728\">Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media</a></strong></td><td>A Phase 1 / 2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04398303\">NCT04398303</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04393792\">NCT04393792</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2 : a Multicenter Open Label Randomized Control Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04393727\">NCT04393727</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB14828\">ABX-464</a></strong></td><td>A Phase 2 / 3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged = 65 and Patients Aged =18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04393038\">NCT04393038</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358081\">NCT04358081</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358081\">NCT04358081</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355143\">NCT04355143</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390503\">NCT04390503</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372979\">NCT04372979</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359537\">NCT04359537</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Pilot Study on the Use of Sarilumab in Patients With COVID-19 Infection</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04386239\">NCT04386239</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04385043\">NCT04385043</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04352751\">NCT04352751</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB12849\">Clazakizumab</a></strong></td><td>A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04381052\">NCT04381052</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB16207\">Itolizumab</a></strong></td><td>A Multi-Centre, Open label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications</td><td>Treatment</td><td>2</td><td>Completed</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42878\">CTRI/2020/05/024959</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Effect of BCG-Denmark (Green Signal) on prevention of COVID 19 infection in health care workers \\xc3\\xa2?? a double blind randomized controlled trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43105\">CTRI/2020/04/024833</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897\">CTRI/2020/04/024773</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897\">CTRI/2020/04/024773</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897\">CTRI/2020/04/024773</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897\">CTRI/2020/04/024773</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897\">CTRI/2020/04/024773</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Evaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19 : randomized clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3k4wxb/\">RBR-3k4wxb</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19 : randomized clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3k4wxb/\">RBR-3k4wxb</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47577\">IRCT20080901001165N51</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Investigating the efficacy and safety of Azithromycin inhaled spray in controlling the symptoms of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47576\">IRCT20080901001165N50</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB16530\">Dialyzable leukocyte extract</a></strong></td><td>Assessment of the Clinical Effect of Dialyzable Leukocyte Extracts in Individuals With Acute Respiratory Infection (Suspected or Confirmed Cases of COVID-19) (FUTURE-T)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04379479\">NCT04379479</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB14644\">Methylprednisolone hemisuccinate</a></strong></td><td>Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377503\">NCT04377503</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377503\">NCT04377503</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00472\">Fluoxetine</a></strong></td><td>Fluoxetine to Reduce Intubation and Death After COVID19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377308\">NCT04377308</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15687\">Tridecactide</a></strong></td><td>An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN\\xc2\\xae as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374032\">NCT04374032</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB12668\">Metenkefalin</a></strong></td><td>An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN\\xc2\\xae as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374032\">NCT04374032</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374019\">NCT04374019</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374019\">NCT04374019</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB14291\">Wormwood</a></strong></td><td>Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374019\">NCT04374019</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374019\">NCT04374019</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374019\">NCT04374019</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00877\">Sirolimus</a></strong></td><td>A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371640\">NCT04371640</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363216\">NCT04363216</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374903\">NCT04374903</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374903\">NCT04374903</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00877\">Sirolimus</a></strong></td><td>Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374903\">NCT04374903</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19 : Favipiravir and StaNdard Care vErsEs Standard CaRe</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373733\">NCT04373733</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373291\">NCT04373291</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372082\">NCT04372082</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372082\">NCT04372082</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00343\">Diltiazem</a></strong></td><td>Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04372082\">NCT04372082</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health : A Randomized, Double-blind, Placebo-controlled Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04364815\">NCT04364815</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00569\">Fondaparinux</a></strong></td><td>Increased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359212\">NCT04359212</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Increased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359212\">NCT04359212</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 Patients</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354597\">NCT04354597</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 Patients</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354597\">NCT04354597</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Can a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals? - SINUS WASH pilot study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001721-31\">EUCTR2020-001721-31-GB</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE) : A Parallel Randomized Controlled Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371523\">NCT04371523</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359654\">NCT04359654</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00563\">Methotrexate</a></strong></td><td>Treatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles : A Phase I / II Study</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04352465\">NCT04352465</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363866\">NCT04363866</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>The LEAD COVID-19 Trial : Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363840\">NCT04363840</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>The LEAD COVID-19 Trial : Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363840\">NCT04363840</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients : A Tanta University Hope</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361318\">NCT04361318</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients : A Tanta University Hope</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361318\">NCT04361318</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Multi-centre Randomised Controlled Trial of Chloroquine / Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360759\">NCT04360759</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Multi-centre Randomised Controlled Trial of Chloroquine / Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360759\">NCT04360759</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients : A Tanta University Hope</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360356\">NCT04360356</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients : A Tanta University Hope</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360356\">NCT04360356</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358211\">NCT04358211</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for Patients With COVID-19 : A Pilot Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04332380\">NCT04332380</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection : HyPreC Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354441\">NCT04354441</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB12534\">Mavrilimumab</a></strong></td><td>Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04337216\">NCT04337216</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Phase II study on chloroquine and hydroxychloroquine in patients with manifestations serious cases of COVID-19 infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-8h7q82/\">RBR-8h7q82</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Phase II study on chloroquine and hydroxychloroquine in patients with manifestations serious cases of COVID-19 infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-8h7q82/\">RBR-8h7q82</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Phase II study on chloroquine and hydroxychloroquine in patients with manifestations serious cases of COVID-19 infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-8h7q82/\">RBR-8h7q82</a></td></tr><tr><td>2020-05-01</td><td><strong><a href=\"/drugs/DB16207\">Itolizumab</a></strong></td><td>A Multi-Centre, Open Label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04475588\">NCT04475588</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04471051\">NCT04471051</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised participants with COVID-19 (The COVASE trial) - Dornase alfa to reduce hyperinflammation in COVID19 - The COVASE trial</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001937-11\">EUCTR2020-001937-11-GB</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Mesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371393\">NCT04371393</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB06168\">Canakinumab</a></strong></td><td>Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362813\">NCT04362813</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB14242\">Honey</a></strong></td><td>The Role of Honey and Nigella Sativa in the Management of COVID-19 ; A Randomized Controlled, Open-label, Add-on Trial in Lahore, Pakistan</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347382\">NCT04347382</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04388527\">NCT04388527</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB15148\">Lenzilumab</a></strong></td><td>A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351152\">NCT04351152</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB01392\">Yohimbine</a></strong></td><td>Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI</td><td>Treatment</td><td>1</td><td>Completed</td><td><a href=\"http://www.drks.de/DRKS00021573\">DRKS00021573</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00683\">Midazolam</a></strong></td><td>Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI</td><td>Treatment</td><td>1</td><td>Completed</td><td><a href=\"http://www.drks.de/DRKS00021573\">DRKS00021573</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00213\">Pantoprazole</a></strong></td><td>Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI</td><td>Treatment</td><td>1</td><td>Completed</td><td><a href=\"http://www.drks.de/DRKS00021573\">DRKS00021573</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI</td><td>Treatment</td><td>1</td><td>Completed</td><td><a href=\"http://www.drks.de/DRKS00021573\">DRKS00021573</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04397523\">NCT04397523</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361253\">NCT04361253</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. - BCG-DENMARK-COVID</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001888-90\">EUCTR2020-001888-90-DK</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB01042\">Melphalan</a></strong></td><td>Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380376\">NCT04380376</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363203\">NCT04363203</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363203\">NCT04363203</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB15798\">Mycobacterium w. Vaccine</a></strong></td><td>A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347174\">NCT04347174</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB15798\">Mycobacterium w. Vaccine</a></strong></td><td>A clinical trial to evaluate the safety and efficacy of Mycobacterium W in critically ill patients suffering from COVID 19 infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43004\">CTRI/2020/04/024846</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis : A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374942\">NCT04374942</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB15736\">Alunacedase alfa</a></strong></td><td>Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335136\">NCT04335136</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374149\">NCT04374149</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350320\">NCT04350320</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS. RANDOMIZED CONTROLLED CLINICAL TRIAL - CORTIVID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001827-15\">EUCTR2020-001827-15-ES</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Azithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363060\">NCT04363060</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB01060\">Amoxicillin</a></strong></td><td>Azithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363060\">NCT04363060</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00766\">Clavulanic acid</a></strong></td><td>Azithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363060\">NCT04363060</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361461\">NCT04361461</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB15798\">Mycobacterium w. Vaccine</a></strong></td><td>A Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19.</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04353518\">NCT04353518</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB11942\">Selinexor</a></strong></td><td>A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355676\">NCT04355676</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04323631\">NCT04323631</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Aspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11037\">PACTR202006473370201</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Aspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11037\">PACTR202006473370201</a></td></tr><tr><td>2020-04-30</td><td><strong><a href=\"/drugs/DB00641\">Simvastatin</a></strong></td><td>Aspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11037\">PACTR202006473370201</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB04216\">Quercetin</a></strong></td><td>Evaluation of the effect of quercetin on the effectiveness of antiviral drug regimen in patients with COVID19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47396\">IRCT20200419047128N2</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Proactive Care of Ambulatory COVID19 Patients : Open-labeled Randomized Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371107\">NCT04371107</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB15695\">BNT162b1 SARS-CoV-2 Vaccine</a></strong></td><td>A PHASE 1 / 2 / 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04368728\">NCT04368728</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB15696\">Pfizer-BioNTech COVID-19 Vaccine</a></strong></td><td>A PHASE 1 / 2 / 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04368728\">NCT04368728</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-LT</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-LT</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-LT</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-LT</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-LT</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-LT</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Chloroquine / Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting ; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04303507\">NCT04303507</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Chloroquine / Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting ; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04303507\">NCT04303507</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04364802\">NCT04364802</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB15689\">Azoximer bromide</a></strong></td><td>A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of Polyoxidonium\\xc2\\xae, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04381377\">NCT04381377</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01221\">Ketamine</a></strong></td><td>Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365985\">NCT04365985</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00704\">Naltrexone</a></strong></td><td>Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365985\">NCT04365985</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Evaluation of colchicine tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad : A triple-blind randomized placebo controlled clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47468\">IRCT20200408046990N2</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Therapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47387\">IRCT20200421047155N1</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB14126\">Tenofovir</a></strong></td><td>Therapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47387\">IRCT20200421047155N1</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47152\">IRCT20200406046968N3</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47022\">IRCT20150808023559N20</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47022\">IRCT20150808023559N20</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47022\">IRCT20150808023559N20</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47022\">IRCT20150808023559N20</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Evaluation of the effect of Arbidol drug in the treatment of hospitalized patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46897\">IRCT20180725040596N2</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00062\">Albumin human</a></strong></td><td>Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation : a Randomized Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374539\">NCT04374539</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation : a Randomized Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374539\">NCT04374539</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe &amp; Azithromycin &amp; Zinc vErsEs Standard CaRe - PIONEER</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001449-38\">EUCTR2020-001449-38-GB</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe &amp; Azithromycin &amp; Zinc vErsEs Standard CaRe - PIONEER</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001449-38\">EUCTR2020-001449-38-GB</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe &amp; Azithromycin &amp; Zinc vErsEs Standard CaRe - PIONEER</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001449-38\">EUCTR2020-001449-38-GB</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe &amp; Azithromycin &amp; Zinc vErsEs Standard CaRe - PIONEER</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001449-38\">EUCTR2020-001449-38-GB</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB06779\">Dalteparin</a></strong></td><td>Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001709-21\">EUCTR2020-001709-21-FR</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB08813\">Nadroparin</a></strong></td><td>Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001709-21\">EUCTR2020-001709-21-FR</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001709-21\">EUCTR2020-001709-21-FR</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001709-21\">EUCTR2020-001709-21-FR</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB06822\">Tinzaparin</a></strong></td><td>Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001709-21\">EUCTR2020-001709-21-FR</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB06168\">Canakinumab</a></strong></td><td>Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30\">EUCTR2020-001370-30-DE</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCE</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001766-11\">EUCTR2020-001766-11-FR</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00421\">Spironolactone</a></strong></td><td>Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCE</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001766-11\">EUCTR2020-001766-11-FR</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>WHO SOLIDARITY Finland : The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - SOLIDARITY Finland</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001784-88\">EUCTR2020-001784-88-FI</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00477\">Chlorpromazine</a></strong></td><td>Repurposing of Chlorpromazine in Covid-19 Treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366739\">NCT04366739</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB15807\">BBIBP-CorV</a></strong></td><td>Evaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above : a randomized, double-blind, placebo parallel-controlled phase I / II clinical trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53003\">ChiCTR2000032459</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN10207947\">ISRCTN10207947</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN10207947\">ISRCTN10207947</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB09274\">Artesunate</a></strong></td><td>Randomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11103\">PACTR202006899597082</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Randomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11103\">PACTR202006899597082</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Study of Tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients : a ?crinical trial study</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48396\">IRCT20081027001411N4</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB00051\">Adalimumab</a></strong></td><td>Evaluation of adalimumab effect on clinical symptoms including respiratory distress, oxygen saturation and lung involvement of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47696\">IRCT20171105037262N4</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04547127\">NCT04547127</a></td></tr><tr><td>2020-04-29</td><td><strong><a href=\"/drugs/DB09241\">Methylene blue</a></strong></td><td>A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04547127\">NCT04547127</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445285\">NCT04445285</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>PROTECT : A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). - PROTECT</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001501-24\">EUCTR2020-001501-24-IT</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Open, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04434131\">NCT04434131</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative Study</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349228\">NCT04349228</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04411667\">NCT04411667</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB15636\">Zilucoplan</a></strong></td><td>ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001736-95\">EUCTR2020-001736-95-GB</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001736-95\">EUCTR2020-001736-95-GB</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB12411\">Bemcentinib</a></strong></td><td>ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001736-95\">EUCTR2020-001736-95-GB</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001736-95\">EUCTR2020-001736-95-GB</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB12895\">TD-139</a></strong></td><td>ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001736-95\">EUCTR2020-001736-95-GB</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355897\">NCT04355897</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370782\">NCT04370782</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB09322\">Zinc sulfate</a></strong></td><td>A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370782\">NCT04370782</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370782\">NCT04370782</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370782\">NCT04370782</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB15742\">MultiStem</a></strong></td><td>A Phase 2 / 3 Study to Assess the Safety and Efficacy of MultiStem\\xc2\\xae Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04367077\">NCT04367077</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19 - ANA-COVID-GEAS</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001825-29\">EUCTR2020-001825-29-ES</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB06168\">Canakinumab</a></strong></td><td>Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30\">EUCTR2020-001370-30-GB</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB00146\">Calcifediol</a></strong></td><td>Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366908\">NCT04366908</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation : a Multicentric Randomized, Open-label Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345848\">NCT04345848</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Gu\\xc3\\xa9rin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers.\\xe2\\x80\\x9d COVID-BCG - COVID BCG</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001678-31\">EUCTR2020-001678-31-FR</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study - COV-ENOX</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001823-15\">EUCTR2020-001823-15-FR</a></td></tr><tr><td>2020-04-28</td><td><strong><a href=\"/drugs/DB06546\">Atibuclimab</a></strong></td><td>Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346277\">NCT04346277</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB09036\">Siltuximab</a></strong></td><td>Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001854-23\">EUCTR2020-001854-23-IT</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001854-23\">EUCTR2020-001854-23-IT</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001854-23\">EUCTR2020-001854-23-IT</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB06168\">Canakinumab</a></strong></td><td>Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001854-23\">EUCTR2020-001854-23-IT</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001854-23\">EUCTR2020-001854-23-IT</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001854-23\">EUCTR2020-001854-23-IT</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia - ESCAPE</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001390-76\">EUCTR2020-001390-76-IT</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366323\">NCT04366323</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358783\">NCT04358783</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Efficacy and Safety of ANAkinra During Adult &quot; COVID-19 &quot; With Aggravating Respiratory Symptoms : a Multicenter Open-label Controlled Randomized Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04364009\">NCT04364009</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Comparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patients</td><td>Treatment</td><td>4</td><td>Completed</td><td><a href=\"http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=5995\">TCTR20200404004</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Comparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patients</td><td>Treatment</td><td>4</td><td>Completed</td><td><a href=\"http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=5995\">TCTR20200404004</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://lbctr.moph.gov.lb/Trials/Details/4522\">LBCTR2020043495</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://lbctr.moph.gov.lb/Trials/Details/4522\">LBCTR2020043495</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://lbctr.moph.gov.lb/Trials/Details/4522\">LBCTR2020043495</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://lbctr.moph.gov.lb/Trials/Details/4522\">LBCTR2020043495</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://lbctr.moph.gov.lb/Trials/Details/4522\">LBCTR2020043495</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://lbctr.moph.gov.lb/Trials/Details/4522\">LBCTR2020043495</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB15721\">Natural Killer Cell</a></strong></td><td>Evaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47264\">IRCT20200417047113N1</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>&quot;STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE&quot; GERONIMO 19 - GERONIMO19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001768-27\">EUCTR2020-001768-27-FR</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04369365\">NCT04369365</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363450\">NCT04363450</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for the Treatment of Moderate-severe COVID-19 : A Proof-of-principle Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365439\">NCT04365439</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00396\">Progesterone</a></strong></td><td>A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365127\">NCT04365127</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357860\">NCT04357860</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB01118\">Amiodarone</a></strong></td><td>Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351763\">NCT04351763</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB00661\">Verapamil</a></strong></td><td>Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351763\">NCT04351763</a></td></tr><tr><td>2020-04-27</td><td><strong><a href=\"/drugs/DB15809\">CIGB-258 peptide</a></strong></td><td>Expanded clinical use of CIGB-258 in the treatment of serious or critically ill patients by COVID-19 (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000321-En\">RPCEC00000321</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB11135\">Selenium</a></strong></td><td>Investigating the effectiveness of selenium on recovery of hospitalized patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47209\">IRCT20190418043307N1</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04401293\">NCT04401293</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB00753\">Isoflurane</a></strong></td><td>Volatile agents for sedation in patients with COVID-19-associated acute respiratory distress syndrome \\xe2\\x80\\x93 a pilot study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8523\">NL8523</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>Efficacy of Imatinib in mild SARS CoV2 infection : A randomized study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42843\">CTRI/2020/04/024806</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB04951\">Pirfenidone</a></strong></td><td>The evaluation of pirfenidone effects on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46533\">IRCT20200314046764N1</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363437\">NCT04363437</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB01914\">D-glucose</a></strong></td><td>Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000705-86\">EUCTR2020-000705-86-ES</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB11133\">Omega-3 fatty acids</a></strong></td><td>Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000705-86\">EUCTR2020-000705-86-ES</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB09393\">Amino acids</a></strong></td><td>Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000705-86\">EUCTR2020-000705-86-ES</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335071\">NCT04335071</a></td></tr><tr><td>2020-04-26</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04476888\">NCT04476888</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>Investigation the effects medical Ozone Autohemotherapy on clinical and para clinical features of patients with Covid19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47363\">IRCT20190618043923N4</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB15688\">Vazegepant</a></strong></td><td>BHV3500-203 : Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant* (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346615\">NCT04346615</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB11720\">Angiotensin 1-7</a></strong></td><td>Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04375124\">NCT04375124</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>\\xc3\\xa2??To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID 19 cases. A Pilot Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43236\">CTRI/2020/04/024858</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>PROTECT-Surg</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10981\">PACTR202004893013257</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>PROTECT-Surg</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10981\">PACTR202004893013257</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>PROTECT-Surg</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10981\">PACTR202004893013257</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB00627\">Niacin</a></strong></td><td>Evaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection : A Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47268\">IRCT20200418047122N1</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB12618\">Apocynin</a></strong></td><td>Evaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection : A Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47268\">IRCT20200418047122N1</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04373824\">NCT04373824</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355728\">NCT04355728</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355728\">NCT04355728</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>COVID-19 : Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361903\">NCT04361903</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359953\">NCT04359953</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359953\">NCT04359953</a></td></tr><tr><td>2020-04-25</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359953\">NCT04359953</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04573270\">NCT04573270</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Evolution of the efficacy and safety of Dexamethasone administration in patients with mild to moderate COVID-19 acute respiratory disease syndrome</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48153\">IRCT20151227025726N17</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB00633\">Dexmedetomidine</a></strong></td><td>Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04413864\">NCT04413864</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB12849\">Clazakizumab</a></strong></td><td>A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab\\xc2\\xae (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348500\">NCT04348500</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB15800\">VA-MENGOC-BC\\xc2\\xae</a></strong></td><td>Population impact of intervention based on the administration of a single dose of the Outer Membrane Vesicle (OMV) complex contained in VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2 (COVID-19) - VME-CORONA</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000314-En\">RPCEC00000314</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB06168\">Canakinumab</a></strong></td><td>Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365153\">NCT04365153</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB00877\">Sirolimus</a></strong></td><td>Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341675\">NCT04341675</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB11942\">Selinexor</a></strong></td><td>A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection - Low Dose Oral Selinexor in Patients with Severe COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25\">EUCTR2020-001411-25-GB</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB11803\">Sirukumab</a></strong></td><td>Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380961\">NCT04380961</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47244\">IRCT20200415047092N1</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB15733\">Lactobacillus coryniformis K8</a></strong></td><td>Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366180\">NCT04366180</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Randomized, Controlled Clinical Trial to Test the Safety and Efficacy of Convalescent Donor Plasma to Treat COVID-19 in Hospitalized Adults</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362176\">NCT04362176</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td>Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001541-39\">EUCTR2020-001541-39-ES</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Protecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis : A Randomized, Placebo-controlled Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04352946\">NCT04352946</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB14767\">Peginterferon lambda-1a</a></strong></td><td>A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331899\">NCT04331899</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB00058\">Alpha-1-proteinase inhibitor</a></strong></td><td>A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001391-15\">EUCTR2020-001391-15-IE</a></td></tr><tr><td>2020-04-24</td><td><strong><a href=\"/drugs/DB00803\">Colistin</a></strong></td><td>A multicenter, randomized, open, controlled trial for the efficacy and safety of oral kolimycin in the treatment of patients with new coronavirus pneumonia (CoVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52824\">ChiCTR2000032242</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>PILOT STUDY ON THE USE OF SARILUMAB IN PATIENTS WITH COVID-19 INFECTION - COVID-SARI-001</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001745-40\">EUCTR2020-001745-40-IT</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04434248\">NCT04434248</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A Phase I / II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324606\">NCT04324606</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection - A Multicenter Phase II Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04408209\">NCT04408209</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366245\">NCT04366245</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Outcomes of patients with COVID-19 related cytokine release syndrome under immunosuppressive treatment</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8551\">NL8551</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Outcomes of patients with COVID-19 related cytokine release syndrome under immunosuppressive treatment</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8551\">NL8551</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>Comparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47149\">IRCT20191125045492N2</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Comparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47149\">IRCT20191125045492N2</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB13127\">Olokizumab</a></strong></td><td>An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04380519\">NCT04380519</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) - COVIDNA</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001697-30\">EUCTR2020-001697-30-ES</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC in patients with acute respiratory distress syndrome secondary to infection by COVID-19 - COVIDMES</td><td>Treatment</td><td>1</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001505-22\">EUCTR2020-001505-22-ES</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB00062\">Albumin human</a></strong></td><td>Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation : a randomized study - REP-COVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001722-66\">EUCTR2020-001722-66-ES</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation : a randomized study - REP-COVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001722-66\">EUCTR2020-001722-66-ES</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland : an Open-label Cluster Randomized Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04364022\">NCT04364022</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland : an Open-label Cluster Randomized Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04364022\">NCT04364022</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB01236\">Sevoflurane</a></strong></td><td>Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury : a Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355962\">NCT04355962</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04329572\">NCT04329572</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04329572\">NCT04329572</a></td></tr><tr><td>2020-04-23</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>COVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents \\xe2\\x80\\x93 a randomized controlled trial - COVID-19 PREVENTION</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001363-85\">EUCTR2020-001363-85-DK</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Front line treatment with Ruxolitinib in stage II / III Covid-19 patients with defined Hyperinflammation - RuxCoFlam</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001481-11\">EUCTR2020-001481-11-DE</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine for the treatment of mild COVID-19 disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001512-26\">EUCTR2020-001512-26-DE</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Covid-19 : A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19 DAWN AZITHRO</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001614-38\">EUCTR2020-001614-38-BE</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334148\">NCT04334148</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine for the Treatment of Mild COVID-19 Disease</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04340544\">NCT04340544</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. - PLACID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43149\">CTRI/2020/04/024775</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>evaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections : A randomized interventional study in Imam Reza Hospital, Mashhad.</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47200\">IRCT20200325046859N2</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>evaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections : A randomized interventional study in Imam Reza Hospital, Mashhad.</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47200\">IRCT20200325046859N2</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB00009\">Alteplase</a></strong></td><td>A Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356833\">NCT04356833</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349631\">NCT04349631</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>A Phase-II Clinical Trial for First Line Treatment of Stage II / III Covid-19 Patients to Treat Hyperinflammation</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338958\">NCT04338958</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB12038\">Ulinastatin</a></strong></td><td>Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52506\">ChiCTR2000032135</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study. - Ruxolitinib Treatment in Patients with Severe COVID-19 Infection.A Danish Safety and Efficacy Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001459-42\">EUCTR2020-001459-42-DK</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB06292\">Dapagliflozin</a></strong></td><td>An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350593\">NCT04350593</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338698\">NCT04338698</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338698\">NCT04338698</a></td></tr><tr><td>2020-04-22</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338698\">NCT04338698</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced Acute Respiratory Distress Syndrome (ARDS)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355364\">NCT04355364</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351516\">NCT04351516</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB01606\">Tazobactam</a></strong></td><td>Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394182\">NCT04394182</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00319\">Piperacillin</a></strong></td><td>Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394182\">NCT04394182</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394182\">NCT04394182</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394182\">NCT04394182</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394182\">NCT04394182</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394182\">NCT04394182</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394182\">NCT04394182</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394182\">NCT04394182</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394182\">NCT04394182</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>COVID 19 : Experimental use of tocilizumab (Roactemra\\xc2\\xae) in severe SARS-CoV-2 related pneumonia.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001770-30\">EUCTR2020-001770-30-BE</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB15801\">VPM1002</a></strong></td><td>A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2 / COVID-19 Among High-Risk Subjects</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42972\">CTRI/2020/04/024749</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Topical Chloroquine Nasal Drops in Early Stage Covid 19- Impact on Viral load and cure rates</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42933\">CTRI/2020/04/024729</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47021\">IRCT20200406046968N1</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355637\">NCT04355637</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359810\">NCT04359810</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>A Randomized Trial of Anticoagulation Strategies in COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359277\">NCT04359277</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia - TOC-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001408-41\">EUCTR2020-001408-41-DE</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td>Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324463\">NCT04324463</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324463\">NCT04324463</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324463\">NCT04324463</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324463\">NCT04324463</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMIC</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001327-13\">EUCTR2020-001327-13-AT</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>COVID-19 : addition of azithromycin to chloroquine treatment - CO VOR IT</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001527-14\">EUCTR2020-001527-14-NL</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>COVID-19 : addition of azithromycin to chloroquine treatment - CO VOR IT</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001527-14\">EUCTR2020-001527-14-NL</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00421\">Spironolactone</a></strong></td><td>The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345887\">NCT04345887</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344288\">NCT04344288</a></td></tr><tr><td>2020-04-21</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients : A Pilot Randomized Controlled Trial.</td><td>Treatment</td><td>2</td><td>Completed</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43039\">CTRI/2020/04/024706</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA - ColCOVID19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001258-23\">EUCTR2020-001258-23-IT</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Evaluating effectiveness and safety of Umifenovir in the treatment (COVID-19)infection In patients referred to Tehran Imam Khomeini Hospital Complex</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48495\">IRCT20200523047550N1</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB06761\">Beractant</a></strong></td><td>The effect of surfactant on clinical outcome of patients with COVID-19 under mechanical ventilation</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46983\">IRCT20091201002804N12</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Cell therapy in patients with COVID-19 using mesenchymal stem cells</td><td>Treatment</td><td>1</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47110\">IRCT20190717044241N2</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients : A Pilot Randomized Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346446\">NCT04346446</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01117\">Atovaquone</a></strong></td><td>Open-Label, Non-Randomized Study to Evaluate Anti-Malarial / Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04339426\">NCT04339426</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Open-Label, Non-Randomized Study to Evaluate Anti-Malarial / Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04339426\">NCT04339426</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15698\">BNT162c2 SARS-CoV-2 Vaccine</a></strong></td><td>A Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001038-36\">EUCTR2020-001038-36-DE</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15697\">BNT162a1 SARS-CoV-2 Vaccine</a></strong></td><td>A Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001038-36\">EUCTR2020-001038-36-DE</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15696\">Pfizer-BioNTech COVID-19 Vaccine</a></strong></td><td>A Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001038-36\">EUCTR2020-001038-36-DE</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15695\">BNT162b1 SARS-CoV-2 Vaccine</a></strong></td><td>A Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001038-36\">EUCTR2020-001038-36-DE</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00115\">Cyanocobalamin</a></strong></td><td>Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407572\">NCT04407572</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407572\">NCT04407572</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04407572\">NCT04407572</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341610\">NCT04341610</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2 : A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348370\">NCT04348370</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Efficacy and safety of ANAkinra during Adult \\xc2\\xab COVID-19 \\xc2\\xbb with Aggravating respiratory symptoms : a multicenter open-label controlled randomized trial - ANACONDA-COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001734-36\">EUCTR2020-001734-36-FR</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322565\">NCT04322565</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00158\">Folic acid</a></strong></td><td>The host Epigenetic methylation repair in COVID-19 using Folic acid : A new suggested prevention and treatment.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10971\">PACTR202005599385499</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10928\">PACTR202004801273802</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10928\">PACTR202004801273802</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10928\">PACTR202004801273802</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10928\">PACTR202004801273802</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00860\">Prednisolone</a></strong></td><td>Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47641\">IRCT20080901001165N52</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47641\">IRCT20080901001165N52</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47516\">IRCT20180425039414N2</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Comparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19)</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47508\">IRCT20140305016852N4</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Comparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19)</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47508\">IRCT20140305016852N4</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB14317\">Pomegranate</a></strong></td><td>The effect of pomegranate tea on symptom relief of COVID-19 patients : a double-blind randomized clinical trial study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47251\">IRCT20200416047104N1</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prevention of COVID-19 disease after contact with an infected patient with coronavirus after taking hydroxychloroquine in the community</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47090\">IRCT20190122042450N4</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>To evaluate the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of COVID-19-induced cytokine storm</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47014\">IRCT20200317046797N3</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB05974\">Transcrocetinate</a></strong></td><td>Clinical trial of the effect of crocetin in improving the clinical and laboratory symptoms of patients with COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46978\">IRCT20081019001369N3</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01017\">Minocycline</a></strong></td><td>Clinical trial of minocycline against COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46977\">IRCT20081019001369N4</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prospective post-exposure hydroxycloroquine prophylaxis for Covid 19 (PROSCLOROCOV 19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46932\">IRCT20130306012728N8</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Evaluation of the therapeutic effects of Convalescent Plasma (CP) of recovered people from Covid-19 in improving clinical and laboratory symptoms of hospitalized patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46931\">IRCT20151228025732N53</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB10675\">Licorice</a></strong></td><td>Evaluation the effect of aqueous extract of licorice on coronavirus outpatients : A randomized, double-blind, placebo-controlled clinical trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46893\">IRCT20200404046933N1</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB04115\">Berberine</a></strong></td><td>Clinical trial of berberine against COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46868\">IRCT20081019001369N2</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00788\">Naproxen</a></strong></td><td>The effect of naproxen on the healing process of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46718\">IRCT20200324046850N3</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00146\">Calcifediol</a></strong></td><td>Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS)</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001717-20\">EUCTR2020-001717-20-ES</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Phase I / II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia</td><td>Treatment</td><td>1</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001364-29\">EUCTR2020-001364-29-ES</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>Phase I / II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia</td><td>Treatment</td><td>1</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001364-29\">EUCTR2020-001364-29-ES</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362943\">NCT04362943</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362943\">NCT04362943</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized, Controlled, Double-Blind, Clinical Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359615\">NCT04359615</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00783\">Estradiol</a></strong></td><td>Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359329\">NCT04359329</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Efficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19 : A Randomized, Controlled, Double-Blind, Clinical Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359316\">NCT04359316</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04353128\">NCT04353128</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348474\">NCT04348474</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348474\">NCT04348474</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356937\">NCT04356937</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351295\">NCT04351295</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350931\">NCT04350931</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00633\">Dexmedetomidine</a></strong></td><td>Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350086\">NCT04350086</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Plasma Rich Antibodies From Recovered Patients From COVID19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348877\">NCT04348877</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19 : A RCT</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347889\">NCT04347889</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19 : A RCT</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347889\">NCT04347889</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346329\">NCT04346329</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344756\">NCT04344756</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB06822\">Tinzaparin</a></strong></td><td>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344756\">NCT04344756</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04273646\">NCT04273646</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>Virucidal pilot study of Nasodine\\xc2\\xae Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000470998.aspx\">ACTRN12620000470998</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331665\">NCT04331665</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00753\">Isoflurane</a></strong></td><td>To Observe Whether Isoflurane Can Treat COVID-19 Patients</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492943\">NCT04492943</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB13281\">Bromelains</a></strong></td><td>The effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49112\">IRCT20150725023332N3</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00471\">Montelukast</a></strong></td><td>The effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49112\">IRCT20150725023332N3</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>The effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48083\">IRCT20180425039414N3</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB00163\">Vitamin E</a></strong></td><td>The effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48083\">IRCT20180425039414N3</a></td></tr><tr><td>2020-04-20</td><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>Verification of the efficacy of bromhexine hydrochloride in the prevention of COVID-19 disease</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50556\">IRCT20200317046797N7</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Evaluation of the effect of oral Ivermectin on the outcome of patients with COVID-19 and compare it with the effect of conucntional therapics in patients admitted to Ziaeian, Baharloo, Imam Khomeini in the spring and summer 2020</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/50305\">IRCT20180922041089N4</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia : a Prospective Randomized Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356534\">NCT04356534</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Use of convalescent plasma submitted to pathogen inactivation for the treatment of patients with severe COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-4vm3yy/\">RBR-4vm3yy</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370288\">NCT04370288</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB00151\">Cysteine</a></strong></td><td>The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370288\">NCT04370288</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB09241\">Methylene blue</a></strong></td><td>The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370288\">NCT04370288</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare personnel. - PrevenCOVID-19</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001440-26\">EUCTR2020-001440-26-ES</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001622-64\">EUCTR2020-001622-64-ES</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Study of the effect of Vitamin C on duration of hospital stay in patients with Covid-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46751\">IRCT20200324046850N5</a></td></tr><tr><td>2020-04-19</td><td><strong><a href=\"/drugs/DB09241\">Methylene blue</a></strong></td><td>Evaluation of the efficacy and safety of methylene blue administration for treatment of COVID-19 patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49767\">IRCT20191228045924N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Efficacy of Ivermectin as Add on Therapy in COVID19 Patients : A Pilot Randomized Study</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343092\">NCT04343092</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001536-98\">EUCTR2020-001536-98-ES</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347681\">NCT04347681</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338828\">NCT04338828</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47437\">IRCT20200422047168N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47437\">IRCT20200422047168N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47437\">IRCT20200422047168N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB14126\">Tenofovir</a></strong></td><td>Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47437\">IRCT20200422047168N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB14240\">Echinacea</a></strong></td><td>The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47234\">IRCT20200415047089N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB10344\">Ginger</a></strong></td><td>The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47234\">IRCT20200415047089N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19 : A randomized clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47212\">IRCT20200413047056N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19 : A randomized clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47212\">IRCT20200413047056N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00983\">Formoterol</a></strong></td><td>The efficacy of inhaled formoterol on symptom improvement in covid 19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47173\">IRCT20170210032478N3</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47078\">IRCT20200411047025N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47078\">IRCT20200411047025N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB01072\">Atazanavir</a></strong></td><td>Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47078\">IRCT20200411047025N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47078\">IRCT20200411047025N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>Effect of Bromhexine Hydrochloride on clinical improvement and outcome of COVID-19-induced pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46969\">IRCT20200317046797N4</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB15615\">Fennel</a></strong></td><td>Evaluation of the effect of herbal medicine containing Saatar, Hofarigon and Fennel on reduction of pulmonary complications of COVID-19 in patients : a clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46940\">IRCT20200404046935N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Treatment With COLchicine of Patients Affected by COVID-19 : a Pilot Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04375202\">NCT04375202</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2) : a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343729\">NCT04343729</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001531-27\">EUCTR2020-001531-27-ES</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB11598\">Antithrombin III human</a></strong></td><td>Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001659-42\">EUCTR2020-001659-42-ES</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Efficacy and Safety of Favipiravir in Management of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349241\">NCT04349241</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td>Efficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46810\">IRCT20120225009124N4</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Efficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46810\">IRCT20120225009124N4</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Efficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46810\">IRCT20120225009124N4</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluate the efficacy of hydroxychloroquine in the prevention of SARS-COV2 infection in high risk health care workers</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47286\">IRCT20200414047076N1</a></td></tr><tr><td>2020-04-18</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04535063\">NCT04535063</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>CONTAIN COVID-19 : Convalescent Plasma to Limit Coronavirus Associated Complications : a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04364737\">NCT04364737</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB00177\">Valsartan</a></strong></td><td>PRAETORIAN-COVID : A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335786\">NCT04335786</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB00009\">Alteplase</a></strong></td><td>A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS : The Plasminogen Activator COVID-19 ARDS (PACA) trial - Nebulised rtPA for ARDS due to COVID-19 \\xe2\\x80\\x93 The PACA trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001640-26\">EUCTR2020-001640-26-GB</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04321993\">NCT04321993</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB00741\">Hydrocortisone</a></strong></td><td>Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348305\">NCT04348305</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB11942\">Selinexor</a></strong></td><td>A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349098\">NCT04349098</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized Phase 2 / 3 Trial of Hydroxychloroquine In Covid-19 Kinetics</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04353271\">NCT04353271</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>The ECLA PHRI COLCOVID Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328480\">NCT04328480</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOV</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001723-13\">EUCTR2020-001723-13-FR</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOV</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001723-13\">EUCTR2020-001723-13-FR</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOV</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001723-13\">EUCTR2020-001723-13-FR</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOV</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001723-13\">EUCTR2020-001723-13-FR</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Expanded Access : Pulsed, Inhaled Nitric Oxide (iNO) for the Treatment of Patients With Mild or Moderate Coronavirus Disease (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358588\">NCT04358588</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358549\">NCT04358549</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>COVID-19 Ring-based Prevention Trial With Lopinavir / Ritonavir</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04321174\">NCT04321174</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>COVID-19 Ring-based Prevention Trial With Lopinavir / Ritonavir</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04321174\">NCT04321174</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Chloroquine and hydroxychloroquine for treatment of COVID-19 : systematic review of randomized and non-randomized controlled trial - Chloroquine and hydroxychloroquine for treatment of COVID-19 : systematic review of randomized and non-randomized controlled trial</td><td>Other</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045825\">JPRN-UMIN000040188</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Chloroquine and hydroxychloroquine for treatment of COVID-19 : systematic review of randomized and non-randomized controlled trial - Chloroquine and hydroxychloroquine for treatment of COVID-19 : systematic review of randomized and non-randomized controlled trial</td><td>Other</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045825\">JPRN-UMIN000040188</a></td></tr><tr><td>2020-04-17</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52142\">ChiCTR2000032011</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04376034\">NCT04376034</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB01236\">Sevoflurane</a></strong></td><td>Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359862\">NCT04359862</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00818\">Propofol</a></strong></td><td>Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359862\">NCT04359862</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04420247\">NCT04420247</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04420247\">NCT04420247</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Gu\\xc3\\xa9rin Vaccination, a Randomized Controlled Trial</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04417335\">NCT04417335</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354428\">NCT04354428</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00158\">Folic acid</a></strong></td><td>Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354428\">NCT04354428</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354428\">NCT04354428</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354428\">NCT04354428</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331600\">NCT04331600</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392531\">NCT04392531</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>REDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GU\\xc3\\x89RIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"https://trialregister.nl/trial/8547\">NL8547</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>Evaluation of the Effect of Trifluoperazin in Treatment of Patients with Confirmed 2019 Novel Coronavirus(COVID- 19) : An Open-Label Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47006\">IRCT20200408046992N1</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344457\">NCT04344457</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344457\">NCT04344457</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00328\">Indomethacin</a></strong></td><td>An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344457\">NCT04344457</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO) : A Phase I / II Safety, Tolerability, and Efficacy Clinical Trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357782\">NCT04357782</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB15806\">CoronaVac</a></strong></td><td>A Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04352608\">NCT04352608</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB12849\">Clazakizumab</a></strong></td><td>A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351724\">NCT04351724</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351724\">NCT04351724</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351724\">NCT04351724</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB13919\">Candesartan</a></strong></td><td>A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351724\">NCT04351724</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351724\">NCT04351724</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351724\">NCT04351724</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351724\">NCT04351724</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB01257\">Eculizumab</a></strong></td><td>CORIMUNO19-ECU : Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346797\">NCT04346797</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19.</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001255-40\">EUCTR2020-001255-40-ES</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>Two-center, randomized, controlled clinical trial with two treatment arms to evaluate the safety and efficacy of intravenous administration of expanded allogeneic adipose tissue adult mesenchymal cells in critically ill patients COVID-19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001266-11\">EUCTR2020-001266-11-ES</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19 : An Open Label Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04558463\">NCT04558463</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19 : An Open Label Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04558463\">NCT04558463</a></td></tr><tr><td>2020-04-16</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>A Study of Mesenchymal Stem Cells as a Treatment in Patients With Acute Respiratory Distress Syndrome Caused by COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04456361\">NCT04456361</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01041\">Thalidomide</a></strong></td><td>The efficacy and safety of Thalidomide in severe Covid19 pneumonia : Arandomized controlled clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47119\">IRCT20170207032444N3</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB09027\">Ledipasvir</a></strong></td><td>Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530422\">NCT04530422</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04530422\">NCT04530422</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB05941\">Leronlimab</a></strong></td><td>A Phase 2b / 3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347239\">NCT04347239</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346589\">NCT04346589</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti-PD-1 (Nivolumab), an Anti-NKG2A (Monalizumab), an Anti-interleukine-6 Receptor (Tocilizumab) and an Anti-C5aR (Avdoralimab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333914\">NCT04333914</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti-PD-1 (Nivolumab), an Anti-NKG2A (Monalizumab), an Anti-interleukine-6 Receptor (Tocilizumab) and an Anti-C5aR (Avdoralimab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333914\">NCT04333914</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB12824\">Monalizumab</a></strong></td><td>A Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti-PD-1 (Nivolumab), an Anti-NKG2A (Monalizumab), an Anti-interleukine-6 Receptor (Tocilizumab) and an Anti-C5aR (Avdoralimab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333914\">NCT04333914</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB09035\">Nivolumab</a></strong></td><td>A Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti-PD-1 (Nivolumab), an Anti-NKG2A (Monalizumab), an Anti-interleukine-6 Receptor (Tocilizumab) and an Anti-C5aR (Avdoralimab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333914\">NCT04333914</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345991\">NCT04345991</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392713\">NCT04392713</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for the Treatment of Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389710\">NCT04389710</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB10316\">Mumps virus strain B level jeryl lynn live antigen</a></strong></td><td>Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10953\">PACTR202004693933092</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB10317\">Rubella virus vaccine</a></strong></td><td>Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10953\">PACTR202004693933092</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10953\">PACTR202004693933092</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00146\">Calcifediol</a></strong></td><td>The efficacy of oral 25-hydroxyvitamin D3 on COVID-19 treatment in adults : A Randomized, Controlled Double-Blind Clinical Trial.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46875\">IRCT20200401046909N1</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>COvid-19 and Vitamin D Supplementation : a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344041\">NCT04344041</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001302-30\">EUCTR2020-001302-30-AT</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001302-30\">EUCTR2020-001302-30-AT</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB15160\">Asunercept</a></strong></td><td>A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001302-30\">EUCTR2020-001302-30-AT</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001302-30\">EUCTR2020-001302-30-AT</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001302-30\">EUCTR2020-001302-30-AT</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00796\">Candesartan cilexetil</a></strong></td><td>A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001302-30\">EUCTR2020-001302-30-AT</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Treating COVID-19 With Hydroxychloroquine : A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04369742\">NCT04369742</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351191\">NCT04351191</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351191\">NCT04351191</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00879\">Emtricitabine</a></strong></td><td>Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial Controlled With Placebo</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334928\">NCT04334928</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00300\">Tenofovir disoproxil</a></strong></td><td>Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial Controlled With Placebo</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334928\">NCT04334928</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial Controlled With Placebo</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334928\">NCT04334928</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00041\">Aldesleukin</a></strong></td><td>Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19 LILIADE-COVID - LILIADE-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001571-32\">EUCTR2020-001571-32-FR</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00633\">Dexmedetomidine</a></strong></td><td>Impact of Dexmedetomidine Infusion on the Time Course and Outcomes of Acute Respiratory Distress Syndrome (ARDS) in Patients Affected by the SARS-CoV-2 (COVID-19) Admitted to Critical Care Unit</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358627\">NCT04358627</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01015\">Sulfamethoxazole</a></strong></td><td>suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19 : The SAVE Open-label, Non-randomized Single-arm Trial</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357366\">NCT04357366</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19 : The SAVE Open-label, Non-randomized Single-arm Trial</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357366\">NCT04357366</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00440\">Trimethoprim</a></strong></td><td>suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19 : The SAVE Open-label, Non-randomized Single-arm Trial</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357366\">NCT04357366</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>An Open-Label Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355793\">NCT04355793</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB14325\">Schisandra chinensis fruit</a></strong></td><td>A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52662\">ChiCTR2000032205</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01404\">Ginseng</a></strong></td><td>A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52662\">ChiCTR2000032205</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19) : a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356495\">NCT04356495</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19) : a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356495\">NCT04356495</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19) : a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356495\">NCT04356495</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19) : a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356495\">NCT04356495</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19 : A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350684\">NCT04350684</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350671\">NCT04350671</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345445\">NCT04345445</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345445\">NCT04345445</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01197\">Captopril</a></strong></td><td>Randomized Trial of ACEIs in Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345406\">NCT04345406</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00584\">Enalapril</a></strong></td><td>Randomized Trial of ACEIs in Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345406\">NCT04345406</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344782\">NCT04344782</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB09035\">Nivolumab</a></strong></td><td>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343144\">NCT04343144</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334044\">NCT04334044</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB09036\">Siltuximab</a></strong></td><td>Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04329650\">NCT04329650</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04329650\">NCT04329650</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB14242\">Honey</a></strong></td><td>The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04323345\">NCT04323345</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 - COVIDSurgRCT_v1.0_20200330</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24\">EUCTR2020-001448-24-GB</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 - COVIDSurgRCT_v1.0_20200330</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24\">EUCTR2020-001448-24-GB</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 - COVIDSurgRCT_v1.0_20200330</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24\">EUCTR2020-001448-24-GB</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19 : THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001466-11\">EUCTR2020-001466-11-GR</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB00440\">Trimethoprim</a></strong></td><td>suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19 : THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001466-11\">EUCTR2020-001466-11-GR</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01015\">Sulfamethoxazole</a></strong></td><td>suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19 : THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001466-11\">EUCTR2020-001466-11-GR</a></td></tr><tr><td>2020-04-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The Danish Pre-HCQ Dialysis Study : Hydroxychloroquine for prevention of COVID-19 in dialysis-treated patients with end-stage renal disease - A multicenter parallel-group open randomized clinical trial - The Danish Pre-HCQ COVID19 Dialysis Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001257-51\">EUCTR2020-001257-51-DK</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Off Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2</td><td>Prevention</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435808\">NCT04435808</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345653\">NCT04345653</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328285\">NCT04328285</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328285\">NCT04328285</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328285\">NCT04328285</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB11942\">Selinexor</a></strong></td><td>A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25\">EUCTR2020-001411-25-AT</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB06280\">Senicapoc</a></strong></td><td>Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency \\xe2\\x80\\x93 A Randomized, Open-Label, Phase II Trial - COVIPOC</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001420-34\">EUCTR2020-001420-34-DK</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00146\">Calcifediol</a></strong></td><td>Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04386850\">NCT04386850</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB05974\">Transcrocetinate</a></strong></td><td>A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04378920\">NCT04378920</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Clinical Trial using N-acetylcysteine for treatment of 2019-nCoV Pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-8969zg/\">RBR-8969zg</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Experimental Use of COVID-19 Convalescent Plasma for the Purpose Of Passive Immunization in Current COVID-19 Pandemic</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47163\">IRCT20200414047072N1</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings : A double-blind randomized and placebo controlled trial</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47142\">IRCT20200408046988N1</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>Evaluation of adding melatonin to routine treatment on outcomes and quality of sleep in COVID-19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47099\">IRCT20200411047030N1</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00146\">Calcifediol</a></strong></td><td>Investigating preventive effects of oral 25-hydroxyvitamin D3 on COVID-19 in adults : A Randomized, Controlled Double-Blind Clinical Trial.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47010\">IRCT20200401046909N2</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Evaluation of Methylprednisolone Administration as a Therapeutic Option in the 2019 Novel Coronavirus (COVID-19) : A Non-Randomized Controlled Study</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46776\">IRCT20200204046369N1</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00860\">Prednisolone</a></strong></td><td>Evaluation of Methylprednisolone Administration as a Therapeutic Option in the 2019 Novel Coronavirus (COVID-19) : A Non-Randomized Controlled Study</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46776\">IRCT20200204046369N1</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346667\">NCT04346667</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346667\">NCT04346667</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform - CCAP-RCT</td><td>Treatment</td><td>3</td><td>Completed</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001367-88\">EUCTR2020-001367-88-DK</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform - CCAP-RCT</td><td>Treatment</td><td>3</td><td>Completed</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001367-88\">EUCTR2020-001367-88-DK</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform - CCAP-RCT</td><td>Treatment</td><td>3</td><td>Completed</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001367-88\">EUCTR2020-001367-88-DK</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362332\">NCT04362332</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04362332\">NCT04362332</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Anti COVID-19 Convalescent Plasma Therapy</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345679\">NCT04345679</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomised, Double Blind, Placebo-Controlled Trial of the Efficacy of Hydroxychloroquine for the Community-Based Treatment of Adults With Diagnosed COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000457943.aspx\">ACTRN12620000457943</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB09035\">Nivolumab</a></strong></td><td>COVID-19 : A Pilot Study of Adaptive Immunity and Anti-PD1</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04356508\">NCT04356508</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355247\">NCT04355247</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients : A Randomized Controlled Trial (PHYDRA Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04318015\">NCT04318015</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease : Randomised Clinical Trial (HYDRA Trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04315896\">NCT04315896</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 - COL-COVID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001511-25\">EUCTR2020-001511-25-ES</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01236\">Sevoflurane</a></strong></td><td>Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001379-34\">EUCTR2020-001379-34-ES</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00818\">Propofol</a></strong></td><td>Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001379-34\">EUCTR2020-001379-34-ES</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial) - PROLIFIC Trial (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001331-26\">EUCTR2020-001331-26-GB</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349592\">NCT04349592</a></td></tr><tr><td>2020-04-14</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349592\">NCT04349592</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>COVID-19-associated ARDS Treated With DEXamethasone : an Open-label, Randomized, Controlled Trial : CoDEX (Alliance Covid-19 Brasil III)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04327401\">NCT04327401</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04312009\">NCT04312009</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04329611\">NCT04329611</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346147\">NCT04346147</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346147\">NCT04346147</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346147\">NCT04346147</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346147\">NCT04346147</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346147\">NCT04346147</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Open labelled Randomised controlled trial to study the effect of Hydroxychloroquine in addition to standard therapy in COVID-19 patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42713\">CTRI/2020/04/024479</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The prophylactic effect of Hydroxychloroquine on Novel Corona virus (COVID-19) in health care providers</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47319\">IRCT20151222025660N2</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>Evaluating the efficacy of Atorvastatin in clinical improvement, prognosis and hospitalization course in patients with COVID-19 infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47146\">IRCT20200413047062N1</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>The effect of plasma administration of COVID-19 survivors in patients with acute respiratory distress syndrome due to COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47058\">IRCT20200409047007N1</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB00788\">Naproxen</a></strong></td><td>Evaluation of the role of naproxen as adjunctive therapy with standard therapies and its efficacy in the early improvement and reduced mortality rate of COVID-19 patients</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47052\">IRCT20200410047009N1</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Randomized, parallel-controlled and multi-center clinical study evaluating the efficacy and safety of convalescent plasma, in the treatment of patients with severe SARS-CoV-2 infection (COVID-19)</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46973\">IRCT20200404046948N1</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Effect of Hydroxychloroquine on Novel Coronavirus Disease (COVID-19) prevention in cancer patients under treatment</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46946\">IRCT20200405046958N1</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357808\">NCT04357808</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>COPLA Study : Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04357106\">NCT04357106</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB00159\">Icosapent</a></strong></td><td>A Randomized Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalized Subjects With Confirmed SARS-CoV-2</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335032\">NCT04335032</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Protecting frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis : a randomized, placebo-controlled multi-site trial in Toronto, Canada</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN14326006\">ISRCTN14326006</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease : A Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344444\">NCT04344444</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease : A Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344444\">NCT04344444</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>Protective Role of Inhaled Steroids for Covid-19 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331054\">NCT04331054</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB00983\">Formoterol</a></strong></td><td>Protective Role of Inhaled Steroids for Covid-19 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331054\">NCT04331054</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB12580\">Tradipitant</a></strong></td><td>ODYSSEY : A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04326426\">NCT04326426</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB00788\">Naproxen</a></strong></td><td>Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04325633\">NCT04325633</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Double-blind, placebo-controlled phase I / II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV\\xc2\\xae-allo) in acute respiratory failure in patients with COVID-19 pneumonia. - Treatment of COVID.19 with allogeneic mesenchymal cells (MSV\\xc2\\xae).</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001682-36\">EUCTR2020-001682-36-ES</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>Cortico\\xc3\\xafdes au cours de la pneumonie virale Covid-19 li\\xc3\\xa9e \\xc3\\xa0 l\\xe2\\x80\\x99infection par le SARS-Cov-2 - CORTI-Covid</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001553-48\">EUCTR2020-001553-48-FR</a></td></tr><tr><td>2020-04-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A questionnaire investigation of hydroxychloroquine for its potential protective effect against Severe Acute Respiratory Syndromes-coronavirus-2 infection</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51934\">ChiCTR2000031782</a></td></tr><tr><td>2020-04-12</td><td><strong><a href=\"/drugs/DB15280\">Gimsilumab</a></strong></td><td>A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351243\">NCT04351243</a></td></tr><tr><td>2020-04-12</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333654\">NCT04333654</a></td></tr><tr><td>2020-04-12</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341389\">NCT04341389</a></td></tr><tr><td>2020-04-12</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8490\">NL8490</a></td></tr><tr><td>2020-04-12</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8490\">NL8490</a></td></tr><tr><td>2020-04-12</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 - COVIDAM</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001417-21\">EUCTR2020-001417-21-BE</a></td></tr><tr><td>2020-04-12</td><td><strong><a href=\"/drugs/DB00641\">Simvastatin</a></strong></td><td>Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348695\">NCT04348695</a></td></tr><tr><td>2020-04-12</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348695\">NCT04348695</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19 : a Multicenter Open-label 1 : 1 Randomized Controlled Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341870\">NCT04341870</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19 : a Multicenter Open-label 1 : 1 Randomized Controlled Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341870\">NCT04341870</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19 : a Multicenter Open-label 1 : 1 Randomized Controlled Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341870\">NCT04341870</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to &quot;no Treatment&quot; in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355052\">NCT04355052</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to &quot;no Treatment&quot; in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355052\">NCT04355052</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to &quot;no Treatment&quot; in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355052\">NCT04355052</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350580\">NCT04350580</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345861\">NCT04345861</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345861\">NCT04345861</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB12136\">Solnatide</a></strong></td><td>COVID-19 : Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001244-26\">EUCTR2020-001244-26-AT</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00105\">Interferon alfa-2b</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01087\">Primaquine</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01190\">Clindamycin</a></strong></td><td>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349410\">NCT04349410</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Pragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts : patients with oncohaematological disease and SARS-CoV-2 positive without radiological alteration and sars-cov-2 positive professionals without radiological alteration</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001765-37\">EUCTR2020-001765-37-ES</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001689-12\">EUCTR2020-001689-12-ES</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31\">EUCTR2020-001321-31-ES</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31\">EUCTR2020-001321-31-ES</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31\">EUCTR2020-001321-31-ES</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31\">EUCTR2020-001321-31-ES</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31\">EUCTR2020-001321-31-ES</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care - SARICOVID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001290-74\">EUCTR2020-001290-74-ES</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study - COVID-Aging</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001303-16\">EUCTR2020-001303-16-FR</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study - COVID-Aging</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001303-16\">EUCTR2020-001303-16-FR</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study - COVID-Aging</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001303-16\">EUCTR2020-001303-16-FR</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized clinical trial for the treatment of moderate to severe cases of COVID-19 with Chloroquine and Colchicine</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-8jyhxh/\">RBR-8jyhxh</a></td></tr><tr><td>2020-04-11</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Randomized clinical trial for the treatment of moderate to severe cases of COVID-19 with Chloroquine and Colchicine</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-8jyhxh/\">RBR-8jyhxh</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Sarilumab for Patients With Moderate COVID-19 Disease : A Randomized Controlled Trial With a Play-The-Winner Design</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04359901\">NCT04359901</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00105\">Interferon alfa-2b</a></strong></td><td>Evaluation of the effect and safety of HeberFERON versus Heberon alfa in patients infected with the SARS-CoV-2 coronavirus (COVID-19).</td><td>Treatment</td><td>2</td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000307-En\">RPCEC00000307</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB15753\">Interferon Gamma</a></strong></td><td>Evaluation of the effect and safety of HeberFERON versus Heberon alfa in patients infected with the SARS-CoV-2 coronavirus (COVID-19).</td><td>Treatment</td><td>2</td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000307-En\">RPCEC00000307</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB15661\">Molnupiravir</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392219\">NCT04392219</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00176\">Fluvoxamine</a></strong></td><td>A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04342663\">NCT04342663</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Australasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir / ritonavir and / or hydroxychloroquine compared to standard of care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000445976.aspx\">ACTRN12620000445976</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Australasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir / ritonavir and / or hydroxychloroquine compared to standard of care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000445976.aspx\">ACTRN12620000445976</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Australasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir / ritonavir and / or hydroxychloroquine compared to standard of care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000445976.aspx\">ACTRN12620000445976</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04390178\">NCT04390178</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma in the Treatment of COVID 19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343261\">NCT04343261</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04340050\">NCT04340050</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized, pragmatic, open study evaluating Hydroxychloroquine for prevention of Hospitalization and Respiratory Complications in outpatients with confirmed or presumptive diagnosis of Infection by (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3cbs3w/\">RBR-3cbs3w</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Safety and efficacy of \\xe2\\x80\\x9cHydroxychloroquine + Azithromycin + Naproxen + Prednisolone\\xe2\\x80\\x9d and \\xe2\\x80\\x9cHydroxychloroquine + Azithromycin + Naproxen\\xe2\\x80\\x9d regimens in comparison with \\xe2\\x80\\x9cHydroxychloroquine + kaletra\\xe2\\x80\\x9d on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46968\">IRCT20200318046812N2</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00860\">Prednisolone</a></strong></td><td>Safety and efficacy of \\xe2\\x80\\x9cHydroxychloroquine + Azithromycin + Naproxen + Prednisolone\\xe2\\x80\\x9d and \\xe2\\x80\\x9cHydroxychloroquine + Azithromycin + Naproxen\\xe2\\x80\\x9d regimens in comparison with \\xe2\\x80\\x9cHydroxychloroquine + kaletra\\xe2\\x80\\x9d on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46968\">IRCT20200318046812N2</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00788\">Naproxen</a></strong></td><td>Safety and efficacy of \\xe2\\x80\\x9cHydroxychloroquine + Azithromycin + Naproxen + Prednisolone\\xe2\\x80\\x9d and \\xe2\\x80\\x9cHydroxychloroquine + Azithromycin + Naproxen\\xe2\\x80\\x9d regimens in comparison with \\xe2\\x80\\x9cHydroxychloroquine + kaletra\\xe2\\x80\\x9d on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46968\">IRCT20200318046812N2</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Safety and efficacy of \\xe2\\x80\\x9cHydroxychloroquine + Azithromycin + Naproxen + Prednisolone\\xe2\\x80\\x9d and \\xe2\\x80\\x9cHydroxychloroquine + Azithromycin + Naproxen\\xe2\\x80\\x9d regimens in comparison with \\xe2\\x80\\x9cHydroxychloroquine + kaletra\\xe2\\x80\\x9d on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46968\">IRCT20200318046812N2</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355026\">NCT04355026</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04355026\">NCT04355026</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344730\">NCT04344730</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>COvid-19 and Vitamin D supplementation : a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients - CoVitTrial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001602-34\">EUCTR2020-001602-34-FR</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00177\">Valsartan</a></strong></td><td>A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease (COVID-19) - PRAETORIAN-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001320-34\">EUCTR2020-001320-34-NL</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334005\">NCT04334005</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 - COVID19-COVIDornase</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001492-33\">EUCTR2020-001492-33-FR</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUS</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001457-43\">EUCTR2020-001457-43-FR</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUS</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001457-43\">EUCTR2020-001457-43-FR</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treatments to reduce the risk of hospitalization or death (COVERAGE trial) - COVERAGE</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001435-27\">EUCTR2020-001435-27-FR</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treatments to reduce the risk of hospitalization or death (COVERAGE trial) - COVERAGE</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001435-27\">EUCTR2020-001435-27-FR</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treatments to reduce the risk of hospitalization or death (COVERAGE trial) - COVERAGE</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001435-27\">EUCTR2020-001435-27-FR</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB00788\">Naproxen</a></strong></td><td>Efficacy of Addition of Naproxen in the Treatment of critically ill Patients Hospitalized for COVID-19 Infection / Enacovid Study - ENACOVID</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001301-23\">EUCTR2020-001301-23-FR</a></td></tr><tr><td>2020-04-10</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Clearing the Fog : Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04491994\">NCT04491994</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients. Hydro-Stop-COVID19 Trial - Hydro-STOP-COVID19 Trial</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001558-23\">EUCTR2020-001558-23-IT</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB14312\">Glycyrrhiza glabra</a></strong></td><td>Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product, on pulmonary and other clinical and laboratory manifestations of patients with probable or confirmed COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46961\">IRCT20200405046960N1</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB15615\">Fennel</a></strong></td><td>Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product, on pulmonary and other clinical and laboratory manifestations of patients with probable or confirmed COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46961\">IRCT20200405046960N1</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB10675\">Licorice</a></strong></td><td>Evaluating the therapeutic effect of a mixed herbal drink of Marshmallow and Licorice on COVID 19 patients, A double blind clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46903\">IRCT20200404046937N1</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343768\">NCT04343768</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343768\">NCT04343768</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04329923\">NCT04329923</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04311177\">NCT04311177</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IT</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IT</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IT</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IT</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IT</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-IT</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19 - NOSARSCOVID19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001329-30\">EUCTR2020-001329-30-AT</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An Open-label Randomized Controlled Trial on Interferon \\xc3\\x9f-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350281\">NCT04350281</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>An Open-label Randomized Controlled Trial on Interferon \\xc3\\x9f-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350281\">NCT04350281</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB05382\">Iodine</a></strong></td><td>A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344236\">NCT04344236</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00878\">Chlorhexidine</a></strong></td><td>A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344236\">NCT04344236</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB11061\">Povidone</a></strong></td><td>A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344236\">NCT04344236</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343755\">NCT04343755</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB11676\">Galidesivir</a></strong></td><td>A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT03891420\">NCT03891420</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection.</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001634-36\">EUCTR2020-001634-36-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>Randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts. COVID-19</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001530-35\">EUCTR2020-001530-35-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001437-12\">EUCTR2020-001437-12-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001437-12\">EUCTR2020-001437-12-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11\">EUCTR2020-001262-11-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11\">EUCTR2020-001262-11-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11\">EUCTR2020-001262-11-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11\">EUCTR2020-001262-11-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11\">EUCTR2020-001262-11-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00421\">Spironolactone</a></strong></td><td>Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11\">EUCTR2020-001262-11-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01264\">Darunavir</a></strong></td><td>Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11\">EUCTR2020-001262-11-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11\">EUCTR2020-001262-11-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneumonia Who Are Unresponsive to Standard Care - Tocilizumab plus Pembrolizumab in COVID-19 (COPERNICO Study)</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001160-28\">EUCTR2020-001160-28-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB09037\">Pembrolizumab</a></strong></td><td>A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneumonia Who Are Unresponsive to Standard Care - Tocilizumab plus Pembrolizumab in COVID-19 (COPERNICO Study)</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001160-28\">EUCTR2020-001160-28-ES</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial - DHYSCO</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001333-13\">EUCTR2020-001333-13-FR</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial - DHYSCO</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001333-13\">EUCTR2020-001333-13-FR</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 years</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52006\">ChiCTR2000031781</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB15689\">Azoximer bromide</a></strong></td><td>Open Observational Study of Efficacy and Safety of Polyoxidonium in Complex Therapy of Hospitalized Patients With COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04542226\">NCT04542226</a></td></tr><tr><td>2020-04-09</td><td><strong><a href=\"/drugs/DB11091\">Hydrogen peroxide</a></strong></td><td>Clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2 (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.drks.de/DRKS00022484\">DRKS00022484</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB15736\">Alunacedase alfa</a></strong></td><td>Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 - APN01-01-COVID19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001172-15\">EUCTR2020-001172-15-DE</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB01410\">Ciclesonide</a></strong></td><td>A Trial of Ciclesonide in Adults with Mild COVID-19</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16795\">KCT0005105</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Interventional study of intravenous vitamin C in definitive patients with covid 19 and its effect on changes in lung CT scan and clinical and laboratory symptoms of patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48176\">IRCT20200516047468N1</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Evaluation the efficacy and safety of Umifenovir (Arbidol) Administration in comparison with Lopinavir-ritonavir (Kaletra) in COVID-19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48018\">IRCT20151227025726N15</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00358\">Mefloquine</a></strong></td><td>An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC &quot;Farmzashita&quot; of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347031\">NCT04347031</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04342182\">NCT04342182</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04342728\">NCT04342728</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB11248\">Zinc gluconate</a></strong></td><td>Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study</td><td>Supportive Care</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04342728\">NCT04342728</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection- A Tertiary Hospital based study - CORONA study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42638\">CTRI/2020/03/024402</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46930\">IRCT20200405046953N1</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46930\">IRCT20200405046953N1</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46930\">IRCT20200405046953N1</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46930\">IRCT20200405046953N1</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46930\">IRCT20200405046953N1</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46930\">IRCT20200405046953N1</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients : A Clinical Trial Study</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46926\">IRCT20200403046926N1</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients : A Clinical Trial Study</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46926\">IRCT20200403046926N1</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Comparative assessment of the efficacy and safety of addon treatment with \\xe2\\x80\\x9cSofosbuvir-Daclatasvir\\xe2\\x80\\x9d, \\xe2\\x80\\x9cLithium\\xe2\\x80\\x9d,and \\xe2\\x80\\x9cTrifluoprazine\\xe2\\x80\\x9d to \\xe2\\x80\\x9cstandard of care in three groups of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46853\">IRCT20130812014333N147</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Comparative assessment of the efficacy and safety of addon treatment with \\xe2\\x80\\x9cSofosbuvir-Daclatasvir\\xe2\\x80\\x9d, \\xe2\\x80\\x9cLithium\\xe2\\x80\\x9d,and \\xe2\\x80\\x9cTrifluoprazine\\xe2\\x80\\x9d to \\xe2\\x80\\x9cstandard of care in three groups of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46853\">IRCT20130812014333N147</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB14509\">Lithium carbonate</a></strong></td><td>Comparative assessment of the efficacy and safety of addon treatment with \\xe2\\x80\\x9cSofosbuvir-Daclatasvir\\xe2\\x80\\x9d, \\xe2\\x80\\x9cLithium\\xe2\\x80\\x9d,and \\xe2\\x80\\x9cTrifluoprazine\\xe2\\x80\\x9d to \\xe2\\x80\\x9cstandard of care in three groups of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46853\">IRCT20130812014333N147</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00831\">Trifluoperazine</a></strong></td><td>Comparative assessment of the efficacy and safety of addon treatment with \\xe2\\x80\\x9cSofosbuvir-Daclatasvir\\xe2\\x80\\x9d, \\xe2\\x80\\x9cLithium\\xe2\\x80\\x9d,and \\xe2\\x80\\x9cTrifluoprazine\\xe2\\x80\\x9d to \\xe2\\x80\\x9cstandard of care in three groups of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46853\">IRCT20130812014333N147</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB11613\">Velpatasvir</a></strong></td><td>Comparative assessment of the efficacy and safety of add ontreatment with \\xe2\\x80\\x9cSofosbuvir plus Velpatasvir\\xe2\\x80\\x9d to \\xe2\\x80\\x9cstandard of care therapeutic regimen\\xe2\\x80\\x9d in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46790\">IRCT20130812014333N145</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Comparative assessment of the efficacy and safety of add ontreatment with \\xe2\\x80\\x9cSofosbuvir plus Velpatasvir\\xe2\\x80\\x9d to \\xe2\\x80\\x9cstandard of care therapeutic regimen\\xe2\\x80\\x9d in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46790\">IRCT20130812014333N145</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377750\">NCT04377750</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB15121\">AT-001</a></strong></td><td>A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365699\">NCT04365699</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for patients with SARS-CoV-2 infection with the risk of developing complications to reduce the risk of COVID-19-related hospitalization and death.</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001469-35\">EUCTR2020-001469-35-PL</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB04932\">Defibrotide</a></strong></td><td>Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348383\">NCT04348383</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection : A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344535\">NCT04344535</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2) : a Double-blind, Randomized, Placebo-controlled Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04342650\">NCT04342650</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB08868\">Fingolimod</a></strong></td><td>Effect of Fingolimod for treatment of COVID-19-induced cytokine storm</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46786\">IRCT20200317046797N2</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001587-29\">EUCTR2020-001587-29-ES</a></td></tr><tr><td>2020-04-08</td><td><strong><a href=\"/drugs/DB00848\">Levamisole</a></strong></td><td>Evaluation of Levamisole efficacy and safety in combination with routine therapy in patients with Covid-19 : a clinical trial</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46826\">IRCT20190810044500N7</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>A study on melatonin and Vitamin C and zinc efficacy in patients with COVID19 hospitalized in intensive care unit of Semnan Kowsar Hopsital</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46963\">IRCT20151228025732N52</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>A study on melatonin and Vitamin C and zinc efficacy in patients with COVID19 hospitalized in intensive care unit of Semnan Kowsar Hopsital</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46963\">IRCT20151228025732N52</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB09322\">Zinc sulfate</a></strong></td><td>A study on melatonin and Vitamin C and zinc efficacy in patients with COVID19 hospitalized in intensive care unit of Semnan Kowsar Hopsital</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46963\">IRCT20151228025732N52</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications : A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Patients With Severe Respiratory Distress Due to COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04411602\">NCT04411602</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328493\">NCT04328493</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB02701\">Nicotinamide</a></strong></td><td>Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease - COVit</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021214\">DRKS00021214</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB00927\">Famotidine</a></strong></td><td>A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04370262\">NCT04370262</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria : FALP 001-2020 Trial (FALP-COVID)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04384588\">NCT04384588</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB00162\">Vitamin A</a></strong></td><td>Comparison of the effectiveness of standard treatment with stand treatment plus Vitamin A in treatment in covid19 patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46974\">IRCT20180520039738N2</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46849\">IRCT20130917014693N10</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Will Hydroxychloroquine Impede or Prevent COVID-19 : WHIP COVID-19 Study</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341441\">NCT04341441</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2 : An Open-Labeled, Randomized Phase 3 Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361552\">NCT04361552</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>PATCH 2 &amp; 3 : (Prevention and Treatment of COVID-19 With Hydroxychloroquine) An Open Label Multi-arm Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04353037\">NCT04353037</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB09036\">Siltuximab</a></strong></td><td>Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001413-20\">EUCTR2020-001413-20-ES</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001413-20\">EUCTR2020-001413-20-ES</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001406-27\">EUCTR2020-001406-27-FR</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001406-27\">EUCTR2020-001406-27-FR</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001606-33\">EUCTR2020-001606-33-ES</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001606-33\">EUCTR2020-001606-33-ES</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers : a randomized double-blind placebo-controlled clinical trial - COVIDAXIS</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001188-96\">EUCTR2020-001188-96-FR</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers : a randomized double-blind placebo-controlled clinical trial - COVIDAXIS</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001188-96\">EUCTR2020-001188-96-FR</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers : a randomized double-blind placebo-controlled clinical trial - COVIDAXIS</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001188-96\">EUCTR2020-001188-96-FR</a></td></tr><tr><td>2020-04-07</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04312243\">NCT04312243</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19) : The HOPE Open-Label, Non Randomized Clinical Trial</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04344951\">NCT04344951</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 - Convalescent Plasma against COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001310-38\">EUCTR2020-001310-38-DE</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00115\">Cyanocobalamin</a></strong></td><td>A cohort study to evaluate the effect of combination vitamin D, magnesium and vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"http://isrctn.com/ISRCTN15324611\">ISRCTN15324611</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>A cohort study to evaluate the effect of combination vitamin D, magnesium and vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"http://isrctn.com/ISRCTN15324611\">ISRCTN15324611</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Pre-exposure Prophylaxis for SARS-Coronavirus-2 : A Pragmatic Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328467\">NCT04328467</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8504\">NL8504</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID : A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322396\">NCT04322396</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID : A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322396\">NCT04322396</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB14545\">Hydrocortisone succinate</a></strong></td><td>Low dose hydrocortisone in patients with COVID-19 and severe hypoxia \\xe2\\x80\\x93 the COVID STEROID trial - COVID-STEROID trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001395-15\">EUCTR2020-001395-15-DK</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Platelet Inhibition With GP IIb / IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04368377\">NCT04368377</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00758\">Clopidogrel</a></strong></td><td>Platelet Inhibition With GP IIb / IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04368377\">NCT04368377</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00569\">Fondaparinux</a></strong></td><td>Platelet Inhibition With GP IIb / IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04368377\">NCT04368377</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00775\">Tirofiban</a></strong></td><td>Platelet Inhibition With GP IIb / IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04368377\">NCT04368377</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341493\">NCT04341493</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341493\">NCT04341493</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>Two-treatment,Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348461\">NCT04348461</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB15737\">Dental Mesenchymal Pulp Stem Cells</a></strong></td><td>Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19 : a Single-center, Prospective, Randomised Clinical Trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04336254\">NCT04336254</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection</td><td>Prevention</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330495\">NCT04330495</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328012\">NCT04328012</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328012\">NCT04328012</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328012\">NCT04328012</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001421-31\">EUCTR2020-001421-31-ES</a></td></tr><tr><td>2020-04-06</td><td><strong><a href=\"/drugs/DB04932\">Defibrotide</a></strong></td><td>Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335201\">NCT04335201</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB15615\">Fennel</a></strong></td><td>Evaluating efficacy and safety of Stopcivir (Zataria multiflora Boiss+ Alium Sativum+ Heracleum persicum+ Satureja hortensis+ Dianthus+ Foeniculum vulgare+ opium) syrup on length of hospitalization in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47044\">IRCT20200411047016N1</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB11130\">Opium</a></strong></td><td>Evaluating efficacy and safety of Stopcivir (Zataria multiflora Boiss+ Alium Sativum+ Heracleum persicum+ Satureja hortensis+ Dianthus+ Foeniculum vulgare+ opium) syrup on length of hospitalization in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47044\">IRCT20200411047016N1</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Use of convalescent plasma in the treatment of patients with severe COVID-19 pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47266\">IRCT20200416047099N1</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 2-3 Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47073\">IRCT20200217046526N2</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46942\">IRCT20151227025726N14</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46942\">IRCT20151227025726N14</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46942\">IRCT20151227025726N14</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>Atorvastatin effect in Clinical and Laboratory findings of patiens with COVID-19 admitted RAZI referral hospital in Mazandaran State : A Randomized Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46639\">IRCT20190727044343N2</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 2-3 Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366063\">NCT04366063</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia : An Open-Label, Multicenter Sequential and Cluster Randomized Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322773\">NCT04322773</a></td></tr><tr><td>2020-04-05</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia : An Open-Label, Multicenter Sequential and Cluster Randomized Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322773\">NCT04322773</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB15867\">Autologous Non-Hematopoietic Peripheral Blood Stem Cells</a></strong></td><td>Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04473170\">NCT04473170</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Investigation of the efficacy and safety of colchicine In combination with standard treatment on covid-19 patients : A clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46867\">IRCT20190810044500N5</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331795\">NCT04331795</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB10983\">Thyme</a></strong></td><td>Evaluation of the effect of herbal oral product (thyme syrup) in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47639\">IRCT20131129015584N2</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Evaluation of the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 (Before intubation phase) who have not responded to treatment with the standard three-drug protocol (hydroxychloroquine / chloroquine + lupinavir / ritonavir + ribavirin)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46811\">IRCT20200325046859N1</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>The Impact of Camostat Mesilate on COVID-19 Infection : An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04321096\">NCT04321096</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB00545\">Pyridostigmine</a></strong></td><td>Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343963\">NCT04343963</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine for Outpatients With Confirmed COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04342169\">NCT04342169</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB15737\">Dental Mesenchymal Pulp Stem Cells</a></strong></td><td>Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46668\">IRCT20140911019125N6</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB00983\">Formoterol</a></strong></td><td>Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331470\">NCT04331470</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB00848\">Levamisole</a></strong></td><td>Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331470\">NCT04331470</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331470\">NCT04331470</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infecci\\xc3\\xb3n Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04552951\">NCT04552951</a></td></tr><tr><td>2020-04-04</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infecci\\xc3\\xb3n Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04552951\">NCT04552951</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>The Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, Iraq</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04441424\">NCT04441424</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB12764\">Opaganib</a></strong></td><td>Compassionate Use of Opaganib in Patients With Severe COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435106\">NCT04435106</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB15693\">INO-4800</a></strong></td><td>Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04336410\">NCT04336410</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04320615\">NCT04320615</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00741\">Hydrocortisone</a></strong></td><td>Neuroendocrine mechanisms Social isolation and psychobiological stress during the Covid-19 pandemic - SoDi Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021671\">DRKS00021671</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00107\">Oxytocin</a></strong></td><td>Neuroendocrine mechanisms Social isolation and psychobiological stress during the Covid-19 pandemic - SoDi Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.drks.de/DRKS00021671\">DRKS00021671</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>SOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTS</td><td>Treatment</td><td>0</td><td>Completed</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=010-20\">PER-010-20</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>SOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTS</td><td>Treatment</td><td>0</td><td>Completed</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=010-20\">PER-010-20</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>SOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTS</td><td>Treatment</td><td>0</td><td>Completed</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=010-20\">PER-010-20</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>SOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTS</td><td>Treatment</td><td>0</td><td>Completed</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=010-20\">PER-010-20</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>SOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTS</td><td>Treatment</td><td>0</td><td>Completed</td><td><a href=\"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=010-20\">PER-010-20</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01410\">Ciclesonide</a></strong></td><td>A multicenter, open-label, randomized controlled phase II study to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 - RACCO trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs031190269\">JPRN-jRCTs031190269</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333225\">NCT04333225</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04326790\">NCT04326790</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial - PreToVid</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001375-32\">EUCTR2020-001375-32-NL</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia : An Open-Label Multicenter Sequential Randomized Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001275-32\">EUCTR2020-001275-32-DK</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia : An Open-Label Multicenter Sequential Randomized Controlled Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001275-32\">EUCTR2020-001275-32-DK</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Proactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID - ProPAC-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001198-55\">EUCTR2020-001198-55-DK</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Proactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID - ProPAC-COVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001198-55\">EUCTR2020-001198-55-DK</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04354870\">NCT04354870</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330638\">NCT04330638</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB09036\">Siltuximab</a></strong></td><td>A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330638\">NCT04330638</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330638\">NCT04330638</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB09036\">Siltuximab</a></strong></td><td>A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001500-41\">EUCTR2020-001500-41-BE</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001500-41\">EUCTR2020-001500-41-BE</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001500-41\">EUCTR2020-001500-41-BE</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345523\">NCT04345523</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04325061\">NCT04325061</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Effects of High-dose Vitamin C on Treatment, Clinical Symptoms and Laboratory Signs of Iranian COVID-19 Patients : A Double Blind Randomized Clinical Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46804\">IRCT20190917044805N2</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB13293\">Ipecac</a></strong></td><td>Double blind clinical trial study on Evaluation of the effectiveness of Ipecac homeopathic remedy in control of Clinical manifestations of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46736\">IRCT20140907019073N4</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB14317\">Pomegranate</a></strong></td><td>The Effect of Persian Medicine Products on the Clinical and Laboratory Symptoms of Patients With or Suspected of Covid-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46637\">IRCT20140617018126N2</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00162\">Vitamin A</a></strong></td><td>evaluation the effect of vitamin A on respiratory signs and hospitalization in patients with COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46564\">IRCT20170117032004N3</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341207\">NCT04341207</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341207\">NCT04341207</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00338\">Omeprazole</a></strong></td><td>Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333407\">NCT04333407</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00758\">Clopidogrel</a></strong></td><td>Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333407\">NCT04333407</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333407\">NCT04333407</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333407\">NCT04333407</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333407\">NCT04333407</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic : A Multicentre, Double-Blinded Randomized Controlled Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331834\">NCT04331834</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID) : A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. - PrEP_COVID</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001565-37\">EUCTR2020-001565-37-ES</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients - ONCOVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001250-21\">EUCTR2020-001250-21-FR</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients - ONCOVID</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001250-21\">EUCTR2020-001250-21-FR</a></td></tr><tr><td>2020-04-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04522466\">NCT04522466</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04332991\">NCT04332991</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB13959\">Medium-chain triglycerides</a></strong></td><td>Evaluation of the effect of oral intermediate chain triglyceride on prognosis and course of disease in suspected outpatients with COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46762\">IRCT20160313027033N2</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19) : THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL - HOPE</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001345-38\">EUCTR2020-001345-38-GR</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach : the ESCAPE Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04339712\">NCT04339712</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach : the ESCAPE Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04339712\">NCT04339712</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An adaptive Phase 2 / 3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001270-29\">EUCTR2020-001270-29-GB</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00162\">Vitamin A</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00121\">Biotin</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00165\">Pyridoxine</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB01783\">Pantothenic acid</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00163\">Vitamin E</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00152\">Thiamine</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00140\">Riboflavin</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB02701\">Nicotinamide</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00158\">Folic acid</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00115\">Cyanocobalamin</a></strong></td><td>Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46838\">IRCT20200319046819N1</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB09079\">Nintedanib</a></strong></td><td>Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04338802\">NCT04338802</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT) : A Prospective Pragmatic Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334382\">NCT04334382</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT) : A Prospective Pragmatic Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334382\">NCT04334382</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04332094\">NCT04332094</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04332094\">NCT04332094</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04332094\">NCT04332094</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>A Phase 2 / 3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324021\">NCT04324021</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB14724\">Emapalumab</a></strong></td><td>A Phase 2 / 3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324021\">NCT04324021</a></td></tr><tr><td>2020-04-02</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) - TCOVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001442-19\">EUCTR2020-001442-19-ES</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>The Effect of the Short-term Use of Systemic Corticosteroids in COVID-19 Patients in Regard to Hospital Length of Stay, Morbidly and / or Mortality.</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04445506\">NCT04445506</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Low-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04336748\">NCT04336748</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB05941\">Leronlimab</a></strong></td><td>A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343651\">NCT04343651</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322123\">NCT04322123</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322123\">NCT04322123</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore : a Review of Process Feasibility, Safety, and Clinical Outcomes</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04350450\">NCT04350450</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB12453\">Chlorine dioxide</a></strong></td><td>Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343742\">NCT04343742</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392778\">NCT04392778</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04392141\">NCT04392141</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication : a Prospective, Multicentre, Randomised, Double-blind Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04325893\">NCT04325893</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04384380\">NCT04384380</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of patients treated by telemedicine in the Covid-19 pandemic in Brazil in a medical clinic in the supplementary health sector in S\\xc3\\xa3o Paulo, Brazil - : MAZZEI MEDICAL CENTER</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-658khm/\">RBR-658khm</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Evaluation of patients treated by telemedicine in the Covid-19 pandemic in Brazil in a medical clinic in the supplementary health sector in S\\xc3\\xa3o Paulo, Brazil - : MAZZEI MEDICAL CENTER</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-658khm/\">RBR-658khm</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46783\">IRCT20200318046812N1</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46783\">IRCT20200318046812N1</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46783\">IRCT20200318046812N1</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04336332\">NCT04336332</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04336332\">NCT04336332</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00746\">Deferoxamine</a></strong></td><td>Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333550\">NCT04333550</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women : an Open-label Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365231\">NCT04365231</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Efficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women : an Open-label Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365231\">NCT04365231</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04361942\">NCT04361942</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Intermediate-size Expanded Access of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome Due to COVID-19 Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366830\">NCT04366830</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333589\">NCT04333589</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>IV Infusion of Autologous Adipose Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04352803\">NCT04352803</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB12598\">Nafamostat</a></strong></td><td>RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04352400\">NCT04352400</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351620\">NCT04351620</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB11248\">Zinc gluconate</a></strong></td><td>Impact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351490\">NCT04351490</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>Impact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04351490\">NCT04351490</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04349371\">NCT04349371</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB06168\">Canakinumab</a></strong></td><td>Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04348448\">NCT04348448</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19) : a Multicentre, Randomised Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347980\">NCT04347980</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19) : a Multicentre, Randomised Controlled Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04347980\">NCT04347980</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19) : A Phase 1 / 2 Randomized Controlled Trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346368\">NCT04346368</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19- A Cluster Randomized Controlled Trial (SHARP COVID-19 RCT)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04342156\">NCT04342156</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>CORIMUNO-ANA : Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341584\">NCT04341584</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333628\">NCT04333628</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs031190227\">JPRN-jRCTs031190227</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs031190227\">JPRN-jRCTs031190227</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs031190227\">JPRN-jRCTs031190227</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs031190227\">JPRN-jRCTs031190227</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Evaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46706\">IRCT20200324046852N1</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46706\">IRCT20200324046852N1</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>Evaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46706\">IRCT20200324046852N1</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00983\">Formoterol</a></strong></td><td>Evaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46706\">IRCT20200324046852N1</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00848\">Levamisole</a></strong></td><td>Evaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46706\">IRCT20200324046852N1</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46706\">IRCT20200324046852N1</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>Observation of the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52529\">ChiCTR2000032040</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343677\">NCT04343677</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341038\">NCT04341038</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00864\">Tacrolimus</a></strong></td><td>Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04341038\">NCT04341038</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19 : a Proof of Concept Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04332913\">NCT04332913</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV ; GS-5734\\xe2\\x84\\xa2)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04302766\">NCT04302766</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH : THE ESCAPE CLINICAL TRIAL - PERSONALIZED IMMUNOTHERAPY FOR SARS-CoV-2 ASSOCIATED ORGAN DYSFUCTION</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001039-29\">EUCTR2020-001039-29-GR</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH : THE ESCAPE CLINICAL TRIAL - PERSONALIZED IMMUNOTHERAPY FOR SARS-CoV-2 ASSOCIATED ORGAN DYSFUCTION</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001039-29\">EUCTR2020-001039-29-GR</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. - Steroids In Coronavirus (SIC)</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001307-16\">EUCTR2020-001307-16-ES</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB04932\">Defibrotide</a></strong></td><td>A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19. - DEFACOVID</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001409-21\">EUCTR2020-001409-21-ES</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB09035\">Nivolumab</a></strong></td><td>IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection - IMMUNONCOVID-20</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001373-70\">EUCTR2020-001373-70-FR</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection - IMMUNONCOVID-20</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001373-70\">EUCTR2020-001373-70-FR</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333251\">NCT04333251</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01410\">Ciclesonide</a></strong></td><td>A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330586\">NCT04330586</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330144\">NCT04330144</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB09079\">Nintedanib</a></strong></td><td>Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19) : a single-center, randomized, placebo-controlled trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51859\">ChiCTR2000031453</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB15737\">Dental Mesenchymal Pulp Stem Cells</a></strong></td><td>Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19 : a Single-center, Prospective, Randomised Clinical Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51647\">ChiCTR2000031319</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492501\">NCT04492501</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492501\">NCT04492501</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492501\">NCT04492501</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04492501\">NCT04492501</a></td></tr><tr><td>2020-04-01</td><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>Short Term Low Dose Corticosteroids for Management of Post Covid-19 Pulmonary Fibrosis</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04551781\">NCT04551781</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04346355\">NCT04346355</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB15809\">CIGB-258 peptide</a></strong></td><td>Administration of the CIGB-258 peptide in patients with COVID-19 under intensive therapy regimen (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000313-En\">RPCEC00000313</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389944\">NCT04389944</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>Countering Lung Damage in COVID-19 infection (CounterCovid) study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8491\">NL8491</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>Nebulized In-line Endotracheal Dornase Alfa and Albuterol Administered to Mechanically Ventilated COVID-19 Patients : A Case Series</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04387786\">NCT04387786</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19) : a Blinded, Randomized Study</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328961\">NCT04328961</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB12849\">Clazakizumab</a></strong></td><td>A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04343989\">NCT04343989</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB16416\">Vilobelimab</a></strong></td><td>A Pragmatic Adaptive Randomized, Controlled Phase II / III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04333420\">NCT04333420</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Multicenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205238\">JPRN-JapicCTI-205238</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Evaluation of the effects of Losartan in patients with corona virus disease 2019</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46824\">IRCT20180802040678N4</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB00381\">Amlodipine</a></strong></td><td>Evaluation of the effects of Losartan in patients with corona virus disease 2019</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46824\">IRCT20180802040678N4</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001445-39\">EUCTR2020-001445-39-ES</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB00864\">Tacrolimus</a></strong></td><td>PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001445-39\">EUCTR2020-001445-39-ES</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Use of therapeutic drug monitoring (TDM) to optimise oral / enteral hydroxychloroquine dosing in critically ill patients with COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000447954.aspx\">ACTRN12620000447954</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19 \\xe2\\x80\\x93 a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease - CounterCovid Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001236-10\">EUCTR2020-001236-10-NL</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19 \\xc3\\xa0 risque d\\xe2\\x80\\x99aggravation secondaire : \\xc3\\xa9tude prospective multicentrique randomis\\xc3\\xa9e en double aveugle - HYCOVID</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001271-33\">EUCTR2020-001271-33-FR</a></td></tr><tr><td>2020-03-31</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A multicentre, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults \\xe2\\x80\\x93 version for European Union / United Kingdom sites</td><td>Treatment</td><td>3</td><td>Completed</td><td><a href=\"http://isrctn.com/ISRCTN13035264\">ISRCTN13035264</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04334967\">NCT04334967</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS) : A Prospective Pragmatic Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04329832\">NCT04329832</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS) : A Prospective Pragmatic Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04329832\">NCT04329832</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers Following Coronavirus Exposure (BRACE) Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04327206\">NCT04327206</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Open and controlled trial of hydroxychloroquine and azytromicyn use to prevent complications in patients infected by new coronavirus (COVID-19) : a randomized controlled trial - Brazil COVID Coalition I Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-9d8z6m/\">RBR-9d8z6m</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Open and controlled trial of hydroxychloroquine and azytromicyn use to prevent complications in patients infected by new coronavirus (COVID-19) : a randomized controlled trial - Brazil COVID Coalition I Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-9d8z6m/\">RBR-9d8z6m</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB14346\">Mentha arvensis top</a></strong></td><td>Evaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47401\">IRCT20080901001165N49</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB10763\">Urtica dioica pollen</a></strong></td><td>Evaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47401\">IRCT20080901001165N49</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB14312\">Glycyrrhiza glabra</a></strong></td><td>Evaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47401\">IRCT20080901001165N49</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with ARDS</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47088\">IRCT20200406046963N1</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47087\">IRCT20080901001165N46</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB06149\">Teicoplanin</a></strong></td><td>Study of the Efficacy of Teicoplanin on mortality rate of patients with COVID-19 Infection : A randomized clinical trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46814\">IRCT20161204031229N3</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04363034\">NCT04363034</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331808\">NCT04331808</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Multi-Site, Randomized, Open-Label, Parallel-Group, Placebo-Controlled Study to Assess the Chemoprophylactic Efficacy of Chloroquine Against SARS-CoV-2 / COVID-19 in Healthcare Workers at High-Risk of Exposure</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://anzctr.org.au/ACTRN12620000417987.aspx\">ACTRN12620000417987</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB00358\">Mefloquine</a></strong></td><td>Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) - MEFLOCOVID-19</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001194-69\">EUCTR2020-001194-69-ES</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the concentration / viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit.</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001281-11\">EUCTR2020-001281-11-FR</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td>A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN\\xc3\\x9f-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN14241621\">ISRCTN14241621</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the effect of chronic use of Antimalarials on the frequency of infection with the New Corona Virus 2019 (Severe Acute Respiratory Syndrome Coronavirus 2 - SARS-CoV-2) in patients with Immunomedical Rheumatic Diseases</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-9ktwx6/\">RBR-9ktwx6</a></td></tr><tr><td>2020-03-30</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Evaluation of the effect of chronic use of Antimalarials on the frequency of infection with the New Corona Virus 2019 (Severe Acute Respiratory Syndrome Coronavirus 2 - SARS-CoV-2) in patients with Immunomedical Rheumatic Diseases</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-9ktwx6/\">RBR-9ktwx6</a></td></tr><tr><td>2020-03-29</td><td><strong><a href=\"/drugs/DB00860\">Prednisolone</a></strong></td><td>Study of Prednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients : a clinical trial study</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46975\">IRCT20081027001411N3</a></td></tr><tr><td>2020-03-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir / Ritonavir Plus Hydroxychloroquine Regimen : an Open-label, Non-randomized Clinical Trial Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04376814\">NCT04376814</a></td></tr><tr><td>2020-03-29</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir / Ritonavir Plus Hydroxychloroquine Regimen : an Open-label, Non-randomized Clinical Trial Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04376814\">NCT04376814</a></td></tr><tr><td>2020-03-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients : A NYC Community-Based Randomized Clinical Trial</td><td>Prevention</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04318444\">NCT04318444</a></td></tr><tr><td>2020-03-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Effect of hydroxychloroquine on prevention of covid-19 virus infection among treatment staff in Arash hospital-A double-blind clinical trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46603\">IRCT20120826010664N6</a></td></tr><tr><td>2020-03-29</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04342221\">NCT04342221</a></td></tr><tr><td>2020-03-29</td><td><strong><a href=\"/drugs/DB16416\">Vilobelimab</a></strong></td><td>A pragmatic adaptive randomized controlled Phase II / III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - &quot;PANAMO&quot; - Panamo</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001335-28\">EUCTR2020-001335-28-NL</a></td></tr><tr><td>2020-03-29</td><td><strong><a href=\"/drugs/DB00898\">Ethanol</a></strong></td><td>Investigating the effect of Medical Beer on the fever of patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47530\">IRCT20200428047229N1</a></td></tr><tr><td>2020-03-29</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Evaluation of Dexamethasone treatment in high-risk covid19 patients in Qom</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48310\">IRCT20160118026097N4</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04327388\">NCT04327388</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04321278\">NCT04321278</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04321278\">NCT04321278</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB16207\">Itolizumab</a></strong></td><td>Treatment of patients with severe SARS-CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab. (COVID-19) - VICTORIA</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000311-En\">RPCEC00000311</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Study of Methylprednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian ?COVID-19 patients : a clinical trial study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46904\">IRCT20200404046947N1</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Evaluation of the efficacy and safety of Umifenovir in the treatment of hospitalized patients with covid-19 : A randomized clinical trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46731\">IRCT20200322046833N1</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB14327\">Purslane</a></strong></td><td>Efficacy evaluation of an herbal compound \\xe2\\x80\\x9cFluherb\\xe2\\x80\\x9d on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46715\">IRCT20200323046841N1</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB10675\">Licorice</a></strong></td><td>Efficacy evaluation of an herbal compound \\xe2\\x80\\x9cFluherb\\xe2\\x80\\x9d on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46715\">IRCT20200323046841N1</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB14585\">Plantago ovata seed</a></strong></td><td>Efficacy evaluation of an herbal compound \\xe2\\x80\\x9cFluherb\\xe2\\x80\\x9d on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46715\">IRCT20200323046841N1</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB14256\">Centella asiatica</a></strong></td><td>Efficacy evaluation of an herbal compound \\xe2\\x80\\x9cFluherb\\xe2\\x80\\x9d on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46715\">IRCT20200323046841N1</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB14276\">Turmeric</a></strong></td><td>Efficacy evaluation of an herbal compound \\xe2\\x80\\x9cFluherb\\xe2\\x80\\x9d on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46715\">IRCT20200323046841N1</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04321616\">NCT04321616</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04321616\">NCT04321616</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Mesenchymal stem cell utilization in reducing complications and enhancing pneumonia healing in patients infected with 2019-nCoV (phase I clinical trial)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46789\">IRCT20200325046860N2</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial controlled with placebo - EPICOS</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001385-11\">EUCTR2020-001385-11-ES</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB00300\">Tenofovir disoproxil</a></strong></td><td>Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial controlled with placebo - EPICOS</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001385-11\">EUCTR2020-001385-11-ES</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB00879\">Emtricitabine</a></strong></td><td>Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial controlled with placebo - EPICOS</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001385-11\">EUCTR2020-001385-11-ES</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Effectiveness of Hydroxychloroquine in Covid-19 Patients : A Single Centred Single-blind RCT Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328272\">NCT04328272</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Effectiveness of Hydroxychloroquine in Covid-19 Patients : A Single Centred Single-blind RCT Study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328272\">NCT04328272</a></td></tr><tr><td>2020-03-28</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome : A Clinical Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04327349\">NCT04327349</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB15808\">CIGB 2020 Vaccine</a></strong></td><td>Randomized control clinical trial of CIGB 2020 in contacts and SARS-CoV-2 infection suspects (COVID-19)</td><td>Treatment</td><td>1, 2</td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000306-En\">RPCEC00000306</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB00005\">Etanercept</a></strong></td><td>Evaluation the efficacy of Tumor Necrosis Factor alpha inhibitor in COVID-19 outcomes : a prospective clinical trial study.</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46551\">IRCT20200312046749N1</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324073\">NCT04324073</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>the efficacy of Interferon beta 1 a (ReciGen) in treatment of patients with Covid-19 in Sina Hospital Emergency Department</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46665\">IRCT20150914024017N1</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001156-18\">EUCTR2020-001156-18-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001156-18\">EUCTR2020-001156-18-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001156-18\">EUCTR2020-001156-18-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001156-18\">EUCTR2020-001156-18-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11\">EUCTR2020-001366-11-ES</a></td></tr><tr><td>2020-03-27</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Uno studio randomizzato multicentrico in aperto per valutare l\\xe2\\x80\\x99efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19. - TOCI-RE</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001386-37\">EUCTR2020-001386-37-IT</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345692\">NCT04345692</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A phase I / II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers - A phase I / II trial of a candidate COVID-19 vaccine (COV001)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001072-15\">EUCTR2020-001072-15-GB</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCT2031190264\">JPRN-jRCT2031190264</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366089\">NCT04366089</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04366089\">NCT04366089</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). - N-ReCOVID 19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18\">EUCTR2020-000982-18-NO</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). - N-ReCOVID 19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18\">EUCTR2020-000982-18-NO</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Study for using sulfate in the prevention and control of novel coronavirus pneumonia (COVID-19) in high and low prevalence communities</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52394\">ChiCTR2000032487</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN83971151\">ISRCTN83971151</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN83971151\">ISRCTN83971151</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN83971151\">ISRCTN83971151</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN83971151\">ISRCTN83971151</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN83971151\">ISRCTN83971151</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN83971151\">ISRCTN83971151</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>A prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46463\">IRCT20200128046294N2</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>A prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46463\">IRCT20200128046294N2</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB01167\">Itraconazole</a></strong></td><td>Covid-19 : A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001243-15\">EUCTR2020-001243-15-BE</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>An adaptive phase 2 / 3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12\">EUCTR2020-001162-12-FR</a></td></tr><tr><td>2020-03-26</td><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>A phase I / II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers</td><td>Treatment</td><td>1, 2</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN15281137\">ISRCTN15281137</a></td></tr><tr><td>2020-03-25</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04421664\">NCT04421664</a></td></tr><tr><td>2020-03-25</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Norwegian Coronavirus Disease 2019 Study : An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04316377\">NCT04316377</a></td></tr><tr><td>2020-03-25</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 \\xe2\\x80\\x93 COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001224-33\">EUCTR2020-001224-33-DE</a></td></tr><tr><td>2020-03-25</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN86534580\">ISRCTN86534580</a></td></tr><tr><td>2020-03-25</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>Efficacy and safety evaluation of therapeutic regimen of lopinavir / ritonavir and interferon beta 1b in patients with COVID-19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46741\">IRCT20190804044429N1</a></td></tr><tr><td>2020-03-25</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Gu\\xc3\\xa9rin Vaccination, a Randomized Controlled Trial.</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04328441\">NCT04328441</a></td></tr><tr><td>2020-03-25</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04335123\">NCT04335123</a></td></tr><tr><td>2020-03-25</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04336904\">NCT04336904</a></td></tr><tr><td>2020-03-25</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51809\">ChiCTR2000031427</a></td></tr><tr><td>2020-03-24</td><td><strong><a href=\"/drugs/DB00020\">Sargramostim</a></strong></td><td>A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine\\xc2\\xae) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04326920\">NCT04326920</a></td></tr><tr><td>2020-03-24</td><td><strong><a href=\"/drugs/DB10667\">Tragacanth</a></strong></td><td>Evaluation of the effect of Traditional medicine product incorporated in the base of Astragalus gossypinus with food spice on improvement of clinical menifestation of COVID -19 patients with conventional protocol</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46775\">IRCT20101219005416N2</a></td></tr><tr><td>2020-03-24</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Evaluation of the efficacy and safety of cord-derived mesenchymal stem cell transplantation in the treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46623\">IRCT20140528017891N8</a></td></tr><tr><td>2020-03-24</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients : A Clinical Trial Study</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46424\">IRCT20200310046736N1</a></td></tr><tr><td>2020-03-24</td><td><strong><a href=\"/drugs/DB00020\">Sargramostim</a></strong></td><td>A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine\\xc2\\xae) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - SARPAC</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001254-22\">EUCTR2020-001254-22-BE</a></td></tr><tr><td>2020-03-24</td><td><strong><a href=\"/drugs/DB15804\">LV-SMENP Vaccine</a></strong></td><td>Phase I / II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04276896\">NCT04276896</a></td></tr><tr><td>2020-03-24</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04458948\">NCT04458948</a></td></tr><tr><td>2020-03-24</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04458948\">NCT04458948</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04323592\">NCT04323592</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB13525\">Althea root</a></strong></td><td>Formulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46782\">IRCT20180712040449N2</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB10763\">Urtica dioica pollen</a></strong></td><td>Formulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46782\">IRCT20180712040449N2</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB14256\">Centella asiatica</a></strong></td><td>Formulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46782\">IRCT20180712040449N2</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB14312\">Glycyrrhiza glabra</a></strong></td><td>Formulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46782\">IRCT20180712040449N2</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB14357\">Chamomile</a></strong></td><td>Formulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46782\">IRCT20180712040449N2</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB14317\">Pomegranate</a></strong></td><td>Formulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46782\">IRCT20180712040449N2</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51437\">ChiCTR2000031174</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322682\">NCT04322682</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04353336\">NCT04353336</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04353336\">NCT04353336</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB10675\">Licorice</a></strong></td><td>Comparison of the Effectiveness of Standard Treatment with Standard Treatment plus licorice extract in Improving Respiratory Symptoms and Survival Rate in COVID-19 Patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46678\">IRCT20160316027081N1</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY : AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION - NO-COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001010-38\">EUCTR2020-001010-38-NO</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB15907\">Escin</a></strong></td><td>Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients</td><td>Supportive Care</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322344\">NCT04322344</a></td></tr><tr><td>2020-03-23</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04290871\">NCT04290871</a></td></tr><tr><td>2020-03-22</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04315948\">NCT04315948</a></td></tr><tr><td>2020-03-22</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04315948\">NCT04315948</a></td></tr><tr><td>2020-03-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04315948\">NCT04315948</a></td></tr><tr><td>2020-03-22</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04315948\">NCT04315948</a></td></tr><tr><td>2020-03-22</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04315948\">NCT04315948</a></td></tr><tr><td>2020-03-22</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Clinical validation and application of high-throughput novel coronavirus (2019-ncov) screening detection kit</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51035\">ChiCTR2000030833</a></td></tr><tr><td>2020-03-21</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild / Moderate COVID-19 : a Randomized Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04305457\">NCT04305457</a></td></tr><tr><td>2020-03-21</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Use of Hydroxychloroquine in Patients With COVID-19 : A Randomized Controlled Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04394442\">NCT04394442</a></td></tr><tr><td>2020-03-21</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2 : a Randomized Clinical Trial.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04306393\">NCT04306393</a></td></tr><tr><td>2020-03-21</td><td><strong><a href=\"/drugs/DB15725\">IL15-NK Cell</a></strong></td><td>A Phase I / II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324996\">NCT04324996</a></td></tr><tr><td>2020-03-21</td><td><strong><a href=\"/drugs/DB15721\">Natural Killer Cell</a></strong></td><td>A Phase I / II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324996\">NCT04324996</a></td></tr><tr><td>2020-03-21</td><td><strong><a href=\"/drugs/DB15727\">NKG2D-ACE2 CAR-NK Cell</a></strong></td><td>A Phase I / II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324996\">NCT04324996</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB00497\">Oxycodone</a></strong></td><td>Evaluation the effects of Oxycodone administration on pain control in patients with COVID-19</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48534\">IRCT20150107020592N24</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>Evaluation of interferon treatment in high-risk covid19 patients in Qom</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48517\">IRCT20160118026097N3</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>Cyclosporin for the Prevention and Treatment of COVID-19 Disease</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48262\">IRCT20150107020592N22</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB15871\">Human Amniotic Fluid</a></strong></td><td>A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04319731\">NCT04319731</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB04216\">Quercetin</a></strong></td><td>The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04377789\">NCT04377789</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB15730\">Placental Mesenchymal Stem Cells</a></strong></td><td>Placental Mesenchymal Stem cells for treatment of ARDS in Coronavirus infection, Phase 1 and 2 Clinical Trials</td><td>Treatment</td><td>1, 2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47156\">IRCT20200413047063N1</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A single-arm multicenter clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients with progressive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46660\">IRCT20171122037571N2</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection : A Randomized Double Blind Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04360980\">NCT04360980</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB00331\">Metformin</a></strong></td><td>Study of the metformin effect on the survival and recovery rate of COVID-19 patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46693\">IRCT20160310026998N10</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB00331\">Metformin</a></strong></td><td>Effect of metformin in COVID-19 mortality rate and symptom improvement</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46690\">IRCT20160310026998N11</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia : An Observational Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04326725\">NCT04326725</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia : An Observational Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04326725\">NCT04326725</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia : An Observational Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04326725\">NCT04326725</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia : An Observational Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04326725\">NCT04326725</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Evaluation of the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosis</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49254\">ChiCTR2000031430</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19) : a retrospective study</td><td>Diagnostic</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51283\">ChiCTR2000030951</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB15734\">Human Embryonic Stem Cell-derived M Cell</a></strong></td><td>Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51404\">ChiCTR2000031139</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>REDUCING HEALTH CARE WORKERS ABSENTEEISM IN SARS-CoV-2 PANDEMIC BY ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GU\\xc3\\x89RIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://trialregister.nl/trial/8477\">NL8477</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Favipiravir prophylactic to reduce the involvement of health care workers in the COVID-19 epidemic</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/48992\">IRCT20150107020592N30</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB11238\">Borage oil</a></strong></td><td>Effectiveness of Borage based solutions in cytokine&#39;s levels in covid-19 ARDS patients with elevated Extravascular Lung Water( EVLW)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48972\">IRCT20150107020592N28</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB15865\">Pentaglobin</a></strong></td><td>The effect of pentaglobin in the treatment of critically ill patients with COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48907\">IRCT20150107020592N27</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Favipiravir effectiveness in patients undergoing COVID19 Acute respiratory distress syndrome (ARDS)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48746\">IRCT20150107020592N26</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma for the Treatment of Coronavirus Disease 2019</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04554992\">NCT04554992</a></td></tr><tr><td>2020-03-20</td><td><strong><a href=\"/drugs/DB01216\">Finasteride</a></strong></td><td>Investigation of the effect of &quot;Finasterid&quot; on the prognosis in the hospitalized over 50 years male patients with COVID-19 pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48007\">IRCT20200505047318N1</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB09036\">Siltuximab</a></strong></td><td>An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04322188\">NCT04322188</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB00860\">Prednisolone</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB15691\">Anti-SARS-CoV-2 REGN-COV2</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB14644\">Methylprednisolone hemisuccinate</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB00741\">Hydrocortisone</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Randomized evaluation of COVID-19 therapy</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN50189673\">ISRCTN50189673</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB06174\">Noscapine</a></strong></td><td>The effect of NOSCOVID on pulmonary &amp; other clinical manifestations of COVID-19 patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46576\">IRCT20160625028622N1</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04317092\">NCT04317092</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB11779\">Danoprevir</a></strong></td><td>Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19) : a randomized, open-label, controlled trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52103\">ChiCTR2000031734</a></td></tr><tr><td>2020-03-19</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19) : a randomized, open-label, controlled trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52103\">ChiCTR2000031734</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345276\">NCT04345276</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB11779\">Danoprevir</a></strong></td><td>An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04345276\">NCT04345276</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO : Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330690\">NCT04330690</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO : Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330690\">NCT04330690</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO : Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330690\">NCT04330690</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO : Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04330690\">NCT04330690</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>An Adaptive Phase 2 / 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04315298\">NCT04315298</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy : a Cluster Randomized Clinical Trial (PEP CoV-2 Study)</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04304053\">NCT04304053</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB14357\">Chamomile</a></strong></td><td>Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris supplements on the Severity and Consequences of COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46828\">IRCT20151228025732N51</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB13525\">Althea root</a></strong></td><td>Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris supplements on the Severity and Consequences of COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46828\">IRCT20151228025732N51</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46713\">IRCT20200324046850N2</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46713\">IRCT20200324046850N2</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46713\">IRCT20200324046850N2</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46713\">IRCT20200324046850N2</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46713\">IRCT20200324046850N2</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46713\">IRCT20200324046850N2</a></td></tr><tr><td>2020-03-18</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Evaluating efficacy and safety of sofosbuvir / ledipasvir in treatment of COVID-19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46567\">IRCT20100228003449N29</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04321421\">NCT04321421</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2 : A Pragmatic Randomized Clinical Trial</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04308668\">NCT04308668</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>The efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19) : a pragmatic, prospective cohort study</td><td>Treatment</td><td>0</td><td>Unknown Status</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50254\">ChiCTR2000031501</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td>The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04305106\">NCT04305106</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN\\xc3\\x9f-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) - Phase II trial of inhaled anti-viral (SNG001) for SARS-CoV-2 infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001023-14\">EUCTR2020-001023-14-GB</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Gu\\xc3\\xa9rin vaccination, a randomized controlled trial (COVID-19). - BCG-CORONA</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000919-69\">EUCTR2020-000919-69-NL</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50696\">ChiCTR2000030929</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Randomised Evaluation of COVID-19 Therapy (RECOVERY) - RECOVERY trial</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21\">EUCTR2020-001113-21-GB</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB00741\">Hydrocortisone</a></strong></td><td>Randomised Evaluation of COVID-19 Therapy (RECOVERY) - RECOVERY trial</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21\">EUCTR2020-001113-21-GB</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomised Evaluation of COVID-19 Therapy (RECOVERY) - RECOVERY trial</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21\">EUCTR2020-001113-21-GB</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Randomised Evaluation of COVID-19 Therapy (RECOVERY) - RECOVERY trial</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21\">EUCTR2020-001113-21-GB</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB15691\">Anti-SARS-CoV-2 REGN-COV2</a></strong></td><td>Randomised Evaluation of COVID-19 Therapy (RECOVERY) - RECOVERY trial</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21\">EUCTR2020-001113-21-GB</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Randomised Evaluation of COVID-19 Therapy (RECOVERY) - RECOVERY trial</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21\">EUCTR2020-001113-21-GB</a></td></tr><tr><td>2020-03-17</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomised Evaluation of COVID-19 Therapy (RECOVERY) - RECOVERY trial</td><td>Treatment</td><td>2</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21\">EUCTR2020-001113-21-GB</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB15654\">Moderna COVID-19 Vaccine</a></strong></td><td>Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04283461\">NCT04283461</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>A Single-center,Open-label,Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old</td><td>Prevention</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04313127\">NCT04313127</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-\\xc3\\x9f1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04385095\">NCT04385095</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>Baricitinib Therapy in COVID-19 : A Pilot Study on Safety and Clinical Impact</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04358614\">NCT04358614</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB04854\">Febuxostat</a></strong></td><td>The effect of febuxostat against lung injury induced by COVID-19 virus in infected patients : A clinical trial study</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46629\">IRCT20190727044343N1</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Treatment of COVID-19 Patients Using Wharton&#39;s Jelly-Mesenchymal Stem Cells</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04313322\">NCT04313322</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB16532\">LL-37</a></strong></td><td>Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51059\">ChiCTR2000030939</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50984\">ChiCTR2000031023</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50759\">ChiCTR2000030721</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB12038\">Ulinastatin</a></strong></td><td>A randomized, open-label, controlled trial for the efficacy and safety of Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50973\">ChiCTR2000030779</a></td></tr><tr><td>2020-03-16</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Clinical Characterisation Protocol for Severe Emerging Infections ISARIC / WHO : COVID-19</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.ensaiosclinicos.gov.br/rg/RBR-3zdynp/\">RBR-3zdynp</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>COvid-19 et VITamine d en EHPAD</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435119\">NCT04435119</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\\xe2\\x84\\xa2) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04292730\">NCT04292730</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04399746\">NCT04399746</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04399746\">NCT04399746</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04399746\">NCT04399746</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Antimalarial and Covid 19 in Rheumatoid Arthritis</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04389320\">NCT04389320</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 1 and 2 clinical trial</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47030\">IRCT20200217046526N1</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Evaluation of the safety and efficacy of tocilizumab (AryoGen ?Pharmed Co., Iran) in patients with severe COVID-19?</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46550\">IRCT20150303021315N17</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Evaluation of Convalescent Plasma as a Potential Therapy for COVID-19 infected patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46759\">IRCT20200325046860N1</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>Evaluating efficacy and safety of interferone \\xc3\\x9f-1b (IFN \\xc3\\x9f-1b) in the treatment of COVID-19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46545\">IRCT20100228003449N27</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>Evaluating efficacy and safety of interferone \\xc3\\x9f-1a in the treatment COVID-19 infection</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46538\">IRCT20100228003449N28</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir / ritonavir combination in patients with COVID-19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46536\">IRCT20100228003449N30</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Evaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir / ritonavir combination in patients with COVID-19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46536\">IRCT20100228003449N30</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir / ritonavir combination in patients with COVID-19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46536\">IRCT20100228003449N30</a></td></tr><tr><td>2020-03-15</td><td><strong><a href=\"/drugs/DB01072\">Atazanavir</a></strong></td><td>Evaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir / ritonavir combination in patients with COVID-19</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46536\">IRCT20100228003449N30</a></td></tr><tr><td>2020-03-14</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs031190226\">JPRN-jRCTs031190226</a></td></tr><tr><td>2020-03-13</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Use of Ascorbic Acid in Patients With COVID 19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04323514\">NCT04323514</a></td></tr><tr><td>2020-03-13</td><td><strong><a href=\"/drugs/DB15721\">Natural Killer Cell</a></strong></td><td>Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49956\">ChiCTR2000030509</a></td></tr><tr><td>2020-03-12</td><td><strong><a href=\"/drugs/DB01097\">Leflunomide</a></strong></td><td>Efficacy and safety of leflunomide for Refractory novel coronavirus pneumonia (COVID-19) : A non-Randomized Controlled Study</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=54408\">ChiCTR2000033372</a></td></tr><tr><td>2020-03-12</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Early Short Course Corticosteroids in Hospitalized Patients With COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374071\">NCT04374071</a></td></tr><tr><td>2020-03-12</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04315480\">NCT04315480</a></td></tr><tr><td>2020-03-12</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Upper Respiratory Tract Virus Detection of Corona Virus Disease 2019(COVID-19)to Evaluation the value of rehabilitation patients</td><td>Diagnostic</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51342\">ChiCTR2000030993</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Randomized Controlled Clinical Trials of Lopinavir / Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04307693\">NCT04307693</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Randomized Controlled Clinical Trials of Lopinavir / Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04307693\">NCT04307693</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Randomized Controlled Clinical Trials of Lopinavir / Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04307693\">NCT04307693</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB00105\">Interferon alfa-2b</a></strong></td><td>Use of Heberon(R) Alfa R in patients confirmed for infection with SARS-CoV-2 in Cuba. Observational clinical study. (COVID-19)</td><td>Basic Science</td><td>4</td><td>Completed</td><td><a href=\"https://rpcec.sld.cu/en/trials/RPCEC00000318-En\">RPCEC00000318</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46681\">IRCT20151227025726N13</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46681\">IRCT20151227025726N13</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46681\">IRCT20151227025726N13</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46681\">IRCT20151227025726N13</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/46681\">IRCT20151227025726N13</a></td></tr><tr><td>2020-03-11</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Accuracy analysis of SARS-CoV-2 IgM antibody screening for diagnosis of COVID-19</td><td>Diagnostic</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50824\">ChiCTR2000030754</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04428268\">NCT04428268</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 Pneumonia</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04428268\">NCT04428268</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>Effect of Intravenous immunoglobulin (IVIG) versus Kaletra (lopinavir and ritonavir) tablets in patients with acute respiratory infection (COVID-19) : A clinical trial studies</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/47219\">IRCT20200418047116N1</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB11874\">Crocin</a></strong></td><td>Assessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in pulmonary problems of the patients with Covid-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46733\">IRCT20160131026298N2</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB14104\">Linoleic acid</a></strong></td><td>Assessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in pulmonary problems of the patients with Covid-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46733\">IRCT20160131026298N2</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB04224\">Oleic Acid</a></strong></td><td>Assessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in pulmonary problems of the patients with Covid-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46733\">IRCT20160131026298N2</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB00825\">Levomenthol</a></strong></td><td>Assessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in pulmonary problems of the patients with Covid-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46733\">IRCT20160131026298N2</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB00132\">alpha-Linolenic acid</a></strong></td><td>Assessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in pulmonary problems of the patients with Covid-19</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46733\">IRCT20160131026298N2</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Severe Acute Respiratory Syndrome Coronavirus 2 of the Genus Betacoronavirus (SARSCoV2) Convalescent Plasma (CP) Expanded Access Protocol (EAP)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04374370\">NCT04374370</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>A single-center, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) in healthy adults aged between 18 and 60 years</td><td>Prevention</td><td>1</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51154\">ChiCTR2000030906</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50795\">ChiCTR2000030701</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB11569\">Ixekizumab</a></strong></td><td>A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50251\">ChiCTR2000030703</a></td></tr><tr><td>2020-03-10</td><td><strong><a href=\"/drugs/DB01097\">Leflunomide</a></strong></td><td>A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49831\">ChiCTR2000030058</a></td></tr><tr><td>2020-03-09</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23\">EUCTR2020-000936-23-FR</a></td></tr><tr><td>2020-03-09</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23\">EUCTR2020-000936-23-FR</a></td></tr><tr><td>2020-03-09</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23\">EUCTR2020-000936-23-FR</a></td></tr><tr><td>2020-03-09</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23\">EUCTR2020-000936-23-FR</a></td></tr><tr><td>2020-03-09</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>The prediction value of prognosis of COVID-19 in elderly patients by modified early warning score (MEWS) : a retrospective observational study</td><td>Diagnostic</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50633\">ChiCTR2000030683</a></td></tr><tr><td>2020-03-09</td><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>An evaluative clinical study : efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50786\">ChiCTR2000030700</a></td></tr><tr><td>2020-03-08</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04310228\">NCT04310228</a></td></tr><tr><td>2020-03-08</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04310228\">NCT04310228</a></td></tr><tr><td>2020-03-07</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Clinical study for rapid detection of novel coronavirus pneumonia (COVID-19) nucleic acid</td><td>Diagnostic</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53845\">ChiCTR2000033104</a></td></tr><tr><td>2020-03-06</td><td><strong><a href=\"/drugs/DB06779\">Dalteparin</a></strong></td><td>Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412304\">NCT04412304</a></td></tr><tr><td>2020-03-06</td><td><strong><a href=\"/drugs/DB06822\">Tinzaparin</a></strong></td><td>Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04412304\">NCT04412304</a></td></tr><tr><td>2020-03-06</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>Expanded Access Treatment Protocol : Remdesivir (RDV ; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04323761\">NCT04323761</a></td></tr><tr><td>2020-03-06</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\\xe2\\x84\\xa2) in Participants With Severe COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04292899\">NCT04292899</a></td></tr><tr><td>2020-03-06</td><td><strong><a href=\"/drugs/DB15313\">DAS-181</a></strong></td><td>DAS181 for Severe COVID-19 : Compassionate Use</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04324489\">NCT04324489</a></td></tr><tr><td>2020-03-06</td><td><strong><a href=\"/drugs/DB11091\">Hydrogen peroxide</a></strong></td><td>Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50660\">ChiCTR2000030539</a></td></tr><tr><td>2020-03-06</td><td><strong><a href=\"/drugs/DB04951\">Pirfenidone</a></strong></td><td>Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis : a prospective exploratory experimental medical study</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51118\">ChiCTR2000030892</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>Evaluation of efficacy and safety of Sovodak (Sofosbuvir+Daclatasvir) in combination with Ribavirin for mild to moderate hospitalized Covid-19 patients compared to standard care regimen (a randomized controlled trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46885\">IRCT20200328046886N1</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>Evaluation of efficacy and safety of Sovodak (Sofosbuvir+Daclatasvir) in combination with Ribavirin for mild to moderate hospitalized Covid-19 patients compared to standard care regimen (a randomized controlled trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46885\">IRCT20200328046886N1</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>Evaluation of efficacy and safety of Sovodak (Sofosbuvir+Daclatasvir) in combination with Ribavirin for mild to moderate hospitalized Covid-19 patients compared to standard care regimen (a randomized controlled trial)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46885\">IRCT20200328046886N1</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04288102\">NCT04288102</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04319900\">NCT04319900</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04319900\">NCT04319900</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB14066\">Tetrandrine</a></strong></td><td>Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04308317\">NCT04308317</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - SARS-CoV2quine</td><td>Treatment</td><td>3</td><td>Unknown Status</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000890-25\">EUCTR2020-000890-25-FR</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51329\">ChiCTR2000030987</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>2, 3</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51329\">ChiCTR2000030987</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB15737\">Dental Mesenchymal Pulp Stem Cells</a></strong></td><td>Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04302519\">NCT04302519</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50380\">ChiCTR2000030442</a></td></tr><tr><td>2020-03-05</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50380\">ChiCTR2000030442</a></td></tr><tr><td>2020-03-04</td><td><strong><a href=\"/drugs/DB04951\">Pirfenidone</a></strong></td><td>A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48801\">ChiCTR2000030333</a></td></tr><tr><td>2020-03-03</td><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46561\">IRCT20151227025726N12</a></td></tr><tr><td>2020-03-03</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46561\">IRCT20151227025726N12</a></td></tr><tr><td>2020-03-03</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46561\">IRCT20151227025726N12</a></td></tr><tr><td>2020-03-03</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46561\">IRCT20151227025726N12</a></td></tr><tr><td>2020-03-03</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/46561\">IRCT20151227025726N12</a></td></tr><tr><td>2020-03-02</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04453501\">NCT04453501</a></td></tr><tr><td>2020-03-02</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04453501\">NCT04453501</a></td></tr><tr><td>2020-03-02</td><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets in Treating Pediatric novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=55097\">ChiCTR2000033774</a></td></tr><tr><td>2020-03-02</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Multicenter, open-label, randomized trial of favipiravir in asymptomatic and minimally symptomatic patients infected with SARS-CoV2 to evaluate viral load reduction</td><td>Treatment</td><td>2</td><td>Completed</td><td><a href=\"https://jrct.niph.go.jp/en-latest-detail/jRCTs041190120\">JPRN-jRCTs041190120</a></td></tr><tr><td>2020-03-02</td><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50241\">ChiCTR2000030328</a></td></tr><tr><td>2020-03-02</td><td><strong><a href=\"/drugs/DB00166\">Lipoic acid</a></strong></td><td>Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50421\">ChiCTR2000030471</a></td></tr><tr><td>2020-03-02</td><td><strong><a href=\"/drugs/DB00041\">Aldesleukin</a></strong></td><td>Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49567\">ChiCTR2000030167</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Efficacy and Safety of Darunavir / Cobicistat vs. Lopinavir / Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425382\">NCT04425382</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB09065\">Cobicistat</a></strong></td><td>Efficacy and Safety of Darunavir / Cobicistat vs. Lopinavir / Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425382\">NCT04425382</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB01264\">Darunavir</a></strong></td><td>Efficacy and Safety of Darunavir / Cobicistat vs. Lopinavir / Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425382\">NCT04425382</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Efficacy and Safety of Darunavir / Cobicistat vs. Lopinavir / Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04425382\">NCT04425382</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild / Moderate COVID19 Infection : a Randomized Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04290858\">NCT04290858</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04408456\">NCT04408456</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04371601\">NCT04371601</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB01115\">Nifedipine</a></strong></td><td>A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52867\">ChiCTR2000032314</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB09026\">Aliskiren</a></strong></td><td>A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52867\">ChiCTR2000032314</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB15803\">Dendritic cells vaccine</a></strong></td><td>A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50928\">ChiCTR2000030750</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB15721\">Natural Killer Cell</a></strong></td><td>Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50613\">ChiCTR2000031735</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB00148\">Creatine</a></strong></td><td>Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49531\">ChiCTR2000029955</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49531\">ChiCTR2000029955</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50279\">ChiCTR2000030417</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51126\">ChiCTR2000030894</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51126\">ChiCTR2000030894</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB10568\">Soybean</a></strong></td><td>Cancelled Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49570\">ChiCTR2000030162</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB15743\">Stem-cell derived exosome vesicle products</a></strong></td><td>A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49963\">ChiCTR2000030261</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Umbilical cord Wharton&#39;s Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49902\">ChiCTR2000030088</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Toclizumam Versus Dexamethasone in Severe Covid-19 Cases</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04519385\">NCT04519385</a></td></tr><tr><td>2020-03-01</td><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>Toclizumam Versus Dexamethasone in Severe Covid-19 Cases</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04519385\">NCT04519385</a></td></tr><tr><td>2020-02-29</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50290\">ChiCTR2000030381</a></td></tr><tr><td>2020-02-29</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50258\">ChiCTR2000030312</a></td></tr><tr><td>2020-02-29</td><td><strong><a href=\"/drugs/DB14692\">Turmeric oil</a></strong></td><td>Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19) : a randomized, open, controlled trial</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50586\">ChiCTR2000030518</a></td></tr><tr><td>2020-02-28</td><td><strong><a href=\"/drugs/DB00051\">Adalimumab</a></strong></td><td>A randomized, open-label, controlled trial for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49889\">ChiCTR2000030089</a></td></tr><tr><td>2020-02-27</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Preliminary efficacy of Tocilizumab in the treatment of the patients with novel coronavirus pneumonia (COVID-19)</td><td>Basic Science</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=54989\">ChiCTR2000033705</a></td></tr><tr><td>2020-02-27</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid</td><td>Diagnostic</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50143\">ChiCTR2000030253</a></td></tr><tr><td>2020-02-27</td><td><strong><a href=\"/drugs/DB09275\">Bismuth subcitrate potassium</a></strong></td><td>A randomized, double-blind, placebo-controlled trial for evaluation of the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50173\">ChiCTR2000030398</a></td></tr><tr><td>2020-02-26</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49968\">ChiCTR2000030224</a></td></tr><tr><td>2020-02-26</td><td><strong><a href=\"/drugs/DB00034\">Interferon alfa-2a</a></strong></td><td>Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51141\">ChiCTR2000030922</a></td></tr><tr><td>2020-02-26</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51141\">ChiCTR2000030922</a></td></tr><tr><td>2020-02-26</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51141\">ChiCTR2000030922</a></td></tr><tr><td>2020-02-26</td><td><strong><a href=\"/drugs/DB04951\">Pirfenidone</a></strong></td><td>Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51416\">ChiCTR2000031138</a></td></tr><tr><td>2020-02-25</td><td><strong><a href=\"/drugs/DB01257\">Eculizumab</a></strong></td><td>Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04288713\">NCT04288713</a></td></tr><tr><td>2020-02-25</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50002\">ChiCTR2000030135</a></td></tr><tr><td>2020-02-25</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50057\">ChiCTR2000030187</a></td></tr><tr><td>2020-02-25</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50057\">ChiCTR2000030187</a></td></tr><tr><td>2020-02-25</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49753\">ChiCTR2000030472</a></td></tr><tr><td>2020-02-25</td><td><strong><a href=\"/drugs/DB11779\">Danoprevir</a></strong></td><td>An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49753\">ChiCTR2000030472</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB14707\">Cemiplimab</a></strong></td><td>Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49840\">ChiCTR2000030028</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB09035\">Nivolumab</a></strong></td><td>Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49840\">ChiCTR2000030028</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB09037\">Pembrolizumab</a></strong></td><td>Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49840\">ChiCTR2000030028</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04293692\">NCT04293692</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia(COVID-19)</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49987\">ChiCTR2000030114</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49592\">ChiCTR2000029975</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49747\">ChiCTR2000030102</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50004\">ChiCTR2000030138</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50059\">ChiCTR2000030179</a></td></tr><tr><td>2020-02-24</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50058\">ChiCTR2000030185</a></td></tr><tr><td>2020-02-23</td><td><strong><a href=\"/drugs/DB13941\">Piperaquine</a></strong></td><td>Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild / common novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49915\">ChiCTR2000030082</a></td></tr><tr><td>2020-02-23</td><td><strong><a href=\"/drugs/DB11638\">Artenimol</a></strong></td><td>Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild / common novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49915\">ChiCTR2000030082</a></td></tr><tr><td>2020-02-22</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49948\">ChiCTR2000030085</a></td></tr><tr><td>2020-02-22</td><td><strong><a href=\"/drugs/DB13293\">Ipecac</a></strong></td><td>A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49797\">ChiCTR2000030022</a></td></tr><tr><td>2020-02-22</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19) : a randomized, open and controlled trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49918\">ChiCTR2000030259</a></td></tr><tr><td>2020-02-22</td><td><strong><a href=\"/drugs/DB11779\">Danoprevir</a></strong></td><td>Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19) : a randomized, open and controlled trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49918\">ChiCTR2000030259</a></td></tr><tr><td>2020-02-22</td><td><strong><a href=\"/drugs/DB08868\">Fingolimod</a></strong></td><td>Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04280588\">NCT04280588</a></td></tr><tr><td>2020-02-22</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49869\">ChiCTR2000030054</a></td></tr><tr><td>2020-02-22</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49869\">ChiCTR2000030054</a></td></tr><tr><td>2020-02-22</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir / ritonavir</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49988\">ChiCTR2000030113</a></td></tr><tr><td>2020-02-21</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04280705\">NCT04280705</a></td></tr><tr><td>2020-02-21</td><td><strong><a href=\"/drugs/DB15127\">Hydrogen</a></strong></td><td>A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49887\">ChiCTR2000030258</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04306705\">NCT04306705</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>the Efficacy and Safety of Favipiravir for novel coronavirus\\xe2\\x80\\x93infected pneumonia : A multicenter, randomized, open, positive, parallel-controlled clinical study</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50137\">ChiCTR2000030254</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB09061\">Cannabidiol</a></strong></td><td>Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50476\">ChiCTR2000030920</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Clinical Study of Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49389\">ChiCTR2000029816</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49384\">ChiCTR2000029817</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild / common patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Unknown Status</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49806\">ChiCTR2000030031</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19) : pilot study</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49435\">ChiCTR2000029993</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB05258\">Interferon alfa</a></strong></td><td>Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49790\">ChiCTR2000030535</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB11742\">Ebastine</a></strong></td><td>Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49790\">ChiCTR2000030535</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49790\">ChiCTR2000030535</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49883\">ChiCTR2000030196</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB01041\">Thalidomide</a></strong></td><td>The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia : a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04273529\">NCT04273529</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49428\">ChiCTR2000029803</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49428\">ChiCTR2000029803</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49510\">ChiCTR2000029996</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB04786\">Suramin</a></strong></td><td>A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49824\">ChiCTR2000030029</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Considering the administration of Desferral supplementary and Vitamin C on the ferritin levels of Quid 19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49132\">IRCT20190121042444N3</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB00746\">Deferoxamine</a></strong></td><td>Considering the administration of Desferral supplementary and Vitamin C on the ferritin levels of Quid 19 patients</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://en.irct.ir/trial/49132\">IRCT20190121042444N3</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB00806\">Pentoxifylline</a></strong></td><td>Evaluation of the effects of Pentoxifylline in improving the condition of patients with Covid-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/49525\">IRCT20200705048013N1</a></td></tr><tr><td>2020-02-20</td><td><strong><a href=\"/drugs/DB11133\">Omega-3 fatty acids</a></strong></td><td>Comparison of the effectiveness of omega-3 and Hydroxychloroquine on Inflammatory factors, liver enzymes and clinical symptoms in diabetic COVID-19 patients</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/48045\">IRCT20200511047399N1</a></td></tr><tr><td>2020-02-19</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)</td><td>Diagnostic</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49491\">ChiCTR2000030334</a></td></tr><tr><td>2020-02-19</td><td><strong><a href=\"/drugs/DB00166\">Lipoic acid</a></strong></td><td>A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49534\">ChiCTR2000029851</a></td></tr><tr><td>2020-02-19</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49777\">ChiCTR2000030010</a></td></tr><tr><td>2020-02-18</td><td><strong><a href=\"/drugs/DB01041\">Thalidomide</a></strong></td><td>The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia : a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04273581\">NCT04273581</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB11779\">Danoprevir</a></strong></td><td>An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04291729\">NCT04291729</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04291729\">NCT04291729</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB00482\">Celecoxib</a></strong></td><td>Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50474\">ChiCTR2000031630</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious / critically ill patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49481\">ChiCTR2000029826</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild / common patients with novel coronavirus pneumon (COVID-19)ia</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49495\">ChiCTR2000029837</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51072\">ChiCTR2000030841</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19) : a Randomized, Open-Label, Parallel, Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49482\">ChiCTR2000029898</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19) : a Randomized, Open-Label, Parallel, Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49482\">ChiCTR2000029898</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19) : a Randomized, Open-label, Parallel, Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49536\">ChiCTR2000029899</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19) : a Randomized, Open-label, Parallel, Controlled Trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49536\">ChiCTR2000029899</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49574\">ChiCTR2000029992</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49574\">ChiCTR2000029992</a></td></tr><tr><td>2020-02-17</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49229\">ChiCTR2000030173</a></td></tr><tr><td>2020-02-16</td><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment / Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04273763\">NCT04273763</a></td></tr><tr><td>2020-02-16</td><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>The correlation between Vitamin D deficient and severe status of novel coronavirus pneumonia (COVID-19) patients</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51390\">ChiCTR2000031163</a></td></tr><tr><td>2020-02-16</td><td><strong><a href=\"/drugs/DB14287\">Trametes versicolor fruiting body</a></strong></td><td>An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49748\">ChiCTR2000030000</a></td></tr><tr><td>2020-02-16</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49748\">ChiCTR2000030000</a></td></tr><tr><td>2020-02-16</td><td><strong><a href=\"/drugs/DB11779\">Danoprevir</a></strong></td><td>An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49748\">ChiCTR2000030000</a></td></tr><tr><td>2020-02-16</td><td><strong><a href=\"/drugs/DB00008\">Peginterferon alfa-2a</a></strong></td><td>An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49748\">ChiCTR2000030000</a></td></tr><tr><td>2020-02-16</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Development and application of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19) based on CRISPR-cas protein</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49407\">ChiCTR2000029810</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB14364\">Scutellaria baicalensis root</a></strong></td><td>A Randomized, Double-blind, Placebo-controlled trial for determination of the Efficacy and Safety of Baicalein in Hospitalized Adult Mild and Moderate Patients of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=54176\">ChiCTR2000033286</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB15721\">Natural Killer Cell</a></strong></td><td>Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04280224\">NCT04280224</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td>Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19 : a Pilot Study (BEST-CP)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04275414\">NCT04275414</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB15813\">Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine</a></strong></td><td>Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04299724\">NCT04299724</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent plasma for the treatment of common COVID-19 : a prospective randomized controlled trial</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50537\">ChiCTR2000030702</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>An artificial intelligence assistant system for suspected new coronavirus pneumonia based on chest CT</td><td>Diagnostic</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51091\">ChiCTR2000030856</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB15743\">Stem-cell derived exosome vesicle products</a></strong></td><td>A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04276987\">NCT04276987</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09 / Ritonavir compound tablets and Lopinavir / Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49352\">ChiCTR2000029759</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB15623\">TMC-310911</a></strong></td><td>A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09 / Ritonavir compound tablets and Lopinavir / Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49352\">ChiCTR2000029759</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09 / Ritonavir compound tablets and Lopinavir / Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49352\">ChiCTR2000029759</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09 / Ritonavir compound tablets and Lopinavir / Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49352\">ChiCTR2000029759</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB15622\">Triazavirin</a></strong></td><td>The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19) : a multicenter, randomized, double blinded, placebo-controlled trial</td><td>Treatment</td><td>3</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49723\">ChiCTR2000030001</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB07615\">Tranilast</a></strong></td><td>Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49738\">ChiCTR2000030002</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50017\">ChiCTR2000030170</a></td></tr><tr><td>2020-02-15</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19) : a prospective cohort study</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49533\">ChiCTR2000029850</a></td></tr><tr><td>2020-02-14</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Efficacy and Safety of Corticosteroids in COVID-19 : A Prospective Randomized Controlled Trails</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04273321\">NCT04273321</a></td></tr><tr><td>2020-02-14</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia : a Prospective Randomized Clinical Trial</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04264533\">NCT04264533</a></td></tr><tr><td>2020-02-14</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51050\">ChiCTR2000030835</a></td></tr><tr><td>2020-02-14</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19) : a prospective randomized controlled trial</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49081\">ChiCTR2000029757</a></td></tr><tr><td>2020-02-14</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49086\">ChiCTR2000029656</a></td></tr><tr><td>2020-02-13</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49400\">ChiCTR2000029761</a></td></tr><tr><td>2020-02-13</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49218\">ChiCTR2000029988</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Efficacy and safety of high-dose vitamin C combined with traditional Chinese medicine in the treatment of moderate and severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53322\">ChiCTR2000032717</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04252664\">NCT04252664</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50843\">ChiCTR2000030718</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49369\">ChiCTR2000029760</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49404\">ChiCTR2000029762</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB15127\">Hydrogen</a></strong></td><td>A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49283\">ChiCTR2000029739</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Efficacy of Chloroquine and Lopinavir / Ritonavir in mild / general novel coronavirus (CoVID-19) infections : a prospective, open-label, multicenter randomized controlled clinical study</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49263\">ChiCTR2000029741</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Efficacy of Chloroquine and Lopinavir / Ritonavir in mild / general novel coronavirus (CoVID-19) infections : a prospective, open-label, multicenter randomized controlled clinical study</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49263\">ChiCTR2000029741</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Efficacy of Chloroquine and Lopinavir / Ritonavir in mild / general novel coronavirus (CoVID-19) infections : a prospective, open-label, multicenter randomized controlled clinical study</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49263\">ChiCTR2000029741</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49131\">ChiCTR2000029768</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>Optimization of treatment and diagnosis plan for critically ill patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49161\">ChiCTR2000029806</a></td></tr><tr><td>2020-02-12</td><td><strong><a href=\"/drugs/DB14776\">Camrelizumab</a></strong></td><td>Optimization of treatment and diagnosis plan for critically ill patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49161\">ChiCTR2000029806</a></td></tr><tr><td>2020-02-11</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>The Single Oral Favipiravir for Patients with Delayed SARS-Cov-2 viral RNA Clearance</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=54278\">ChiCTR2000033491</a></td></tr><tr><td>2020-02-11</td><td><strong><a href=\"/drugs/DB15749\">Interferon Kappa</a></strong></td><td>Clinical study of novel coronavirus (SARS-Cov-2) infection treated with aerosol inhalation (IFN-? plus anti-inflammatory factor TFF2)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50136\">ChiCTR2000030262</a></td></tr><tr><td>2020-02-11</td><td><strong><a href=\"/drugs/DB15750\">Trefoil Factor 2</a></strong></td><td>Clinical study of novel coronavirus (SARS-Cov-2) infection treated with aerosol inhalation (IFN-? plus anti-inflammatory factor TFF2)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50136\">ChiCTR2000030262</a></td></tr><tr><td>2020-02-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19) : a randomized controlled, open label, multicenter trial</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49524\">ChiCTR2000029868</a></td></tr><tr><td>2020-02-11</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49317\">ChiCTR2000029740</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB15752\">Recombinant Super-Compound Interferon</a></strong></td><td>A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus (2019-nCoV) Pneumonia</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49224\">ChiCTR2000029638</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>Protective Effect of Aspirin on COVID-19 Patients</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04365309\">NCT04365309</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An Open-label Randomized Controlled Trial on Lopinavir / Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir / Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04276688\">NCT04276688</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An Open-label Randomized Controlled Trial on Lopinavir / Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir / Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04276688\">NCT04276688</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>An Open-label Randomized Controlled Trial on Lopinavir / Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir / Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04276688\">NCT04276688</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>An Open-label Randomized Controlled Trial on Lopinavir / Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir / Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04276688\">NCT04276688</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51265\">ChiCTR2000030946</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00975\">Dipyridamole</a></strong></td><td>Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)</td><td>Basic Science</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49864\">ChiCTR2000030055</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB14707\">Cemiplimab</a></strong></td><td>Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04268537\">NCT04268537</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB09035\">Nivolumab</a></strong></td><td>Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04268537\">NCT04268537</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04268537\">NCT04268537</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB09037\">Pembrolizumab</a></strong></td><td>Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04268537\">NCT04268537</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49409\">ChiCTR2000029765</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49145\">ChiCTR2000029609</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49145\">ChiCTR2000029609</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49145\">ChiCTR2000029609</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49612\">ChiCTR2000029939</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04261426\">NCT04261426</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB09065\">Cobicistat</a></strong></td><td>A randomised, open, controlled trial for darunavir / cobicistat or Lopinavir / ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48992\">ChiCTR2000029541</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A randomised, open, controlled trial for darunavir / cobicistat or Lopinavir / ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48992\">ChiCTR2000029541</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB01264\">Darunavir</a></strong></td><td>A randomised, open, controlled trial for darunavir / cobicistat or Lopinavir / ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48992\">ChiCTR2000029541</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>A randomised, open, controlled trial for darunavir / cobicistat or Lopinavir / ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48992\">ChiCTR2000029541</a></td></tr><tr><td>2020-02-10</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A randomised, open, controlled trial for darunavir / cobicistat or Lopinavir / ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48992\">ChiCTR2000029541</a></td></tr><tr><td>2020-02-09</td><td><strong><a href=\"/drugs/DB00203\">Sildenafil</a></strong></td><td>A Pilot Study of Sildenafi in the Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04304313\">NCT04304313</a></td></tr><tr><td>2020-02-09</td><td><strong><a href=\"/drugs/DB15748\">Viral Macrophage-Inflammatory Protein</a></strong></td><td>Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19) : a single arm clinical trial</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49215\">ChiCTR2000029636</a></td></tr><tr><td>2020-02-08</td><td><strong><a href=\"/drugs/DB04115\">Berberine</a></strong></td><td>The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04479202\">NCT04479202</a></td></tr><tr><td>2020-02-08</td><td><strong><a href=\"/drugs/DB13654\">Montmorillonite</a></strong></td><td>The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04479202\">NCT04479202</a></td></tr><tr><td>2020-02-07</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff</td><td>Basic Science</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49069\">ChiCTR2000029592</a></td></tr><tr><td>2020-02-07</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49861\">ChiCTR2000030046</a></td></tr><tr><td>2020-02-07</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49165\">ChiCTR2000029621</a></td></tr><tr><td>2020-02-07</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09 / Ritonavir and Lopinavir / Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04261907\">NCT04261907</a></td></tr><tr><td>2020-02-07</td><td><strong><a href=\"/drugs/DB15623\">TMC-310911</a></strong></td><td>A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09 / Ritonavir and Lopinavir / Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04261907\">NCT04261907</a></td></tr><tr><td>2020-02-07</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09 / Ritonavir and Lopinavir / Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04261907\">NCT04261907</a></td></tr><tr><td>2020-02-07</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04260594\">NCT04260594</a></td></tr><tr><td>2020-02-07</td><td><strong><a href=\"/drugs/DB14280\">Lonicera caprifolium flower</a></strong></td><td>A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection</td><td>Treatment</td><td>0</td><td>Unknown Status</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49502\">ChiCTR2000029822</a></td></tr><tr><td>2020-02-06</td><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04257656\">NCT04257656</a></td></tr><tr><td>2020-02-06</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04261517\">NCT04261517</a></td></tr><tr><td>2020-02-06</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49812\">ChiCTR2000030020</a></td></tr><tr><td>2020-02-06</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection</td><td>Prevention</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04269525\">NCT04269525</a></td></tr><tr><td>2020-02-06</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09 / Ritonavir and Lopinavir / Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49075\">ChiCTR2000029603</a></td></tr><tr><td>2020-02-06</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09 / Ritonavir and Lopinavir / Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49075\">ChiCTR2000029603</a></td></tr><tr><td>2020-02-06</td><td><strong><a href=\"/drugs/DB15623\">TMC-310911</a></strong></td><td>A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09 / Ritonavir and Lopinavir / Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49075\">ChiCTR2000029603</a></td></tr><tr><td>2020-02-06</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49607\">ChiCTR2000029935</a></td></tr><tr><td>2020-02-05</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>High dose intravenous vitamin C might be used as an important rescue therapy for aggravation of severe and critical novel coronavirus pneumonia (COVID-19) patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53389\">ChiCTR2000032716</a></td></tr><tr><td>2020-02-05</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19)</td><td>Diagnostic</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51813\">ChiCTR2000031428</a></td></tr><tr><td>2020-02-05</td><td><strong><a href=\"/drugs/DB15745\">Washed Microbiota Transplantation</a></strong></td><td>Washed Microbiota Transplantation for Patients With 2019-nCoV Infection : a Randomized, Double-blind, Placebo-controlled Study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04251767\">NCT04251767</a></td></tr><tr><td>2020-02-05</td><td><strong><a href=\"/drugs/DB15724\">Human umbilical cord blood mononuclear cell-conditioned medium</a></strong></td><td>Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19) : a randomized controlled trial</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49062\">ChiCTR2000029569</a></td></tr><tr><td>2020-02-05</td><td><strong><a href=\"/drugs/DB15723\">Umbilical Cord Blood Hematopoietic Stem Cells</a></strong></td><td>Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19) : a randomized controlled clinical trial</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=41760\">ChiCTR2000029572</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB04951\">Pirfenidone</a></strong></td><td>A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04282902\">NCT04282902</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB05441\">AVAC</a></strong></td><td>Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49799\">ChiCTR2000030016</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48991\">ChiCTR2000029539</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48991\">ChiCTR2000029539</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49013\">ChiCTR2000029544</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB13997\">Baloxavir marboxil</a></strong></td><td>A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49013\">ChiCTR2000029544</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB13997\">Baloxavir marboxil</a></strong></td><td>Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49015\">ChiCTR2000029548</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49015\">ChiCTR2000029548</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49015\">ChiCTR2000029548</a></td></tr><tr><td>2020-02-04</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49015\">ChiCTR2000029548</a></td></tr><tr><td>2020-02-03</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48968\">ChiCTR2000029542</a></td></tr><tr><td>2020-02-02</td><td><strong><a href=\"/drugs/DB15743\">Stem-cell derived exosome vesicle products</a></strong></td><td>HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50263\">ChiCTR2000030484</a></td></tr><tr><td>2020-02-02</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50263\">ChiCTR2000030484</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by SARS CoV-2 in OECD Countries?</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04468802\">NCT04468802</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04339660\">NCT04339660</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>1</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51904\">ChiCTR2000031494</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB15736\">Alunacedase alfa</a></strong></td><td>A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04287686\">NCT04287686</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>An Open, Prospective / Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04263402\">NCT04263402</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB15623\">TMC-310911</a></strong></td><td>A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09 / Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04261270\">NCT04261270</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09 / Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04261270\">NCT04261270</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09 / Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04261270\">NCT04261270</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>An Open, Prospective / Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir / Ritonavir) in the Treatment of 2019-nCoV Pneumonia.</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04255017\">NCT04255017</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>An Open, Prospective / Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir / Ritonavir) in the Treatment of 2019-nCoV Pneumonia.</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04255017\">NCT04255017</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>An Open, Prospective / Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir / Ritonavir) in the Treatment of 2019-nCoV Pneumonia.</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04255017\">NCT04255017</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>An Open, Prospective / Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir / Ritonavir) in the Treatment of 2019-nCoV Pneumonia.</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04255017\">NCT04255017</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>An Open, Prospective / Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04254874\">NCT04254874</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB00051\">Adalimumab</a></strong></td><td>Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19) : A prospective, single-center, randomized, parallel controlled trial</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50693\">ChiCTR2000030580</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19) : A prospective, single-center, randomized, parallel controlled trial</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50693\">ChiCTR2000030580</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB12038\">Ulinastatin</a></strong></td><td>Retrospective study for the efficacy of ulinastatin combined with &#39;&#39;clear lung detoxification soup&#39;&#39; in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Basic Science</td><td>1</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51029\">ChiCTR2000030806</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB00633\">Dexmedetomidine</a></strong></td><td>Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51081\">ChiCTR2000030853</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB14312\">Glycyrrhiza glabra</a></strong></td><td>To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50487\">ChiCTR2000030490</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB10675\">Licorice</a></strong></td><td>To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50487\">ChiCTR2000030490</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Study on the application of convalescent plasma therapy in severe COVID-19</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50727\">ChiCTR2000030627</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49901\">ChiCTR2000030116</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>The early use of lopinavir / litonavir (LPV / r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19) : a real-world study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48919\">ChiCTR2000029468</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>The early use of lopinavir / litonavir (LPV / r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19) : a real-world study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48919\">ChiCTR2000029468</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB09299\">Tenofovir alafenamide</a></strong></td><td>The early use of lopinavir / litonavir (LPV / r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19) : a real-world study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48919\">ChiCTR2000029468</a></td></tr><tr><td>2020-02-01</td><td><strong><a href=\"/drugs/DB00879\">Emtricitabine</a></strong></td><td>The early use of lopinavir / litonavir (LPV / r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19) : a real-world study</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48919\">ChiCTR2000029468</a></td></tr><tr><td>2020-01-31</td><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells : a prospective, single blind, randomized controlled clinical trial</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49088\">ChiCTR2000029580</a></td></tr><tr><td>2020-01-31</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells : a prospective, single blind, randomized controlled clinical trial</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49088\">ChiCTR2000029580</a></td></tr><tr><td>2020-01-31</td><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48880\">ChiCTR2000029559</a></td></tr><tr><td>2020-01-30</td><td><strong><a href=\"/drugs/DB01264\">Darunavir</a></strong></td><td>Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04252274\">NCT04252274</a></td></tr><tr><td>2020-01-30</td><td><strong><a href=\"/drugs/DB09065\">Cobicistat</a></strong></td><td>Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04252274\">NCT04252274</a></td></tr><tr><td>2020-01-30</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of 2019 novel coronavirus-infected pneumonia</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49420\">ChiCTR2000031204</a></td></tr><tr><td>2020-01-30</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)</td><td>Treatment</td><td>1, 2</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49674\">ChiCTR2000029990</a></td></tr><tr><td>2020-01-30</td><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49042\">ChiCTR2000029600</a></td></tr><tr><td>2020-01-29</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Convalescent Plasma in the treatment of 6 COVID-19 Patients</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=53859\">ChiCTR2000033056</a></td></tr><tr><td>2020-01-29</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48809\">ChiCTR2000029496</a></td></tr><tr><td>2020-01-29</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>4</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48809\">ChiCTR2000029496</a></td></tr><tr><td>2020-01-29</td><td><strong><a href=\"/drugs/DB14345\">Forsythia suspensa fruit</a></strong></td><td>Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48775\">ChiCTR2000029550</a></td></tr><tr><td>2020-01-29</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>A study on treatment strategies of novel coronavirus pnueumonia patients</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48777\">ChiCTR2000029386</a></td></tr><tr><td>2020-01-29</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48824\">ChiCTR2000029400</a></td></tr><tr><td>2020-01-29</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48824\">ChiCTR2000029400</a></td></tr><tr><td>2020-01-29</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48907\">ChiCTR2000029431</a></td></tr><tr><td>2020-01-28</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04252885\">NCT04252885</a></td></tr><tr><td>2020-01-28</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04252885\">NCT04252885</a></td></tr><tr><td>2020-01-28</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04252885\">NCT04252885</a></td></tr><tr><td>2020-01-27</td><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04252118\">NCT04252118</a></td></tr><tr><td>2020-01-27</td><td><strong><a href=\"/drugs/DB15734\">Human Embryonic Stem Cell-derived M Cell</a></strong></td><td>Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04331613\">NCT04331613</a></td></tr><tr><td>2020-01-26</td><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19 : a Prospective, Randomized Controlled Trial</td><td>Treatment</td><td>2, 3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04244591\">NCT04244591</a></td></tr><tr><td>2020-01-25</td><td><strong><a href=\"/drugs/DB01129\">Rabeprazole</a></strong></td><td>Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51693\">ChiCTR2000031454</a></td></tr><tr><td>2020-01-25</td><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51693\">ChiCTR2000031454</a></td></tr><tr><td>2020-01-25</td><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir / ritonavir plus interferon-alpha and ribavirin plus lopinavir / ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48782\">ChiCTR2000029387</a></td></tr><tr><td>2020-01-25</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir / ritonavir plus interferon-alpha and ribavirin plus lopinavir / ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48782\">ChiCTR2000029387</a></td></tr><tr><td>2020-01-25</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir / ritonavir plus interferon-alpha and ribavirin plus lopinavir / ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48782\">ChiCTR2000029387</a></td></tr><tr><td>2020-01-25</td><td><strong><a href=\"/drugs/DB15738\">Human Menstrual Blood-derived Stem Cells</a></strong></td><td>Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=49146\">ChiCTR2000029606</a></td></tr><tr><td>2020-01-25</td><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04246242\">NCT04246242</a></td></tr><tr><td>2020-01-23</td><td><strong><a href=\"/drugs/DB15313\">DAS-181</a></strong></td><td>A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects - STOP PIV - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004318-16\">EUCTR2018-004318-16-DK</a></td></tr><tr><td>2020-01-22</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A clinical multicenter study on the occurrence, development and prognosis of 2019 ncov infection</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51083\">ChiCTR2000030854</a></td></tr><tr><td>2020-01-22</td><td><strong><a href=\"/drugs/DB00105\">Interferon alfa-2b</a></strong></td><td>A clinical multicenter study on the occurrence, development and prognosis of 2019 ncov infection</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51083\">ChiCTR2000030854</a></td></tr><tr><td>2020-01-22</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A clinical multicenter study on the occurrence, development and prognosis of 2019 ncov infection</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51083\">ChiCTR2000030854</a></td></tr><tr><td>2020-01-22</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Study of Pinavir / Ritonavir Tablets (Trade Name : Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50115\">ChiCTR2000030218</a></td></tr><tr><td>2020-01-22</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Study of Pinavir / Ritonavir Tablets (Trade Name : Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=50115\">ChiCTR2000030218</a></td></tr><tr><td>2020-01-21</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Effects of Hydrogen / Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea : A Multicenter, Open-label Clinical Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04378712\">NCT04378712</a></td></tr><tr><td>2020-01-21</td><td><strong><a href=\"/drugs/DB15127\">Hydrogen</a></strong></td><td>Effects of Hydrogen / Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea : A Multicenter, Open-label Clinical Trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04378712\">NCT04378712</a></td></tr><tr><td>2020-01-21</td><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area</td><td>Prevention</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04320238\">NCT04320238</a></td></tr><tr><td>2020-01-20</td><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>the efficacy and safety of heparin in the treatment of novel coronavirus pneumonia (COVID-19) : a prospective, randomized, controlled trial</td><td>Treatment</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=55775\">ChiCTR2000034796</a></td></tr><tr><td>2020-01-20</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Early warning model and new biomarker of severe novel coronavirus pneumonia (COVID-19)</td><td>Diagnostic</td><td>0</td><td>Active Not Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52875\">ChiCTR2000032460</a></td></tr><tr><td>2020-01-20</td><td><strong><a href=\"/drugs/DB14336\">Angelica sinensis root</a></strong></td><td>Clinical study for Danggui Shaoyao Powder in the treatment of novel coronavirus pneumonia (COVID-19)</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52477\">ChiCTR2000032098</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00584\">Enalapril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00519\">Trandolapril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00881\">Quinapril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB01197\">Captopril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00492\">Fosinopril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00722\">Lisinopril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB13919\">Candesartan</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00876\">Eprosartan</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00542\">Benazepril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB01029\">Irbesartan</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00790\">Perindopril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00178\">Ramipril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00275\">Olmesartan</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00177\">Valsartan</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB08822\">Azilsartan medoxomil</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-19</td><td><strong><a href=\"/drugs/DB00691\">Moexipril</a></strong></td><td>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04467931\">NCT04467931</a></td></tr><tr><td>2020-01-17</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Serum and urine proteins and metabolomic markers in patients with COVID-19</td><td>Diagnostic</td><td>0</td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51694\">ChiCTR2000031365</a></td></tr><tr><td>2020-01-10</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51112\">ChiCTR2000031196</a></td></tr><tr><td>2020-01-10</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=51112\">ChiCTR2000031196</a></td></tr><tr><td>2020-01-10</td><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48684\">ChiCTR2000029308</a></td></tr><tr><td>2020-01-10</td><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=48684\">ChiCTR2000029308</a></td></tr><tr><td>2020-01-01</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19) : a prospective, randomize, controlled trial</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Recruiting</td><td><a href=\"http://www.chictr.org.cn/showprojen.aspx?proj=52958\">ChiCTR2000032400</a></td></tr><tr><td>2020-01-01</td><td><strong><a href=\"/drugs/DB14312\">Glycyrrhiza glabra</a></strong></td><td>Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine</td><td>Prevention</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04487964\">NCT04487964</a></td></tr><tr><td>2019-12-13</td><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>Incidence and pathogenesis of invasive aspergillosis in intensive care patients with severe influenza or COVID-19 (AspiFlu)</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"http://isrctn.com/ISRCTN51287266\">ISRCTN51287266</a></td></tr><tr><td>2019-12-10</td><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>Phase 1 / 2 clinical study to assess the feasibility, safety, tolerability and preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome. (included patients COVID-19)</td><td>Treatment</td><td>1</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002688-89\">EUCTR2019-002688-89-ES</a></td></tr><tr><td>2019-10-30</td><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>A Phase II Study of IL-1 Receptor Antagonist Anakinra to Prevent Severe Neurotoxicity and Cytokine Release Syndrome in Patients Receiving CD19-Specific Chimeric Antigen Receptor (CAR) T Cells And to Treat Systemic Inflammation Associated With COVID-19</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04148430\">NCT04148430</a></td></tr><tr><td>2019-10-02</td><td><strong><a href=\"/drugs/DB14459\">Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated)</a></strong></td><td>Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine</td><td>Basic Science</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04025580\">NCT04025580</a></td></tr><tr><td>2019-10-02</td><td><strong><a href=\"/drugs/DB14460\">Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (propiolactone inactivated)</a></strong></td><td>Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine</td><td>Basic Science</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04025580\">NCT04025580</a></td></tr><tr><td>2019-10-02</td><td><strong><a href=\"/drugs/DB15516\">Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (formaldehyde inactivated)</a></strong></td><td>Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine</td><td>Basic Science</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04025580\">NCT04025580</a></td></tr><tr><td>2019-10-02</td><td><strong><a href=\"/drugs/DB16518\">Influenza A virus A/South Australia/55/2014 live (attenuated) antigen</a></strong></td><td>Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine</td><td>Basic Science</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04025580\">NCT04025580</a></td></tr><tr><td>2019-10-02</td><td><strong><a href=\"/drugs/DB16517\">Influenza A virus A/Brisbane/10/2010 live (attenuated) antigen</a></strong></td><td>Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine</td><td>Basic Science</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04025580\">NCT04025580</a></td></tr><tr><td>2019-10-02</td><td><strong><a href=\"/drugs/DB14559\">Influenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated)</a></strong></td><td>Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine</td><td>Basic Science</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04025580\">NCT04025580</a></td></tr><tr><td>2019-10-02</td><td><strong><a href=\"/drugs/DB15515\">Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated)</a></strong></td><td>Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine</td><td>Basic Science</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04025580\">NCT04025580</a></td></tr><tr><td>2019-10-02</td><td><strong><a href=\"/drugs/DB11002\">Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated)</a></strong></td><td>Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine</td><td>Basic Science</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04025580\">NCT04025580</a></td></tr><tr><td>2019-10-02</td><td><strong><a href=\"/drugs/DB11037\">Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen</a></strong></td><td>Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine</td><td>Basic Science</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04025580\">NCT04025580</a></td></tr><tr><td>2019-05-05</td><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>Effect of intratracheal Injection of Processed Autologous Serum Derived from Patients with covid-19 in oxygenation parameters and pulmonary Complications</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"http://en.irct.ir/trial/47197\">IRCT20091012002582N21</a></td></tr><tr><td>2019-01-14</td><td><strong><a href=\"/drugs/DB00920\">Ketotifen</a></strong></td><td>Ketotifen : Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19</td><td>Basic Science</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04435028\">NCT04435028</a></td></tr><tr><td>2019-01-07</td><td><strong><a href=\"/drugs/DB15731\">Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells</a></strong></td><td>Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) : An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (COVID-19)</td><td>Treatment</td><td>1, 2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT03042143\">NCT03042143</a></td></tr><tr><td>2018-12-01</td><td><strong><a href=\"/drugs/DB14009\">Medical Cannabis</a></strong></td><td>Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19</td><td>Treatment</td><td>2</td><td>Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT03944447\">NCT03944447</a></td></tr><tr><td>2018-11-08</td><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>Lessening Organ Dysfunction With VITamin C (LOVIT)</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT03680274\">NCT03680274</a></td></tr><tr><td>2018-10-01</td><td><strong><a href=\"/drugs/DB06168\">Canakinumab</a></strong></td><td>Managed Access Program (MAP) to Provide Access to Canakinumab Treatment of Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia</td><td>Treatment</td><td><span class=\\'not-available\\'>Not Available</span></td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT04476706\">NCT04476706</a></td></tr><tr><td>2017-10-24</td><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults &amp; Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT03331445\">NCT03331445</a></td></tr><tr><td>2017-10-24</td><td><strong><a href=\"/drugs/DB09152\">Nitrogen</a></strong></td><td>An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults &amp; Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://clinicaltrials.gov/show/NCT03331445\">NCT03331445</a></td></tr><tr><td>2017-04-25</td><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>Handling oxygenation targets in adults with acute hypoxaemic respiratory failure in the intensive care unit : A randomised clinical trial of a lower versus a higher oxygenation target Addendum : Trial extension including only patients with SARS-CoV-2 positive tests (COVID-19) - Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU)</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000632-34\">EUCTR2017-000632-34-DK</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB00778\">Roxithromycin</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB00319\">Piperacillin</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB06590\">Ceftaroline fosamil</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB00199\">Erythromycin</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB01211\">Clarithromycin</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB01606\">Tazobactam</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB01137\">Levofloxacin</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB01212\">Ceftriaxone</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB00218\">Moxifloxacin</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td>2015-09-16</td><td><strong><a href=\"/drugs/DB00741\">Hydrocortisone</a></strong></td><td>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP</td><td>Treatment</td><td>4</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14\">EUCTR2015-002340-14-NL</a></td></tr><tr><td><span class=\\'not-available\\'>Not Available</span></td><td><strong><a href=\"/drugs/DB01909\">Alpha-Cyclodextrin (Cyclohexa-Amylose)</a></strong></td><td>A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or confirmed SARS-CoV-2 infection - SFX-01 treatment for Acute Respiratory Infections (STAR-Covid19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003486-19\">EUCTR2020-003486-19-GB</a></td></tr><tr><td><span class=\\'not-available\\'>Not Available</span></td><td><strong><a href=\"/drugs/DB12422\">Sulforaphane</a></strong></td><td>A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or confirmed SARS-CoV-2 infection - SFX-01 treatment for Acute Respiratory Infections (STAR-Covid19)</td><td>Treatment</td><td>2</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003486-19\">EUCTR2020-003486-19-GB</a></td></tr><tr><td><span class=\\'not-available\\'>Not Available</span></td><td><strong><a href=\"/drugs/DB01430\">Almitrine</a></strong></td><td>EFFICACY OF INTRAVENOUS ALMITRINE IN REDUCING THE NEED FOR MECHANICAL VENTILATION IN PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE DUE TO COVID-19-RELATED PNEUMONIA : A RANDOMIZED CONTROLLED DOUBLE-BLIND STUDYFROM THE SKIP-ICU CONSORTIUM - AIRVM COVID</td><td>Treatment</td><td>3</td><td>Active Not Recruiting</td><td><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001909-22\">EUCTR2020-001909-22-FR</a></td></tr></tbody></table></dd><dt class=\"col-xl-2 col-md-3 col-sm-4\" id=\"clinical-trial-summary-by-drug\">Clinical Trial Summary by Drug</dt><dd class=\"col-xl-10 col-md-9 col-sm-8\"><div class=\"anchor\" id=\"clinical-trials-count\"></div><table class=\"table table-sm datatable dt-responsive\" style=\"width: 100%\"><thead><tr><th class=\"date-head\">Drug</th><th class=\"name-head\">Count</th></tr></thead><tbody><tr><td><strong><a href=\"/drugs/DB01611\">Hydroxychloroquine</a></strong></td><td>300</td></tr><tr><td><strong><a href=\"/drugs/DB15692\">COVID-19 convalescent plasma</a></strong></td><td>198</td></tr><tr><td><strong><a href=\"/drugs/DB00503\">Ritonavir</a></strong></td><td>95</td></tr><tr><td><strong><a href=\"/drugs/DB06273\">Tocilizumab</a></strong></td><td>87</td></tr><tr><td><strong><a href=\"/drugs/DB01601\">Lopinavir</a></strong></td><td>87</td></tr><tr><td><strong><a href=\"/drugs/DB00207\">Azithromycin</a></strong></td><td>85</td></tr><tr><td><strong><a href=\"/drugs/DB00608\">Chloroquine</a></strong></td><td>65</td></tr><tr><td><strong><a href=\"/drugs/DB12466\">Favipiravir</a></strong></td><td>64</td></tr><tr><td><strong><a href=\"/drugs/DB00602\">Ivermectin</a></strong></td><td>64</td></tr><tr><td><strong><a href=\"/drugs/DB14761\">Remdesivir</a></strong></td><td>46</td></tr><tr><td><strong><a href=\"/drugs/DB00126\">Ascorbic acid</a></strong></td><td>44</td></tr><tr><td><strong><a href=\"/drugs/DB00959\">Methylprednisolone</a></strong></td><td>39</td></tr><tr><td><strong><a href=\"/drugs/DB15726\">Human Umbilical Cord Mesenchymal Stem Cells</a></strong></td><td>39</td></tr><tr><td><strong><a href=\"/drugs/DB13973\">Remestemcel-L</a></strong></td><td>38</td></tr><tr><td><strong><a href=\"/drugs/DB01109\">Heparin</a></strong></td><td>33</td></tr><tr><td><strong><a href=\"/drugs/DB01225\">Enoxaparin</a></strong></td><td>32</td></tr><tr><td><strong><a href=\"/drugs/DB12768\">BCG vaccine</a></strong></td><td>30</td></tr><tr><td><strong><a href=\"/drugs/DB01394\">Colchicine</a></strong></td><td>30</td></tr><tr><td><strong><a href=\"/drugs/DB08877\">Ruxolitinib</a></strong></td><td>28</td></tr><tr><td><strong><a href=\"/drugs/DB00026\">Anakinra</a></strong></td><td>27</td></tr><tr><td><strong><a href=\"/drugs/DB01234\">Dexamethasone</a></strong></td><td>27</td></tr><tr><td><strong><a href=\"/drugs/DB00028\">Human immunoglobulin G</a></strong></td><td>26</td></tr><tr><td><strong><a href=\"/drugs/DB00507\">Nitazoxanide</a></strong></td><td>25</td></tr><tr><td><strong><a href=\"/drugs/DB00060\">Interferon beta-1a</a></strong></td><td>23</td></tr><tr><td><strong><a href=\"/drugs/DB11094\">Vitamin D</a></strong></td><td>23</td></tr><tr><td><strong><a href=\"/drugs/DB14154\">Gold</a></strong></td><td>21</td></tr><tr><td><strong><a href=\"/drugs/DB08934\">Sofosbuvir</a></strong></td><td>21</td></tr><tr><td><strong><a href=\"/drugs/DB11767\">Sarilumab</a></strong></td><td>20</td></tr><tr><td><strong><a href=\"/drugs/DB13609\">Umifenovir</a></strong></td><td>20</td></tr><tr><td><strong><a href=\"/drugs/DB00435\">Nitric Oxide</a></strong></td><td>20</td></tr><tr><td><strong><a href=\"/drugs/DB00169\">Cholecalciferol</a></strong></td><td>19</td></tr><tr><td><strong><a href=\"/drugs/DB06812\">Povidone-iodine</a></strong></td><td>18</td></tr><tr><td><strong><a href=\"/drugs/DB01593\">Zinc</a></strong></td><td>17</td></tr><tr><td><strong><a href=\"/drugs/DB11817\">Baricitinib</a></strong></td><td>17</td></tr><tr><td><strong><a href=\"/drugs/DB00678\">Losartan</a></strong></td><td>16</td></tr><tr><td><strong><a href=\"/drugs/DB15656\">AstraZeneca COVID-19 Vaccine</a></strong></td><td>16</td></tr><tr><td><strong><a href=\"/drugs/DB09102\">Daclatasvir</a></strong></td><td>16</td></tr><tr><td><strong><a href=\"/drugs/DB15729\">Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins</a></strong></td><td>15</td></tr><tr><td><strong><a href=\"/drugs/DB00945\">Acetylsalicylic acid</a></strong></td><td>15</td></tr><tr><td><strong><a href=\"/drugs/DB01065\">Melatonin</a></strong></td><td>14</td></tr><tr><td><strong><a href=\"/drugs/DB00198\">Oseltamivir</a></strong></td><td>13</td></tr><tr><td><strong><a href=\"/drugs/DB06151\">Acetylcysteine</a></strong></td><td>13</td></tr><tr><td><strong><a href=\"/drugs/DB12510\">Ozone</a></strong></td><td>13</td></tr><tr><td><strong><a href=\"/drugs/DB13729\">Camostat</a></strong></td><td>13</td></tr><tr><td><strong><a href=\"/drugs/DB00068\">Interferon beta-1b</a></strong></td><td>12</td></tr><tr><td><strong><a href=\"/drugs/DB00254\">Doxycycline</a></strong></td><td>12</td></tr><tr><td><strong><a href=\"/drugs/DB09140\">Oxygen</a></strong></td><td>12</td></tr><tr><td><strong><a href=\"/drugs/DB00811\">Ribavirin</a></strong></td><td>12</td></tr><tr><td><strong><a href=\"/drugs/DB00003\">Dornase alfa</a></strong></td><td>11</td></tr><tr><td><strong><a href=\"/drugs/DB11672\">Curcumin</a></strong></td><td>11</td></tr><tr><td><strong><a href=\"/drugs/DB00091\">Cyclosporine</a></strong></td><td>10</td></tr><tr><td><strong><a href=\"/drugs/DB00619\">Imatinib</a></strong></td><td>10</td></tr><tr><td><strong><a href=\"/drugs/DB00966\">Telmisartan</a></strong></td><td>10</td></tr><tr><td><strong><a href=\"/drugs/DB15655\">Ad5-nCoV</a></strong></td><td>10</td></tr><tr><td><strong><a href=\"/drugs/DB00635\">Prednisone</a></strong></td><td>9</td></tr><tr><td><strong><a href=\"/drugs/DB04900\">Thymalfasin</a></strong></td><td>9</td></tr><tr><td><strong><a href=\"/drugs/DB01076\">Atorvastatin</a></strong></td><td>9</td></tr><tr><td><strong><a href=\"/drugs/DB09019\">Bromhexine</a></strong></td><td>9</td></tr><tr><td><strong><a href=\"/drugs/DB06228\">Rivaroxaban</a></strong></td><td>9</td></tr><tr><td><strong><a href=\"/drugs/DB11703\">Acalabrutinib</a></strong></td><td>9</td></tr><tr><td><strong><a href=\"/drugs/DB10315\">Measles virus vaccine live attenuated</a></strong></td><td>9</td></tr><tr><td><strong><a href=\"/drugs/DB06803\">Niclosamide</a></strong></td><td>9</td></tr><tr><td><strong><a href=\"/drugs/DB01222\">Budesonide</a></strong></td><td>9</td></tr><tr><td><strong><a href=\"/drugs/DB15446\">Vidofludimus</a></strong></td><td>8</td></tr><tr><td><strong><a href=\"/drugs/DB01410\">Ciclesonide</a></strong></td><td>8</td></tr><tr><td><strong><a href=\"/drugs/DB00741\">Hydrocortisone</a></strong></td><td>8</td></tr><tr><td><strong><a href=\"/drugs/DB12598\">Nafamostat</a></strong></td><td>8</td></tr><tr><td><strong><a href=\"/drugs/DB06168\">Canakinumab</a></strong></td><td>8</td></tr><tr><td><strong><a href=\"/drugs/DB12534\">Mavrilimumab</a></strong></td><td>8</td></tr><tr><td><strong><a href=\"/drugs/DB01072\">Atazanavir</a></strong></td><td>8</td></tr><tr><td><strong><a href=\"/drugs/DB09035\">Nivolumab</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB15801\">VPM1002</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB14999\">Human interferon beta</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB12849\">Clazakizumab</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB10675\">Licorice</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB14312\">Glycyrrhiza glabra</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB14276\">Turmeric</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB15798\">Mycobacterium w. Vaccine</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB11942\">Selinexor</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB11133\">Omega-3 fatty acids</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB11580\">Ravulizumab</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB10316\">Mumps virus strain B level jeryl lynn live antigen</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB10317\">Rubella virus vaccine</a></strong></td><td>7</td></tr><tr><td><strong><a href=\"/drugs/DB11779\">Danoprevir</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB09036\">Siltuximab</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB00848\">Levamisole</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB00788\">Naproxen</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB00177\">Valsartan</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB11997\">Interleukin-7</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB02709\">Resveratrol</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB01264\">Darunavir</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB00879\">Emtricitabine</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB00146\">Calcifediol</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB15743\">Stem-cell derived exosome vesicle products</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB15721\">Natural Killer Cell</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB14767\">Peginterferon lambda-1a</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB09153\">Sodium chloride</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB06822\">Tinzaparin</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB00105\">Interferon alfa-2b</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB15718\">Bamlanivimab</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB09274\">Artesunate</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB00927\">Famotidine</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB16360\">Anti-SARS-CoV-2 immunoglobulin</a></strong></td><td>6</td></tr><tr><td><strong><a href=\"/drugs/DB00860\">Prednisolone</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB04951\">Pirfenidone</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB00162\">Vitamin A</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB00983\">Formoterol</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB09037\">Pembrolizumab</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB15691\">Anti-SARS-CoV-2 REGN-COV2</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB09241\">Methylene blue</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB10520\">Cinnamon</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB15730\">Placental Mesenchymal Stem Cells</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB12764\">Opaganib</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB05258\">Interferon alfa</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB04932\">Defibrotide</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB06779\">Dalteparin</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB00746\">Deferoxamine</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB15857\">Janssen COVID-19 Vaccine</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB15737\">Dental Mesenchymal Pulp Stem Cells</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB01097\">Leflunomide</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB15862\">Inactivated SARS-Cov-2 Vaccine</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB00877\">Sirolimus</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB00009\">Alteplase</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB05974\">Transcrocetinate</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB12038\">Ulinastatin</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB11720\">Angiotensin 1-7</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB00982\">Isotretinoin</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB13132\">Artemisinin</a></strong></td><td>5</td></tr><tr><td><strong><a href=\"/drugs/DB15623\">TMC-310911</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00112\">Bevacizumab</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00633\">Dexmedetomidine</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB01197\">Captopril</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB01041\">Thalidomide</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00421\">Spironolactone</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB01236\">Sevoflurane</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB15661\">Molnupiravir</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB01257\">Eculizumab</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB11135\">Selenium</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB14317\">Pomegranate</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB14828\">ABX-464</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB15313\">DAS-181</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB10344\">Ginger</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB14509\">Lithium carbonate</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00020\">Sargramostim</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB01211\">Clarithromycin</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB14126\">Tenofovir</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB09027\">Ledipasvir</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB06260\">Aviptadil</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00151\">Cysteine</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00058\">Alpha-1-proteinase inhibitor</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00331\">Metformin</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB12386\">Bacillus calmette-guerin substrain danish 1331 live antigen</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB08895\">Tofacitinib</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB15810\">Nuvaxovid</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB15848\">Gam-COVID-Vac</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00898\">Ethanol</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00569\">Fondaparinux</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00471\">Montelukast</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00975\">Dipyridamole</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00051\">Adalimumab</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB00302\">Tranexamic acid</a></strong></td><td>4</td></tr><tr><td><strong><a href=\"/drugs/DB15127\">Hydrogen</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB09065\">Cobicistat</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15615\">Fennel</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00158\">Folic acid</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00115\">Cyanocobalamin</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15736\">Alunacedase alfa</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB16207\">Itolizumab</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB13941\">Piperaquine</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB08813\">Nadroparin</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15636\">Zilucoplan</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB14242\">Honey</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15751\">MRx-4DP0004</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00041\">Aldesleukin</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00328\">Indomethacin</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00753\">Isoflurane</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB01088\">Iloprost</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB13919\">Candesartan</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB11842\">Angiotensin II</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB04216\">Quercetin</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00062\">Albumin human</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00878\">Chlorhexidine</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB06761\">Beractant</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB12895\">TD-139</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB09061\">Cannabidiol</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15849\">SARS-CoV-2 Sclamp</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB08899\">Enzalutamide</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15695\">BNT162b1 SARS-CoV-2 Vaccine</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15806\">CoronaVac</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB09130\">Copper</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB09079\">Nintedanib</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15654\">Moderna COVID-19 Vaccine</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15753\">Interferon Gamma</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB14275\">Indian frankincense</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB06303\">Otilimab</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB14256\">Centella asiatica</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00758\">Clopidogrel</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB08887\">Icosapent ethyl</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15809\">CIGB-258 peptide</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB13281\">Bromelains</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00163\">Vitamin E</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00806\">Pentoxifylline</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB13156\">Inosine pranobex</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15893\">CHO Cells Recombinant Vaccine</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB09113\">Poractant alfa</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15148\">Lenzilumab</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB14352\">Azadirachta indica leaf</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00176\">Fluvoxamine</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15844\">CVnCoV</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB16529\">Biomodulin T</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB04835\">Maraviroc</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB11248\">Zinc gluconate</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00641\">Simvastatin</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB08882\">Linagliptin</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15735\">Virus Specific T-Cell</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB00477\">Chlorpromazine</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB12975\">Pyronaridine</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB15864\">Oral Polio Vaccine</a></strong></td><td>3</td></tr><tr><td><strong><a href=\"/drugs/DB13997\">Baloxavir marboxil</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB14707\">Cemiplimab</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00166\">Lipoic acid</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15734\">Human Embryonic Stem Cell-derived M Cell</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB14357\">Chamomile</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB13525\">Althea root</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB10763\">Urtica dioica pollen</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB16416\">Vilobelimab</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00864\">Tacrolimus</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB13293\">Ipecac</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB02701\">Nicotinamide</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB08868\">Fingolimod</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00358\">Mefloquine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB11091\">Hydrogen peroxide</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00584\">Enalapril</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00440\">Trimethoprim</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01015\">Sulfamethoxazole</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00300\">Tenofovir disoproxil</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB05941\">Leronlimab</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00818\">Propofol</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB04115\">Berberine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00319\">Piperacillin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01606\">Tazobactam</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09322\">Zinc sulfate</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15689\">Azoximer bromide</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15696\">Pfizer-BioNTech COVID-19 Vaccine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB14644\">Methylprednisolone hemisuccinate</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00831\">Trifluoperazine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB07615\">Tranilast</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15745\">Washed Microbiota Transplantation</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01118\">Amiodarone</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00661\">Verapamil</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00178\">Ramipril</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00056\">Gemtuzumab ozogamicin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15638\">Brensocatib</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00099\">Filgrastim</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01050\">Ibuprofen</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00630\">Alendronic acid</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00279\">Liothyronine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB11355\">Propolis wax</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01137\">Levofloxacin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01060\">Amoxicillin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00766\">Clavulanic acid</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15723\">Umbilical Cord Blood Hematopoietic Stem Cells</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15814\">COVID19 s-vax loaded autologous dendritic cell vaccine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00065\">Infliximab</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB06692\">Aprotinin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB06271\">Sulodexide</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01029\">Irbesartan</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00275\">Olmesartan</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00876\">Eprosartan</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15865\">Pentaglobin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB11073\">Cetylpyridinium</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01169\">Arsenic trioxide</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB13127\">Olokizumab</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB06546\">Atibuclimab</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15846\">Covax-19\\xe2\\x84\\xa2</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB16526\">BACTEK-R</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB16531\">KB109</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB06292\">Dapagliflozin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB14291\">Wormwood</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15863\">Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB05382\">Iodine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15693\">INO-4800</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01390\">Sodium bicarbonate</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00673\">Aprepitant</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01117\">Atovaquone</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09112\">Nitrous acid</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB16522\">Sodium copper chlorophyllin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09053\">Ibrutinib</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15304\">iota-Carrageenan</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01261\">Sitagliptin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15728\">Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB06196\">Icatibant</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09299\">Tenofovir alafenamide</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB10672\">Clove</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01281\">Abatacept</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB12610\">Ebselen</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00203\">Sildenafil</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00220\">Nelfinavir</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB12814\">Cepeginterferon alfa-2B</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB14810\">AZD-1656</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB14533\">Zinc chloride</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09298\">Silibinin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB16369\">Matrix-M</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01098\">Rosuvastatin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB12965\">Silver</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09145\">Water</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01075\">Diphenhydramine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB16533\">OM85</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15739\">Mesenchymoangioblast-derived mesenchymal stem cells</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB11758\">Cenicriviroc</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09029\">Secukinumab</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15160\">Asunercept</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB06605\">Apixaban</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15741\">Recombinant Bacterial ACE2 Receptors-like Enzyme</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00107\">Oxytocin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15327\">Abivertinib</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00675\">Tamoxifen</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00472\">Fluoxetine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15895\">XAV-19</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00613\">Amodiaquine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01430\">Almitrine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01132\">Pioglitazone</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB16442\">BNT162b3</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15871\">Human Amniotic Fluid</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09228\">Conestat alfa</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB14933\">Nicotinamide riboside</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00482\">Celecoxib</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB06174\">Noscapine</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB12525\">Molgramostim</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00031\">Tenecteplase</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00155\">Citrulline</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB08954\">Ifenprodil</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB11952\">Duvelisib</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09075\">Edoxaban</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB00755\">Tretinoin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB12592\">Mosedipimod</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB16357\">BGB-DXP593</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB14597\">Lanadelumab</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB16395\">Efineptakin alfa</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB09152\">Nitrogen</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB12665\">Isoquercetin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB10568\">Soybean</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB01128\">Bicalutamide</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15749\">Interferon Kappa</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB15750\">Trefoil Factor 2</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB07795\">Fisetin</a></strong></td><td>2</td></tr><tr><td><strong><a href=\"/drugs/DB12422\">Sulforaphane</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01909\">Alpha-Cyclodextrin (Cyclohexa-Amylose)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00218\">Moxifloxacin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01212\">Ceftriaxone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00199\">Erythromycin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06590\">Ceftaroline fosamil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00778\">Roxithromycin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14009\">Medical Cannabis</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15731\">Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00920\">Ketotifen</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11037\">Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11002\">Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15515\">Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14559\">Influenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16517\">Influenza A virus A/Brisbane/10/2010 live (attenuated) antigen</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16518\">Influenza A virus A/South Australia/55/2014 live (attenuated) antigen</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15516\">Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (formaldehyde inactivated)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14460\">Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (propiolactone inactivated)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14459\">Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00691\">Moexipril</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB08822\">Azilsartan medoxomil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00790\">Perindopril</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00542\">Benazepril</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00722\">Lisinopril</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00492\">Fosinopril</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00881\">Quinapril</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00519\">Trandolapril</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14336\">Angelica sinensis root</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15738\">Human Menstrual Blood-derived Stem Cells</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01129\">Rabeprazole</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14345\">Forsythia suspensa fruit</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05441\">AVAC</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15724\">Human umbilical cord blood mononuclear cell-conditioned medium</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14280\">Lonicera caprifolium flower</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13654\">Montmorillonite</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15748\">Viral Macrophage-Inflammatory Protein</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15752\">Recombinant Super-Compound Interferon</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14776\">Camrelizumab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15622\">Triazavirin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15813\">Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14364\">Scutellaria baicalensis root</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00008\">Peginterferon alfa-2a</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14287\">Trametes versicolor fruiting body</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04786\">Suramin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11742\">Ebastine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11638\">Artenimol</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00034\">Interferon alfa-2a</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB09275\">Bismuth subcitrate potassium</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14692\">Turmeric oil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00148\">Creatine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15803\">Dendritic cells vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB09026\">Aliskiren</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01115\">Nifedipine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14066\">Tetrandrine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11569\">Ixekizumab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00132\">alpha-Linolenic acid</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00825\">Levomenthol</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04224\">Oleic Acid</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14104\">Linoleic acid</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11874\">Crocin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16532\">LL-37</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04854\">Febuxostat</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01216\">Finasteride</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11238\">Borage oil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00497\">Oxycodone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15727\">NKG2D-ACE2 CAR-NK Cell</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15725\">IL15-NK Cell</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15907\">Escin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15804\">LV-SMENP Vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10667\">Tragacanth</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01167\">Itraconazole</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00005\">Etanercept</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15808\">CIGB 2020 Vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14585\">Plantago ovata seed</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14327\">Purslane</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06149\">Teicoplanin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14346\">Mentha arvensis top</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00381\">Amlodipine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12453\">Chlorine dioxide</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14724\">Emapalumab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00140\">Riboflavin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00152\">Thiamine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01783\">Pantothenic acid</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00165\">Pyridoxine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00121\">Biotin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13959\">Medium-chain triglycerides</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00338\">Omeprazole</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00545\">Pyridostigmine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10983\">Thyme</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15867\">Autologous Non-Hematopoietic Peripheral Blood Stem Cells</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11130\">Opium</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00775\">Tirofiban</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14545\">Hydrocortisone succinate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15121\">AT-001</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11613\">Velpatasvir</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11676\">Galidesivir</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11061\">Povidone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01190\">Clindamycin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01087\">Primaquine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12136\">Solnatide</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15280\">Gimsilumab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12580\">Tradipitant</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00159\">Icosapent</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06280\">Senicapoc</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01404\">Ginseng</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14325\">Schisandra chinensis fruit</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00796\">Candesartan cilexetil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12824\">Monalizumab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11598\">Antithrombin III human</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14240\">Echinacea</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00783\">Estradiol</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01017\">Minocycline</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15697\">BNT162a1 SARS-CoV-2 Vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15698\">BNT162c2 SARS-CoV-2 Vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00803\">Colistin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15733\">Lactobacillus coryniformis K8</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11803\">Sirukumab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15800\">VA-MENGOC-BC\\xc2\\xae</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12618\">Apocynin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00627\">Niacin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15688\">Vazegepant</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB09393\">Amino acids</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01914\">D-glucose</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00396\">Progesterone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15742\">MultiStem</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12411\">Bemcentinib</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15807\">BBIBP-CorV</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00704\">Naltrexone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01221\">Ketamine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01042\">Melphalan</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00213\">Pantoprazole</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00683\">Midazolam</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01392\">Yohimbine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00563\">Methotrexate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00343\">Diltiazem</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12668\">Metenkefalin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15687\">Tridecactide</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16530\">Dialyzable leukocyte extract</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01373\">Calcium</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14076\">Interleukin-1 alpha, human recombinant</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12880\">Interleukin-10</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14131\">Basic Fibroblast Growth Factor</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11526\">Masitinib</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10906\">Sugarcane</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB08826\">Deferiprone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12582\">Piperine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01744\">Camphor</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00281\">Lidocaine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13037\">Namilumab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12614\">Reparixin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06683\">Clevudine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00773\">Etoposide</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15740\">Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14991\">Nomacopan</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04977\">Plitidepsin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00457\">Prazosin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15722\">CYNK-001</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10506\">Barley</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15732\">FT516</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06415\">Calfactant</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14500\">Potassium</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB03904\">Urea</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14547\">Chloride ion</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15812\">V-SARS</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14566\">Lavender oil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13925\">Dotatate gallium Ga-68</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00316\">Acetaminophen</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15747\">CoviGlobulin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14690\">Ginger oil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11697\">Pacritinib</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00916\">Metronidazole</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00761\">Potassium chloride</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00143\">Glutathione</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04335\">Inosine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00295\">Morphine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06515\">Resiniferatoxin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04897\">Lucinactant</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05426\">Talactoferrin alfa</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13295\">Atracurium</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00565\">Cisatracurium</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13889\">Meningococcal polysaccharide vaccine group A</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13890\">Meningococcal polysaccharide vaccine group C</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13887\">Meningococcal polysaccharide vaccine group W-135</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13888\">Meningococcal polysaccharide vaccine group Y</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16523\">Deoxyribonuclease I</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB09258\">Bemiparin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00264\">Metoprolol</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06717\">Fosaprepitant</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15799\">LNP-nCoVsaRNA Vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15060\">Human interleukin-6</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04862\">Merimepodib</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15897\">Etesevimab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15891\">GX-19 Vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05463\">ISS-1018</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15805\">SCB-2019</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06817\">Raltegravir</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14952\">Pamrevlumab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12243\">Edaravone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00016\">Erythropoietin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13968\">Plasma protein fraction (human)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB03523\">Brequinar</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15850\">IMM-101</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15855\">SARS-CoV-2 mRNA vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10549\">Orange</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10683\">Spearmint</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00006\">Bivalirudin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB09154\">Sodium citrate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05076\">Fenretinide</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10984\">Peppermint</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15868\">Amniotic Epithelial Cells</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15856\">AG0301-COVID19</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10517\">Celery</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15566\">Prednisolone acetate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00193\">Tramadol</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10804\">Bacillus calmette-guerin substrain connaught live antigen</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15802\">AV-COVID-19</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14803\">AMY-101</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15629\">Garadacimab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06209\">Prasugrel</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04703\">Hesperidin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB08995\">Diosmin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01126\">Dutasteride</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06403\">Ambrisentan</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15035\">Zanubrutinib</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06699\">Degarelix</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05173\">PTC299</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12010\">Fostamatinib</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15271\">Crizanlizumab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15852\">Coronavirus-Like Particle COVID-19 Vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11651\">Dactolisib</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16398\">Efmarodocokin alfa</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16386\">Astegolimab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05768\">Alkaline Phosphatase</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15892\">ZYCOV-D</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15847\">BBV152</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00845\">Clofazimine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10543\">Cow milk</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05611\">Apilimod</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15870\">Probiorinse</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00764\">Mometasone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16520\">COVID-19 Spike-GM-CSF Protein Lactated Ringer&#39;s Injection</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06243\">Eflornithine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15744\">CAP-1002</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10755\">Taraxacum officinale pollen</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14342\">Taraxacum officinale leaf</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14940\">Aspartyl-alanyl-diketopiperazine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16363\">PlasmaCord</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00653\">Magnesium sulfate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16439\">EpiVacCorona</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10557\">Black pepper</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04743\">Nimesulide</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15853\">RUTI\\xc2\\xae Vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15746\">Recombinant Human Plasma Gelsolin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11590\">Thimerosal</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05676\">Apremilast</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16424\">Allocetra</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB02285\">Protoporphyrin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11189\">Magnesium glycinate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14936\">Menaquinone 6</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14513\">Magnesium</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00170\">Menadione</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15664\">Vitamin K7</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00443\">Betamethasone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15869\">Platelet Lysate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13906\">Aloe vera leaf</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16358\">MW33</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14512\">Mometasone furoate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16430\">TMV-083</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16428\">GRAd-COV2</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01240\">Epoprostenol</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14586\">Citrus bioflavonoids</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB03614\">Mecobalamin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11154\">Zinc citrate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15787\">AZD7442</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01039\">Fenofibrate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16525\">Collagen-polyvinylpyrrolidone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11360\">Lactobacillus plantarum</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16563\">Pediococcus acidilactici</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00145\">Glycine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12255\">Vadadustat</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16431\">Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01093\">Dimethyl sulfoxide</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10532\">Garlic</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16524\">FINLAY-FR-1</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16436\">AdimrSC-2f</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16355\">Sotrovimab</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16438\">V591</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12270\">Losmapimod</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16443\">Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06210\">Eltrombopag</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16364\">Recombinant Human Thrombopoietin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16435\">AG0302-COVID19</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13961\">Fish oil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16597\">Artemisia annua leaf</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13771\">Ferric sodium citrate</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00855\">Aminolevulinic acid</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16423\">AK119</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB09122\">Peginterferon beta-1a</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00980\">Ramelteon</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16353\">Razuprotafib</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01645\">Genistein</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16359\">CSL324</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16367\">Autologous peripheral blood-derived CD34+ cells</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00822\">Disulfiram</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB13924\">Varicella zoster vaccine (recombinant)</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00539\">Toremifene</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00618\">Demeclocycline</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16433\">VXA-CoV2-1</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05266\">Ibudilast</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16427\">SARS-CoV-2 vaccine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01323\">St. John&#39;s Wort</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16425\">Rintatolimod</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16365\">Treamid</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05983\">Bardoxolone methyl</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16519\">Zofin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16354\">Avasopasem manganese</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10548\">Onion</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01262\">Decitabine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16361\">Descartes-30</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16521\">Prolectin-M</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15854\">MVC-COV1901</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12612\">Ozanimod</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16356\">Anti-SARS-CoV-2 IgY</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16441\">QazCovid-in</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00468\">Quinine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12326\">Antroquinonol</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00133\">Serine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00583\">Levocarnitine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11114\">Eucalyptus oil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10859\">Melilotus officinalis pollen</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB14358\">Tribulus terrestris</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16130\">Dapansutrile</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16444\">UB-612</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15866\">CK0802</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15859\">NasoVAX</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16429\">CoVac-1</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB12160\">Bucillamine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB03823\">Epigallocatechin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00770\">Alprostadil</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11863\">Alvelestat</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06713\">Norelgestromin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00977\">Ethinylestradiol</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15811\">BacTRL-spike</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00278\">Argatroban</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB06608\">Tafenoquine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16432\">MVA-SARS-2-S</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB05511\">Piclidenoson</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16366\">F-652</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16368\">Anti-SARS-CoV-2 equine immunoglobulin fragments</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16437\">V590</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00052\">Somatotropin</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00480\">Lenalidomide</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10544\">Cultivated mushroom</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB10572\">Corn</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB11859\">Brexanolone</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB00313\">Valproic acid</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB01224\">Quetiapine</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB04968\">PH94B</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15858\">KBP-COVID-19</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB15890\">RAPA-501-Allo</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16434\">IN01</a></strong></td><td>1</td></tr><tr><td><strong><a href=\"/drugs/DB16445\">ChulaCov19 mRNA vaccine</a></strong></td><td>1</td></tr></tbody></table></dd><dt class=\"col-xl-2 col-md-3 col-sm-4\" id=\"publications-using-drugbank\">Publications using DrugBank</dt><dd class=\"col-xl-10 col-md-9 col-sm-8\"><div class=\"anchor\" id=\"publications\"></div><p>The table below highlights current and/or recent research relating to COVID-19 that cites the use of DrugBank.</p><div class=\"alert alert-danger\"><strong>Disclaimer:</strong> These publications may be early-access, and may not have been peer reviewed.</div><table class=\"table table-sm datatable dt-responsive\" style=\"width: 100%\"><thead><tr><th class=\"date-head\">Publication</th></tr></thead><tbody><tr><td><a target=\"_blank\" href=\"https://www.psikiyatri.org.tr/uploadFiles/2432020153314-psikotropetkilesimCOVID.pdf\">Alt\\xc4\\xb1nyazar V. COV\\xc4\\xb0D-19 TEDAV\\xc4\\xb0S\\xc4\\xb0NDE \\xc3\\x96NER\\xc4\\xb0LEN \\xc4\\xb0LA\\xc3\\x87LARIN PS\\xc4\\xb0KOTROPLARLA ETK\\xc4\\xb0LE\\xc5\\x9e\\xc4\\xb0MLER\\xc4\\xb0. 2020</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/files/21739182.pdf&amp;hl=en&amp;sa=X&amp;d=11806981192181434833&amp;scisig=AAGBfm2Cu3eYg6-KQtboo8RVdA50yLHH1w&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Arya R, Das A, Prashar V, Kumar M. Potential inhibitors against papain-like protease of novel coronavirus (COVID-19) from FDA approved drugs.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.researchgate.net/profile/Peter_Fedichev/publication/339998830_AI_for_the_repurposing_of_approved_or_investigational_drugs_against_COVID-19/links/5e71c42d299bf1571845af01/AI-for-the-repurposing-of-approved-or-investigational-drugs-against-COVID-19.pdf?_sg%5B0%5D=VhRsLOgYH807Dtm0OgE6OXbbwX7zmcDNMgQLWSjWTa2Q1jpSE0SdELoqZ1l8-hpvBFwQ0PFAmZz7MpA6SeGMZg.y0kcYUy_Pqapa7khCgaXMhHUw3AQSQs8Z6-mB1wC8_3Oo6FYVWuIOQnr6yhV8ZXwtSfQRsKrPWe1H6pqoK9d2Q&amp;_sg%5B1%5D=IByAEqvNyMNmXkrazP-TZE2-o4WAnnGqXl6HVTCsSLCrvRnIpLY4EuSKGvu7E-d7ioGQ3HvjOi7-8iHjO04mfwBC7UUwUuvhfaneu8lKSTPx.y0kcYUy_Pqapa7khCgaXMhHUw3AQSQs8Z6-mB1wC8_3Oo6FYVWuIOQnr6yhV8ZXwtSfQRsKrPWe1H6pqoK9d2Q&amp;_iepl=\">Avchaciov K, Burmistrova O, Fedichev P. AI for the repurposing of approved or investigational drugs against COVID-19. 2020 March.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/ndownloader/files/22123341&amp;hl=en&amp;sa=X&amp;d=2471529799573911854&amp;scisig=AAGBfm1sFMBeHZ4-eRmXt_oZnvlVq5d_BQ&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Bag A, Bag A. Justicia adhatoda leaves extract is a strong remedy for COVID-19 - Case report analysis and docking based study.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/ndownloader/files/22218153&amp;hl=en&amp;sa=X&amp;d=429755042712603511&amp;scisig=AAGBfm2vuoekjFF7HXGYoBeM0bOvxL_DZA&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Balasubramaniam M, Reis RJS. Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.sciencedirect.com/science/article/pii/S2001037020300490&amp;hl=en&amp;sa=X&amp;d=10699939541677289718&amp;scisig=AAGBfm1DiI3grsGLG1fumxJzdYP_ZtHkGw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. 2020 March.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.sciencedirect.com/science/article/pii/S1477893920301162&amp;hl=en&amp;sa=X&amp;d=13337706888326443664&amp;scisig=AAGBfm095FCHRX7qYnjoqH-eT0KRGkMWQw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Cao Y, Deng Q, Dai S. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19 : An evaluation of the evidence. Travel Med Infect Dis. 2020 April.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/articles/On_the_Generation_of_Novel_Ligands_for_SARS-CoV-2_Protease_and_ACE2_Receptor_via_Constrained_Graph_Variational_Autoencoders/12011157/files/22067451.pdf&amp;hl=en&amp;sa=X&amp;d=1709112337425263538&amp;scisig=AAGBfm3BpmLota5Zs34znnG39_yHfPDYxw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Catapang JK, Billones JB. On the generation of novel ligands for SARS-CoV-2 protease and ACE2 receptor via constrained graph variational autoencoders. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/ndownloader/files/22162401&amp;hl=en&amp;sa=X&amp;d=9219589978457237833&amp;scisig=AAGBfm1iFAraWn3jWHWtBwrZMlFb557hrQ&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Chakraborti S, Srinivasan N. Drug repurposing approach targeted against main protease of SARS-CoV-2 exploiting &#39;neighbourhood behaviour&#39; in 3D protein structural space and 2D chemical space of small molecules.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://europepmc.org/article/ppr/ppr149058&amp;hl=en&amp;sa=X&amp;d=10870180216625520579&amp;scisig=AAGBfm3O9aTS_m9MYz4vNwLlhyxhC5AmIw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Chakrabortya HJ. Drug Repurposing against SARS-CoV-2 RDRP - A computational quest against CoVID-19.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.sciencedirect.com/science/article/pii/S2352304220300544&amp;hl=en&amp;sa=X&amp;d=17463652539977184372&amp;scisig=AAGBfm03yGbLvpqVNmFlQaWEYZI5eMPsTA&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Chen L, Zhong and.L. Genomics functional analysis and drug screening of SARS-CoV-2. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://osf.io/preprints/kcuja/&amp;hl=en&amp;sa=X&amp;d=17221751730024745951&amp;scisig=AAGBfm09xtI--I_n4x97jV6CydXr1NVkag&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Chen L. Genomics functional analysis and drug screening of 2019 novel coronavirus in Wuhan, China.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/ndownloader/files/21656178&amp;hl=en&amp;sa=X&amp;d=11213168918798776484&amp;scisig=AAGBfm1eXiLEi44x6O4BHL6z4GWGY347KQ&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Chen YW, Yiu CB, Wong K. Prediction of the 2019-nCoV 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. 2019.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://f1000research.com/articles/9-129&amp;hl=en&amp;sa=X&amp;d=11941740778876679378&amp;scisig=AAGBfm3uFTdDh_DI958gUgRHh16KsSYCEQ&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Chen YW, Yiu CB, Wong K. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/articles/Screening_of_Clinically_Approved_and_Investigation_Drugs_as_Potential_Inhibitors_of_COVID-19_Main_Protease_A_Virtual_Drug_Repurposing_Study/12032712/files/22111983.pdf&amp;hl=en&amp;sa=X&amp;d=17949056178526182650&amp;scisig=AAGBfm1pAucYzkWhaLhXszt_Kx2b9tgTew&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Durdagi S, Aksoydan B, Dogan B, Sahin K, Shahraki A. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of COVID-19 Main Protease: A Virtual Drug Repurposing Study.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://osf.io/preprints/hczra/\">Ekins S, Mottin M, Ramos P, Sousa B, Neves B, Foil DH, Zorn KM, Braga R, Coffee M, Southan C, Puhl AC, Andrade C. D\\xc3\\xa9j\\xc3\\xa0 vu: Stimulating Open Drug Discovery for SARS-CoV-2.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/articles/Identification_of_FDA_Approved_Drugs_Targeting_COVID-19_Virus_by_Structure-Based_Drug_Repositioning/12003930/files/22052709.pdf&amp;hl=en&amp;sa=X&amp;d=16581557698231107235&amp;scisig=AAGBfm1oixCpZ_04G3fp5j9s1ubtHigPgw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Farag AB, Wang P, Ahmed MS, Sadek HA. Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://revistas.ucv.es/index.php/Nereis/article/view/592\">Galvez J, Zanni R, Galvez-Llompart M. Drugs Repurposing for Coronavirus Treatment: Computational Study Based On Molecular Topology. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.biorxiv.org/content/biorxiv/early/2020/03/12/2020.03.11.986836.full.pdf&amp;hl=en&amp;sa=X&amp;d=2643420419447543790&amp;scisig=AAGBfm2JvDHP2ciidegcfKNyEn-2lBlEig&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Ge Y, Tian T, Huang S, Wan F, Li J. A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://medium.com/@ngough_bioserendipity/a-combination-therapy-that-eliminates-the-covid-19-virus-4e4c6e3864af\">Gough NR. A Combination Therapy that Eliminates COVID-19 Virus. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.biorxiv.org/content/10.1101/2020.03.15.992925v1.abstract\">Guzzi PH, Mercatelli D, Ceraolo C, Giorgi FM. Master Regulator Analysis of the SARS-CoV- 2/Human interactome. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/32294562\">Hall DC, Ji H. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 April.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://chemrxiv.org/articles/Knowledge-Based_Structural_Models_of_SARS-CoV-2_Proteins_and_Their_Complex_with_Potential_Drugs/12021330\">Hijikata A, Shionyu-mitsuyama C, Nakae S, Shionyu M, Ota M. Knowledge-Based Structural Models of SARS-CoV-2 Proteins and Their Complex with Potential Drugs. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/ndownloader/files/22258404&amp;hl=en&amp;sa=X&amp;d=1530095354618139516&amp;scisig=AAGBfm2EVQzWvRpSrQao1wTe_urxF8TG4Q&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Horvath D, Orlov A, Osolodkin DI, Ishmukhametov AA, Marcou G. A Chemographic Audit of Anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL).</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.preprints.org/manuscript/202002.0438/download/final_file&amp;hl=en&amp;sa=X&amp;d=2776187631349714826&amp;scisig=AAGBfm1qEcLWm1ZqnwJJGxHTWuWFs1cGZA&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Hosseini FS, Amanlou M, Medicine E. Simeprevir, potential candidate to repurpose for coronavirus infection: Virtual screening and molecular docking study. 2020 February.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.preprints.org/manuscript/202003.0320\">Jamal S, Singh J, Sheikh JA, Singh H, Khubaib M, Kohli S, Dobrindt U, Rahman SA, Ehtesham NZ, Hasnain SE. Molecular analyses of over hundred sixty clinical isolates of SARS-CoV-2: Insights on likely origin, evolution and spread, and possible intervention. 2020 March.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://osf.io/cmtk6/download%3Fformat%3Dpdf&amp;hl=en&amp;sa=X&amp;d=5207836280623161091&amp;scisig=AAGBfm2fCzdN5QBnlJsNKtsmOubzDz_mTQ&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Joshi T, Mathpal S, Sharma P, Joshi T, Pundir H, Maiti P, Nand M, Chandra S. Molecular Docking Study of drug molecules from Drug Bank database against COVID-19 Mpro protein.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/ndownloader/files/21804363&amp;hl=en&amp;sa=X&amp;d=9468751875160871386&amp;scisig=AAGBfm1GgF1ANayb8lF-uVbUdfP4AW2GAw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Khan RJ, Jha RK, Amera GM, Jain M, Singh E, Pathak A, Singh RP, Muthukumaran J, Singh AK. Targeting Novel Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2&#39;-O-Ribose Methyltra. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.preprints.org/manuscript/202003.0286/download/final_file&amp;hl=en&amp;sa=X&amp;d=18380192985785410088&amp;scisig=AAGBfm2-pnXfSw_Ka4pWewFGOrgtAKakog&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Li X, Yu J, Zhang Z, Ren J, Peluffo AE, Zhang W, Zhao Y, Yan K, Cohen D, Wang W. Network bioinformatics analysis provides insight into drug repurposing for COVID-2019. 2020 March.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://faseb.onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202000502&amp;hl=en&amp;sa=X&amp;d=16365015997632092718&amp;scisig=AAGBfm3eZaAGkGVZsR1GCRy7rHN92wfZHw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Li X. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922.full.pdf&amp;hl=en&amp;sa=X&amp;d=4479185904305560961&amp;scisig=AAGBfm2b9XWOK1MIxhEmFEjreaS1xd_6RQ&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Li Y, Zhang J, Wang N, Li H, Shi Y, Guo G, Liu K, Zeng H, Zou Q. Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/articles/Computational_Evaluation_of_the_COVID-19_3c-like_Protease_Inhibition_Mechanism_and_Drug_Repurposing_Screening/12090426/files/22257321.pdf&amp;hl=en&amp;sa=X&amp;d=13728170319518407931&amp;scisig=AAGBfm0Z1B3R9OdedlqYncAsDGclcnpDZA&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Liu H, Jiang T, Liu W, Zheng Z. Computational Evaluation of the COVID-19 3c-like Protease Inhibition Mechanism , and Drug Repurposing Screening.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.biorxiv.org/content/biorxiv/early/2020/01/29/2020.01.29.924100.full.pdf&amp;hl=en&amp;sa=X&amp;d=689057022562668071&amp;scisig=AAGBfm1LPu63KPiSLNxRXnapYgwWOInU7Q&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Liu X, Wang X. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/ndownloader/files/22278795&amp;hl=en&amp;sa=X&amp;d=4136681278944265451&amp;scisig=AAGBfm1XBvkgUBNPgHLkJDuON4Hy_VNRDw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Mevada V, Dudhagara P, Gandhi H, Vaghamshi N. Drug repurposing of approved drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for combating COVID19.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.preprints.org/manuscript/202003.0302/download/final_file&amp;hl=en&amp;sa=X&amp;d=14822965610094426167&amp;scisig=AAGBfm0hrh8MCQosdvXBZX40KmiOrVZFPw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Nabirotchkin S, Peluffo AE, Bouaziz J, Cohen D. Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19. 2020 March.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.biorxiv.org/content/biorxiv/early/2020/02/13/2020.02.05.936013.full.pdf&amp;hl=en&amp;sa=X&amp;d=14670662013718650408&amp;scisig=AAGBfm2gEP6w2RDw4rJZ6KwWvneKnOFs6Q&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Nguyen DD, Gao K, Chen J, Wang R, Wei GW. Potentially highly potent drugs for 2019-nCoV. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://europepmc.org/article/ppr/ppr148883&amp;hl=en&amp;sa=X&amp;d=13527453593170059684&amp;scisig=AAGBfm1vRYrgUuxMToytPQkxG7Y16JrYzw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Olubiyi OO, Olagunju M, Keutmann M, Strodel B. High throughput virtual screening to discover inhibitors of the main protease of the coronavirus SARS-CoV-2. 2020 April.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://osf.io/xegzu/download%3Fformat%3Dpdf&amp;hl=en&amp;sa=X&amp;d=3542365498656964941&amp;scisig=AAGBfm0UCMhOVmr8rQt9BQ8AZdR3irfpCQ&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Patiyal S, Kaur D, Kaur H, Sharma N, Dhall A, Raghava GPS. A web-based platform on COVID-19 to maintain Predicted Diagnostic, Drug and Vaccine candidates.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.preprints.org/manuscript/202003.0393/download/final_file&amp;hl=en&amp;sa=X&amp;d=9672333249877843189&amp;scisig=AAGBfm1zQtLjO17-Qe4qJrS0pw06swtAXQ&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Patra A, Bhavesh NS. Virtual screening and molecular dynamics simulation suggest Valproic acid Co-A could bind to SARS-CoV2 RNA depended RNA polymerase. 2020 March.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.medrxiv.org/content/10.1101/2020.03.04.20031237v1.abstract\">Rao S, Lau A, So H. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of 2019-nCov: A Mendelian Randomization analysis. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://chemrxiv.org/articles/Energetics_Based_Modeling_of_Hydroxychloroquine_and_Azithromycin_Binding_to_the_SARS-CoV-2_Spike_S_Protein_-_ACE2_Complex/12015792\">Sandeep S. Energetics Based Modeling of Hydroxychloroquine and Azithromycin Binding to the SARS-CoV-2 Spike (S) Protein-ACE2 Complex. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.preprints.org/manuscript/202003.0042/download/final_file&amp;hl=en&amp;sa=X&amp;d=11775537947624942222&amp;scisig=AAGBfm24EIngq2qgVH3INwvKwU0sS4sTuA&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Senathilake KS, Samarakoon SR, Tennekoon KH. Virtual screening of inhibitors against spike glycoprotein of SARS-CoV-2: a drug repurposing approach. 2020 March.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/ndownloader/files/22232385&amp;hl=en&amp;sa=X&amp;d=13662776702420043848&amp;scisig=AAGBfm3pIeaErOj6pCo0o2nKGKWrwMsDlg&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Sharma A, Tiwari V, Sowdhamini R. Computational search for potential COVID-19 drugs from FDA-approved drugs and small molecules of natural origin identifies several anti-virals and plant products.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://chemrxiv.org/ndownloader/files/22217781&amp;hl=en&amp;sa=X&amp;d=8858322727657371240&amp;scisig=AAGBfm26eoMBQaGdWUsK1QTYazAIoAr4cA&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Szymku\\xc4\\x87 S, Grzybowski BA. Suggestions for second-pass anti-COVID-19 drugs based on the Artificial Intelligence measures of molecular similarity, shape and pharmacophore.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://europepmc.org/article/ppr/ppr149933&amp;hl=en&amp;sa=X&amp;d=10939730793731207627&amp;scisig=AAGBfm3lbz6FJsv9wM7svGAEcPFuEmZugw&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">T MK, K R, James N, V S, Karuppasamy R. Discovery of Potent Covid-19 Main Protease Inhibitors Using Machine Learning Based Virtual Screening Strategy. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.preprints.org/manuscript/202002.0418\">Talluri S. Virtual Screening Based Prediction of Potential Drugs for COVID-19. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://chemrxiv.org/articles/Fast_Identification_of_Possible_Drug_Treatment_of_Coronavirus_Disease_-19_COVID-19_Through_Computational_Drug_Repurposing_Study/11875446?utm_source=pubs_content_marketing&amp;utm_medium=axial&amp;utm_campaign=0320_JHS_COVIDpreprints&amp;ref=pubs_content_marketing\">Wang J. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) Through Computational Drug Repurposing Study.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.researchsquare.com/article/rs-17720/v1\">Wei T, Wang H, Lu Y. In silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://chemrxiv.org/articles/Systemic_in_Silico_Screening_in_Drug_Discovery_for_Coronavirus_Disease_COVID-19_with_an_Online_Interactive_Web_Server/12058143\">Xu C, Ke Z, Liu C, Wang Z, Liu D, Zhang L, Wang J, He W, Xu Z, Li Y, Yang Y, Huang Z, Lv P, Wang X, Han D, Li Y, Qiao N, Liu B. Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://www.biorxiv.org/content/10.1101/2020.01.27.921627v1\">Xu Z, Peng C, Shi Y, Zhu Z, Mu K, Wang X. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling , molecular docking and binding free energy calculation. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.preprints.org/manuscript/202003.0267/download/final_file&amp;hl=en&amp;sa=X&amp;d=9708758258504294265&amp;scisig=AAGBfm1x1dW-Ww00Sjd-Zxwbd1SUloat6Q&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Zhang L, Zhou R. Binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase. 2020 March.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.researchgate.net/profile/Alexander_Zhavoronkov/publication/339107940_Potential_2019-nCoV_3C-like_protease_inhibitors_designed_using_generative_deep_learning_approaches/links/5e3df321299bf1cdb9171e56/Potential-2019-nCoV-3C-like-protease-inhibitors-designed-using-generative-deep-learning-approaches.pdf&amp;hl=en&amp;sa=X&amp;d=10892499406475206639&amp;scisig=AAGBfm1ReduqE50ExUVWF_T94grheJWmiA&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Zhavoronkov A, Medicine I, Zhebrak A, Medicine I, Zagribelnyy BA, Bezrukov D. Potential 2019-nCoV 3C-like protease inhibitors designed using generative deep learning approaches. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.medrxiv.org/content/medrxiv/early/2020/02/05/2020.02.03.20020263.full.pdf&amp;hl=en&amp;sa=X&amp;d=14149249211786953198&amp;scisig=AAGBfm1nqR3BRQ673V4a_Wfh1tW56JSQBg&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based Drug Repurposing for Human Coronavirus. 2020.</a></td></tr><tr><td><a target=\"_blank\" href=\"https://scholar.google.com/scholar_url?url=https://www.nature.com/articles/s41421-020-0153-3&amp;hl=en&amp;sa=X&amp;d=17232286640212679583&amp;scisig=AAGBfm2_IXEcP--ZEmsIrJXVUrxP10r89A&amp;nossl=1&amp;oi=scholaralrt&amp;hist=GQm-oWgAAAAJ:5127282955131334551:AAGBfm2ule8pSKHCo13CHk_qLieOnZGcng\">Zhou Y, Hou Y, Shen J, Huang Y, Martin W. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020.</a></td></tr></tbody></table></dd><dt class=\"col-xl-2 col-md-3 col-sm-4\" id=\"references\">References</dt><dd class=\"col-xl-10 col-md-9 col-sm-8\"><ol class=\"cite-this-references\"><li id=\"reference-L12912\">World Health Organization: Rolling updates on Coronavirus Disease (COVID-19) [<a target=\"_blank\" href=\"https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen\">Link</a>] </li><li id=\"reference-L12918\">Centers on Disease Control and Prevention: Coronavirus Disease 2019 [<a target=\"_blank\" href=\"https://www.cdc.gov/coronavirus/2019-ncov/index.html\">Link</a>] </li><li id=\"reference-L12030\">World Health Organization: Naming the coronavirus disease (COVID-19) and the virus that causes it [<a target=\"_blank\" href=\"https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it\">Link</a>] </li><li id=\"reference-L12915\">World Health Organization: Q&A on coronaviruses (COVID-19) [<a target=\"_blank\" href=\"https://www.who.int/news-room/q-a-detail/q-a-coronaviruses\">Link</a>] </li><li id=\"reference-L12921\">European Centre for Disease Prevention and Control: COVID-19 [<a target=\"_blank\" href=\"https://www.ecdc.europa.eu/en/novel-coronavirus-china\">Link</a>] </li></ol></dd></dl><p class=\"mt-4 px-sm-0\" id=\"drug-meta\">Updated on March 31, 2022 </p></div></div></main><footer><div class=\"row p-3 p-sm-4 m-0\"><div class=\"col-md-5 footer-content\"><div class=\"footer-item footer-commercial hidden\"><img style=\"width: 130px; height: 100px;\" src=\"/assets/plus/Data_Pink-68da9b7525141f098e2e0ebcbd888ce950fe6032fd0da3a227c22117cedd7062.png\" /><h2>Interested in using DrugBank in a <strong>commercial product</strong> or <strong>application?</strong></h2><a class=\"btn btn-pink-filled\" target=\"_blank\" href=\"https://www.drugbank.com/\">Visit DrugBank.com <div class=\" drugbank-icon icon-see_more\"><svg class=\"icon\" role=\"img\" title=\"see_more\"> <use xlink:href=\"/assets/plus/icons-3af0be760cdb744eb6fd55a4d4e5ddfbe70059f381e99a13dcfb2dd8c487cc4b.svg#see_more\"> </use></svg></div></a></div><div class=\"footer-item footer-newsletter\" id=\"newsletter-1\"><div class=\"newsletter-header\"><img style=\"width: 131px; height: 100px;\" src=\"/assets/plus/Article_Dark_Pink-17ef3dc892e28e001abbb0ae6bfc47fca8a64cd76af37ec2a80dbce89fe3bc72.png\" /><h2>Stay up-to-date with the <br><strong>latest from DrugBank!</strong></h2></div><form action=\"https://dev.drugbank.com/contacts\" class=\"form\" id=\"newsletter-form\" method=\"post\"><input class=\"form-control hidden\" id=\"contact_name\" name=\"contact[name]\" type=\"hidden\" value=\"New Subscriber\" /><input class=\"form-control hidden\" id=\"contact_mailing_list\" name=\"contact[mailing_list]\" type=\"hidden\" value=\"yes\" /><input class=\"form-control hidden\" id=\"data_type\" name=\"data_type\" type=\"hidden\" value=\"json\" /><input class=\"form-control hidden\" id=\"contact_address\" name=\"contact[address]\" type=\"hidden\" /><input class=\"form-control hidden\" name=\"contact[return_url]\" type=\"hidden\" value=\"https://go.drugbank.com/#newsletter-3\" /><input class=\"form-control hidden\" name=\"contact[form_url]\" type=\"hidden\" value=\"https://go.drugbank.com/\" /><input class=\"form-control hidden\" id=\"referer\" name=\"contact[referer]\" type=\"hidden\" value=\"\" /><input class=\"form-control hidden\" id=\"type\" name=\"contact[type]\" type=\"hidden\" value=\"newsletter\" /><input class=\"form-control hidden\" id=\"ga_client_id\" name=\"contact[ga_client_id]\" type=\"hidden\" /><div class=\"input-group\"><input class=\"form-control\" id=\"contact_email\" name=\"contact[email]\" placeholder=\"Enter your email\" required=\"\" type=\"text\" /><span class=\"input-group-btn\"><button class=\"btn btn-pink-filled\" id=\"subscribe\" type=\"submit\">Subscribe</button></span></div><div class=\"help-block with-errors\"></div></form></div><div class=\"footer-item footer-newsletter hidden\" id=\"newsletter-3\"><div class=\"newsletter-header\"><img style=\"width: 131px; height: 100px;\" src=\"/assets/plus/Article_Dark_Pink-17ef3dc892e28e001abbb0ae6bfc47fca8a64cd76af37ec2a80dbce89fe3bc72.png\" /><h2><strong>Thank you</strong> <br>for subscribing!</h2></div></div></div><div class=\"col-md-7 footer-links\"><div class=\"container\"><div class=\"row footer-row\"><div class=\"col-sm-4 footer-col\"><div class=\"footer-header\">About</div><div class=\"footer-list\"><ul class=\"list-unstyled\"><li><a href=\"/about\">About DrugBank Online</a></li><li><a target=\"_blank\" href=\"https://blog.drugbank.com/\">Blog</a></li><li><a target=\"_blank\" href=\"http://www.wishartlab.com\">Wishart Research Group</a></li><li><a href=\"https://www.drugbank.com/about/careers\">Careers</a></li><li><a href=\"/legal/terms_of_use\">Terms of Use</a></li><li><a href=\"/legal/privacy_policy\">Privacy Policy</a></li></ul></div></div><div class=\"col-sm-4 footer-col\"><div class=\"footer-header\">Support</div><div class=\"footer-list\"><ul class=\"list-unstyled\"><li><a target=\"_blank\" href=\"https://dev.drugbank.com/guides/index\">Help Center</a></li><li><a target=\"_blank\" href=\"https://dev.drugbank.com/guides/faqs\">DrugBank Online FAQs</a></li><li><a href=\"/contact\">Contact Support</a></li></ul></div></div><div class=\"col-sm-4 footer-col\"><div class=\"footer-header\"><a href=\"https://www.drugbank.com/\">Products</a></div><div class=\"footer-list\"><ul class=\"list-unstyled\"><li><a target=\"_blank\" href=\"https://www.drugbank.com/datasets\">Commercial Drug Datasets</a></li><li><a target=\"_blank\" href=\"https://www.drugbank.com/academic_research\">Academic Drug Datasets</a></li><li><a target=\"_blank\" href=\"https://www.drugbank.com/clinical\">Clinical API</a></li><li><a target=\"_blank\" href=\"https://www.drugbank.com/contact/sales\">Contact Sales</a></li></ul></div></div></div><div class=\"row footer-row\"><div class=\"col-sm-12\"><div class=\"social-media\"><a class=\"social-media-link\" href=\"https://www.linkedin.com/company/drugbank/\"><div class=\"drugbank-icon icon-linkedin\"><svg class=\"icon\" role=\"img\" title=\"linkedin\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#linkedin\"></use>\\n</svg>\\n</div></a><a class=\"social-media-link\" href=\"https://twitter.com/DrugBankDB\"><div class=\"drugbank-icon icon-twitter\"><svg class=\"icon\" role=\"img\" title=\"twitter\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#twitter\"></use>\\n</svg>\\n</div></a><a class=\"social-media-link\" href=\"https://www.facebook.com/DrugBankDatabase\"><div class=\"drugbank-icon icon-facebook\"><svg class=\"icon\" role=\"img\" title=\"facebook\">\\n<use xlink:href=\"/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#facebook\"></use>\\n</svg>\\n</div></a></div><h6>Website design by Educe Design & Innovation Inc.</h6></div></div></div></div></div></footer><script defer src=\"https://static.cloudflareinsights.com/beacon.min.js/v652eace1692a40cfa3763df669d7439c1639079717194\" integrity=\"sha512-Gi7xpJR8tSkrpF7aordPZQlW2DLtzUlZcumS8dMQjwDHEnw9I7ZLyiOj/6tZStRBGtGgN6ceN6cMH8z7etPGlw==\" data-cf-beacon=\\'{\"rayId\":\"6f4832e39bc8801e\",\"token\":\"e28ec36f07f74c1ca13c169ca4430981\",\"version\":\"2021.12.0\",\"si\":100}\\' crossorigin=\"anonymous\"></script>\\n</body><script src=\"/assets/analytics-1b5960c76af2e5f1a83c45e21ee367baf13121e0a2d42380a71abadf0edaa402.js\" media=\"all\" data-turbolinks-track=\"true\"></script><script type=\"text/javascript\" id=\"hs-script-loader\" async defer src=\"//js.hs-scripts.com/2224137.js\"></script></html>'"
            ]
          },
          "metadata": {},
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "soup=BeautifulSoup(page.content,\"html.parser\")"
      ],
      "metadata": {
        "id": "Gl6zJx-rsRjm"
      },
      "execution_count": 9,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "a=soup.find_all(\"table\")"
      ],
      "metadata": {
        "id": "IILbHhSisceJ"
      },
      "execution_count": 10,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "b=a[2]\n"
      ],
      "metadata": {
        "id": "HF8QgODLRYIr"
      },
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "c=b.find_all(\"a\")\n",
        "d=c[0:10]\n",
        "d\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "cCJZgnMmRh90",
        "outputId": "36c0e08b-76e3-4649-8203-dd89df4230a2"
      },
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[<a href=\"/drugs/DB00503\">Ritonavir</a>,\n",
              " <a href=\"/drugs/DB00608\">Chloroquine</a>,\n",
              " <a href=\"/drugs/DB01264\">Darunavir</a>,\n",
              " <a href=\"/drugs/DB01601\">Lopinavir</a>,\n",
              " <a href=\"/drugs/DB11676\">Galidesivir</a>,\n",
              " <a href=\"/drugs/DB12466\">Favipiravir</a>,\n",
              " <a href=\"/drugs/DB13609\">Umifenovir</a>,\n",
              " <a href=\"/drugs/DB14999\">Human interferon beta</a>,\n",
              " <a href=\"/drugs/DB15622\">Triazavirin</a>,\n",
              " <a href=\"/drugs/DB15623\">TMC-310911</a>]"
            ]
          },
          "metadata": {},
          "execution_count": 12
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(\"Experimental Unapproved Treatments for COVID-19: \")\n",
        "for i in range(len(d)):\n",
        " print(i+1,d[i].text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Qab250KjRv7o",
        "outputId": "839275b9-9844-4f19-f5a2-bc73a52caf9c"
      },
      "execution_count": 17,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Experimental Unapproved Treatments for COVID-19: \n",
            "1 Ritonavir\n",
            "2 Chloroquine\n",
            "3 Darunavir\n",
            "4 Lopinavir\n",
            "5 Galidesivir\n",
            "6 Favipiravir\n",
            "7 Umifenovir\n",
            "8 Human interferon beta\n",
            "9 Triazavirin\n",
            "10 TMC-310911\n"
          ]
        }
      ]
    }
  ]
}